Investigation of the relationship between iron and high field MRI in healthy and Alzheimer's disease tissue by Finnegan, Mary E.
  
 
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap  
 





This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to 












Candidate’s name: …………………………………………………………………. 
 
Date of birth: ………………………… ID Number: …………………. 
 
I agree that this thesis shall be made available by the University Library in accordance with the 
regulations governing University of Warwick theses. 
 
I agree that the summary of this thesis may be submitted for publication. 
 
I agree that the thesis may be photocopied (single copies for study purposes only)  YES / NO 
 (please delete as appropriate) 
 
 
Theses with no restriction on photocopying will also be made available to the British Library for 
microfilming.  The British Library may supply copies to individuals or libraries, subject to a statement 
from them that the copy is supplied for non-publishing purposes.  All copies supplied by the British 
Library will carry the following statement: “Attention is drawn to the fact that the copyright of this thesis 
rests with its author.  This copy of the thesis has been supplied on condition that anyone who consults it 
is understood to recognise that its copyright rests with its author and that no quotation from the thesis and 
no information derived from it may be published without the author’s written consent.” 
 






1. I undertake not to quote or make use of any information from this thesis without making 
acknowledgement to the author. 
 
2. I further undertake to allow no-one else to use this thesis while it is in my care. 
 
DATE SIGNATURE ADDRESS 
   
   
   
   
   
   
   
   
   
   
   
 
 Investigation of the relationship between iron 
and high field MRI in healthy and Alzheimer’s 
Disease tissue 
by 




Submitted for the degree:  
Doctor of Philosophy 
 
School of Engineering 








List of figures ...........................................................................................................................    XIV 
List of tables ............................................................................................................................    XX 
List of abbreviations ...............................................................................................................  XXIV 
Acknowledgments ................................................................................................................... XXVI 
Declaration  ........................................................................................................................... XXIIX 
Abstract  .................................................................................................................................. XXX 
Publications  ............................................................................................................................  XXXI 
Chapter 1: Introduction and Background ............................................................................... 1 
1.1 Introduction .................................................................................................................. 1 
1.1.1 Motivation ............................................................................................................. 1 
1.1.2 Aims ....................................................................................................................... 3 
1.1.3 Thesis structure ..................................................................................................... 3 
1.2 Background ................................................................................................................... 6 
1.2.1 Alzheimer’s Disease .............................................................................................. 6 
1.2.1.1 Disease pathology ............................................................................................. 6 
1.2.1.2 AD pathogenesis ............................................................................................... 8 
1.2.2 Diagnosis of AD ..................................................................................................... 8 
1.2.2.1 The NINCDS-ADRDA criteria for clinical diagnosis of AD .................................. 9 
1.2.2.2 Developments in AD diagnosis .......................................................................... 9 
1.2.2.3 Magnetic Resonance Imaging ......................................................................... 10 
III 
 
1.2.2.4 Iron as a potential marker in MRI ................................................................... 12 
1.2.3 Non-haem brain iron ........................................................................................... 13 
1.2.3.1 Forms of non-haem iron in the brain .............................................................. 13 
1.2.3.2 Iron in fixed and frozen tissue ......................................................................... 16 
1.2.3.3 Iron concentration and age ............................................................................. 17 
1.2.4 Measuring iron in the brain ................................................................................ 18 
1.2.4.1 Histology ......................................................................................................... 18 
1.2.4.2 Iron quantification in bulk tissue samples ...................................................... 19 
1.2.4.3 Magnetometry ................................................................................................ 20 
1.2.4.4 Synchrotron X-ray analysis .............................................................................. 20 
1.2.4.5 Other ............................................................................................................... 21 
1.2.5 MRI of non-haem brain iron ............................................................................... 22 
1.2.5.1 R1, R2 and R2* mapping ................................................................................... 22 
1.2.5.2 Field Dependent R2 Increase imaging ............................................................. 23 
1.2.5.3 R2’, phase and Susceptibility Weighted Imaging ............................................. 23 
1.2.5.4 High field MRI .................................................................................................. 24 
1.2.5.5 Comparing MRI and tissue iron concentration ............................................... 24 
1.2.5.6 MRI and SXRF .................................................................................................. 26 
1.3 Literature review: iron in the AD brain ....................................................................... 27 
1.3.1 Iron concentration in AD and control tissue ....................................................... 27 
1.3.1.1 Recent publications ......................................................................................... 31 
1.3.2 Altered iron form in AD ....................................................................................... 31 
1.3.3 Iron associated with AD pathology ..................................................................... 32 
IV 
 
1.3.4 Assessment of iron in AD by MRI ........................................................................ 33 
1.3.4.1 R1 R2 and R2* mapping .................................................................................... 33 
1.3.4.2 FDRI ................................................................................................................. 34 
1.3.5 Iron in other neurodegenerative diseases .......................................................... 34 
1.3.6 Conclusion ........................................................................................................... 34 
Chapter 2: Theory ................................................................................................................. 35 
2.1 Magnetic Resonance Imaging ..................................................................................... 35 
2.1.1 Nuclear magnetic resonance .............................................................................. 35 
2.1.2 R1, R2 and R2* ...................................................................................................... 37 
2.1.2.1 Longitudinal recovery ..................................................................................... 38 
2.1.2.2 Transverse decay............................................................................................. 38 
2.1.2.3 R2* and R2’ ....................................................................................................... 39 
2.1.3 MRI hardware ..................................................................................................... 40 
2.1.4 Spatial information ............................................................................................. 41 
2.1.5 Pulse sequences .................................................................................................. 42 
2.1.5.1 Spin-echo sequences ....................................................................................... 42 
2.1.5.2 Gradient-echo sequences ............................................................................... 42 
2.2 Magnetic properties of non-haem brain iron and its effect on MRI .......................... 43 
2.2.1 Ferritin and haemosiderin ................................................................................... 43 
2.2.1.1 Magnetic properties of ferrihydrite in ferritin ................................................ 43 
2.2.1.2 The effect of ferritin on MRI relaxation .......................................................... 45 
2.2.2 Magnetite ............................................................................................................ 46 
2.2.3 Other tissue properties which affect MRI relaxation.......................................... 47 
V 
 
2.3 Synchrotron X-ray fluorescence .................................................................................. 48 
2.3.1 Synchrotron X-ray radiation ................................................................................ 49 
2.3.2 X-ray fluorescence............................................................................................... 50 
2.3.3 Creating SXRF metal maps .................................................................................. 52 
Chapter 3: Samples ............................................................................................................... 54 
3.1 Preventing iron contamination ................................................................................... 57 
3.1.1 Acid washing ....................................................................................................... 57 
3.1.2 A clean lab environment ..................................................................................... 58 
3.2 Brain region selection and sample excision ................................................................ 58 
3.2.1 Brain region selection ......................................................................................... 58 
3.2.1.1 Caudate Nucleus ............................................................................................. 61 
3.2.1.2 Putamen .......................................................................................................... 63 
3.2.1.3 Globus Pallidus ................................................................................................ 64 
3.2.1.4 Substantia nigra .............................................................................................. 65 
3.2.1.5 Amygdala......................................................................................................... 66 
3.2.1.6 Pons ................................................................................................................. 67 
3.2.2 Sample details ..................................................................................................... 67 
3.2.3 Sample excision ................................................................................................... 70 
3.2.3.1 Caudate nucleus and putamen ....................................................................... 71 
3.2.3.2 Globus pallidus ................................................................................................ 73 
3.2.3.3 Substantia nigra .............................................................................................. 74 
3.2.3.4 Amygdala......................................................................................................... 75 
3.2.3.5 Pons ................................................................................................................. 76 
VI 
 
3.3 Sample preparation .................................................................................................... 77 
3.3.1 Preparation for bulk tissue analysis .................................................................... 78 
3.3.2 Preparation for MRI ............................................................................................ 78 
3.3.2.1 600 MHz MRI sample set-up ........................................................................... 79 
3.3.2.2 400 MHz MRI sample set-up ........................................................................... 80 
3.3.2.3 Sample temperature ....................................................................................... 82 
3.3.3 Sectioning MRI tissue blocks ............................................................................... 82 
3.3.3.1 Tissue sections for SXRF mapping ................................................................... 84 
Chapter 4: Methodology ....................................................................................................... 87 
4.1 Superconducting quantum interference device magnetometry ................................ 87 
4.1.1 Isothermal remanent magnetisation .................................................................. 88 
4.1.2 Methodology for measuring IRM ........................................................................ 88 
4.1.2.1 IRM curves at 5 and 50 K ................................................................................. 90 
4.1.2.2 IRM at 5, 50 150 and 300 K ............................................................................. 90 
4.1.3 Correcting SQUID data for sample length ........................................................... 91 
4.1.4 Quality of data .................................................................................................... 91 
4.2 Iron quantification ...................................................................................................... 93 
4.2.1 Graphite furnace atomic absorption spectroscopy ............................................ 93 
4.2.2 Inductively coupled plasma mass spectroscopy ................................................. 93 
4.3 Magnetic resonance imaging ...................................................................................... 95 
4.3.1 MRI data collection ............................................................................................. 95 
4.3.1.1 Common features of measurement protocol at 600 and 400 MHz ............... 95 
4.3.1.2 Imaging at the McKnight Brain Institute, University of Florida .................... 100 
VII 
 
4.3.1.3 Imaging at the University of Warwick ........................................................... 102 
4.3.2 Data Processing ................................................................................................. 110 
4.3.2.1 Paravision ...................................................................................................... 110 
4.3.2.2 ImageJ ........................................................................................................... 110 
4.3.3 Artefacts and data quality ................................................................................. 111 
4.3.3.1 Variation across the sample space ................................................................ 111 
4.3.3.2 Artefacts ........................................................................................................ 112 
4.3.3.3 Rapid decays ................................................................................................. 114 
4.4 Synchrotron X-ray fluorescence mapping ................................................................. 117 
4.4.1 Data collection at the Diamond Light Source ................................................... 118 
4.4.1.1 Hardware....................................................................................................... 118 
4.4.1.2 Software ........................................................................................................ 120 
4.4.1.3 Mapping protocol.......................................................................................... 120 
4.4.2 SXRF data processing ........................................................................................ 122 
4.4.2.1 Output data files ........................................................................................... 122 
4.4.2.2 Fitting SXRF spectra ....................................................................................... 123 
4.4.2.3 Normalising data and subtracting background signal................................... 124 
4.4.2.4 Exporting maps for further analysis in ImageJ .............................................. 126 
4.5 Histology ................................................................................................................... 127 
4.5.1 Staining sections on glass with Congo red and haematoxylin .......................... 127 
4.5.2 Staining post-SXRF ............................................................................................ 128 
4.6 Statistical analysis techniques ................................................................................... 133 
4.6.1 Analysis of variance ........................................................................................... 133 
VIII 
 
4.6.1.1 One-way ANOVA using SSPS ......................................................................... 134 
4.6.2 Non parametric statistics .................................................................................. 135 
4.6.3 Linear regression analysis ................................................................................. 135 
4.6.4 Discriminant analysis......................................................................................... 137 
4.6.4.1 Assessing contribution of variables to the model ......................................... 138 
4.6.4.2 Validating the model ..................................................................................... 138 
Chapter 5: Bulk tissue iron analysis .................................................................................... 139 
5.1 Iron concentration .................................................................................................... 142 
5.1.1 Comparison with the literature......................................................................... 145 
5.2 SQUID magnetometry measurements ...................................................................... 146 
5.2.1 IRM at 5 K .......................................................................................................... 147 
5.2.2 IRM at 50, 150 and 300 K .................................................................................. 150 
5.2.3 IRM curves at 5 and 50 K ................................................................................... 153 
5.2.4 Relative proportion of iron as ferritin and magnetite ...................................... 159 
5.3 The linear relationship between iron concentration and IRM at 5 K ....................... 161 
5.3.1 All samples and individual disease groups ........................................................ 162 
5.3.2 Individual regions .............................................................................................. 164 
5.4 Discriminant analysis ................................................................................................ 167 
5.4.1 Iron concentration or IRM at 5 K in multiple brain regions .............................. 168 
5.4.2 Iron concentration and IRM at 5 K .................................................................... 171 
5.5 Water content of the tissue samples ........................................................................ 172 
5.6 Discussion .................................................................................................................. 173 
IX 
 
5.6.1 Total and particulate iron concentration can differentiate between control and 
AD cases ........................................................................................................................... 173 
5.6.2 Iron concentration measurements are mostly in agreement with the literature .. 
 ........................................................................................................................... 174 
5.6.3 There is no evidence for increased iron with age ............................................. 174 
5.6.4 There is no evidence for increased magnetite concentration in AD ................ 175 
5.6.5 What is the potential clinical significance of these results in terms of detecting 
AD with MRI? .................................................................................................................... 175 
5.7 Summary ................................................................................................................... 176 
Chapter 6: Synchrotron X-ray fluorescence mapping ......................................................... 177 
6.1 SXRF metal maps ....................................................................................................... 178 
6.1.1 Subtracting slide background ............................................................................ 179 
6.1.2 Normalising to slide background ...................................................................... 181 
6.1.3 Final adjustments and error estimation ........................................................... 182 
6.1.3.1 Estimation of measurement error ................................................................ 182 
6.1.3.2 Setting the threshold .................................................................................... 182 
6.1.3.3 Colouring conventions .................................................................................. 183 
6.2 Segmenting SXRF maps ............................................................................................. 184 
6.3 SXRF maps: qualitative and quantitative analysis ..................................................... 191 
6.3.1 Qualitative observations ................................................................................... 191 
6.3.2 Quantitative analysis ......................................................................................... 199 
6.3.3 Standard deviation of pixel intensity in each region ........................................ 202 
6.4 Using bulk tissue iron concentration to calibrate SXRF signal intensity ................... 203 
X 
 
6.4.1 Comparing SXRF and bulk tissue iron measurements ...................................... 203 
6.4.2 Calibrating the SXRF data .................................................................................. 204 
6.4.3 Estimating iron concentration using calibrated SXRF ....................................... 205 
6.5 The pons .................................................................................................................... 206 
6.5.1 Sixty micron resolution SXRF maps ................................................................... 208 
6.5.1.1 Qualitative observations ............................................................................... 208 
6.5.1.2 Quantitative comparison between AD and PD maps ................................... 211 
6.5.2 High resolution SXRF mapping of the pons ....................................................... 213 
6.5.2.1 Making 3 µm SXRF maps of the pons ............................................................ 213 
6.5.2.2 Identifying neurons in the 3 µm maps .......................................................... 216 
6.5.2.3 Relative iron, copper and zinc concentration in the neurons of the control, AD 
and PD pons .................................................................................................................. 217 
6.6 Iron and amyloid deposition ..................................................................................... 219 
6.7 Discussion .................................................................................................................. 220 
6.7.1 Comparison of bulk tissue and SXRF data ......................................................... 220 
6.7.2 Inhomogeneity of metal distribution ................................................................ 220 
6.7.3 The potential of cellular resolution SXRF mapping ........................................... 221 
6.7.4 Novelty of these measurements ....................................................................... 222 
6.8 Summary ................................................................................................................... 222 
Chapter 7: MRI relaxometry ............................................................................................... 224 
7.1 Segmentation of the R2 and R2* maps ...................................................................... 225 
7.1.1 400 MHz maps .................................................................................................. 226 
7.1.2 600 MHz maps .................................................................................................. 230 
XI 
 
7.2 Comparison of means ............................................................................................... 233 
7.2.1 Control and AD samples .................................................................................... 233 
7.2.2 AD, PD and MSA samples .................................................................................. 235 
7.2.3 Discriminant analysis of data from multiple regions ........................................ 236 
7.2.3.1 400 MHz measurements ............................................................................... 236 
7.2.3.2 600 MHz data ................................................................................................ 239 
7.2.4 Further comparisons ......................................................................................... 240 
7.3 Comparison of standard deviations .......................................................................... 241 
7.4 Discussion .................................................................................................................. 243 
7.4.1 R2 and R2* data can be used to differentiate between AD and control cases .. 243 
7.4.2 Contrast between the caudate nucleus and anterior limb of the internal capsule 
is increased in AD .............................................................................................................. 243 
7.4.3 No difference in pixel variance was observed .................................................. 244 
7.5 Summary ................................................................................................................... 244 
Chapter 8: The relationship between iron and MRI ........................................................... 245 
8.1 Comparing SXRF and MRI relaxometry maps ........................................................... 245 
8.1.1 400 MHz data .................................................................................................... 247 
8.1.1.1 Matching SXRF and MRI maps ...................................................................... 247 
8.1.1.2 Segmenting the matched MRI and SXRF maps ............................................. 249 
8.1.1.3 Mean iron concentration, R2 and R2* in the segmented regions ................. 256 
8.1.1.4 Effects of mismatching and of imaging resolution ....................................... 258 
8.1.1.5 The linear relationship between iron concentration, R2 and R2* ................. 260 
8.1.1.6 Iron and R2’ .................................................................................................... 263 
XII 
 
8.1.1.7 Copper and zinc versus R2 and R2* ................................................................ 265 
8.1.2 600 MHz data .................................................................................................... 268 
8.1.2.1 Amygdala....................................................................................................... 268 
8.1.2.2 Pons ............................................................................................................... 271 
8.2 MRI versus bulk tissue iron concentration and SQUID measurements .................... 273 
8.2.1 Data summary ................................................................................................... 273 
8.2.2 Linear regression analysis ................................................................................. 275 
8.2.2.1 MRI at 400 MHz ............................................................................................ 275 
8.2.2.2 MRI at 600 MHz ............................................................................................ 277 
8.3 Discussion .................................................................................................................. 278 
8.3.1 A very strong linear relationship was demonstrated between iron concentration 
and R2, R2* and R2’ at 9.4 T ............................................................................................... 278 
8.3.1.1 The linear relationship between iron and R2 is shown in both grey and white 
matter ....................................................................................................................... 278 
8.3.2 Predicting the concentration of iron from an MRI measurement .................... 279 
8.3.3 Iron concentrations below 50 µg/g did not dominate the value of R2* at 14.1 T .. 
 ........................................................................................................................... 280 
8.4 Summary ................................................................................................................... 281 
Chapter 9: Discussion and conclusions ............................................................................... 282 
9.1 The linear relationship between iron and MRI ......................................................... 282 
9.1.1 Comparison with the literature......................................................................... 282 
9.1.1.1 R2 ................................................................................................................... 283 
9.1.1.2 R2’ .................................................................................................................. 284 
XIII 
 
9.1.2 Measuring iron by MRI ...................................................................................... 285 
9.2 Combining information from multiple brain regions enables the differentiation of 
control and AD tissue ............................................................................................................ 285 
9.2.1 Would 3 T MRI measurements give the same result? ...................................... 287 
9.2.2 Other comments ............................................................................................... 288 
9.3 The inhomogeneous distribution of iron within nuclei of the basal ganglia ............ 289 
9.4 The form of iron in Alzheimer’s disease tissue ......................................................... 290 
9.5 Development and demonstration of techniques ...................................................... 291 
9.5.1 Matching MRI and SXRF maps .......................................................................... 291 
9.5.2 Bulk iron analysis in adjacent blocks of tissue .................................................. 292 
9.5.3 High field MRI .................................................................................................... 292 
9.5.4 Staining section post-SXRF mapping ................................................................. 293 
9.6 Further work ............................................................................................................. 293 
9.6.1 The discriminant analysis model ....................................................................... 293 
9.6.2 T1 data ............................................................................................................... 294 
9.7 Conclusions ............................................................................................................... 294 
Appendix A: Brain Anatomy Reference Material ........................................................................  i 
Appendix B: Sample dissection for MRI and bulk tissue analysis ............................................... vii 
Appendix C: SQUID Sequences .................................................................................................. xxx 
Appendix D: Fitting SXRF spectra in PyMCA ...........................................................................  xxxii 
Appendix E: Segmentation of MRI maps made at 9.4 T .........................................................  xxxv 
Appendix F: MRI maps of the pons at 14.1 T ..........................................................................    xlv 
Appendix G: Matching SXRF and MRI maps  ...........................................................................  xlvii 
Appendix H: Paper: Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in 
Parkinson’s Disease and Multiple System Atrophy  
XIV 
 
List of figures 
Chapter 1: Introduction and background 
Figure 1.1: The ‘eye of the tiger’ pattern observed in a T2-weighted MRI of a patient with 
neurodegeneration with brain iron accumulation (NBIA). 
Figure 1.2: A simplified diagram of ferritin. 
Figure 1.3: Summary of literature review.  
 
Chapter 2: Theory 
Figure 2.1: Precession about a magnetic field. 
Figure 2.2: Arrangement of proton magnetic moments in the presence of an external field.  
Figure 2.3: A 90° RF pulse flips the NMV into the xy plane.  
Figure 2.4: T1 and T2 decay.  
Figure 2.5: The alignment of magnetic moments in antiferromagnetic and ferrimagnetic 
materials.  
Figure 2.6: The Diamond Light Source synchrotron.  
Figure 2.7: The electron transitions that give rise to X-ray fluorescence. 
Figure 2.8: A typical biological fluorescence spectrum from a human brain tissue sample.  
 
Chapter 3: Samples 
Figure 3.1: Experimental path for tissue samples. 
Figure 3.2: A coronal view of the basal ganglia. 
Figure 3.3: A coronal section of the brain showing the caudate nucleus and putamen of the 
basal ganglia. 
Figure 3.4: A coronal section of the brain showing the caudate nucleus, putamen, globus 
pallidus and amygdala. 
Figure 3.5: An axial view of the substantia nigra and surrounding structures.  
XV 
 
Figure 3.6: An axial view of the pons. 
Figure 3.7: Preparation of putamen and caudate nucleus sample C1 for MRI and bulk tissue 
analysis.  
Figure 3.8: Preparation of globus pallidus sample C1 for MRI.  
Figure 3.9: Preparation of substantia nigra sample C2 for MRI and bulk tissue analysis.  
Figure 3.10: Preparation of amygdala sample C3 for MRI. 
Figure 3.11: Preparation of pons sample C1 for MRI.  
Figure 3.12: Tissue compression for SQUID magnetometry. 
Figure 3.13: The effect of 12 hours of imaging on the shape of a tissue sample.  
Figure 3.14: The tissue support for imaging at 400 MHz and the result of 12 hours imaging on 
the shape of the tissue.  
Figure 3.15 Tissue sectioning.  
 
Chapter 4: Methodology 
Figure 4.1: Comparison of IRM data from individual IRM measurements and IRM curves. 
Figure 4.2: FLASH image of a partially frozen tissue sample.   
Figure 4.3: Setting up slice geometry for MRI mapping.  
Figure 4.4: MRI hardware at the University of Warwick.  
Figure 4.5: Example data collected using the 400 MHz probe at the University of Warwick.  
Figure 4.6: Typical T2 and T2* data collected at AMRIS, University of Florida. 
Figure 4.7: Typical artefacts in MRI maps.  
Figure 4.8:  ImageJ maps and Origin fitting of the same MRI data.  
Figure 4.9: Experimental set-up for SXRF mapping at beamline I18.  
Figure 4.10: A typical fitted fluorescence spectrum in PyMCA.  
Figure 4.11: Variation of I0 over the course of SXRF map data acquisition.  
Figure 4.12: Staining of SXRF mapped tissue compared to non-mapped tissue.  
Figure 4.13: Staining of high resolution SXRF-mapped tissue.  
XVI 
 
Chapter 5: Bulk tissue iron analysis 
Figure 5.1: Literature review of publications comparing iron in control and AD tissue. 
Figure 5.2: Iron concentration per gram of fresh-frozen tissue.  
Figure 5.3: Isothermal remanent magnetisation at 5 K, after an applied field of 10 kOe, per 
gram of fresh-frozen tissue.  
Figure 5.4: Isothermal remanent magnetisation (IRM) at 50, 150 and 300 K per gram of fresh 
tissue.  
Figure: 5.5: Ratio of IRM at 50 K to IRM at 5 K.  
Figure 5.6 IRM curves at 5 K and 50 K for substantia nigra sample MSA1. 
Figure 5.7: IRM curves at 5 K and 50 K for putamen sample C1.  
Figure 5.8: IRM curves at 5 K and 50 K for putamen samples AD1 and AD2.  
Figure 5.9: IRM curves at 5 K and 50 K for putamen sample PD4 
Figure 5.10: IRM curves at 5 K and 50 K for putamen samples MSA1, MSA2 and MSA3.  
Figure 5.11: IRM curves at 5 K and 50 K for caudate nucleus samples C1, C2 and C3.  
Figure 5.12: IRM curves at 5 K and 50 K for caudate nucleus sample AD2.  
Figure 5.13: Estimation of the relative proportion of iron in ferritin and magnetite.  
Figure 5.14: IRM at 5 K versus iron concentration for all samples.  
Figure 5.15: IRM at 5 K versus iron concentration in each brain region.  
Figure 5.16: Dry to wet mass ratio of tissue samples.  
 
Chapter 6: Synchrotron X-ray fluorescence mapping 
Figure 6.1: Typical fluorescence spectrum of an area of quartz slide, with the signal intensity 
averages of the number of pixels sampled. 
Figure 6.2: Quartz slide SXRF signal intensity.  
Figure 6.3: Segmentation of the SXRF map of caudate nucleus sample C2.  
Figure 6.4: Segmentation of the SXRF map of caudate nucleus sample AD1.  
Figure 6.5: Segmentation of the SXRF map of putamen sample C3. 
XVII 
 
Figure 6.6: Segmentation of the SXRF map of putamen sample AD3.  
Figure 6.7: Segmentation of the SXRF map of globus pallidus sample C3. 
Figure 6.8 Segmentation of the SXRF map of globus pallidus sample AD2.  
Figure 6.9: Segmentation of the SXRF map of the substantia nigra sample C2.  
Figure 6.10: Segmentation of the SXRF map of the substantia nigra sample AD2.  
Figure 6.11:  SXRF map of the amygdala sample C3.   
Figure 6.12: SXRF map of the amygdala sample AD2.   
Figure 6.13: Iron, copper and zinc distribution in the caudate nucleus.  
Figure 6.14: Iron, copper and zinc distribution in the putamen.  
Figure 6.15: Iron, copper and zinc distribution in the globus pallidus.  
Figure 6.16: Iron, copper and zinc distribution in the substantia nigra.  
Figure 6.17: Iron, copper and zinc distribution in the amygdala.  
Figure 6.18: Mean relative iron, copper and zinc concentration in the segmented regions of 
SXRF maps from experiment DLS5. 
Figure 6.19: Standard deviations of pixel values in the segmented regions of the SXRF maps. 
Figure 6.20: Iron SXRF signal intensity for the quartz slide background for the pons samples. 
Figure 6.21: Metal distribution in the control and MSA pons. 
Figure 6.22: Metal distribution in the AD and PD pons 
Figure 6.23 Segmentation of the SXRF map of pons sample AD2.  
Figure 6.24: Segmentation of the SXRF map of pons sample PD1.  
Figure 6.25: Relative metal concentrations in the segmented regions of the AD and PD pons 
maps.  
Figure 6.26: Choosing the position of a high resolution SXRF map for the AD pons sample.  
Figure 6.27: Three micron resolution SXRF metal distribution maps of the control, AD and PD 
pons. 
Figure 6.28: Identification of neurons in the 3 micron resolution SXRF maps. 
XVIII 
 
Figure 6.29: Relative metal concentrations in the neurons, grey matter and white matter of the 
pons.   
 
Chapter 7: MRI relaxometry 
Figure 7.1 Segmentation of the MRI maps of caudate nucleus sample C1. 
Figure 7.2: Segmentation of the MRI maps of putamen sample C3. 
Figure 7.3 Segmentation of the MRI maps of globus pallidus sample AD2.   
Figure 7.4: MRI of globus pallidus sample C2.  
Figure 7.5: Segmentation of the MRI maps of substantia nigra sample C2.   
Figure 7.6: A representative slice from each of the R2* MRI maps of the control and AD 
amygdala. 
Figure 7.7: Segmentation of the R2* map of pons sample PD4 
Figure 7.8: Mean R2 and R2* values in the segmented regions of MRI maps of the control and 
AD samples. 
Figure 7.9: Data from MRI maps of control, AD, PD and MSA tissue.  
Figure 7.10: Mean ratio of R2 in the caudate nucleus (CN) to R2 in the anterior limb of the 
internal capsule (AIC).  
Figure 7.11: Mean standard deviation of R2 and R2*. 
 
Chapter 8: The relationship between iron and MRI 
Figure 8.1: Matching the SXRF and MRI maps of the caudate nucleus for case C2.  
Figure 8.2: Segmentation of matched SXRF and MRI maps of caudate nucleus sample C2.  
Figure 8.3: Segmentation of matched SXRF and MRI maps of caudate nucleus sample AD1.  
Figure 8.4: Segmentation of matched SXRF and MRI maps of putamen sample C3.  
Figure 8.5: Segmentation of matched SXRF and MRI maps of putamen sample AD3.  
Figure 8.6: Segmentation of matched SXRF and MRI maps of globus pallidus sample C3.  
Figure 8.7: Segmentation of matched SXRF and MRI maps of globus pallidus sample AD2.  
XIX 
 
Figure 8.8: Segmentation of matched SXRF and MRI maps of substantia nigra sample C2.  
Figure 8.9: Segmentation of matched SXRF and MRI maps of substantia nigra sample AD2.  
Figure: 8.10: Iron concentration, R2 and R2* in the matched SXRF and MRI maps.  
Figure 8.11: Relative standard deviation in control and AD SXRF and MRI maps.  
Figure 8.12: R2 and R2* of high and low resolution maps of the globus pallidus. 
Figure 8.13: Iron concentration versus R2 and R2* at 9.4 T.  
Figure 8.14: Iron concentration versus R2’.  
Figure 8.15: Copper and zinc concentration versus R2 and R2*.  
Figure 8.16: Matched SXRF and R2* maps of the amygdala with a grid of square ROIs overlaid 
on each map. 
Figure 8.17: Iron concentration vs. R2* in maps of the control and AD amygdala.  
Figure 8.18: The result of matching the SXRF and R2* maps of the AD and PD pons.  
Figure 8.19: Relative iron concentration and R2* in the grey and white matter of the AD and PD 
pons.  
Figure 8.20: Summary of bulk tissue and MRI relaxometry measurements of tissue from the 
caudate nucleus, putamen, substantia nigra and pons.  
Figure 8.21: IRM at 5 K versus R2 and R2*.   
XX 
 
List of tables 
Chapter 1: Introduction and background 
Table 1.1 Iron concentration in regions of the brain as reported by Hallgren and Sourander.  
Table 1.2: Papers referenced in the literature review in Figure 1.3. 
 
Chapter 2: Theory 
Table 2.1: Energy of fluorescence lines for iron, copper, zinc, nickel, chromium and manganese.  
 
Chapter 3: Samples 
Table 3.1: A summary of the measurements that were made on each case.  
Table 3.2: Iron concentration in brain regions of healthy adults. 
Table 3.3: Iron concentration in control and AD tissue. 
Table 3.4: Case details for the samples used in this project. 
Table 3.5: Predicted iron concentration for the control and AD sample set. 
 
Chapter 4: Methodology 
Table 4.1: Scan parameters for MRI relaxometry at 600 MHz.  
Table 4.2: Scan parameters for MRI relaxometry at 400 MHz.  
Table 4.3: The order of scans for MRI at 400 MHz.  
Table 4.4: Comparing ImageJ calculations of T2 and T2* by ImageJ and Origin in a region of high 
signal drop out.   




Chapter 5: Bulk tissue iron analysis 
Table 5.1: Age and sex of each case measured by bulk tissue analysis.  
Table 5.2: A summary of the bulk tissue iron and magnetometry measurements.  
Table 5.3: Mean iron concentration in each brain region.  
Table 5.4: Literature iron concentrations in control and AD putamen and caudate nucleus. 
Table 5.5: Average IRM at 5 K normalised to control.  
Table 5.6: Summary of samples which showed an elevated IRM at 50 K. 
Table 5.7: Results of simple linear regression analysis of iron concentration versus IRM at 5 K, 
with data grouped by disease state.  
Table 5.8: Properties of the linear fits to IRM at 5 K versus iron concentration.  
Table 5.9: Proportion of cases correctly classified by discriminant analysis of iron concentration 
or IRM at 5 K. 
Table 5.10: Results of discriminant analysis of iron concentration and IRM at 5 K. 
 
Chapter 6: Synchrotron X-ray fluorescence mapping 
Table 6.1: Percentage difference of the measured iron fluorescence intensity of the quartz 
slides for AD samples compared to the control. 
Table 6.2: Ratio of AD to control iron concentration (ARC). 
Table 6.3: Estimation of iron concentration per unit of normalised iron SXRF intensity. 
Table 6.4: Estimated iron concentrations in the control and AD amygdala and globus pallidus 
and the values reported in the literature.  
Table 6.5: Percentage difference of the measured iron fluorescence intensity of the quartz 
slides for disease samples compared to control. 
Table 6.6: Iron concentration ratio between disease groups in the pons.  
Table 6.7: Metal concentration in the neurons, grey matter and white matter of the pons for 




Chapter 7: MRI Relaxometry 
Table 7.1: List of samples measured with MRI relaxometry.  
Tables 7.2: Results of discriminant analysis of R2 data collected at 400 MHz.  
Table 7.3: The results of discriminant analysis using combinations of R2 data from different 
brain regions.  
Tables 7.4: Results of discriminant analysis of R2* data collected at 400 MHz.   
Table 7.5: The result of discriminant analysis using combinations of R2* data. 
Tables 7.6: Results of discriminant analysis of R2* data collected at 600 MHz.  
Table 7.7: The results of discriminant analysis using combinations of R2* data collected at 600 
MHz. 
  
Chapter 8: The relationship between iron and MRI 
Table 8.1: SXRF experiment number and the MRI spectrometer frequency for 1H imaging used 
to image each sample.  
Table 8.2: Percentage difference in R2 and R2* in low compared to high resolution maps of the 
globus pallidus.  
Table 8.3: Results of linear regression analysis of iron versus R2 or R2*. 
Table 8.4: Results of linear regression analysis of iron concentration and R2’.  
Table 8.5: Results of linear regression analysis of zinc and copper with R2 and R2* for 
segmented regions of control and AD tissue.  
Table 8.6: Results of multiple linear regression analysis of iron, copper and zinc with R2 and R2* 
for control and AD tissue.  




Chapter 9: Discussion 
Table 9.1: Summary of the best results from discriminant analysis of different measurements. 
Table 9.2: The mean predicted R2 of the caudate nucleus and anterior limb of the internal 




List of abbreviations  
AD Alzheimer’s Disease 
Amyg Amygdala 
Aβ Amyloid beta peptide 
CAR Ratio of the iron concentration in control tissue to AD tissue 
CN Caudate nucleus 
DLS Diamond Light Source  
emu Electromagnetic unit 
FDRI Field dependent R2 increase 
FID Free induction decay 
FLASH Fast low-angle shot 
FOV Field of view 
GFAAS Graphite furnace atomic absorption spectrometry 
GP Globus pallidus 
HD Huntington’s Disease 
ICP-MS Inductively coupled plasma mass spectrometry 
INAA Instrumental neuron activation analysis 
IRM Isothermal remanent magnetisation 
LA-ICP-MS Laser ablation inductively coupled plasma mass spectrometry 
MCI Mild cognitive impairment 
MGE Multiple gradient-echo 
MRI Magnetic resonance imaging  
MSA Multiple System Atrophy 
MSME Multi-slice mutli-echo 
NBIA Neurodegeneration with brain iron accumulation 
XXV 
 
NMV Net magnetisation vector 
NTF Neurofibrillary tangles 
Oe Oersted  
PD Parkinson’s Disease 
PIXE Particle induced X-ray emission 
Pu Putamen 
RF Radio frequency 
ROI Region of interest 
SN Substantia nigra 
SP Senile plaques 
SQUID Superconducting quantum interference device 
SXRF Synchrotron X-ray fluorescence 
T Tesla 
Te Echo time 
TR Repetition time 
XANES X-ray absorption near edge spectroscopy 







First of all I would like to thank my supervisor Joanna Collingwood, for all of her support and 
encouragement and for always pushing me to achieve more than I thought I could. I think that 
the last four years have been an adventure for both of us! Thanks also to my two second 
supervisors: Michael Chappell who gave advice on statistics and Jon Dobson who was always 
enthusiastic and encouraging. 
I would also really like to thank all of the excellent scientists with whom I have worked during 
this project. In particular: Naomi Visaji and Lili-Naz Hazrati who provided the samples for this 
project, and gave continual neuroanatomical advice; the past and present beamline scientists 
for beamline I18 at the Diamond Light Source: Fred Mosselmans, Tina Geraki and Paul Quinn, 
who helped with data collection and processing and generally made sure the experiments 
happened at all! At the University of Florida: JP Bullivant, Dan Plant, Vijay Antharam, Mark 
Davidson and Albina Mikhailova who gave me my first MRI and sectioning experience, before 
we had the facilities at Warwick. The Exley group at Keele University, in particular Emily House 
who carried out the GFAAS measurements. Also to Joe Gallagher who provided advice on 
histology.  
At The University of Warwick I would like to thank: Martin Davis who helped multiple times 
with practicalities in the lab; Martin Lees and his student Michael Smidman, who gave advice 
on SQUID measurements; everyone who helped me as an interloper with an MRI probe at the 
NMR facility, particularly John Hanna and Thomas Kemp; The Sadler group in the department 
of Chemistry, especially Isolda Romero who made the ICP-MS measurements happen and 
Kevin Ray, a summer project student who tested ImageJ protocols.  
Thanks to my parents, Helen Sang and David Finnegan, for all their support and 
encouragement - particularly for putting me up over the last four and a half months! I’d also 
like to wish good luck to my brother John who is just one year into his PhD. Thanks also go to 
XXVII 
 
my extended family on both the Finnegan and Sang side, in particular Dave and Jan Sang and 
my Grandmother, Elizabeth Finnegan. A special thank you should go to my proof readers: my 
parents and my lovely friends Lisa Campbell, Grace Huxford and Sophie Rees. Sophie deserves 
an extra mention for being a brilliant housemate and keeping me sane, even from holiday in 
Canada! 
I would like to thank all my friends from Warwick and further afield who have supported and 
encouraged me with words like “You can do it!” and “Keep going!”, which have made all the 
difference over the last few months in particular. A special mention to: Jenny Crane, Alex 
Sinclair, Becky Vanderkar, Sarah Cawley, Andrew Denty, Adam Wollman, Rachel Thwaites, Abi 
Jaitman, Nefeli Chatzstefani, Jen Dring, Claire Sewell, Jane Hand, Marcus Ong, Matt Jackson 
and David Doddington. I’d also like to mention members of Warwick Anti Sexism Society who 
really helped to make my time at Warwick special and provided my extra-curricular education: 
Kate Arnold, Joe Doherty-Bailey, Fi Grieg, Clare Stone, Anjeli Shah and Daniel Woodhouse. 
Synchrotron measurements were supported by the Diamond Light Source and the MRI work 
was supported by the Milburn House NMR suit at the University of Warwick. The Bruker micro-
imaging MicWB40 probe used in this research was obtained through the Science City 
Translational Medicine: Experimental Medicine Network of Excellence project and the SQUID 
magnetometer was bought through the Science City Advanced Materials: Creating and 
Characterising Next Generation Advanced Materials project. Both had support from Advantage 
West Midlands (AWM) and the SQUID magnetometer was part funded by the European 
Regional Development Fund (ERDF).      
A portion of this work was performed at the National High Magnetic Field Laboratory, which is 
supported by National Science Foundation Cooperative Agreement No. DMR-1157490, the 
State of Florida, and the U.S. Department of Energy. 
XXVIII 
 
This research was made possible by a PhD studentship grant from the Alzheimer’s Society. 
Thank you to the society and to the Research Network Volunteers: Jean Dutton, Sue Harris, 
Sue Boex and Chris West. I very much enjoyed meeting with them and have really appreciated 
their support.  
I must also thank Julian and Kim Piercey for their kind donation to fund the purchase of the 
cryomicrotome at which I have spent many hours. Also, thank you to the staff at DARO Capitals 
for finding support for my work. 
Finally, thank you to the Canadian Brain Tissue Bank for providing the samples used in this 
thesis and to all those who donated tissue used in this project. Also thank you to anyone who 




This thesis is submitted to the University of Warwick in support of my application for the 
degree of Doctor of Philosophy. It has been composed by myself and has not been submitted 
in any previous application for any degree to this, or any other university. 
The work presented (including data generated and data analysis) was carried out by the author 
except in the cases outlined below:  
 Initial preparation and measurement of the pons samples was carried out before this 
project began. The samples were prepared for SQUID magnetometry by Dr Joanna 
Collingwood, who also measured one sample from each disease (control, AD, PD and 
MSA) with MRI at the McKnight Brain Institute, University of Florida. Each of these 
samples were sectioned by Albina Mikhailova and the control and MSA example 
mapped at the Diamond Light Source by Dr Joanna Collingwood.  
 Graphite furnace atomic absorption spectroscopy (GFAAS) measurements of the pons 
and substantia nigra samples were carried out by Dr Emily House at Keele University. 
Parts of this thesis have been published by the author: 
Visanji NP, Collingwood JF, Finnegan ME, Tandon A, House E, Hazrati LN. (2013) 'Iron 
Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson's Disease 






It has been proposed that increased tissue iron concentration, which has been observed in 
certain regions of the brain in individuals with Alzheimer’s Disease (AD), could provide a 
marker for diagnosis through detection with MRI. This is investigated in this thesis using high 
field MRI to examine post mortem human brain tissue. It is shown here that by using data from 
multiple brain regions discriminant analysis can successfully differentiate between AD and 
control samples, even when no statistically significant differences are observed in individual 
brain regions.  
A unique set of complementary techniques was used to investigate iron content, R2 and R2* of 
tissue samples from the caudate nucleus, putamen, globus pallidus substantia nigra, amygdala 
and pons, from a set of three control and AD cases. The particulate iron content of the samples 
was investigated by SQUID magnetometry and was followed by iron quantification. A trend of 
increased particulate and total iron concentration was observed in the AD tissue compared to 
control, however this did not reach statistical significance in any brain region. High resolution 
MRI relaxometry at 9.4 T was carried out on tissue from the caudate nucleus, putamen, globus 
pallidus and substantia nigra using a custom design Bruker micro-imaging MicWB40 probe. As 
part of the work towards this PhD the probe was tested, and MRI relaxometry protocols 
optimised for high resolution (86 x 86 µm in plane, 150 µm slice thickness) mapping of tissue 
samples with high iron concentration. Again, no statistically significant differences were 
observed between AD and control tissue.  
However, discriminant analysis of these data (particulate or total iron or R2 or R2*) from 
multiple brain regions achieved differentiation between control and AD cases with 100% 
sensitivity and specificity for this small sample set. This demonstrates the potential clinical 
usefulness of MRI of measurements of non-haem brain iron to aid in disease diagnosis. 
Synchrotron X-ray fluorescence (SXRF) mapping of 30 µm thick sections, cut from the MRI 
samples, showed the relative concentration distribution of iron, copper and zinc in one AD and 
control sample from each brain region. Each metal was shown to have a distinct distribution. 
In particular, the inhomogeneity of iron concentration within individual brain regions, such as 
the putamen, was demonstrated. This may explain the wide variation in iron concentration 
reported in the literature for the same brain regions, and highlights the importance of close 
anatomical matching of samples when making comparisons. The ability of high resolution SXRF 
mapping to investigate the metal content within individual cells was demonstrated and used to 
show an increase in iron in individual AD neurons, in addition to the surrounding grey and 
white matter tissue. 
Spatially matched SXRF and MRI maps were used to demonstrate a strong, statistically 
significant linear relationship between tissue iron concentration and R2, R2* and R2’ at 9.4 T. 
The gradient of the linear relationship between iron and R2, agrees extremely well with the 
predicted gradient at this field, where the prediction was made by Vymazal et al. (1996) using 
MRI relaxometry at 0.05 to 1.5 T. To the best of my knowledge, this is the first time that this 
relationship has been quantified at 9.4 T, or at any field above 7 T.  
MRI at 14.1 T was carried out on low iron concentration regions (the pons and amygdala). 
Matched SXRF and R2* maps did not show a strong linear relationship between iron and R2*. 
The iron concentration in these regions is less than 50 µg/g  and it was concluded that in tissue 
with low iron content, other tissue properties - such as water content - are dominating the 
value of R2*. This result was replicated with data measured at 9.4 T, when only tissue with an 




The following publications have arisen from work related to this thesis: 
Visanji NP, Collingwood JF, Finnegan ME, Tandon A, House E, Hazrati LN. (2013) 'Iron 
Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in Parkinson's Disease 
and Multiple System Atrophy'. J Parkinsons Dis. 2013 PMID: 24113558 
Antharam V, Collingwood JF, Bullivant JP, Davidson MR, Chandra S, Mikhaylova A, 
Finnegan ME, Batich C, Forder JR, Dobson J (2012). High field magnetic resonance 
microscopy of the human hippocampus in Alzheimer's disease: Quantitative imaging 
and correlation with iron. Neuroimage 59(2): 1249-1260. 
Gallagher JJ, Finnegan ME, Grehan B, Dobson J, Collingwood JF, Lynch MA (2012). 
‘Modest Amyloid Deposition is Associated with Iron Dysregulation, Microglial 
Activation, and Oxidative Stress.’ Journal of Alzheimers Disease 28(1): 147-161. 
Ugarte M, Grime GW, Lord G, Geraki K, Collingwood JF, Finnegan ME, Farnfield H, 
Merchant M, Bailey MJ, Ward NI, Foster PJ, Bishop PN, Osborne NN (2012). 
‘Concentration of various trace elements in the rat retina and their distribution in 





The following posters, presented at international conferences, have included work related to 
this thesis: 
At the 10th International Conference on Alzheimer's & Parkinson's Diseases (March 2011, 
Barcelona): 
M. Finnegan, J.F. Collingwood, N Visanji, E. House, M. R. Lees, V. Antharam, A. 
Mikhailova, J. Dobson, L.-N. Hazrati (2011) Determining the source of elevated iron 
concentrations: The human pons in neurodegenerative disorders, published in 
‘Neurodegenerative Diseases’, ISBN 978-3-8055-9738-8  
At the 15th International Congress of Parkinson’s Disease and Movement Disorders (June 
2011, Toronto): 
 Visanji NP, Collingwood JF, Finnegan M, House E, Tandon A, Hazrati LN (2011). 
‘Disregulation of iron storage in multiple system atrophy.’ Movement Disorders 26: 
S30-S30. 
The 11th International Conference on Alzheimer's & Parkinson's Diseases (March 2013, 
Florence): 
Mary E. Finnegan, Naomi Visanji, Emily House, Vijay Antharam, John-Paul Bullivant, 
Martin R. Lees, Albina Mikhailova, Jon Dobson, Lili-Naz Hazrati, Joanna F. Collingwood 
(2013) Tissue iron accumulation in Alzheimer’s disease parallels increased grey/white 
matter contrast in MRI of the human pons 
The 5th meeting of the International Bioiron Society (April 2013, London): 
Joanna Collingwood, Mary E. Finnegan, Naomi P. Visanji, Emily House, Lili−Naz Hazrati, 
Vijay Antharam, John−Paul Bullivant, Lees MR, Mikhailova A, Batich C, Davidson MR, 
Dobson J (2013) Brain iron and MRI in Alzheimer's Disease, Parkinson's Disease, and 
Multiple System Atrophy 
Chapter 1:  
Introduction and Background 
1.1 Introduction 
1.1.1 Motivation 
Alzheimer’s disease (AD) is a very common neurodegenerative disease, which affects almost 
half a million people in the UK [1]. The global and national cost of dementia is huge. The 
estimated total cost for informal (family), social and medical care was reported as $604 billion 
in the World Alzheimer Report 2010 - The Global Economic Impact of Dementia [2]. 
Only a small proportion of AD cases have been identified as autosomal dominant and these 
cases are known as familial Alzheimer’s disease (FAD) [3]. The vast majority of cases are 
sporadic AD for which the aetiology is unclear. Determining the pathogenesis of AD is a major 
area of interest in AD research with conflicting opinions on whether the disease is triggered by 
the accumulation of amyloid [4] or whether this is in response to another initial cause of 
oxidative stress [5, 6], such as the accumulation of iron [7, 8] or breakdown of myelin [9, 10]. 
Currently there is no proven diagnosis of the disease until post mortem when the underlying 
disease pathology can be examined and during life only a diagnosis of probable AD can be 
made based on the assessment of clinical symptoms [11, 12]. Although AD is the most 
common cause of dementia, there are a number of different neurodegenerative diseases 
which present with similar symptoms, such as vascular dementia and dementia with Lewy 
bodies. Current diagnosis criteria are based on the reported progression of disease symptoms 
by the patient and their carers and the cognitive assessment by tests, such as the mini metal 
state examination [11].  
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A more definitive test, or series of tests, which enable a sensitive and specific diagnosis of AD 
is highly desirable. Recent developments in PET (positron emission tomography) imaging of 
amyloid deposition, volumetric MRI (magnetic resonance imaging) of brain atrophy and 
measurement of amyloid in the cerebral spinal fluid have led to proposals for potential new AD 
diagnosis criteria [13, 14]. 
MRI is a particularly attractive option as it is non-invasive and does not involve exposure to 
ionising radiation. However, volumetric changes in the AD brain due to atrophy have shown 
significant overlap with atrophy in normal aging [15] and rely on a change that has occurred 
due to cell death.  
Increased iron concentration has been observed in particular regions of the AD brain [16-22] 
and a number of other neurodegenerative diseases [23]. Tissue iron concentration shows a 
positive linear correlation with MRI transverse relaxation rate (R2) and the susceptibility 
related relaxation (R2*). Therefore it may be possible for the iron changes observed in AD to be 
detected by quantitative MRI mapping (MRI relaxometry) and iron disregulation has been 
suggested as a possible marker for Alzhiemer’s Disease via its effect on MRI [24]. 
The effect of iron on MRI is field dependent and increases linearly with field, therefore high 
field MRI provides a more sensitive investigative tool. However, it has been suggested that the 
effect will saturate at higher fields [25]. The linear relationship of the field dependence has 
been shown at fields of up to 4.7 T [26] and 7 T [27] respectively. However, this area warrants 
further investigation as the relationship at fields above 7 T is under-studied.  
Additionally, the number of studies which have investigated the relationship between iron 
concentration and R2 and R2* using post mortem tissue is small. These studies are important as 
they allow direct comparison of MRI, followed by tissue iron quantification, rather than relying 




The aim of this thesis is to investigate whether iron changes in Alzheimer’s disease could aid 
diagnosis via the measurable effect it has on the MRI relaxation rate R2 and the susceptibility 
related R2*. This question will be addressed by measuring iron content and carrying out high 
field MRI relaxometry on a set of control and AD human post mortem tissue samples from 
multiple regions of the brain. Three questions will be investigated: i) are there changes to the 
iron content of the samples which can be used to differentiate between disease and control? 
ii) are corresponding changes observed in MRI relaxometry measurements which also allow 
differentiation between AD and control? iii) what is the relationship between tissue iron 
content at high field (9.4 T and 14.1 T) and is this the same for control and AD tissue? 
The measurements made in this project contribute to further understanding the nature of the 
changes to iron (and copper and zinc) in AD, however the main focus of the project is to 
examine the potential role of iron in AD diagnosis.  
1.1.3 Thesis structure 
A brief background to Alzheimer’s disease and its diagnosis is given in Section 1.2 as well as an 
introduction to non-haem brain iron and its measurement by MRI. This is followed by a 
detailed review of the literature showing comparative studies of iron content in control and AD 
tissue in Section 1.3 and summarised in Figure 1.3. In Chapter 2: Theory, the magnetic 
properties of tissue iron and its interaction with MRI are described in addition to introducing 
synchrotron X-ray fluorescence (SXRF), which will be used to map iron distribution in tissue 
samples. 
The literature review demonstrates that there is evidence of increased iron concentration and 
a change in the form of iron in certain regions of the brain. However, a wide variety of 
measurement techniques have been used in these previous studies, and there are conflicting 
results from the different studies. Due to the conflicting results it is hypothesised that a 
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multiregional approach may be necessary to differentiate between control and AD tissues. 
Therefore six regions of the brain are investigated: the caudate nucleus, putamen, globus 
pallidus, substantia nigra, amygdala and pons. The rationale behind the choice of regions and 
the preparation of the samples for each measurement technique is detailed in Chapter 3: 
Samples.  
Three Parkinson’s Disease (PD) and Multiple System Atrophy (MSA) cases are also examined 
from a subset of the regions, in order to begin to investigate how AD may be differentiated 
from other neurodegenerative diseases as well as from normal aging. Some of the data from 
these regions form part of a collaborative study with the University of Toronto and are 
included in the paper Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in 
Parkinson's Disease and Multiple System Atrophy by Visanji et al. [28], attached in Appendix H. 
A unique set of complementary measurement techniques was used to examine the form, 
concentration and distribution of iron in the samples set. The methodology used, including 
newly developed and improved laboratory protocols, is described in Chapter 4. This included 
testing and setting up MRI protocols with the new custom design Bruker micro-imaging 
MicWB40 probe funded through the Birmingham Science City Translational Medicine project. 
The probe was purchased in early 2010 and became the first MRI probe in the Milburn House 
NMR suit at the University of Warwick. This work and the final MRI relaxometry protocols are 
described in Section 4.3.1.3.   
Additionally, a histochemical staining protocol was developed to stain tissue sections which 
had been mapped with SXRF. This was challenging due to the fragile nature of the tissue, 
which had been exposed to high intensity X-rays, but important to enable identification of 




In Chapter 5: Bulk tissue iron analysis the particulate and iron content of tissue samples is 
investigated. This provides information about the quantity and form of iron in the samples. In 
Chapter 6 SXRF mapping is used to produce high resolution, high sensitivity maps of the iron, 
copper and zinc distribution in a control and AD example from each brain region. The results of 
high resolution MRI mapping are presented in Chapter 7, with some brain regions mapped at 
14.1 T, and the majority mapped at 9.4 T. T1 data were also collected for each sample, 
however these were not analysed due to time constraints. The analysis of T2 and T2* data was 
prioritised due to their higher sensitivity to iron concentration. In each of these chapters a 
comparison is made between the control and AD samples and discriminant analysis is used to 
combine data from multiple brains to predict the disease state of each sample. 
Finally, in Chapter 8 the relationship between iron and MRI is examined by comparing the iron 
measurements (Chapters 5 and 6) with the results of MRI relaxometry (Chapter 7). In 
particular, matching of high resolution SXRF iron maps with MRI maps is used to test the linear 





1.2.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 62 % of 
dementia and affecting almost half a million people in the UK alone [1]. Worldwide the 
number of people living with dementia is set to rise from 35.6 million people in 2010 to 65.7 
million people in 2030 [2], mainly due to the aging population. The rate of dementia increases 
with age: for people aged 65-69 years the rate is 1 in 100, whereas for those over 80 the rate is 
1 in 6 [29]. 
Memory impairment is usually the first symptom of AD followed by degeneration of 
communication, learning, movement and changes to personality such as increased irritability 
and depression. As the disease progresses patients become less able to perform the basic tasks 
of daily life and rely more on care from the state and family. The nature of the memory loss 
and altered personality with progressing AD is often very distressing not only for the patient, 
but has been shown to increase the rate of depression in carers [30]. 
1.2.1.1 Disease pathology 
The development of AD pathology is thought to begin up to decades before presentation of 
the first clinical symptoms. Individuals who show some AD pathology, but no clinical symptoms 
can be termed as having pre-symptomatic AD. However, when this assessment is made of post 
mortem tissue this categorisation assumes that they would have developed symptoms if they 
had lived long enough, which cannot be proven. The second phase in the disease is Mild 
Cognitive Impairment (MCI) which is shown by individuals who also display cognitive 
symptoms, such as some memory loss, but who do not meet the criteria for dementia. Again 
these individuals may die before developing dementia [4].  
At a cellular level AD pathology is characterised by the presence of senile plaques (SPs) and 
neurofibrillary tangles (NFTs). The main constituent of SPs is the peptide beta amyloid (Aβ) 
7 
 
[31]. Aβ is one product of the amyloid precursor protein (APP) and is deposited extracellularly.  
Senile plaques can range in size from 2 – 500 µm and can be diffuse or neuritic and contain 
neuropeptides, ubiquitin, APP and a number of other enzymes in addition to Aβ. SPs are 
visualised in pathology sections using histochemical stains such as Congo red or antibodies that 
bind to Aβ.  
NFTs are bundles of filaments that form in neuronal bodies and are made from tau protein. 
Tau is an abnormally phosphorylated component of paired helical filaments [32].  NFTs 
correlate more strongly with dementia than SPs and their numbers increase throughout the 
disease [33]. Loss of grey matter throughout the progression of AD has been shown to follow 
the accumulation of NFTs [34]. 
Non-haem brain iron is altered from the norm in many neuropathological diseases [35]. It is 
thought to contribute to oxidative stress and neuronal degeneration in AD through the 
production of hydroxyl radicals [5, 36]. Redox-active iron has been shown to be associated 
with senile plaques and NFTs in vivo [37] and with Aβ in vitro [38].  Changes in the 
concentration, form and distribution of iron in AD are discussed in depth in the literature 
review in Section 1.3. 
There is also evidence for changes in concentration of other metals, such as copper and zinc, in 
the AD brain. For example, Deibel et al. measured a statistically significant increase in iron and 
zinc and a decrease in copper in the hippocampus and amygdala of the AD brain [39]. A 
number of other studies have also found a decrease in the concentration of copper in AD [40], 
although copper has also been associated with senile plaques [41].  
Cell death in AD causes a physical shrinking of the brain. General atrophy of the cerebral 
hemispheres [42] is observed in AD as well as specifically in the hippocampus [43] and 
amygdala [15]. Atrophy is observed to some extent in the normal aging brain and AD atrophy 
overlaps with the normal range [42].  
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1.2.1.2 AD pathogenesis 
The amyloid cascade hypothesis is that Aβ accumulation and subsequent deposition into SPs is 
the first stage in AD pathology which is followed by a series of events leading to neuronal cell 
death and onset of dementia. Evidence in support of this hypothesis includes the presence of 
genetic mutations that increase the processing of APP into Aβ in FAD [44]. There is also 
evidence for NFT formation later in disease progression, after initial amyloid plaque deposition 
[45]. However, there are also findings which refute the amyloid cascade hypothesis. This 
includes the fact that the degree of amyloid deposition does not correlate well with disease 
severity [45] and some normal aging patients show SPs in autopsy tissue. Additionally clinical 
trials of drugs targeting Aβ have proved inconclusive [46]. 
Oxidative stress has been proposed as an alternative mechanism of AD pathogenesis, with 
increased production of APP and tau in response to the initial redox imbalance [6, 44]. 
Disregulation or disrupted homeostasis of non-haem brain iron is one possible [7, 8, 36] cause 
of oxidative stress. 
1.2.2 Diagnosis of AD 
Currently there is no proven diagnosis of AD until post mortem tissue can be examined and the 
pathology of AD identified. This is a major problem as AD is only one of a number of dementias 
including: vascular dementia, dementia with Lewy bodies and frontotemporal dementia [33]. 
These all have differing underlying disease pathology, but often similar or overlapping 
symptoms. For clinicians it is important to have a confident diagnosis for a patient in order to 
administer the right treatment and in drug trials it is vital to be able to have a cohort of 
subjects with the underlying disease the drug is targeting. Therefore there is huge interest in 
finding a biomarker of Alzheimer’s disease that can be measured pre mortem and ideally 
before significant disease pathology develops. 
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The traditional route to AD diagnosis (the NINCDS-ADRDA criteria for clinical diagnosis of AD) 
and some of potential biomarkers that are being investigated are described below.  
1.2.2.1 The NINCDS-ADRDA criteria for clinical diagnosis of AD 
Before a probable diagnosis of AD is given, a patient must first be diagnosed with dementia. 
This diagnosis is often considered after they present with symptoms such as short-term 
memory loss, inability to remember names of people or objects, depression, problems with 
dressing or eating. Tests such as the Cambridge Examination for Mental Disorders of the 
Elderly (CAMDEX) can be used to gain a clinical diagnosis of dementia [11]. Scaled tests for 
dementia such as the mini-mental state examination or the Blessed scale are often used on the 
road to a diagnosis of AD and can be repeated over time to assess symptomatic progression. 
The combination of symptoms and the manner in which they present can be indicative of the 
underlying cause of dementia, for example vascular dementia often has a more rapid onset 
than AD [47]. 
The NINCDS-ADRDA criteria for clinical diagnosis of AD is widely used. It provides criteria for 
possible and probable AD based on clinical examination of dementia and the assessment of 
symptoms, but requires additional histopathological evidence for a diagnosis of definite AD 
[12].  
1.2.2.2 Developments in AD diagnosis 
The International Working Group for New Research Criteria [13, 48] for the Diagnosis of AD 
and National Institute on Aging–Alzheimer’s Association (NIA-AA) [14] have proposed revised 
criteria for the diagnosis of AD. The proposals consider the use of in vivo biological markers of 
AD pathology in addition to the clinical symptoms as outlined above. 
The markers can be divided into two groups. The first being pathophysiological markers which 
are directly linked to the pathology of AD. Samples of the cerebral spinal fluid (CSF) can be 
taken and the reduced concentration of Aβ, and increased tau and phospho-tau have been 
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shown to be associated with AD [49]. Additionally Positron Emission Tomography (PET), with a 
tracer that binds to amyloid, has been used to predict the development of AD in healthy adults 
[50]. The second category is topographical markers which covers measurement of atrophy as 
measured by structural MRI (see next section) and reduced glucose metabolism which can be 
observed using fluorodeoxyglucose PET [51]. 
Although studies using the markers described above have shown promising results, the general 
consensus is that they are not yet ready to be used clinically [52, 53]. In particular the difficulty 
in standardising the assessment of these markers is highlighted [14].  
Another hurdle is determining the order and rate of progression of AD pathology and 
monitoring this through measurement of biomarkers [4]. This would not only enable improved 
diagnosis of AD, but also identify the stage of the disease.  Understanding the state of the 
underlying disease pathology is particularly important when considering clinical trials of 
disease-modifying treatments.  
There is still plenty of room for further investigation of potential biomarkers to improve 
diagnosis and monitoring of AD. 
1.2.2.3 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a commonly used clinical imaging technique. Structural 
MRI is used to image soft tissue, such as the brain, and aid diagnosis of tumours, internal 
bleeding and more. MRI (without the use of tracers) has an advantage over some of the other 
biomarker detection methods, as unlike CSF measurement it is non-invasive and does not 
involve the exposure to the ionising radiation that PET does. 
MRI and the different relaxation processes are described in more detail in Chapter 2 along with 
details of how relaxation rates can be measured and how tissue iron content affects their 
value. At a basic level MRI works by imputing a pulse of energy into the hydrogen nuclei of the 
tissue. This energy then dissipates at different rates (relaxation rates) depending on the 
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composition of the tissue: it is this difference in relaxation rate that provides image contrast. 
Clinical MRI does not usually measure the relaxation rates in the tissue, it merely takes a 
snapshot of the energy distribution sometime shortly after the energy pulse. However, it is 
possible to use clinical scanners to quantitatively map the relaxation rates of tissue which is 
called MRI relaxometry. 
There are two different mechanisms of MR relaxation: i) the longitudinal relaxation which is 
described by a time T1 and a rate of R1=1/T1 and ii) the transverse relaxation which is described 
by T2 and has a rate of R2=1/T2. Transverse relaxation is readily affected by MRI field 
inhomogeneities and therefore MRI scans usually correct for this. When these effects are not 
corrected for, the relaxation time is T2* which is always shorter than T2. 
Structural MRI has been used to observe the atrophy of the brain during ageing and with 
neurodegenerative diseases [42, 43, 54] and has had mixed success in separating AD and 
normal ageing brains. For example, Laakso et al. demonstrated statistically significant atrophy 
in the AD amygdala compared to control. However, there was a significant overlap between 
the size of the amygdala in AD and normal aging individuals, reducing the clinical usefulness of 
this measurement [15]. A major disadvantage of measuring brain atrophy to diagnose AD is 
that by the time atrophy is measurable, significant cell death will have occurred. However, in a 
study of subjects with familial AD, atrophy was shown to begin before symptomatic onset [55].  
More recently, MRI mapping has been considered as a technique to examine the changing 
properties of the brain on a cellular level [26, 56]. There are many factors which can contribute 
to changes in transverse relaxation time T2 and longitudinal relaxation time T1 in the ageing 
and demented brain. For example, demyelination of the frontal lobe white matter in AD [56, 
57], water concentration [19] and the form and concentration of non-haem brain iron. The 
linear relationship between T2 shortening and iron concentration has been demonstrated in 
the human liver [58] and in post mortem human AD brain tissue [26]. 
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MRI has also been used to directly examine AD pathology, with the imaging of SPs achieved in 
histological sections of post mortem human tissue [59, 60] and in vivo in mouse models of AD 
[61]. 
1.2.2.4 Iron as a potential marker in MRI 
Non-haem brain iron homeostasis is altered in AD and this has been considered a possible 
biomarker for AD diagnosis. However, in order to achieve this, the concentration, form and 
clustering of iron in the normal and AD brain must be understood and suitably sensitive and 
specific detection methods developed.   
Tissue iron concentration plays a major role in determining the contrast in MRI (see Section 2.2 
for more details) and therefore it is possible that iron changes in AD and other 
neurodegenerative diseases could be observed with MRI and thus aid diagnosis. An extreme 
example of this is seen in the disease Neurodegeneration with Brain Iron Accumulation (NBIA, 
formerly known as Hallervorden-Spatz disease) where accumulation of iron causes an ‘eye-of-
the-tiger’ pattern in the region of the globus pallidus [62] (see Figure 1.1).   
 
Figure 1.1: The ‘eye of the tiger’ pattern observed in a T2-weighted MRI of a patient with 
neurodegeneration with brain iron accumulation (NBIA). In a) the coronal and b) the axial view there is a 
hypo-intense region in the vicinity of the globus pallidus, which produces an eye-of-the-tiger pattern 





The iron changes observed in AD are much more subtle than in NBIA and therefore more 
sensitive MRI techniques must be utilised. These are discussed in more detail later in the 
chapter.  
1.2.3 Non-haem brain iron 
Non-haem iron refers to iron that is not bound in haemoglobin (and some other enzymes). 
Iron is the most abundant metal in the in the body and is involved in a very large number of 
cell functions including myelination and synthesis of neurotransmitters [63, 64]. Therefore the 
body has a sophisticated iron regulatory system involving a number of storage and transport 
proteins. Genetic mutations which affect these proteins have been demonstrated in some 
neurodegenerative diseases, for example neuroferritinopathy [65] and acaeruloplasminemia 
[66]. There is also evidence for disruption of iron homeostasis in AD and Parkinson’s disease 
(PD), but the underlying cause of this is currently unknown [67]. 
The regulation and function of trace metals in the brain are interdependent. For example, 
caeruloplasmin is a multi-copper oxidase which oxidizes Fe2+ to Fe3+ and is the major plasma 
anti-oxidant. It has been shown to be decreased in the PD substantia nigra where there is 
increased iron [68]. Conversely, caeruloplasmin has been shown to be increased in other 
regions of the PD and AD brain [69]. 
1.2.3.1 Forms of non-haem iron in the brain 
Iron can be present in the brain as ferric (Fe3+) or ferrous (Fe2+) ions. Ferric iron is relatively 
unreactive, whereas ferrous iron is very redox active. It is this ability to switch between redox 
states that makes iron such a useful element in the body. However, ferrous iron can react with 
hydrogen peroxide and produce hydroxyl radicals (∙OH) by the Fenton reaction [70, 71]:  
            
             (1.1) 
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The hydroxyl radicals are highly reactive and cause cellular damage. It has been hypothesised 
that iron could play a major role in cell death in AD and other neurodegenerative diseases 
through the oxidative stress caused by free radical production [72, 73]. 
1.2.3.1.1 Ferritin  
The majority of non-haem iron in the brain (up to 90% [74]) is found in a storage protein called 
ferritin. Ferritin consists of a 12 nm outer diameter protein shell which sequesters iron in a 
mineral core of up to about 8 nm in diameter [75] (Figure 1.2). This iron is often referred to as 
‘ferritin iron’ or just ‘ferritin’ and is in the non-toxic ferric form. 
 
Figure 1.2: A simplified diagram of ferritin. The spherical protein shell has a 12 nm outer 
diameter and an 8 nm inner diameter. Iron is sequestered inside the protein to form a 




Ferritin cores are typically a single nanocrystal with a ferrihydrite-like structure, which has the 
approximate chemical formula 5Fe2O3 9(H2O). However, other phases such as hematite and 
magnetite are also observed within the nanocrystal [76, 77].  
The controlled mineralisation of iron occurs in such a way as to minimise the Fenton chemistry 
[76]. The size of the cores is controlled by ferritin and the soluble protein shell ensures that no 
insoluble aggregates are deposited.  
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Up to 4500 iron atoms can be stored in the core of one ferritin protein and the number of iron 
atoms in the core is known as the loading factor. Dedman et al. reported an average of around 
1500 iron atoms per ferritin in the cerebral cortex of healthy controls with no statistically 
significant difference in AD [21].  
Ferritin is found throughout the human body and across the animal kingdom. It is both an iron 
store and an iron reserve. The substructure protein shell varies based on the iron requirements 
of the tissue [70]. 
1.2.3.1.2 Haemosiderin 
Haemosiderin is another form of stored non-haem iron in the brain. It is thought to be a 
degradation product of ferritin [75] and has a less easily characterised structure, although 
studies have shown a ferritin-like core [76]. Additional iron phases have also been identified in 
haemosiderin (and in some pathological ferritin), such as magnetite, goethite and wustite [76-
78], but examination of these phases is beyond the scope of this PhD. 
Haemosiderin is associated with an excess of iron [70]. The iron in its core may be more easily 
released than in ferritin [78], but it has also been suggested that haemosiderin may play a 
protective role where there is an overload of iron [79]. 
1.2.3.1.3 Transferrin 
Transferrin is the most prolific iron transport protein and its concentration has been shown to 
be altered in AD. Conner et al. found decreased transferrin throughout the AD brain [22] in 
contrast to increased ferritin and iron in some regions.  
1.2.3.1.4 Magnetic iron oxides 
Magnetite has a ferrimagnetic structure and the chemical formula Fe3O4. It is present in many 
organisms and in 1992 was identified in the human brain using magnetometry by Kirschvink et 
al. [80]. It has since been extracted from tissue and identified using TEM and electron 
diffraction [81] and in situ in autopsy tissue by X-ray spectroscopy [82].  
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As magnetite has been associated particularly with brain regions with a high iron content, such 
as the hippocampus [81], there is interest in its role and prevalence in neurodegenerative 
diseases. A small study of neuroferritinopathy (an iron overload disorder) patients indicated an 
increase in magnetite concentration [83]. In men, but not women, an increase in magnetite 
concentration with age has been observed [84], which is interesting in light of the fact that 
men have an increased risk of developing AD at a younger age. 
1.2.3.1.5 Neuromelanin  
Non-haem brain iron is also found in the neurons of the substantia nigra and locus coeruleus 
as part of the complex molecule neuromelanin. Iron in neuromelanin (NM) is also in the Fe3+ 
state and makes up 10-20% of iron total in the SN [85] (with the majority of the remainder in 
ferritin in glial cells). 
NM has been shown to have similar properties to ferritin [86]. A study of substantia nigra 
tissue from control and PD cases showed only ferritin-like iron [87]. However, unlike ferritin 
NM contains different magnetic domains which vary in size [88]. 
1.2.3.2 Iron in fixed and frozen tissue 
Fixed tissues have been used in some imaging and iron quantification studies [89, 90]. Fixed 
tissues are easier to work with than fresh-frozen tissue as they remain stable over long periods 
of time at room temperature. However, the process of fixing tissue in formalin has been shown 
to leach metals, including iron, from the tissue into the fixing solution. The degree of leaching 
depends on the duration of storage of the tissue in the solution and also on the element [91]. 
Furthermore, metals that are known to be strongly bound to proteins, such as gold, do not 
leach into formalin as much as other elements. This suggests that the degree of leaching 
depends on how the metal is bound within the tissue [91].  
Additionally, a study of iron in the SN in control and PD tissue showed the presence of non-
ferritin iron in formalin-fixed tissue only [87], suggesting that the formalin had altered the form 
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of iron in the tissue. Furthermore reduced Perls’ staining intensity has been associated with 
exposure to fixatives [92].  
1.2.3.3 Iron concentration and age 
In 1958 Hallgren and Sourander reported a study of iron concentration from 11 regions 
(frontal white matter, globus pallidus, cerebellar cortex, prefrontal cortex, temporal cortex, 
sensory cortex, parietal cortex, occipital cortex, motor cortex, caudate nucleus and putamen) 
of 81 brains. They plotted iron concentration in the brain with age from 0 to 100 years [93] and 
produced a set of empirical exponential equations for iron with age in each of the 11 regions. 
In general iron was shown to increase at an approximately linear rate in each region until the 
age of around 20 to 30 years, after which iron concentration begins to plateau.  
More recently Bartzokis et al. [94] calculated ferritin iron concentration in the brain and 
showed a linear increase of iron with age in the hippocampus, putamen, caudate nucleus and 
globus pallidus, but a linear reduction of iron in the frontal lobe white matter. The iron 
concentration was also compared between male and female patients and women were found 
to have a lower iron concentration than men in multiple grey and white matter brain regions. 
This is significant as men have a high risk of developing AD at an earlier age than women.  
Loeffler et al. [18] reported iron concentration in the caudate nucleus, putamen, globus 
pallidus, substantia nigra and frontal cortex for young (n=8; average age = 45.4 ± 13.8 years) 
and aged (n=8; average age = 74.6 ± 7.6) controls. No comparisons reached statistical 
significance, but the trend was that iron was increased in the elderly controls. The exception to 
this being the globus pallidus which showed reduced iron concentration.  
Laakso et al. [15] also showed an increase in iron concentration with age. The spread of data in 
both this and the above paper is fairly large, meaning that any attempt to estimate the iron 
concentration of a sample based on age has a wide margin of error. 
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1.2.4 Measuring iron in the brain 
Since Goodman first reported positive staining for iron in AD cerebral cortex tissue in 1953 
[95], various measurement techniques have been used to examine the changes in iron in AD 
and other neurodegenerative diseases. Each technique examines different properties of the 
tissue iron. Some measure total iron quantification from dissected tissue samples, others give 
a spatial distribution of iron within a section of tissue and some can provide information about 
the form of iron in the tissue. A selection of some iron analysis techniques which have been 
used to examine iron in the brain are described below.  
1.2.4.1 Histology 
Intensity and distribution of Perls’ stain has been used to compare control and AD tissue. 
Increased staining in AD tissue has been reported as well as positive staining in cells associated 
with senile plaques [96, 97]. Multiple slices can be stained and imaged to build a 3D image of 
iron distribution in an area of brain [98].  
Perls’ stain is a histochemical stain for non-haem iron based on the ferrocyanide-Prussian blue 
reaction. The Prussian blue colour is produced when ferric ions, which are released from the 
sample using a hydrochloric acid solution, react with potassium ferrocyanide [99]. Therefore 
this is a stain for ferric iron. Modifications to the Perls’ staining technique have increased 
staining intensity and enable staining of less ‘accessible’ iron, in particular in white matter 
[100].  
Although staining provides information about iron distribution with high spatial resolution it 
has a number of disadvantages when considering its use for concentration comparison, 
including the fact that it can only stain ferric iron. This was demonstrated in the first published 
work quantifying iron in AD brain tissue: in 1960 Hallgren and Sourander positively stained for 
iron in the frontal temporal cortex of AD tissue, but not of control. However, when the total 
iron was measured no significant increase was observed in AD compared to control [97]. 
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Despite the fact that Perls’ staining cannot provide a good estimate of total iron concentration 
or show a true distribution of all tissue iron, changes in staining pattern do indicate a change in 
the form of iron in the tissue and therefore altered iron homeostasis.  
Morris et al. showed that exposure of tissue sections to common fixatives reduced the 
intensity of Perls’ staining [92]. This could be due to fixatives leaching iron from the tissue or 
reducing the concentration of stainable ferric iron. Any comparative study must use very 
consistent protocols.  
Relevant literature reports that oligodendrocytes are the cell which most strongly stains 
positively for iron, with occasional staining in astrocytes and microglia [101, 102]. Neurons do 
not generally stain strongly with Perls’ despite the fact that other measurement techniques 
have shown that they do contain iron. 
Immunochemistry and immunofluorescence are used to stain for iron-associated proteins such 
as ferritin and transferrin [40, 103].  
1.2.4.2 Iron quantification in bulk tissue samples 
The iron concentration of dissected tissue can be measured using a number of different 
techniques. Ion Coupled Plasma Mass Spectrometry (ICP-MS) [23, 104] and Atomic Absorption 
Spectroscopy (AAS) [105, 106] both require tissue digestion in acid before iron quantification. 
Instrumental Neutron Activation Analysis (INAA) has also been used to quantify brain iron 
content [17, 39]. Brain tissue is dissected and freeze dried before irradiation with neutrons and 
analysis of iron content based on nuclear decays. 
Hallgren and Sourander used colorimetry by the orthophenalthroline method to determine 
iron concentration in their 1958 landmark study The effect of age on the non-haemin iron in 
the human brain [93]. Hydrochloric acid is used to extract iron from tissue homogenate, which 
is reacted with orthophenalthroline to produce a dark red colour. A spectrophotometer is then 
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used to measure the absorption of the solution from which the iron concentration can be 
calculated using Beer’s Law. 
All of the iron quantification methods mentioned above can be carried out on specific regions 
of the brain when they are dissected from the surrounding tissue. High resolution spatial 
information about the distribution of iron in the tissue is not obtained and total iron is 
measured with no information about the form of iron. Blood vessels need to be removed from 
dissected samples to give a measurement of non-haem iron only.  
The result of bulk tissue analysis is also dependent on how precisely a particular brain region is 
dissected. This may be a source of experimental error which contributes to the spread in 
reported iron concentration for the same brain regions, which can be seen in the data collated 
by Haacke et al. [107]. 
1.2.4.3 Magnetometry 
The magnetic properties of iron are determined by its form and therefore the hypothesis that 
there are changes in the form of non-haem iron in AD can be tested using Superconducting 
QUantum Interference Device magnetometry (SQUID). SQUID magnetomety of freeze dried 
brain tissue samples has been used to examine the magnetic properties of brain iron [108, 
109] and has shown an increase in magnetite or maghemite in AD tissue when compared to 
control [110]. 
Magnetite has a greater effect on local field inhomogeneities than ferritin and it is therefore 
useful to consider the magnetic properties of the tissue samples when trying to identify 
regions which may provide useful targets for MRI identification of AD.  
1.2.4.4 Synchrotron X-ray analysis 
Synchrotron X-ray fluorescent mapping of biological tissues can be used to produce highly 
sensitive and specific maps of iron (and other metals) concentration, and relative distribution, 
at high resolution [82, 111].   
21 
 
As SXRF mapping is a non-destructive technique, the tissue sections can be mapped at multiple 
resolutions. Gallagher et al. (in collaboration with our group) mapped a large area of tissue 
from a mouse model of AD at 60 µm resolution and then selected areas which showed high 
iron concentration for further high resolution mapping at 5 µm [112]. Tissue can also be 
stained post mapping in order examine the cell distribution and disease pathology.  
Popescue et al. have developed rapid scanning SXRF to a speed which allows large areas of the 
brain to be mapped in short periods of time. For example, they mapped the basal ganglia [89] 
in less than one hour. This technique uses thick fixed tissues of around 1 cm which is 
problematic because the full depth of the tissue is not penetrated equally by the X-rays and 
the escape/penetration thickness is different for the different metals being compared. 
Consequently the depth resolution is different for the different elements. Also fixatives have 
been shown to leach metals from tissues and therefore the results may not accurately 
represent the concentration of metals in vivo. 
X-ray Absorption Near Edge Spectroscopy (XANES) using synchrotron radiation has been used 
to investigate the form of iron present by collecting absorption spectra from regions of interest 
first identified using SXRF mapping [111-113].  
1.2.4.5 Other 
Electron and X-ray analysis techniques such as Particle Induced X-Ray Emission (PIXE) [114] and 
Energy Dispersive X-ray (EDX) spectroscopy [115] have been used to examine iron in and 
around senile plaques. Transmission electron microscopy (TEM) can be used to examine the 
crystalline structure of ferritin cores [77, 80, 116], and together with electron energy-loss 
spectroscopy (EELS) and electron tomography has been used to characterise the iron content 
of AD plaques [115]. However, these techniques have a number of disadvantages compared to 
SXRF. They are less sensitive, require working within an ultra-high vacuum and cause more 
damage to the sample [117]. 
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Laser Ablation Inductively Coupled Plasma Mass Spectroscopy (LA-ICP-MS) can produce a 
quantitative map of metal distribution in thin slices of brain tissue [118, 119] at a similar 
resolution and sensitivity to SXRF. The quantitative nature of LA-ICP-MS gives an advantage 
over SXRF mapping, which only provides a relative concentration distribution unless careful 
calibration can be carried out. However, unlike SXRF mapping, LA-ICP-MS is a destructive 
technique and therefore can only be mapped once and does not allow multiple maps, XANES 
or staining to be carried out on the same section. 
1.2.5 MRI of non-haem brain iron 
Tissue non-haem iron content has been shown to have a significant effect on MRI relaxation in 
phantoms [120], animals [121] and human post mortem tissue [19]. Since this was first 
demonstrated a number of different techniques have been developed to calculate tissue iron 
content in the brain (and the liver [58]) of living patients using data obtained by MRI.  
Some of the methods used for imaging brain iron are described below. In 2005 Haacke et al. 
published a detailed review on this subject [107]. The magnetic properties of non-haem iron 
and its interaction with MRI relaxation is described in detail in Chapter 2, Section 2.2. 
1.2.5.1 R1, R2 and R2* mapping 
MRI imaging techniques which quantitatively map the relaxation rates R1, R2 and R2* (known as 
MRI relaxometry) have been shown to reveal subtle differences in brain tissue. For example, 
enabling differentiation between anatomical features in the brain that cannot be achieved 
with relaxation-weighted imaging [122].  
Both the transverse relaxation rate R2, and to a lesser extent the longitudinal relaxation rate 
R1, have been shown to be linearly proportional to the iron content of tissue at field strengths 
similar to that of a clinical scanner [121].  A linear correlation has also been shown between 
R2* and iron concentration [27], with a steeper gradient (and therefore greater sensitivity) 
than R2 [123].  
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1.2.5.2 Field Dependent R2 Increase imaging 
The field dependent R2 increase (FDRI) is the degree to which the value of R2 depends on the 
external magnetic field. Bartzokis et al. have used this property to develop a means of 
examining iron content from R2 MRI scans [124]. R2 is measured at two different field strengths 
and the difference calculated to give the FDRI. They showed that FDRI of the frontal white 
matter, caudate nucleus, putamen, and globus pallidus correlated strongly with published iron 
concentration values in healthy adults and with phantoms of ferritin containing agarose gels 
[124]. FDRI has since been used to study ferritin iron concentration in AD compared to control 
[125] and also in other neurodegenerative diseases such as PD and HD [126, 127]. 
A disadvantage of FDRI is that it requires MRI mapping with two different instruments. This 
increases the cost and time of the imaging and also requires careful matching of anatomical 
features across the two data sets.  
1.2.5.3 R2’, phase and Susceptibility Weighted Imaging  
Tissue degeneration in AD causes increased water concentration in the tissue. This has the 
opposite effect to increased iron concentration and reduces R2 [125, 128]. Therefore a number 
of groups have been developing new imaging techniques which separate the effect of iron 
from that of tissue water concentration.  
 R2’ is the portion of R2* that is caused by the dephasing of spins due to local field 
inhomogeneities. Ordidge et al. developed a method for mapping R2’ that reduces the 
influence of background field variations (which can inflate changes in R2*). Using this 
technique, they measured an increase in iron in the SN of PD patients that agrees with post 
mortem studies, but had not been observed in R2 mapping [129]. 
In susceptibility weighted imaging (SWI) a mask of phase information is applied to a magnitude 
MRI image to enhance the contrast. The mask can be chosen to highlight particular phases 
(features) and has been used to enhance contrast between grey and white matter [130], 
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resolve structures not observable with T2 or T1 weighted imaging [131] and examine the iron 
concentration distribution of brain tissue [27]. 
1.2.5.4 High field MRI 
Although most clinical scanners typically have a magnetic field strength of around 1.5 T, higher 
field research instruments have become more common. The field dependent R2 increase 
described above means that the contrast caused by variation in tissue iron content should 
increase at higher field. It has been suggested that the effect will reach saturation due to the 
saturation of magnetisation of ferritin iron. This was reported in a study of monkey brain by 
Bizzi et al. at field of up to 4.7 T [25]. However, in a study of human post mortem tissue House 
et al. report a strong linear relationship between iron and R2 at 4.7 T [26].  
7 T MRI measurements of human brains in vivo and post mortem (Yao et al.) have been used to 
quantitatively described the linear relationship between iron and R2*. In the same study they 
demonstrated that R2* is linearly dependent on field by imaging at fields of 1.5, 3 and 7 T [27]. 
In a study published by our group the linear relationship between relative iron concentration 
and R2 and R2* was shown in tissue from the hippocampus at 14.1 T [132]. However, as iron 
was not quantified in that preliminary study it is not possible to check whether the field 
dependent R2 and R2* increase follows the same trend as predicted at lower fields. 
1.2.5.5 Comparing MRI and tissue iron concentration 
When MRI is used to make an estimation of brain iron without using direct tissue iron 
measurement to corroborate the results, for example when estimating iron in the brain of 
living patients, the values published by Hallgren and Sourander in 1958 [93] are often still used 
for calibration [133, 134]. The age range of the subjects was 30 to 100 years and iron 
concentration was measured by the orthophenalthroline method. Table 1.1 reproduces the 
iron concentration in micrograms per gram of fresh tissue.  
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Brain Region Number of Samples Fe µg/g fresh mass SD µg/g 
Globus Pallidus 55 213 34.9 
Red Nucleus 44 194.8 68.6 
Substantia Nigra 52 184.6 65.2 
Putamen 56 133.2 34.3 
Dentate Nucleus 45 103.5 48.6 
Caudate Nucleus 58 92.8 21.4 
Thalamus 52 47.6 11.6 
Cerebellar Cortex 53 33.5 8.7 
Motor Cortex 46 50.3 8.8 
Occipital Cortex 38 45.5 6.7 
Sensory Cortex 45 43.2 5.8 
Parietal Cortex 37 38.1 6.7 
Temporal Cortex 47 31.3 5.7 
Prefontal Cortex 58 29.2 4.1 
Frontal White Matter 59 42.4 8.8 
Medulla Oblongata  41 14.0 11.6 
Meninges 10 10.2 2.9 
 
Table 1.1: Iron concentration in regions of the brain as reported by Hallgren and 
Sourander. Concentrations were determined by colorimetry from healthy adults aged 30 
to 100 years [93]. 
 
 
Other studies have used post mortem samples to directly compare iron concentration with the 
measured R2 and R2* of the samples. These included studies by Vymazal et al. (human and 
monkey brain) at fields from 0.5 to 1.5 T [135]; House et al. at 1.4 T [19] and 4.7 T [26] and 
Langkammer et al. at 3 T [123]. 
The number of studies of post mortem tissue is fairly small, due to the difficulty in obtaining 
samples. These studies are important as they do not rely on the assumption that the iron 
concentration quoted in the literature accurately reflects the iron concentration in the 
individual involved in the study. Reported iron concentration values vary considerably as is 
shown in a review by Haacke et al. [107], which likely reflects some natural variation as well as 
measurement errors within and between studies.  
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However, there are also a number of disadvantages in studying post mortem tissue, in 
particular the changes in MRI relaxation rates which occur over time. Vymazal et al. have 
reported a decrease of 6-9% in R2 over the first 12 hours post mortem and of 13-22% in 
samples which had been frozen [135]. 
1.2.5.6 MRI and SXRF 
Recently MRI maps of post mortem tissue have been compared to SXRF fluorescence maps of 
sections cut from the imaged sample. This allows direct spatial comparison of iron distribution 
and MRI, using the highly sensitive and specific X-ray fluorescence maps.  
McCrea et al. used rapid scanning SXRF to compare iron distribution with MRI maps and 
conclude that susceptibility weight imaging (SWI) was the best MRI indicator of iron 
concentration [136]. The same group carried out SWI on fixed brains at a clinical resolution, 
using a 1.5 T scanner. They then mapped 1 mm thick sections of these samples using rapid 
scanning SXRF and matched these sections to the MRI maps [90]. Metal foils were used to 
calibrate the SXRF signal and to produce quantitative iron maps, showing a linear relationship 
between iron concentration and phase. 
Antharam et al. mapped fresh hippocampal tissue at very high resolution at a field of 14.1 T 
[132]. Tissues were then sectioned at 30 µm and air dried onto quartz slides before mapping (a 
very similar protocol is used in this thesis and described in detail Chapter 4). Fresh tissue was 
used to avoid metal leaching by fixatives and the thin sections used ensure the full depth of 




1.3 Literature review: iron in the AD brain 
In AD (and other neurodegenerative diseases) there is evidence of iron disregulation with 
increased concentration in some regions of the brain, as well as changes in the distribution and 
concentration of some of the associated regulatory proteins. 
One aim of this project is to investigate the potential for MRI to aid diagnosis of AD by 
detecting iron changes in the brain. This question was investigated using high resolution, pre-
clinical MRI of human post mortem tissue. The bore size of the high resolution MRI probe 
means that only a small volume of tissue can be imaged at a time. The careful analysis 
required, instrument time and the availability of samples limited the number of brain regions 
which could be investigated. A careful literature review was carried out to assess which six 
regions of the brain may be most useful in aiding diagnosis. 
1.3.1 Iron concentration in AD and control tissue 
A summary of literature reporting comparisons between tissue iron concentration in specific 
brain regions of AD cases compared to control is shown in Figure 1.3. Each row represents data 
published for a different region of the brain and these regions have been grouped 
approximately according to their neuroanatomy. Red cells indicate a study in which a decrease 
in iron was observed in AD, blue cells show no change and yellow cells indicate a statistically 
significant increase. The reported statistical significance is indicated with one asterisk for 
p<0.05 and two asterisks for p<0.01. Where a change approached significance this is indicated 
in a blue cell with an arrow showing the direction of change and the p value stated. Each cell 
also contains the iron measurement method used in that study and a letter in bold that relates 
to Table 1.2 which gives the details of the paper in which the data were published. 
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Letter Lead Author (year) Method 
Number of samples 
(control, AD) 
Reference 
A Bartzokis (1994) FDRI 8, 5 [125] 
B Bartzokis (2000) FDRI 68, 31 [133] 
C Bartzokis (2004) FDRI 36, 10 [126] 
D Connor (1992) Ferrochem II serum 11, 13 [22] 
E Cornett (1998) INAA 21, 58 [17] 
F Dedman (1992) Ferrozine reagent 11, 11 [21] 
G Deibel (1996) INAA 11, 10 [39] 
H Ding (2009) Phase shift MRI 24, 26 [137] 
I House (2008) ICP-AES 3 to 5 [19] 
J Laakso (1996) T2 mapping  18, 54 [138] 
K Loeffler (1995) Ferrochem II serum 8, 14 [18] 
L Lovell (1998) micro PIXE 5, 9 [114] 
M Magaki (2007) GFAAS 6, 8 [40] 
N Samudralwar (1995) INAA 56, 98 [16] 
O Thompson (1988) INAA 15, 14 [20] 
P Zhu (2009) Phase shift MRI 15, 15 [139] 
 
Table 1.2: Papers referenced in the literature review in Figure 1.3. The lead author, year of 
publication, methodology and number of control and AD samples are given.  FDRI = field 
dependent R2 increase; INAA = instrumental neutron activation analysis; ICP-AES = inductively 
coupled plasma atomic emission spectroscopy; PIXE = particle induced X-ray emission; GFAAS = 
graphite furnace atomic absorption spectroscopy. 
 
 
Comparing between studies is difficult due to the large variety of iron quantification 
techniques used (these were described in more detail in Section 1.2.4). Studies also vary in 
their use of fixed or fresh tissue; however only studies of fresh tissue are included in this 
review. Papers mostly reported concentrations per gram of fresh tissue, but others gave values 
per gram of freeze dried tissue. Both are included in the literature summary. 
Some published data are from small sample size studies, which is unsurprising due to the 
limited availability of donated human brain tissue for research. This means assessing statistical 
significance is non-trivial and in some reports n<3 and no statistical comparisons are made. 
Where no statistical comparison can be made data was not included in Figure 1.3, for example 
in a number of regions in the paper by House et al. [19]. Any data from studies that compared 
iron concentration through Perls’ staining are also excluded from the summary, as this 






























































































































































































































































































































































































Some of the data included in Figure 1.3 are from living patients where MRI has been used to 
estimate the iron content of the tissue and no secondary direct iron measurements could be 
made. Zhu et al. used phase corrected MRI to show increased iron in multiple brain regions 
and also to show an increase in iron with disease severity that was particularly strong in the 
parietal cortex [139]. Bartzokis has published a number of studies showing increased iron in AD 
in regions of the basal ganglia [125, 126, 133] as measured by FDRI.  
Magaki et al. looked at loosely bound, as well as total, iron in the grey and white matter of the 
hippocampus and frontal cortex [40]. They found a decrease in loosely bound iron in the 
frontal cortex white matter; hippocampal grey matter and a statistically significant decrease in 
the hippocampal white matter. However, when the total non-haem iron was considered the 
differences between groups disappeared.  
In Figure 1.3 it can be seen that different studies of the same brain regions sometimes show 
different results. For example, in the parietal cortex some MRI and direct measures of iron 
have found no increase of iron in AD, whereas other studies have shown an increase.  
Certain nuclei in the brain have reported increased iron in a number of studies, for example 
the caudate nucleus and putamen. Nuclei are made up of a relatively dense cluster of neurons: 
they are grey matter structures. Conversely, none of the white matter structures or isolated 
cortical white matter tissues have shown a statistically significant increase in iron.  
The literature review only uncovered one region for which a statistically significant decrease in 
iron concentration with AD was reported. Connor et al. reported decreased iron in both the 
grey and white matter of the occipital cortex [22]. On the other hand, some regions of the 
brain, such as the amygdala and the caudate nucleus, have widely been reported to show 
significant increases of iron in AD.  
The hippocampus has shown increased iron concentration in the greatest number of studies. 
However, this region was studied in depth in a recent publication by our group (Antharam et 
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al. [132]). We showed a statistically significant decrease in R2* in two of nine sub-fields of the 
hippocampus, but no statistically significant change in R2. Increased R2 and R2* variance was 
observed two sub-fields in AD compared to control with a high statistical significance of 
p<0.001. 
It is possible that underreporting of negative (no change) results means that the review is 
skewed towards positive findings. However, many studies examine multiple brain regions 
where not all regions show a statistically significant increase. These studies help to identify 
regions where there is likely no change in iron in AD, such as white matter structures and the 
thalamus.  
1.3.1.1 Recent publications  
Tissues samples for analysis were requested in late 2010 and therefore studies published since 
that time were not included in the initial literature review shown in Figure 1.3. A search using 
Web of Science for papers published from 2010-2013 uncovered just one study measuring 
tissue iron concentration with AD in individual brain regions. In a post mortem study using ICP-
MS Akatsu et al. found a statistically significant increase in iron in the amygdala in AD 
compared to control, but no change in the hippocampus [140].  
1.3.2 Altered iron form in AD 
Ferritin has been shown to increase in some regions of the brain in AD, following a similar 
trend to iron concentration [22]. Dedman et al. also reported a similar increase in iron and 
ferritin in the AD parietal cortex [21]. 
Conversely, some studies have shown that although overall levels of iron increase in AD tissue, 
this is not paralleled by an increase in ferritin molecules [133], which may mean an increase in 
iron loading in ferritin or an increase in other forms of iron. For example, Quintana et al. have 
shown differences in the structure of ferritin cores in AD compared to control [77, 116].  
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SQUID magnetometry has been used to demonstrate increased magnetite concentration in AD 
tissue from the superior temporal gyrus [110, 141]. This is significant not only because of the 
increased magnetisation of magnetite compared to ferritin, but also because magnetite is the 
only stable iron oxide containing the redox active Fe2+ ion. 
1.3.3 Iron associated with AD pathology  
A number of studies have shown altered iron and its regulatory proteins associated with AD 
pathology, but as with reports of iron concentration and form there are some apparently 
conflicting results. For example, in the amygdala Lovell et al. showed that in addition to an 
increase in iron in AD neuropil compared to control, the iron concentration in the AD senile 
plaques was statistically significantly higher in than in the surrounding neuropil [114]. 
However, a study by House et al. found no correlation between plaque burden and iron 
concentration [19]. 
Collingwood et al. showed magnetite in situ in sections taken from the superior frontal gyrus 
of a confirmed AD patient [82]. Conner et al. [96] observed transferrin surrounding senile 
plaques in AD tissue as well as ferritin-containing cells around the plaque cores. Positive iron 
staining was also observed in cells surrounding plaques and diffusely around the area. 
Quintana et al. used TEM to demonstrate ferritin and haemosiderin around senile plaques 
[78]. 
Iron specifically in a redox active form has been shown to be associated with senile plaques 
and neurofibrillary tangles in hippocampal tissue [37]. In vitro experiments have shown that 
chelation of iron from Aβ solutions prevents plaque formation [142]. 
Samudralwar et al. investigated iron concentration in the olfactory system as deficits in 
olfactory function had been observed even in mild cases of AD [16]. They found a statistically 
significant increase in iron in the olfactory system of 98 AD cases compared to 56 controls.  
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1.3.4 Assessment of iron in AD by MRI 
As described in Section 1.2.3 MRI techniques to investigate brain iron concentration have been 
developed and these have been used to investigate iron in the AD brain. 
1.3.4.1 R1 R2 and R2* mapping 
Laakso et al. showed decreased T2 with statistical significance in some regions of the AD brain 
[15], but they concluded that the overlap between AD and control values would prevent T2 
from being a useful diagnostic tool for AD. However, the effect of iron is proportional to field 
strength and therefore T2 may provide more useful information at higher field strengths. 
House et al. looked at the correlation between iron concentration and R1 and R2 in a small 
sample set of post mortem tissues across 14 brain regions at 1.4 T [19]. Although they 
observed a linear correlation between R1 and R2 in some brain regions, they showed that tissue 
water content was a more significant factor in determining R1 and R2 at 1.4 T. However, in the 
AD samples iron contributed more to the value of R1 and R2 than it did in the control samples.  
In the same paper House et al. showed no linear correlation between plaque density and R2, 
despite the widely reported association between AD pathology and iron. A 7 T post mortem 
imaging study of the hippocampus by Huesgen et al. also showed no correlation between T2 
and the number of SPs or NFTs [143]. 
Brar et al. mapped T2 in the substantia nigra of patients with AD and with AD and parkinsonism 
[144]. Instead of comparing the average T2 values they considered the number of voxels with 
T2 values below 30 ms, which correspond to tissue with high iron content (note that this cut off 
is field dependent). This approach may help to separate the effect of T2 shortening by iron and 
T2 lengthening due to increased water concentration in degrading tissues, but only if the effect 




The results of a number of FDRI studies by Bartzokis et al. are included in Figure 1.3. 
Additionally they have used FDRI to calculate brain iron concentration in a sample set that was 
split into AD patients with an age of onset was before and after 70 years. The results showed 
an increase in the iron in multiple brain regions of the early onset group [126].  
1.3.5 Iron in other neurodegenerative diseases 
Iron has also been shown to increase in other neurodegenerative diseases and importantly this 
appears to occur in different regions than with AD. For example, increased iron has been 
observed in the substantia nigra (SN) in PD [23, 145, 146] with iron increases directly observed 
in the dopaminergic neurons [147]. In contrast no change or a decrease in iron is observed in 
the SN in AD [18, 106], although increases have been observed in patients who developed PD 
alongside AD [144].  
1.3.6 Conclusion 
Although a number of studies have found an increase in iron concentration in AD in certain 
brain regions, other studies contradict these results showing no change in the same region. As 
the changes seem to affect a number of different brain regions a multiregional approach may 
be interesting. In addition to direct measurements of tissue, increased iron content has also 
been observed indirectly through MRI measurements. This ultimately supports the hypothesis 
that changes in brain iron could aid diagnosis.  
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Chapter 2:  
Theory 
This Chapter introduces magnetic resonance imaging (MRI) and the nuclear relaxation rates R1, 
R2 and the susceptibility related R2*. The magnetic properties of non-haem brain iron are also 
described and the effect it has on R2 and R2* discussed. Synchrotron X-ray radiation and X-ray 
fluorescence mapping are also introduced. 
2.1 Magnetic Resonance Imaging 
1H MRI was carried out on two different nuclear magnetic resonance (NMR) systems: a 600 
MHz system (14.1 T) and a 400 MHz (9.4 T) system. MRI scan sequences were used which 
facilitate measurement of R2, R2* and R1, rather than merely producing contrast images. Here 
the basic principles of MRI are outlined and the scan sequences which were used to measure 
R2 and R2* introduced.  
The reference materials used for writing this section were two text books: MRI In Practice by 
Westbrook, Kaut Roth and Talbot [148] and Magnetic Resonance Imaging: Physical Principles 
and Sequence Design by Haacke et al. [149]. 
2.1.1 Nuclear magnetic resonance 
Odd mass numbered nuclei possess a property called spin which creates magnetic moment (µ) 
due to the positive electrical charge all nuclei possess. This moment causes the nuclei to 
interact with external magnetic fields, such as that of an MRI scanner B0. The nuclei will 
precess about the external field at a frequency, called the Larmor frequency (ω0), which 
depends on the size of the external field and a constant property for that type of nucleus 
called the gyromagnetic ratio (λ). Equation 2.1 gives the Larmor frequency [149]: 
        (2.1)  
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Hydrogen (1H) nuclei are by far the most common spin-possessing nuclei in the human body, in 
particular due to the abundance of water. It is therefore the nucleus used in clinical MRI and 
the MRI in this thesis. The frequency of an NMR system refers to the Larmor frequency of the 
hydrogen nuclei in that magnetic field.  
 
 
Figure 2.1: Precession about a magnetic field. The 
hydrogen nucleus (a proton) has a magnetic 
moment µ which precesses about the external 
magnetic field B0 at the Larmor frequency ω0. 
 
 
The precession about the magnetic field creates an average magnetic moment for each 
nucleus (Figure 2.1), which can be aligned parallel (low energy) or antiparallel (high energy) to 
the external field. At equilibrium the majority of the nuclei will be in the low energy state. 
Therefore the total hydrogen nuclei in a volume of tissue (or in MRI, a voxel) have an average 
magnetic moment in the direction of B0, known as the net magnetisation vector (NMV) – see 
Figure 2.2. 
 
Figure 2.2: Arrangement of the 
magnetic moments of protons in 
the presence of an external field. 
At equilibrium the majority of the 
nuclei will align parallel to B0 and 
create a net magnetic vector 




Application of a pulse of energy with a frequency equal to the Larmor frequency (the resonant 
frequency) increases the energy of the system by exciting nuclei into the high energy state. 
The result of this is to change the direction of the NMV so that it is at an angle to B0. The 
duration and amplitude of the resonant radio frequency (RF) pulse, applied to the system by a 
set of coils, determines the size of the angle of the NMV to B0. In an MRI system B0 is in the z 
direction, or longitudinal plane, parallel to the bore of the magnet.  
 
Figure 2.3: A 90° RF pulse flips the NMV 
into the xy plane. The NMV rotates 
about the z axis at the Larmor 
frequency and induces a current in the 
RF coils. 
 
A 90° RF pulse will flip the NMV from lying parallel to z into the xy, or transverse, plane. 
Resonance also brings all of the nuclear spins into phase with one another and so the NMV is 
also rotating in the transverse plane at the Larmor frequency (Figure 2.3).  This induces a 
voltage and alternating current in the RF coil, which is perpendicular to the transverse plane. 
Once the RF pulse is switched off the nuclei will i) begin to dephase and ii) to flip back into 
their equilibrium state meaning the NMV will move back in line with z. As this happens the 
induced voltage in the RF coils will decrease: this is the Free Induction Decay (FID) signal. 
2.1.2 R1, R2 and R2* 
The process of spin dephasing and the returning of the NMV to the longitudinal plane is called 
relaxation and the two independent processes require dispersion of energy. 
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2.1.2.1 Longitudinal recovery 
The return of the NMV into the longitudinal plane is called T1 recovery (Figure 2.4a), where T1 
is the time take for 63% of the NMV to return to the longitudinal plane. The energy released 
during T1 recovery is transferred from the nuclei to the surrounding lattice and is therefore 
known as spin-lattice relaxation. The spin-lattice relaxation rate, R1, is equal to the reciprocal 
of T1: 




Where T1 is in usually given in milliseconds and R1 in s
-1. 
Equation 2.3 describes the recovery of the magnetisation into the longitudinal plane (Mz) over 
time, after a 90° excitation pulse is applied [149]: 
            
 
 
      (2.3) 
where M0 is the size of the magnetisation in the longitudinal plane at equilibrium. 
T1 data were collected for all samples, however the focus of this thesis is examining the effect 
of iron changes in the brain on T2 and T2*. Therefore T1 data and in-depth detail of T1 
measurement are not included.  
2.1.2.2 Transverse decay 
The decay of the NMV from the transverse plane (Figure 2.4b) is called T2 decay and can be 
described by Equation 2.4 [149]: 
              
      (2.4) 
Where Mxy(0) is the magnetisation in the transverse plane when the NMV has been fully 
excited into the transverse plane.  
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This is caused by energy exchange through magnetic moment interactions between 
neighbouring nuclei and is termed spin-spin relaxation. T2 is the time taken for 63% of the 
transverse relaxation to be lost and the transverse relaxation rate (R2) is equal to the reciprocal 
of T2. 
    
 
  
  (2.5) 




Figure 2.4: T1 and T2 decay. a) Individual spins flip back into the low energy state giving rise to T1 
recovery as the NMV moves back in line with B0. b) The precessing nuclei lose phase causing T2 
relaxation and reducing the size of NMV in the xy plane. 
 
 
2.1.2.3 R2* and R2’ 
The dephasing of magnetic moments can be greatly accelerated by localised field 
inhomogeneities. Areas of altered magnetic field cause rapid dephasing by changing the local 
Larmor frequency. Measurements of T2 correct for this effect, but measurements of T2* do 
not. Therefore T2* is the spin-spin decay plus the dephasing due to local field inhomogeneities, 










   
  (2.6) 
The value of T2’ is both sample and machine dependent. 
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2.1.3 MRI hardware  
The main magnetic field of the MRI systems used in this investigation is provided by 
superconducting magnets which are cooled by liquid nitrogen and liquid helium. These 
produce a close to homogeneous field, B0, through the bore of the magnet (the z 
axis/longitudinal plane).  
Clinical imaging systems generally have a field strength of 0.5 to 1.5 T, and image at a 
resolution of around 1 mm3. Pre-clinical imaging systems can use much higher magnetic fields, 
which increases the size of the NMV. This produces higher signal from the same volume of 
sample and allows higher resolution imaging whilst still achieving good a signal to noise ratio. 
Most high field research instruments have a vertical bore, which is smaller than that found in 
clinical scanners. The bore is smaller due to the difficultly in creating strong, uniform magnetic 
fields. 
Within the cooled system there is also a set of shim coils. The current through these coils can 
be manually or automatically adjusted to compensate for field inhomogeneities. Field 
inhomogeneities will be introduced whenever a sample is positioned within the bore of the 
magnet due to its magnetic properties interacting with B0. Therefore the shim must be 
adjusted for every sample. The quality of the shim is assessed by examining the size and shape 
of the FID. As field inhomogeneities cause rapid dephasing of nuclear spins, a small FID is 
produced. To reduce field inhomogeneities the current to the shim coils is adjusted until the 
area under the FID is maximised and the shape is that of an exponential decay.   
Inside the bore of the magnet the gradient coils are positioned. They apply gradient fields to 
the imaging space to provide the spatial encoding of the MR signal (see the following section). 
Gradient coils are cooled by a cool water supply to prevent over heating due to the currents 
which are ramped up and down in the coils as the gradients are switched on and off. The MRI 
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probe contains the RF coils which transmit RF pulses to the sample and pick up the signal from 
the proportion of the NMV in the transverse plane (as shown in Figure 2.3).  
2.1.4 Spatial information 
The gradient coils in an MR imaging system provide the means of spatially encoding the signal 
for the sample. They alter the magnetic field in the x, y, or z direction, by producing a magnetic 
field which either adds to or subtracts from the static magnetic field to produce a linear 
gradient. The steepness of this gradient can be controlled by the coils and coils can be used in 
combination to alter the gradient in any direction within the bore of the magnet. As the 
Larmor frequency is directly proportional to the external magnetic field (see Equation 2.1), 
applying a gradient to the sample space means that the frequency of the nuclear precession 
varies with position. The size gradient is controlled and the resulting field with position is 
known, and therefore the Larmor frequencies of the nuclei at a particular position can be 
calculated. 
As the Larmor frequency changes the resonant frequency for nuclear excitation also changes. 
This allows the nuclei to be selectively excited by an RF pulse at the correct frequency. Slice 
selection is achieved by applying an RF pulse with a band of frequencies that match the Larmor 
frequencies of hydrogen nuclei within a particular physical slice of tissue, so that only these 
nuclei are excited. The gradient for slice selection is switched on during RF excitation pulses.  
Gradients also facilitate frequency encoding and phase encoding to spatially locate signal along 
the other two axes. For example, if a slice is selected along the z axis, frequency and phase 
encoding locate the position of pixels along the x and y axis. The frequency encoding gradient 
is switched on to alter the frequency along one axis as the signal is collected. The phase 
encoding gradient is used to alter the phase of the nuclear spins, so that their position within a 
slice is linked to their phase. It is usually applied just before the 180° refocusing pulse. High 
resolution imaging requires steep gradients and increased power to the gradient coils. 
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2.1.5 Pulse sequences 
In order to measure T1, T2 and T2* different sequences of RF pulses, ‘pulse sequences’, are 
used. In general the sequence starts with an excitation RF pulse: usually a 90 ° pulse for T2 
measurements and 180 ° for T1. The RF receiver only measures signal in the transverse plane 
(Figure 2.3). TR is the repetition time of the entire sequence. To ensure that the system has 
reached equilibrium between measurements, TR should be at least four times the value of T1.  
To fit the exponential recovery curve or decay curves the FID must be measured at several 
different times after the excitation pulse. The most time efficient way to do this is by 
measuring the FID multiple times within one TR, using a multi-echo sequence. 
2.1.5.1 Spin-echo sequences 
A spin-echo sequence is used to correct for the rapid spin dephasing seen in T2*. A 90 ° pulse is 
applied, which is followed by rapid dephasing caused by local field inhomogeneities. After a 
short time interval (τ) a 180° pulse is applied. This reverses the order of the dephasing, so that 
at the time 2τ the spins will have regained phase. At this point the signal produced is called a 
spin echo and this occurs at echo time TE after the initial excitation pulse. The signal decay at 
this time is due to the spin-spin relaxation, rather than the dephasing due to local field 
inhomogeneities.  
2.1.5.2 Gradient-echo sequences 
To produce a gradient-echo two successive, but opposite gradients are applied to the sample. 
The first gradient causes the nuclei to dephase and the second reverses the direction of 
dephasing creating a gradient-echo at a time TE, similar to a spin-echo. The gradient-echo 
sequence does not compensate for field inhomogeneities and therefore is used to measure 




2.2 Magnetic properties of non-haem brain iron and its 
effect on MRI 
The main forms of non-haem brain iron were introduced in Section 1.3.1. In this section their 
magnetic properties and influence on MRI are discussed. 
2.2.1 Ferritin and haemosiderin 
Non-haem iron in the brain is primarily found in the spherical iron storage protein ferritin, in 
the form of a nanoparticle with a ferrihydrite-like structure (approximate formula 5Fe2O3 
9(H2O)) up to 8 nm in diameter. 
2.2.1.1 Magnetic properties of ferrihydrite in ferritin 
Ferrihydrite has an antiferromagnetic structure. Classically antiferromagnetic materials have 
zero magnetic moment due to the antiparallel arrangement of the magnetic moments of the 
atoms in the material (Figure 2.5 a). However, nanoparticles of ferrihydrite (for example in 
ferritin) have uncompensated iron spins and therefore ferritin iron has a magnetic moment. It 
also means that fully iron loaded ferritin can act as an ideal monodispersed superparamagnetic 
system [150].   
Superparamagnetic nanoparticles are individual magnetic domains with a magnetic moment 
that flips rapidly at a speed dependent (in addition to particle size and material) on the 
temperature [151]. Above the blocking temperature of the material it is superparamagnetic 
and in the absence of an applied field the net magnetisation of the sample will be zero, due to 
average direction of the flipping magnetic moment. However, below the blocking temperature 
the magnetisation of each nanoparticle will be non-zero. The blocking temperature of a 
superparamagnet depends on the material and size of the nanoparticles as described in 
Equation 2.6 [152]: 
   
  
  
  (2.7) 
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where kB is the Boltzmann constant; K is the nanoparticle’s magnetic anisotropy energy density 
and V the volume of the nanoparticle.  
 
 
Figure 2.5: The alignment of magnetic moments in antiferromagnetic and ferrimagnetic materials. a) In 
antiferromagnetic materials the magnetic moments of the atoms or molecules align in an antiparallel 
formation and the net magnetisation is zero. b) In ferrimagnetic materials the magnetic moments are 
also antiparallel, but the magnitude of the moments in one direction is greater than those in the other 
and therefore there is a non-zero net magnetisation. 
 
 
In the presence of an external magnetic field the magnetic moment of a superparamagnetic 
material will align with the field and create a net magnetisation. This means that individual 
ferritins in tissue create local field inhomogeneities in the external MRI field B0. This effect is 
increased for clusters of ferritin [153]. The superparamagnetic properties of ferrihydrite in 
ferritin at body temperature mean that the net magnetisation will immediately disappear once 
the applied field is removed [152].  
Below the blocking temperature, and in the absence of an applied field, the magnetisation of a 
sample containing ferritin will remain zero as the magnetic moments of individual ferrihydrite 
nanoparticles point in random directions. However, under an applied magnetic field the 
magnetic moments will align with the field, as described above. If the temperature is below TB 
a remanent magnetisation will remain [83] once the field is switched off. The remanent 
magnetisation at a constant temperature is called isothermal remanent magnetisation (IRM). 
An IRM curve is produced by measuring the IRM of a sample after a series of applied fields 
with increasing magnitude.  
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As blocking temperature depends on the size of the nanoparticle (Equation 2.7) ferritin in the 
brain will have a range of blocking temperatures, depending on the iron loading of each ferritin 
molecule. However, ferritin is typically blocked below around 15 K [154]. Bell et al. showed 
that haemosiderin (isolated from iron-overload human spleens) also displays 
superparamagnetic properties and likely has a similar chemical form to that of ferritin. 
However, they also showed that the cores are markedly smaller [150] and therefore the 
blocking temperature will be lower. 
2.2.1.2 The effect of ferritin on MRI relaxation 
The superparamagnetic properties of the ferrihydrite-like core of ferritin mean that in the 
magnetic field of an MRI scanner ferritin creates local field inhomogeneities in the tissue. As 
hydrogen nuclei of water molecules diffuse through field inhomogeneities, these cause spin 
dephasing and therefore R2 shortening [24]. The mechanism of dephasing is called the outer 
sphere mechanism because it applies to magnetic nanoparticles separated from water: in this 
case by a protein shell [155].  
Ferritin in the human brain has been shown to shorten T2 relaxation and to a lesser extent T1 
[153] and a linear relationship has been demonstrated between tissue iron concentration and 
the transverse relaxation rate, R2, at a number of different field strengths [19, 26, 135]. As R2* 
is more sensitive than R2 to local field inhomogeneities, it is more sensitive to tissue iron 
concentration. Linear relationships between iron and R2* [123] and R2’ [134] have also been 
measured. 
At increased MRI fields, the magnetization of the ferrihydrite-like ferritin cores is increased 
and therefore the effect on R2 is also increased [155]. This has been shown to be linear with 
imaging field strength [153, 156]. This property has been harnessed by Bartzokis et al. to 
develop a protocol for evaluating iron concentration from R2 maps at two different field 
strengths [124]. It has been suggested that this effect will saturate higher imaging fields due to 
the saturation of ferritin magnetisation [25]. 
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Vymazal et al. measured the relaxation rate of solutions of ferritin with different loading 
factors at typical clinical MRI field strengths. They found that the linear relationship between 
R2 and iron concentration was independent of the loading factor of ferritin [157]. This supports 
the hypothesis that MRI could be used to measure total ferritin iron and without the need to 
make assumptions about the loading factor of ferritin. 
The time taken for water molecules to diffuse through the local field inhomogeneities 
associated with ferritin is comparable to the inter-echo time of spin-echo of MRI sequences. In 
spin-echo sequences (see Section 2.1.5.1) with short τ times, the refocusing pulse occurs 
before the water molecule has had time to fully diffuse through the field and therefore it does 
not experience the maximum dephasing. Vymazal et al. showed that short τ times, less than 
about 25 ms, reduced the effect of iron concentration on T2 [135]. The effect is τ dependent 
and reduces towards zero as τ increased towards 25 ms.  
2.2.2 Magnetite 
Magnetite is a ferrimagnetic iron oxide made of alternating lattices of Fe2+ and Fe3+. The 
arrangement of a ferrimagnet is similar to that of an antiferromagnet, with magnetic moments 
antiparallel. However, the magnetic moment in one direction is greater than the other, 
resulting in a net magnetisation (Figure 2.5 b). 
Magnetite has a magnetisation more than 100 times larger than that of ferrihydrite iron [110]. 
The same concentration of magnetite in solution has an affect approximately 200 times 
greater on T1 and T2 than the same concentration of ferritin and therefore synthetic magnetic 
nanoparticles are currently used as MRI contrast agents [158]. However, there is evidence that 
not all of the ‘magnetite-like’ iron in tissue has such a great effect on relaxation rates 
suggesting it does not have the same magnetic moment as true magnetite [159]. 
Nanoparticles of magnetite with a diameter of more than approximately 13 nm, which have 
been observed in human brain tissue [83], are magnetically blocked at 50 K. The IRM curve for 
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magnetite at 50 K typically saturates above an applied field of around 3000 Oe. Note that in a 
sample containing both ferrihydrite and magnetite, a 5 K IRM measurement will contain a 
contribution from both minerals, including smaller magnetite particles that have become 
magnetically blocked between 50 and 5 K. However, the fraction of iron in the form of 
magnetite will likely be very small and therefore the majority of the signal will be due to 
ferrihydrite.  
2.2.3 Other tissue properties which affect MRI relaxation 
In pure water and aqueous solutions the values of T1 and T2 are approximately equal, but in 
tissue T1 is usually 10 to 20 times greater than T2. Physically T2 must always be equal to or less 
than T1 [156]. Tissue, including brain tissue, is a complex system and there are a number of 
factors contributing to the rate of longitudinal recovery and transverse decay. 
One of the major factors is the water and fat content of the tissue [148]. More fatty tissue 
(white matter) has a low inherent energy compared to water and therefore can more readily 
absorb energy into its lattice allowing rapid spin-lattice relaxation and a short T1. T2 is also 
short in fat as the molecular tumbling rate in fat is similar to the Larmor frequency and the 
molecules are closely packed together, allowing efficient spin-spin exchange. Water molecules 
are more spread out and the tumbling rate is faster than the Larmor frequency. 
The amount of ‘free water’ (water not constrained by other molecules) affects the relaxation 
properties of the tissue. Increased free water causes T2 lengthening and the effect of this can 
be seen where there is damage to the tissue with neurodegeneration [125, 160], for example 
due to demyelination [161]. 
Paramagnetic metals such as copper, manganese, nickel and iron, cause shortening of T1 and 
to a greater extent T2 and T2* and have therefore been used as contrast agents in MRI imaging 
[156, 162]. Iron has by far the highest concentration in tissue, and a large proportion of it is in 
the form of superparamagnetic nanoparticles, and therefore it contributes the most to MRI 
48 
 
relaxation (as described in Section 2.2.2). The contribution of iron to the speed of relaxation in 
tissue becomes larger and begins to dominate over other tissue properties, with increased iron 
concentration or imaging field [26]. 
In this study fresh frozen, rather than fixed, tissue is used primarily because fixatives have 
been shown to leach metals from tissues [91]. However, fixing also causes protein cross-linking 
and therefore affects the mobility of water within the tissue. Kamman et al. showed a 
reduction in T1 and an increase in T2, over 24 hours, in rat brain tissue which had been perfused 
with formaldehyde [163].   
The samples in is this study were frozen at -80 °C for several years before measurement, when 
they were defrosted and imaged just above freezing. Vymazal et al. showed that freezing of 
tissue decreased T2 by 13-22% [135]. This could be due to cell membrane damage increasing 
the diffusion of water within the sample. A 6-9% decrease of T2 with time was also observed 
over the first 12 hours post mortem (in tissue which had not been frozen) and it is proposed 
that this is due to changes in diffusion effects due to membrane damage.  
In most ex vivo studies the measurement of human tissue directly post mortem is not practical 
and therefore a compromise must be made between preserving the longevity of the samples 
and changing their physical properties compared to in vivo measurements. In this study frozen 
samples are used, which were then warmed to just above freezing for measurement. Although 
T2 is slower at low temperatures [164], the further degradation of the tissue (in addition to 
damage from freezing) is reduced.  
2.3 Synchrotron X-ray fluorescence 
Synchrotrons provide a very high intensity source of light, primarily in the X-ray region of the 
electromagnetic spectrum.  The synchrotron X-rays can be used to produce maps of relative 
metal distribution through a technique called Synchrotron X-ray Fluorescence (SXRF) mapping. 
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2.3.1 Synchrotron X-ray radiation 
In general synchrotrons are composed of: an electron source; accelerators to bring the 
electrons to relativistic speeds; a storage ring under vacuum into which the electrons are fed 
and maintained at relativistic speed; insertion devices and bending magnets which produce 
light tangentially to the storage ring. Typically light is produced at a number of different 
positions (beamlines) around the storage ring with the wavelength of light determined by the 
bending magnets and insertion devices. At each beamline the light can be further focused and 
tuned to achieve the desired properties for specific experiments. 
A diagram of the UK’s synchrotron, the Diamond Light Source (DLS), is shown in Figure 2.6. The 
electrons are produced by an electron gun and accelerated to 100 MeV by the linear 
accelerator. The booster synchrotron accelerates the electrons to the full beam energy of 
3GeV, before they are injected into the storage ring. The ‘ring’ has 22 straight sections where   
insertion devices produce synchrotron light at the beamlines.  
 
 
Figure 2.6: The Diamond Light Source synchrotron. The synchrotron is formed of 1: the electron gun and 
linear accelerator; 2: the booster synchrotron; 3: the storage ring; 9: the radiofrequency cavity and 4: 
the beamlines. Once a beam of synchrotron light is produced (5) it travels into the optics hutch (6) and 
then in to experimental hutch (7). The experiment is control from the control cabin (8). This image is 




2.3.2 X-ray fluorescence  
 
Figure 2.7: The electron transitions that give 
rise to X-ray fluorescence. The allowed 
transitions and their nomenclature are 
shown. Figure reproduced from the X-Ray 
Data Booklet by Thompson et al. [165]. 
 
When an X-ray photon is absorbed by an atom a core electron is expelled. The hole left behind 
is filled by an outer shell electron, which releases an X-ray in the process. The energy of the 
emitted X-ray is equal to the difference between the two energy levels. Possible energy 
transitions are well defined and produce narrow fluorescence lines. Fluorescence lines are 
named first according to which shell the electron falls into (see Figure 2.7): for example, K lines 
are produced by electrons relaxing into the K shell. Secondly, they are named for the electron 
shell from which the electron is relaxing: α, β, γ starting with the lowest energy transition. The 
lines are further split due to the spin-interactions and labelled with the suffix 1, 2, 3 and so on. 
The ratio between the intensity of different fluorescence lines for a particular element is 
constant. When a sample is irradiated X-ray fluorescence (XRF) will occur at energies below the 
incident X-rays and so the incident X-ray energy can be chosen to examine particular elements 
of interest. As each element has its own characteristic fluorescence spectrum, the combined 




Figure 2.8: A typical biological fluorescence spectrum from a human brain tissue sample. The 
fluorescence lines Kα1 (6403.8 eV) and Kα2 (6390.8 eV) for iron are shown. These produce the 
fluorescence peak Kα. As the iron concentration is high, the Kβ peak is also seen. The Kα peaks of copper 
and zinc, which include the Kα1 and Kα2 fluorescence, are also present. The edge of the large scatter 
peak for the 10 keV incident beam is included. 
 
 
For biological samples an incident X-ray beam of 10 keV will cause iron, copper and zinc to 
fluoresce. Figure 2.8 shows a typical florescence spectrum from an incident beam of 10 keV, 
averaged over an area of approximately 0.5 mm2 of a 30 µm thick section of brain tissue. Table 
2.1 gives the fluorescence energy for some of the typical metals and potential contaminants 
which could be found in a tissue section.  
The main fluorescence lines of iron are Kα1 at 6403.8 eV, with Kα2 at 6390.8 eV and these 
combine to form a broader fluorescence peak as indicated by Fe Kα, as shown in Figure 2.8. 
Tissue iron content is relatively high and therefore the Kβ peak is also usually observed. 
Typically concentrations of copper and zinc are high enough for the Kα peaks to be observed; 
however, the Kβ peaks (at 8.9 and 9.6 keV respectively) tend to be masked by the large 10 keV 





Fluorescence Peak (keV) 
Kα1 Kα2 Kβ2 
Fe 6.404 6.391 7.058 
Cu 8.048 8.028 8.905 
Zn 8.639 8.027 9.572 
Ni 7.478 7.461 8.264 
Cr 5.415 5.406 5.947 
Mn 5.899 5.888 6.490 
 
Table 2.1: Energy of fluorescence lines for iron, copper, zinc, nickel, 
chromium and manganese. These fluorescence lines could all be 
excited by an incident beam of 10 keV. 
 
 
The finely tuned, extremely high brilliance X-ray radiation of third generation synchrotrons 
enables a detection limit of less than 100 ng/g for many elements, and a spatial resolution of 
up to around 1 µm [117]. XRF carried out using synchrotron radiation is known as Synchrotron 
X-ray Fluorescence (SXRF). 
2.3.3 Creating SXRF metal maps 
A map of metal concentration distribution can be produced by collecting a fluorescence 
spectrum at consecutive points on a sample using a focused X-ray beam. If the flux of the 
incident beam remains constant then the changing area under an SXRF peak is directly 
proportional to the changing concentration of the metal to which the peak belongs. Therefore, 
the relative iron concentration of a section of brain tissue can be mapped by calculating the 
area under Kα peak at each point on the map.  
The beamline I18, at the Diamond Light Source, can be tuned to a specific, stable energy of 
between 2 and 20 keV. When the X-ray beam is tuned to 10 keV the flux at the sample is very 
high: 4 x 1012 photons per second (ph/s). This very high flux allows iron, copper and zinc to be 
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mapped with high sensitivity. Iron concentrations of parts per billion can be measured with a 
collection time of around 1 s. The fact that the beam can also be focussed to just a few 
microns means that high spatial resolution mapping can also be achieved. The flux of the X-ray 
beam is not completely constant due to beam top-up, but this can be corrected for by 
normalisation to I0, as described in Section 4.4, along with the full methodology used for SXRF 
mapping in this project.  
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Chapter 3:  
Samples 
The literature review in Chapter 1 showed that increased iron concentration and 
corresponding changes to MRI relaxation parameters have been measured in a number of 
different brain regions in Alzheimer’s Disease (AD). However, for most regions there is also at 
least one conflicting study which reported no statistically significant change. It was 
hypothesised that a combining data from multiple regions may provide a way of differentiating 
between AD and control cases. 
Six different regions of the brain were chosen for investigation, based on the literature review. 
Tissue from all six regions was obtained from a set of three healthy controls and three AD 
cases. In order to begin to compare AD to other neurodegenerative diseases, some of the 
measurements were also carried out on three Parkinson’s Disease (PD) and three Multiple 
System Atrophy (MSA) cases for a subset of regions. 
The iron and MRI properties of the samples were investigated using a unique set of 
complementary techniques which are detailed in Chapter 4. This chapter deals with the 
selection and preparation of the samples. In Section 3.1 the protocols used to minimise the 
possibility of metal contamination whilst handling tissue are described. The rationale behind 
the selection of the six brain regions and how each sample was dissected is given in Section 3.2 
and in Section 3.3 the tissue preparation for each measurement technique is detailed. 
Figure 3.1 gives an overview of the experimental model used. Two adjacent samples of tissue, 
of approximately 1 cm3, are taken from a brain region. Sample A is taken for high resolution 
MRI mapping, followed by sectioning and histological staining to show cell distribution and 
look for amyloid plaques. A sub-selection of these samples had sections taken for high 




Figure 3.1: Experimental path for tissue samples. Tissue sample A is mapped with high field MRI and 
then it is sectioned and stained. For a sub-set of cases a section is taken for SXRF (Synchrotron X-ray 
Fluorescence) mapping before it is subsequently stained. Tissue sample B is freeze dried for SQUID 
(Superconducting Quantum Interference Device) magnetometry and then the total iron content is 
measured by GFAAS (Graphite Furnace Atomic Absorption Spectrometry) or ICP-MS (Inductively 
Coupled Plasma Mass Spectrometry). Numbers represent the sections of the chapter in which the 














































































































































































































































































































































































































































































































taken for bulk tissue analysis: SQUID (Superconducting QUantum Interference Device) 
magnetometry followed by iron quantification by GFAAS (Graphite Furnace Atomic Absorption 
Spectrometry) or ICP-MS (Inductively Coupled Plasma Mass Spectrometry). 
Not every technique was applied to each case from every brain region due to limited tissue in 
some regions and limited access to experimental facilities (in particular for SXRF mapping at 
the Diamond Light Source). Table 3.1 provides a record of the measurements made on each 
sample, with the reason for making each measurement on each sample explained in greater 
detail throughout the following chapters. 
3.1 Preventing iron contamination 
The study of iron, both directly through iron quantification and SXRF mapping and indirectly 
through SQUID magnetometry and MRI, is the main focus of this project. Therefore minimising 
contamination of the samples with iron is paramount. This was achieved through careful acid 
washing of tools and by cutting samples using non-metal blades. 
3.1.1 Acid washing  
The protocol for washing plastic and other acid resistant tools is: 30 minutes in a 3% HCl 
solution; 10 mins in ultra-pure, 18 MΩ water and a final wash in 18 MΩ water. Tools were then 
left to air dry in the biohazard hood which provides a relatively dust-free environment. Plastic 
tools were acid washed between every sample, with a few of sets of tweezers washed and 
ready to prepare a number of samples in a row. 
Materials that were susceptible to damage or etching from exposure to acid (for example the 
sapphire sectioning blade and quartz slides) were washed for 10 minutes in a solution of 0.1% 
HCl in ethanol. They were then rinsed with at least two changes of ultra-pure water. After 
every sample preparation blades were wiped down with dust free Whatman lens cleaning 
tissue and analytical grade ethanol to remove any tissue fragments and after every third 
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sample they were again acid washed. Washing was not carried out between every sample so 
as to minimise degradation of tools. 
3.1.2 A clean lab environment 
To reduce the potential for metal contamination, tissue handling environments were kept as 
free from metal particulates as possible. This meant avoiding the use of even weak acids 
around metal surfaces and checking the fume hood, biohazard cabinet and the cryomicrotome 
for any signs of corrosion.  
Tools and slides were left to air dry in the biohazard cabinet as the air flow is designed to 
minimise transfer of particulates in and out of the cabinet. Therefore, in addition to providing 
a safe environment for working with the human tissue samples, it reduced the chance of 
contamination compared to fume hood or lab bench.  
3.2  Brain region selection and sample excision 
3.2.1  Brain region selection 
The brain regions studied in this project were chosen based on the literature review of iron in 
the AD brain that is given in full in Chapter 1. The main criterion for selection was whether 
increased iron with AD had been observed in published studies. However, other factors were 
considered including whether iron changes have been observed in the region in other 
neurodegenerative diseases.  
The six regions chosen for investigation include four of the five nuclei of the basal ganglia 
[166], shown in Figure 3.2. From the basal ganglia the caudate nucleus (CN), putamen (Pu), 
globus pallidus (GP) and substantia nigra (SN) were included in the study, but the subthalamic 
nucleus was not. These regions all work closely together and are involved in motor control, 




Figure 3.2: A coronal view of the basal ganglia. The nuclei of the basal ganglia are the caudate nucleus, 
putamen, globus pallidus, substantia nigra and subthalmic nucleus. This figure is reproduced from Basal 
Ganglia—An Integrative View, edited by Barrios and Bauer [166]. 
 
 
The rationale behind choosing each of these regions is outlined below along with a brief 
introduction to the anatomy, function and AD pathology in each region. Appendix A contains a 
more expansive anatomical reference for the regions, with the main anatomical reference 
material used being Atlas of the Human Brain by J.K. Mai, G, Paxinos and T. Voss [167] and the 
accompanying website (thehumanbrain.info) from which the images are reproduced. 
The tables below provide iron concentration information for each of the regions gathered from 
a number of sources. Table 3.2 shows iron concentration values for the regions to be studied 
as taken from a literature review by Haacke et al. [107]. Only the data from whole tissue 
samples (rather than supernatant) is reproduced here, with the number of samples in the 
study and quantification method given in brackets. The table shows the fairly large range of 
reported values for each region, with sub regions of the substantia nigra and globus pallidus 
also included. No data for iron concentration in the pons was included by Haacke et al. or 




Reported Iron Concentrations 
µg/g fresh tissue 
(no of samples, technique) 
Amygdala 49.0 (21, INAA); 48.6 (11, INAA); 48.9 (15, INAA);  
Caudate Nucleus 
79 (58, Col); 115.6 (4, INAA); 92.5 (10, AAS);  
117.4 (59, ICP); 99.6 (6, AAS);  
Globus Pallidus 
- GP lateral 
- GP medial 
- GP total 
213 (55, Col); 175.3 (10, AAS); 182.0 (6, AAS) 
159.4 (24, ICP); 207.0 (6, AAS) 
141.2 (23, ICP); 163.8 (6, AAS) 
300.6 (23, ICP); 370.8 (6, AAS) 
Pons Not available 
Putamen 
130.0 (56, Col); 120.8 (10, AAS); 110 (6, AAS);  
163.8 (31, ICP); 119.8 (6, AAS) 
Substantia Nigra 
- Substantia Nigra ZC 
185.0 (52, Col); 139.9 (6, AAS) 
159.4 (59, ICP) 
 
Table 3.2: Iron concentration in brain regions of healthy adults. A large range of iron 
concentrations have been reported in each region and a large number of different 
measurement techniques used.  Data reproduced from the review table in Haacke et al. 
[107]. INAA = instrumental neutron activation analysis; Col=colorimetry; ICP = inductively 




Table 3.3 shows the iron concentration, as reported in the literature, for AD and control tissue 
from the six brain regions studied. It reveals a similar spread of values as for those shown in 
Table 3.2. These data were collected during the literature review in Section 1.3 and the table 
includes data from all papers which published numerical values, or for which values could be 
interpreted from graphs. The number of samples, method of iron quantification and reference 
to paper are given in brackets. Statistical significance between disease and control is indicated 
where it was reported. Only studies in which the iron concentration is directly measured are 
included and not those which made calculations from MRI data. (For a summary of the full 
result of the literature review refer to Figure 1.3). Likewise, data are only included from fresh 
not fixed tissue due to the potential iron leaching caused by fixatives. Data are quoted in 
micrograms of iron per gram (µg/g) of fresh tissue (wet mass) where possible, but in some 







Iron Concentration: Control 
µg/g (no of samples, 
technique, ref) 
Iron Concentration: AD 




48.3 ± 3.0 (14, RAC, [20]) 
49 ± 4 (21, INAA, [17]) 
50.8 ± 3.7 (56, INAA, [16]) 
34 (2, ICP-AES, [19]) 
60.6 ± 4.9 (15, INAA, [20])* 
64 ± 3 (58, INAA, [17])** 
70.8 ± 4 (98, INAA, [16])* 
40 (2, ICP-AES, [19]) 
dm 243 ± 11 (11, INAA, [39]) 322 ± 29 (10, INAA, [39]) 
 Caudate Nucleus wm 
100 (2, ICP-AES, [19]) 
93.1 (1, GFAAS, [26]) 
137 (2, ICP-AES, [19]) 
95.1 ± 21.1 (5, GFAAS, [26]) 
 Globus Pallidus wm 
 250 (2, ICP-AES, [19]) 
132.7 (1, GFAAS, [26]) 
252 (2, ICP-AES, [19]) 
160.0 ± 49.4 (8, GFAAS, [26]) 
 Pons wm Not available Not available 
 Putamen wm 
102 (2, ICP-AES, [19]) 
85.8 ± 24.0 (2, GFAAS, [26]) 
131 (2, ICP-AES, [19]) 
157.5 ± 48.6 (8, GFAAS, [26]) 
 Substantia Nigra wm 145.6 (1, GFAAS, [26]) 136.1 ± 36.8 (2, GFAAS, [26]) 
 
Table 3.3: Iron concentration in control and AD tissue. The iron concentration in the 6 brain regions 
chosen for investigation from studies of AD and healthy aged matched control tissue. Only studies using 
fresh not fixed tissue are included. The number of samples, quantification method; reference to the 
study and level of statistical significance reported is included is given in curved brackets after the iron 
concentration. ICP-AES = ion coupled plasma atomic emission spectroscopy; INAA = instrumental 
neutron activation analysis; GFAAS = graphite furnace atomic absorption spectroscopy. Where 
statistically significant differences were observed this is indicated as: * p < 0.05; **p < 0.01. 
 
 
3.2.1.1 Caudate Nucleus 
Together with the putamen the caudate nucleus makes up the striatum and these are the 
input nuclei of the basal ganglia [168]. The caudate nucleus is C shaped and is made up of a 
head, body and tail. Figure 3.3 shows a coronal section of the brain which includes the head 
portion of the caudate nucleus. The white matter separating the caudate nucleus from the 
putamen is the anterior portion of the internal capsule (AIC). The caudate nucleus is involved 
in emotion, language comprehension, memory and learning. The head of the CN has been 
specifically linked to processing feedback and the body and tail linked to successful learning 
[169]. 
Hallgren and Sourander [93] found an iron concentration of 93 ± 21 µg/g of tissue in the CN 
and described the relationship between iron concentration and age as:  
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                        (3.1) 
Where y = iron concentration in mg/100g of tissue and x = age in years.  
This region was chosen for investigation because several studies have inferred an increase in 
iron in AD based on MRI experiments [126, 127, 133, 139]. This suggests that iron in this region 
could be of use as an indicator of AD. House et al. [19] measured a direct increase in iron in AD 
CN compared to control and a corresponding increase in R2. However, with a sample size of 2 
no statistical significance was reached.  
 
 
Figure 3.3: A coronal section of the brain showing the caudate nucleus and putamen of 
the basal ganglia. This image is at level coronal section level -7.5 mm and reproduced 





The putamen is another structure of the basal ganglia. It is rostrally continuous with the head 
of the caudate nucleus. Figure 3.3 shows a coronal section of the putamen at a level at which it 
is separated from the head of the caudate nucleus by the anterior part of the internal capsule. 
Figure 3.4 is a more posterior section, which shows the putamen neighbouring the globus 
pallidus. The putamen is interconnected with the other structures of the basal ganglia and like 
them is involved in movement and learning. Like the body of the CN the putamen is associated 
with successful learning [169]. 
 
 
Figure 3.4: Coronal section of the brain showing the caudate nucleus, putamen, globus 
pallidus and amygdala. This image is at coronal section level 8 mm and is reproduced 





The putamen (Pu) is another iron rich region of the brain with an iron concentration of 130-
200 µg/g [93, 102]. Hallgren and Sourander’s [93] empirical equation for iron concentration (y, 
in mg/100g) with age (x, in years) is: 
                         (3.2) 
In the putamen the concentration of iron has been shown, through MRI measurement 
techniques [126, 127, 139], to increase with AD and so it was selected for inclusion in this 
study. As with the CN, House et al. [19] showed an increase in iron with AD through ICP-AES 
measurements, but this did not reach statistical significance.  
3.2.1.3 Globus Pallidus 
The globus pallidus is found medial to the putamen as shown in Figure 3.4. It is divided into 
two parts: the globus pallidus external and internal (GPe and GPi respectively), which are 
separated by a thin lamina of white matter [170]. The GP works in conjunction with the rest of 
the basal ganglia and is involved in regulating voluntary movement. 
The globus pallidus (GP) is the region of the brain where the highest concentration of iron can 
be expected. Hallgren and Sourander [93] measured an average value of 213 ± 34.9 μg/g in a 
healthy adult and show a variation of iron concentration (y, in mg/100g) with age (x, in years) 
of: 
                         (3.2.1.3) 
Although there is a study showing reduced iron in the medial section of the GP [106] with AD 
and another showing no change [19], direct iron measurements published by Loeffler et al. 
showed a statistically significant increase in iron for both AD and PD compared to control [18]. 
There is evidence for increased iron with AD in a number of MRI studies of the globus pallidus 
[125, 126, 133, 139] and therefore it is included in this study. 
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The literature shows evidence of both increased and decreased iron in the globus pallidus with 
AD, possibly depending on whether the GPe or GPi is measured. Therefore this could be an 
interesting area to study with high resolution MRI mapping and SXRF metal maps as the sub-
regions of the GP can be examined in detail. 
3.2.1.4 Substantia nigra 
The substantia nigra is also part of the basal ganglia. It is situated in the midbrain, towards the 
top of the brain stem, inferior to the rest of the basal ganglia. An axial view of the substantia 
nigra is shown in Figure 3.5. The SN can be divided into the pars compacta (SNc) and pars 
reticulata (SNr) [171]. A striking feature of the SNc is the strongly pigmented dopaminergic 
neurons [172], which cause the dark band in the tissue and can be seen under a microscope 
without additional staining.  On the other hand, the neurons of the SNr are smaller and more 
dispersed. The SNr and the internal globus pallidus have a similar structure and function and 
can be considered part of the same structure separated by the internal capsule. Together they 
form the major output of the basal ganglia [168].  
 
 
Figure 3.5: An axial view of the substantia nigra and surrounding structures. Note: the cerebral crus is 





The SN is important in movement and emotion. It is not generally affected by AD pathology, 
but experiences huge neuronal loss in PD, which leads to the characteristic resting tremor 
[171].  
This region was included in the study despite the fact that no literature was found describing 
increased iron in this region in AD. Studies either showed no change by bulk iron [106] or MRI 
[139] measurements or showed a decrease [18] in iron in AD compared to control. However, 
iron in the substantia nigra (SN) has been shown to increase in Parkinson’s disease (PD) [147] 
and Brar et al. showed that patients with AD who also had Parkinsonism had a statistically 
significantly higher iron concentration than those who had only AD [144]. The SN could 
therefore be an interesting region for comparing AD and PD and may be a useful area to target 
in differentiating between the diseases. 
3.2.1.5 Amygdala 
The amygdala is part of the limbic system and is made from a collection of nuclei found within 
the medial temporal lobe (Figure 3.4). The amygdala is involved in fear, anger and emotional 
memory [173]. 
The amygdala is significantly and consistently affected by AD pathology causing 
neuropsychiatric symptoms which begin to present early in the disease [174]. Senile plaques 
are formed and the pyramidal neurons are susceptible to neurofibrillary tangle formation [175] 
leading to cell death and atrophy [15, 34]. 
Direct measurements of iron in the amygdala have shown an increase of iron in AD compared 
to control with statistical significance of p<0.05 [16, 17, 20] or p<0.10 [39]. Additionally iron 
was shown to be increased in the neurophil of the amygdala in AD compared to control [114]. 
However, no studies were found that looked at the effects of iron on MRI of the amygdala in 




The pons is a fibrous structure in the brain stem. An axial view of the pons is given in Figure 
3.6. It is important in motor function, and lesions in the pons are associated with a variety of 
motor syndromes [176]. 
The literature review did not reveal any studies of iron in the pons in AD. However, iron was 
measured in a singular AD pons sample during a collaborative study with Dr Naomi Visanji and 
Dr Lili-Naz Hazrati (from the University of Toronto). The focus of the collaboration was to 
investigate iron dysregulation in the pons in MSA and PD [28]. The singular AD sample showed 
increased iron compared to control and PD tissue and therefore two additional AD samples 
were requested from this region. A benefit of studying this region was that tissue and data 
from MSA, PD and control data were already available for comparison to the AD samples.  
 
 
Figure 3.6: An axial view of the pons. This figure is adapted from the horizontal in situ atlas from 
thehumanbrain.info [167]. 
 
3.2.2 Sample details 
Tissue samples were requested from the Canadian Brain Tissue Bank, which provided three 
disease and control samples from each of the regions that were requested. The work in this 
project was done under multi regional ethics committee (MREC) approval for the project 
'Metal-ion accumulation in neurodegenerative disease' (REC ref: 07/MRE08/12) held by Dr 
Joanna Collingwood at University of Warwick, current until 2015. 
68 
 
For the putamen, substantia nigra and pons three PD and MSA cases were also provided as 
these regions and diseases were being investigated as part of a collaborative study recently 
published in the Journal of Parkinson’s Disease: Iron Deficiency in Parkinsonism: Region-
Specific Iron Dysregulation in Parkinson's Disease and Multiple System Atrophy by Visanji et al. 
(2013) [28]. Note that for PD a total of 4 cases were used, as the pons from one case was 
missing and therefore a different brain was used. 
Each region was dissected, including some surrounding tissue, by the group in Toronto and the 
resulting tissue blocks shipped to the University of Warwick in dry ice. Dr Naomi Visanji (PhD) 
and neuropathologist Dr Lili-Naz Hazrati (MD, PhD) at the University of Toronto provided 
support in identifying the anatomy, structures and regions of interest in the tissue throughout 
the project. 
Fresh frozen, rather than fixed, tissue was used as fixing has been shown to leach metals from 
tissue [91], potentially changing the concentration and distribution of metal within the sample. 
Once received at the University of Warwick, all tissues used in the study were stored at -80 °C.  
The samples were received with assigned case numbers. To ensure anonymity and for ease of 
data presentation the samples were renamed with a number from 1 to 3 (and 4 for PD cases) 
and the letters C, AD, PD or MSA to indicate their disease state. 
Table 3.4 gives the details of the tissue received for each case, including the age, sex and 
pathology information. For the AD cases the Braak stage of the disease pathology is given as 
either V or VI which describes the pathology of fully developed AD [177]. All Parkinson’s 
Disease cases present as akinetic-rigid and all multiple system atrophy (MSA) cases as MSA-P. 
Table 3.4 shows that the control and AD samples are not perfectly age-matched: the mean 
ages are 67 and 82 respectively. The potential consequence of this can be estimated using the 
empirical equations for iron concentration with age that were produced by Hallgren and 
Sourander [93] and were given above: Equation 3.1 for the CN, 3.2 for the putamen and 3.3 for 
69 
 
the globus pallidus.  
Case Number Brain regions Sex Age Pathology information 
C1 
Amyg, CN, GP, 
Pu, Pons, SN 
F 47 Pulmonary embolism 
C2 
Amyg, CN, GP, 
Pu, Pons, SN 
M 78 Lung cancer 
C3 
Amyg, CN, GP, 
Pu, Pons, SN 
M 76 Cardiac infarction 
AD1 
Amyg, CN, GP, 
Pu, Pons, SN 
M 73 Braak vi 
AD2 
Amyg, CN, GP, 
Pu, Pons, SN 
F 75 Braak vi 
AD3 
Amyg, CN, GP, 
Pu, Pons, SN 
F 98 Braak v 
PD1 Pu, Pons, SN M 73 Akinetic-rigid 
PD2 Pu, Pons, SN M 56 Akinetic-rigid 
PD3 Pons F 79 Akinetic-rigid 
PD4 Pu, Pons, SN M 76 Akinetic-rigid 
MSA1 Pu, Pons, SN M 76 MSA-P 
MSA2 Pu, Pons, SN M 66 MSA-P 
MSA3 Pu, Pons, SN F 46 MSA-P 
 
Table 3.4: Case details for the samples used in this project. The regions studied from each 
case are given, where: Amyg = amygdala; CN = caudate nucleus; Pu = putamen; GP = globus 
pallidus; SN = substantia nigra. The sex and age of each individual at death is given. For the 
control cases the cause of death is stated. For the Alzheimer’s Disease (AD) cases the Braak 
stage of the disease pathology is given. All Parkinson’s Disease cases present as akinetic-









for iron in AD 
samples due to age 
Caudate Nucleus 96.5 98.3 1.9% 
Putamen 140.8 145.3 3.2% 
Globus Pallidus 217.3 217.7 0.2% 
 
Table 3.5: Predicted iron concentration for the control and AD sample set. The mean age of the three 
control and AD cases was used to predict the mean iron concentration in caudate nucleus, putamen and 
globus pallidus. As the AD cases had a greater mean age they are predicted to have slightly higher iron 
concentrations. The largest predicted change of 3.2% is in the putamen. 
 
 
Table 3.5 gives the mean predicted iron concentration for the control and AD samples and the 
difference between them due to the difference in mean age of the sample set. The largest 
predicted difference is for the putamen, which shows a predicted 3.2% increase in the AD 
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sample set. No empirical equations were available for the pons, substantia nigra or amygdala. 
3.2.3 Sample excision 
The blocks of tissue received from the University of Toronto were much larger than the 
imaging space in either of the high resolution imaging probes. Additionally the blocks 
contained tissue from surrounding structures that were not intended for inclusion in bulk 
tissue analysis. Therefore, smaller samples appropriate to the different measurement 
techniques were cut from the original blocks. 
Before cutting, tissue was placed overnight in a -25 °C freezer. It was then allowed to warm to 
just below freezing so that it was just soft enough to cut without fracturing the block. To 
prevent uncontrolled defrosting and to keep the tissue just frozen, cutting was carried out in 
the cool environment of either a cryostat or biohazard hood cooled with dry ice. Tissue was cut 
with a ceramic blade and stored in clean cryotubs or weigh boats sealed in double layered zip-
lock bags to prevent the tissue drying. 
For the pons, SN, Pu and CN two adjacent tissue samples were cut: one for MRI and one for 
SQUID magnetometry and iron quantification as shown in Figure 3.1. This was not done for the 
GP as there was not enough tissue available and MRI was prioritised. For the amygdala, region 
identification was particularly tricky and confidence about anatomical identification was not 
great enough to cut a second block for SQUID magnetometry. 
For the samples to be imaged with the 400 MHz probe, which has the larger internal diameter, 
some surrounding tissue was purposefully included in the tissue block taken for MRI. This 
context can help to identify the structure in the resulting data. It also provides information 
about the contrast between the structure and its surroundings, which may be relevant when 
comparing cases and could be useful in considering how the MRI data collected in the lab 
would compare to clinical MRI imaging of living subjects.   
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Each case was shipped with accompanying photos identifying the brain region within the 
block. Tissue was further photographed and a cutting plan made and sent to Dr Lili-Naz Hazrati 
for confirmation that each region had been identified correctly and that the samples cut from 
each region would produce a comparable set. After confirmation was received tissue was cut 
as described below. 
Accompanying the description of the cutting protocols for each brain region is a Figure 
showing the cutting of an example case. A photographical record of the cutting of each sample 
can be found in Appendix B. In each case part A is taken for MRI and part B for bulk tissue 
analysis.  
For the same brain regions from different cases, care was taken to cut from approximately the 
same part of each region so as to provide a good match between control and AD and more 
comparable imaging and iron concentration data.  
Photos show how the surface of each MRI block is scored with the ceramic blade before 
cutting, in order to help keep track of tissue orientation throughout preparation and imaging. 
Tissues were cut to either fit the 8 mm diameter NMR tubes for imaging at 600 MHz or the 20 
mm tubes for imaging at 400 MHz. Samples had to be small enough to be slipped easily in and 
out of the tubes, but large enough to best utilise the imaging volume. The thickness of the 
original tissue blocks was around 1 to 2 cm and the full thickness of each sample was retained 
for imaging. 
3.2.3.1 Caudate nucleus and putamen 
For each case the caudate nucleus and putamen samples were cut from the same block of 
tissue. Using the coronal sections in The Atlas of the Human Brain [167] and the associated 
website (thehumanbrain.info) as a reference, each sample’s position in the brain was 





Figure 3.7: Preparation of putamen and caudate nucleus sample C1 for MRI and bulk tissue analysis. a) 
The approximate level of the tissue (image adapted from thehumanbrain.info), with the planned cutting 
of tissue for MRI (A) and bulk tissue analysis (B)  outlined.  b) Tissue from case C1 with the caudate 
nucleus and putamen outlined. First the caudate nucleus MRI sample is cut c) and then the putamen 
sample d). Then the putamen bulk tissue sample e) is cut, followed by the caudate nucleus sample which 
is shown on the right hand side of the dashed line in f). 
 
 
Figure 3.7 shows how the CN and Pu tissue was cut from the main block of sample C1. MRI 
tissue (A) was cut to fit inside the 20 mm diameter NMR tubes of the 400 MHz probe. Tissue 
from the surrounding structures was included in these samples. Samples that were for bulk 
tissue analysis (B) were carefully cut to keep within the specific brain region. In some cases the 
white matter surrounding the grey matter was trimmed off after the initial cuts. For example, 
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tissue often needed to be removed at the back of the sample where the region of interest did 
not run through the full depth of the block.  
Bulk tissue MSA and PD putamen samples were cut following the same principle. However, no 
tissue was cut for MRI as there was not sufficient time to image these samples and priority was 
given to the control and AD tissue. Appendix B-1 shows the cutting of all CN and Pu samples. 





Figure 3.8: Preparation of globus pallidus 
sample C1 for MRI. a) The approximate level 
of the tissue (image adapted from 
thehumanbrain.info), with the planned MRI 
region outlined (A). b) A photograph of the 
original tissue block with the tissue 
structures outlined. From left to right they 
are: internal globus pallidus (GPi), external 
globus pallidus (GPe) and putamen (Pu). c) 
shows the tissue after the sample is cut . 
 
Samples for the globus pallidus ranged from coronal level 4 to 12 mm as identified by 
referencing coronal sections from The Atlas of the Human Brain [167]. MRI samples were all 
cut to try and include tissue from the internal and external globus pallidus as well as the 
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neighbouring part of the putamen. Not enough tissue from the regions of interest was present 
in the blocks to allow for samples to also be cut for bulk tissue analysis. An example of globus 
pallidus preparation is shown for case C1 in Figure 3.8. The globus pallidus was imaged at 400 
MHz and was cut to fit inside the 20 mm diameter NMR tube. Appendix B-2 shows the cutting 
of all of the other GP samples.   
3.2.3.3 Substantia nigra 
 
 
Figure 3.9: Preparation of substantia nigra sample C2 for MRI and bulk tissue analysis. a) An in situ view 
of the SN as shown in the axial atlas from thehumanbrain.info. The original tissue block is shown in b). 
The substantia nigra was cut from the surrounding tissue c) & d) and then bisected axially e) into block A 




The tissue block from the SN was cut axially, rather than coronally. The whole substantia nigra 
was cut out of the larger block and cut in half along its length as shown in Figure 3.9. Block B is 
the top half and was prepared for bulk tissue analysis.  
The preparation of all other SN samples is shown in Appendix B-3 and this includes tissue from 
the three PD and MSA cases. SQUID and iron quantification were prioritised over MRI for the 
SN in order to complete the MSA study [28]. This meant that for a few cases the whole SN was 
taken for bulk tissue analysis. This was the case for samples C3 and AD3, where only a small 
amount of SN tissue was available and bisecting the sample would have resulted in samples 
too small for either MRI or SQUID magnetometry to be carried out. Note, limited experimental 
time meant that no MRI mapping was carried out on MSA samples. 
The bottom half of the bisected sample is part A and was reserved for MRI where enough 
tissue was present. The SN was imaged using the 400 MHz system which was large enough to 
image almost the entire sample in each case. Where necessary a small portion (maximum 2 
mm) of the sample was trimmed at either end in order for the sample to sit horizontally in the 
NMR tube. 
3.2.3.4 Amygdala 
The amygdala was a challenging area to dissect. Therefore extra care was taken to obtain 
advice before tissue was cut for MRI. Figure 3.10 shows the MRI sample cut from amygdala 
case C3. Part a) shows the feedback from Dr Hazrati and Dr Visanji who draw the blue oval 
over photos of the tissue block to indicate the position of the amygdala. The amygdala was 
imaged at 600 MHz and the pieces were cut from the block to fit the 8 mm diameter NMR 





Figure 3.10: Preparation of amygdala sample C3 for MRI. a) The sample with a blue oval drawn 
over the position of the amygdala. b) The sample before cutting; c) score marks indicating where 
cuts will be made and d) the sample for MRI. 
 
3.2.3.5 Pons 
As part of the collaborative study with The University of Toronto, tissue for bulk iron analysis 
was cut from the pons for all samples (apart from AD1 and AD3) before the commencement of 
this project. Figure 3.11 shows how tissue was cut for MRI imaging from the pons using sample 
C1 as an example. Part a) shows the cutting reference used for the pons. Tissue for the bulk 
iron analysis was cut by Dr Joanna Collingwood, University of Warwick, before the beginning of 
this PhD. The same guide as shown in a) was used, but tissue was cut from the adjacent block 
of tissue. Pons samples were imaged using the 600 MHz system at the University of Florida and 





Figure 3.11: Preparation of pons sample C1 for MRI. The reference for the planned cutting is shown in 
a), and the original tissue block is shown in b). The cuts are first marked out by scoring the surface of the 
tissue as shown in c). Finally the sample for MRI is cut from the main block d). 
 
3.3 Sample preparation 
Figure 3.1 showed the experimental path for each sample. Section 3.3.1 describes how block B 
was freeze-dried for SQUID magnetometry and iron quantification and Sections 3.3.2 and 3.3.3 
detail how block A was prepared for MRI relaxometry and then sectioned for histology and 
metal mapping.  
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3.3.1 Preparation for bulk tissue analysis 
Tissue was prepared for SQUID measurement as described by Hautot et al., 2005 [108]. The 
excised tissue was freeze dried for at least 8 hours until the sample mass stabilised. After 
drying, the mass of the sample had typically reduced by a factor of 3 to 4. Freeze dried tissue 
was cut into small pieces using an acid washed, non-metallic knife and fed into a SQUID straw. 
It was then compressed into a pellet using non-metallic rods as shown in Figure 3.12. The 
SQUID straw was supported with a strong tube during this process to prevent bending or 
buckling around the tissue.  
 
Figure 3.12: Tissue compression for SQUID magnetometry. The freeze dried tissue was compressed 
inside a SQUID straw using two non-metallic compression rods which were pushed towards each other 
by hand. The SQUID straw was positioned inside a non-metallic, strong supporting tube during the 
compression to prevent bulging or splitting of the SQUID straw. 
 
 
As the SQUID straw is held vertically during measurement the pellet was supported inside the 
straw using a second straw that was cut in two, folded along its length and fed into either end 
of the straw containing the sample.  
3.3.2 Preparation for MRI 
MRI of the pons and amygdala was carried out at the McKnight Brain Institute at the University 
of Florida using a probe with a 10 mm bore that held an 8 mm diameter NMR tube. At the 
University of Warwick a 30 mm bore probe containing a 20 mm diameter NMR tube was used 
to image the putamen, globus pallidus, caudate nucleus and substantia nigra.  
For both probes the tissue was suspended in Fluorinert (3M, Belgium NV), which gives zero 
MRI signal, in Wilmad-Labglass NMR tubes. Both the NMR tubes and Fluorinert were cooled to 
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-20 °C before being brought into contact with the frozen tissue. In both set-ups, care was taken 
to minimise the number of bubbles present in the vicinity of the sample as they cause artefacts 
in the MRI, particularly in T2* measurements. Although the sample environment for MRI was 
similar, the different sized systems required two slightly different mechanisms to support the 
tissue samples during measurement.  
3.3.2.1 600 MHz MRI sample set-up 
 
 
Figure 3.13: The effect of 12 hours of imaging on the shape of a tissue sample. a) The still frozen tissue 
block submerged in Fluorinert by a gauze plug. b) The defrosted sample immediately after imaging. c) A 
FLASH image shows the tissue after around 30 minutes in the scanner—the period of time taken for the 
sample to defrost and for initial imaging set-up to be carried out. The top of the tissue has already 
begun to mould around the gauze plug and the side of the NMR tube. d) After 12 hours imaging the 
FLASH image shows the tissue has further moulded around the gauze and to the shape of the NMR tube. 
However the gauze has remained in place. 
 
 
For the smaller bore magnet, where the inner diameter of the NMR tube is around 8 mm, the 
tissue was held just below the surface of the Fluorinert using a plug of cotton gauze as 
described by Antharam et al. 2012 [132] and shown in Figure 3.13 a) and b). Approximately 1.5 
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ml of Fluorinert was poured into the NMR tube before the tissue was dropped carefully into 
place. Gauze, which had been soaked in cold Fluorinert, was then pushed into the tube using a 
plastic stick. The stick was also used to manipulate the gauze and free any trapped air bubbles.  
Although the gauze plug remained firmly in place inside the narrow tubes, it did not provide a 
flat support surface. This allowed tissue samples sit an angle within the tube and for the tissue 
to deform around the curved bottom of the plug. This deformation was due to the upwards 
pressure of the relatively dense Fluorinert on the soft, defrosted tissue. Figure 3.13 shows a 
particularly bad example of tissue deforming during imaging. 
3.3.2.2 400 MHz MRI sample set-up 
As the 400 MHz magnet has a larger bore and the NMR tubes used to hold the samples had an 
inner diameter of 20 mm, a new method of holding the tissue below the surface of the 
Fluorinert was devised. Figure 3.14 shows the new support and the resulting tissue shape over 
the course of the MRI scan.  
A small three-part insert was designed, in collaboration with Peter Kimber (School of 
Engineering, University of Warwick). As shown in Figure 3.13, the device was made of two 
pieces of plastic which clip together and hold a disk of nylon stocking. This creates a firm, but 
gentle support for the tissue. The diameter of the device is just below 20 mm and therefore 
drops easily down into the NMR tube. Tapping and gently tipping the NMR tube was enough to 
encourage most bubbles to pass through the nylon or around the sides of the support. The 
weight of the support was enough to hold the tissue block just below the surface of the 
Fluorinert and the stretched nylon was firm enough to provide a flat support for the tissue 
samples. The design includes a lip which allows a specially designed plastic rod to hook the 
support from the tube after imaging. All of the plastic parts of the support are reusable and 
were acid washed between uses. The nylon was thrown out and replaced after each use. 
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Figure 3.14 e) and f) show that the new design, with much more even tissue support, is an 
improvement to the gauze plug design and results in greatly reduced deformation of the tissue 
during imaging.  
 
 
Figure 3.14: The tissue support for imaging at 400 MHz and the result of 12 hours imaging on the shape 
of the tissue. a) The plastic parts of the tissue support clip together to hold a piece of nylon tights b). c) 
This creates a firm, flat surface which held the tissue just below the surface of Fluorinert in a 20 mm 
NMR tube. d) A plastic was rod designed to hook into the plastic support and remove it from the NMR 
tube after imaging was complete. e) and f) show the typical effect of 12 hours of imaging on the shape 




3.3.2.3 Sample temperature 
In both protocols tissue was positioned in the NMR in the cold environment of a -20 °C 
cryomicrotome to prevent any defrosting. After preparation the samples were kept at -25 °C 
until just before imaging, with minimal temperature cycling and storage at temperature of -25 
°C for no longer than 24 hours before imaging to minimise tissue degradation. Initially samples 
were refrozen to -80 °C before imaging, which froze the Fluorinert. However, this meant a 
longer time was required before measurement temperature was reached and more 
importantly air bubbles formed as the Fluorinert melted, increasing the incidence of artefacts 
in the imaging. 
During imaging at the University of Florida the samples were warmed to 3.0 ± 0.1 °C and 
during imaging at the University of Warwick the temperature was kept to 2.0 ± 0.1 °C. Once 
imaging was completed, the imaged tissue was thoroughly refrozen before being removed 
from the NMR tube. The gauze or the plastic support was pulled from the tube using a plastic 
hook and this usually brought the tissue with it. If the tissue remained in the tube it was 
encouraged out using the plastic hook. The gauze or nylon was then carefully pulled from the 
tissue using plastic, acid washed tweezers, again working inside the cryomicrotome. Tissue was 
then stored in cryotubs at -80 °C until required for sectioning. 
3.3.3 Sectioning MRI tissue blocks 
MRI mapped tissue blocks were sectioned using a Leica cyromicrotome (model: Jung CM3000) 
so that the tissue sections could be histochemically stained to aid with anatomical 
identification (Section 4.5 Histology). 
Samples were carefully mounted onto the sectioning block at the same orientation that they 
were in during MRI. For samples imaged at 400 MHz, the flat surface of the tissue blocks, 
where they had rested against the nylon support, made this alignment straightforward. For 
samples measured at 600 MHz, where the top of the sample had slightly moulded around the 
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gauze plug, alignment was judged by eye using the MRI FLASH images as a guide. Tissue-Tek 
mounting medium was used to stick the samples to the chuck using just enough to firmly 
attach the sample. As shown in Figure 3.15, the samples were not embedded in the mounting 
medium. 
Sectioning was carried out with the blade at an angle of 10 degrees and a thickness of 30 µm. 
The object temperature was set to around -17 °C and adjusted to suit the sample. Covered 
samples were left in the cryotome for at least 1 hour before sectioning to allow the 
temperature to equilibrate from -80 °C. The fresh-frozen, not embedded tissue required very 
careful sectioning. The tip of a paint brush (Figure 3.15) was used to control the sections as 
they were cut, to prevent curling and manipulate the sample onto the slide. Sections for 
histology were captured on glass slides, kept cold in the sample chamber, and the heat from a 
finger was used to melt the sample onto the slide.  
 
 
Figure 3.15 Tissue sectioning. Just enough mounting medium was used to anchor the sample to the 
chuck, without embedding the sample. As the tissue was cut with the sapphire blade, the paintbrush 





Some samples were particularly difficult to section, especially those made largely of grey 
matter which was more likely to splinter during sectioning. Careful temperature control 
allowed good sections to be captured for most of the samples. 
Not every section was collected, but particular care was taken to sample heavily from the high 
resolution MRI region of each sample. In addition to visual comparison of the surface of the 
sectioning block and the MRI maps, the MRI records and the cyromicrotome’s section counter 
were used to calculate the approximate position within the tissue block and determine when 
the high resolution MRI region had been entered. Detailed notes were made of the sections 
collected on each slide including the section number, where counting was started at first 
contact between the blade and the tissue block. 
3.3.3.1 Tissue sections for SXRF mapping 
Features of the sectioning protocol described above, such as non-embedded samples, use of a 
sapphire blade and the 30 µm sectioning thickness, have been used as part of a protocol 
designed to provide sections suitable for SXRF mapping in addition to histochemical staining. 
This is a similar protocol as previously described by Antharam et al. [132].  
The SXRF metal mapping technique is highly sensitive, and any contamination can lead to false 
results or could provide such a strong signal so as to overshadow the neighbouring area. 
Therefore it is imperative to avoid metal particulate contamination in the preparation of the 
sample. As iron is the main focus of this study, elimination of potential iron contamination was 
a priority. 
The sapphire blade was used to avoid the potential for metal contamination that would arise if 
using a metal blade, which would necessarily come into contact with the whole of the surface 
of the section as it was cut. The sapphire blade was held in a metal blade holder within the 
cryomicrotome in such a way that approximately 15 mm of blade protrudes from the clamp 
(Figure 3.15). Therefore, as sections were cut they fell onto the blade rather than the metal 
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surface. With sections that were to be mapped, particular care was taken to avoid them 
coming into contact with any metal surface in the cryomicrotome. This was not important for 
sections cut for immediate staining. 
Mounting medium was not used to embed the samples for two reasons. Firstly, it would 
provide a possible route for contamination as mounting medium may contain traces of iron 
and other metals. Secondly, although the sapphire blade cuts the brain tissue cleanly and 
effectively, it struggled to cut the mounting medium and if used to do so it rapidly 
deteriorated.  
Sections were cut at 30 µm thickness as experience from previous SXRF mapping experiments 
by our group has shown that at this thickness a strong, above background SXRF signal can be 
achieved with a measurement time of 1 second per point. Comparatively, the MRI slice 
thicknesses are 80 µm for imaging at the University of Florida and 150 µm at the University of 
Warwick and therefore one MRI slice represents several sections.  
Once the high resolution MRI region of the sample was entered sections were collected for 
SXRF mapping. At least four sections spaced throughout the high resolution region were 
collected onto high quality quartz slides for each sample. Quartz slides have a low iron content 
and produce a much more homogeneous fluorescence signal than normal glass slides, 
providing a reasonably consistent background that can be subtracted from SXRF metal maps. 
Sections for SXRF were collected for every MRI sample, however due to limited beam time at 
the Diamond Light Source, only one control and one AD sample from each brain region was 
mapped, with an additional PD and MSA pons case. The specific cases to be mapped were 
chosen based on the quality of the MRI images and whether they were judged to show a good 
example of the regions of interest. SXRF mapping is described in detail in Section 4.4. All 
unmapped samples have been stored for future use if desired. 
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The sections on quartz slides were prepared for mapping by air-drying for at least 4 hours. The 
samples were left to dry inside a biohazard hood to minimise the chance of iron particulate 
containing dust landing on them. The slides were then sealed with a layer of X-ray transparent 
kapton film, fixed around the edge of the slide with PAP pen and sealed with epoxy resin. This 
procedure both protected the samples from damage or contamination and sealed in the 
human tissue in order to comply with the health and safety requirements of the Diamond Light 
Source.  
Finally, the sections to be mapped were selected based on section quality and matching to the 
high resolution MRI maps. Where good matching was not achieved, for example due to 
sectioning in a slightly different plane to MRI imaging, a section was chosen that contained the 
same structural features as were visible in the high resolution MRI scans. Using the same 
protocol to cut sections for histology and for SXRF mapping (rather than switching to a metal 
blade, or reducing section thickness) meant that sectioning was continuous. Therefore, 
sections immediately adjacent to the SXRF sections were captured on glass and could be 
stained with haematoxylin. These were then taken to experiments at the Diamond Light 
Source and used as a guide when choosing the positioning of SXRF maps.  
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Chapter 4:  
Methodology 
This chapter describes the different methods used to investigate iron content and MRI 
relaxation rates in the samples that were described in Chapter 3, where Figure 3.1 showed the 
experimental model and Table 3.1 gave a summary of the measurements made on each 
sample. Bulk tissue analysis is described in Sections 4.1 Superconducting quantum interference 
device magnetometry and 4.2 Iron quantification. The high resolution MRI mapping is 
described in Section 4.3 and the synchrotron X-ray Fluorescence (SXRF) mapping in 4.4. Section 
4.5 describes the basic histology used to stain tissue sections cut from the samples analysed by 
MRI and the protocol developed to stain tissue sections after SXRF mapping. Finally Section 4.6 
details the statistical methods that are used to examine the data from the above experiments.  
4.1 Superconducting quantum interference device 
magnetometry  
Super Conducting QUantum Interference Device (SQUID) magnetometers are capable of 
measuring very small magnetic moments as well as accurately controlling the temperature of 
the sample and applied field. The SQUID sits inside a superconducting magnet which is used to 
apply fields to the sample. Liquid nitrogen and helium cool the superconducting magnet and 
are used to control the temperature of the sample. The sample is moved through a 
superconducting ring containing two Josephson junctions in parallel, inducing a current and 
voltage proportional to the magnetic moment of the sample. The SQUID is shielded from the 
surrounding superconducting magnet so that it only detects signal from the sample.  
Magnetisation measurements were made using a Quantum Design MPMS-5S SQUID capable of 
measuring over a temperature range of 1.8 to 400 K and with an applied field of ± 50 000 
Oersted (Oe). It can measure down to a magnetic moment of around 5 x 10-8 electromagnetic 
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units (emu). The sample is moved through a distance of 4 cm in a series of 32 steps and the 
resulting signal is fitted to giving the magnetic moment of the sample.  
The SQUID was used to examine magnetic properties of the freeze-dried, bulk tissue from 
control, Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Multiple System Atrophy 
(MSA) samples from the pons, substantia nigra and putamen and from the control and AD 
caudate nucleus.  
4.1.1 Isothermal remanent magnetisation 
The magnetic properties of the non-haem iron in the brain have been described in Section 2.2. 
However, the dominating signal from biological samples under an applied field is diamagnetic. 
The diamagnetic signal can be subtracted from the magnetic hysteresis of a biological sample 
in order to examine non-diamagnetic components in the sample, including contributions from 
particulate iron [108]. One simple way to avoid the diamagnetic contributions and examine 
only the material that can retain a net magnetisation after exposure to an applied field 
(primarily particulate iron in tissue) is to measure the isothermal remanent magnetisation. 
Isothermal remanent magnetisation (IRM) is the magnetic moment of a sample, at a fixed 
temperature, after a magnetic field is applied and then abruptly removed. After the field is 
switched off the diamagnetic contribution will be lost and only material that is magnetically 
blocked will retain a magnetic moment. Typically, ferrihydrite-like iron oxide nanoparticles in 
ferritin are still blocked at temperatures below 15 K [154], whereas nanoparticles of magnetite 
of greater than ~ 13 nm in diameter will be blocked at 50 K [83].  
4.1.2 Methodology for measuring IRM 
Before measuring the magnetic moment of a sample it is important that it be centred in the 
SQUID. This was achieved for each sample by applying a small field to the sample and running 
the built in direct current centring scan. The position of the sample was adjusted automatically 
and the dipole position checked by eye. The centring was repeated until the dipole was 
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properly centred.  Slight shifts in the position of the sample are possible due to the wide range 
of temperatures at which IRM was measured. Therefore auto-centring, under the IRM applied 
field, was included in the scan sequences after any change in temperature.  
The magnetic history of the sample can affect the IRM. Therefore it was important to 
‘demagnetise’ the samples by applying a field and cycling it slowly to zero in the ‘No 
Overshoot’ mode, before beginning measurements. This ensured that all samples began the 
IRM measurements with the same magnetic history. For the same reason the order of 
subsequent IRM measurements, at the different temperatures, is the same for all samples. 
In order to measure IRM the field of the superconducting magnet must be switched off 
abruptly, which is achieved by using the ‘Magnet Reset’ function of the SQUID to quench the 
magnet. The energy released during the controlled quench causes a large amount of liquid 
helium to boil off when compared to other typical magnetometry measurements. This helium 
use restricted the number of IRM measurements that could be made on each sample. 
After switching off the magnetic field the IRM of each sample was measured 8 times over a 
period of about 10 minutes, where each of the 8 measurements given by the magnetometer 
was the average of 5 measurements. The final IRM quoted was the average of the last 4 
values. 
The linear regression fit mode was selected for all data above 5 K. In this mode the software 
fits the magnetisation data with the centre of the dipole fixed, unlike the iterative regression 
mode which allows for sample movement. As the sample is centred under an applied field 
before scanning at a new temperature, the centre position is reliable. The benefit of using 
linear regression mode for samples with very small magnetic moments is that iterative 
regression mode is more likely to falsely report a non-zero magnetic moment.  
A full record of the IRM measurements made on each sample is given at the beginning of 
Chapter 5 Bulk tissue iron analysis and Appendix C contains the full scan protocols. 
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4.1.2.1 IRM curves at 5 and 50 K  
IRM curves are made by measuring the IRM of a sample at a fixed temperature, after a series 
of applied fields with increasing magnitude. IRM curves were made at 5 and 50 K for a 
selection of putamen and caudate nucleus samples and for one substantia nigra sample. 
Before each curve was obtained, the temperature of the sample was raised to 300 K and the 
demagnetising sequence run. The sample temperature was then reduced to the measurement 
temperature and a 250 Oe field was applied to centre the sample. This field was abruptly 
switched off and the IRM measured to give the first point on the IRM curve. The curve was 
completed with IRM measurements from applied fields of 500, 750, 1000, 1500, 2000, 3000, 
4000, 5000, 7500 and 10000 Oe. The full scan sequence is given in Appendix C-1. 
4.1.2.2 IRM at 5, 50 150 and 300 K 
IRM from an applied field of 10 kOe was measured at 300, 150, 50 and 5K in that order. The 
same order was used for each sample to ensure that all samples had the same magnetic 
history. Ideally the demagnetising sequence would have been run in between each 
measurement, but the time and helium used in raising the temperature to 300 K to run the 
‘demag’ sequence was prohibitive. As the temperature of the IRM measurements decreases 
more nanoparticles will become magnetically blocked, therefore the IRM measurements were 
made in order of decreasing temperature. As the magnetic history of the samples was the 
same, and the measurements were made in the same order, the results between samples are 
comparable.  
The data reported in the literature [83] and the IRM curves show that IRM at 5 K, which is 
dominated by ferrihydrite, will very likely not have reached saturation from an applied field of 
1 T. Therefore it is important that the same field is applied for each sample and the SQUID 
magnetometer’s no-overshoot mode was used. The full SQUID sequence used to measure IRM 
at 300, 150, 50 and 5 K is given in Appendix C-2. 
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4.1.3 Correcting SQUID data for sample length 
The SQUID magnetometer assumes a point-like sample and consequently there is a loss of 
signal for samples over 3 mm long. All data were corrected for sample length using the 
empirical formula described by Hautot et al. [108]:  
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Where: A is the distance between coils of the SQUID; R is the radius of pickup coils; z is the on-
axis coordinate and b is the sample length. For the Quantum Design MPMS-5 A = 1.519 cm and 
R = 0.97 cm.  
The length of each compressed sample, to the nearest 0.5 mm, was measured by holding a 
vernier calliper to the side of the transparent SQUID straw. The mathematical software Maple 
14 was then used to substitute the length of each sample into Equation 4.2 and find the loss of 
signal due to length. Maximum sample length was 13.5 mm and this resulted in f = 0.75. IRM 
values were then corrected by a factor of 1/f and are given as emu per gram of freeze dried or 
fresh frozen tissue.  
4.1.4 Quality of data 
Above, the assumption is made that the IRM data obtained at 5 K are not significantly affected 
by the fact that the sample has previously been subjected to 10 kOe at 300, 150 and 50 K. This 
assumption can be tested to some extent by comparing the IRM at 5 K measurement to the 
value of the last point in the IRM curves for the same sample. The demagnetisation sequence 
was run before each IRM curve was measured, and therefore the last point on the curve 
represents the first time that the sample was exposed to a field of 10 kOe (all other points on 
the curve are from smaller fields). If the data from the two measurements agree well it 
suggests that the IRM measurement at 5 K is not significantly affected by the measurements at 
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300, 150 and 50 K. The comparison of these two measurements is shown in Figure 4.1 a) for 
the 5 K data and similarly for the 50 K data in 4.1 b). Note that IRM measurements were not 




Figure 4.1: Comparison of IRM data from individual IRM measurements and IRM curves. The IRM after 
an applied field of 10 kOe at 5 K, a), and 50 K, b), for each putamen and caudate nucleus sample is 
shown with a grey diamond. Overlaid as a brown square is the last point of the IRM curve of the same 
sample, which was also made after an applied field of 10 kOe. Note IRM curves were only collected for a 
sub-set of samples. The data agree well. 
 
 
Typically the first few points on the IRM curves have an extremely small magnitude, often 
below the reliable detection limit of the instrument of 5 x 10-8 emu. However, quantitative 
comparisons are only being made with data from an applied field of 10 kOe. All 5 K IRM values 
are well above the detection limit and only a couple of 50 K values are below it. These data are 
indicated in the data set in Chapter 5 as appropriate. 
The error given for each IRM measurement is the combined error from: the standard deviation 
of the averaged IRM measurements, the measurement error in weighing the sample and the 
measurement error in measuring sample length. 
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4.2 Iron quantification 
The concentration of iron in each of the SQUID samples was subsequently measured using 
either Graphite Furnace Atomic Absorption Spectroscopy (GFAAS) or Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS). The method used for each sample is shown in Table 5.2 
at the beginning of Chapter 5 Bulk tissue iron analysis. 
4.2.1 Graphite furnace atomic absorption spectroscopy  
GFAAS was carried out by Dr Emily House in the Birchall Centre at Keele University and was 
used to measure the iron concentration of the pons and substantia nigra samples (with the 
exception of SN, MSA3). A Mars Xpress microwave was used to digest the tissue samples in 1 
ml HNO3 and 1 ml H2O2 using a CEM-provided Tissue Xpress program. Ultrapure water (3 ml) 
was added and the digest volume corrected for venting. The iron concentration was 
determined from 800-fold dilutions using a hollow-cathode lamp at 30 mA and atomic 
absorption measured at 248.3 nm. 
4.2.2 Inductively coupled plasma mass spectroscopy 
Inductively coupled plasma mass spectroscopy (ICP-MS) was carried out in collaboration with 
Dr Isolda Romero using the ICP-MS Agilent Technologies 7500 series from the Mass 
Spectrometry Facility of the University of Warwick. The compressed, freeze dried SQUID 
samples were transferred into acid washed 3 ml capacity glass Wheaton v-vials for digestion in 
72 % double distilled nitric acid. To transfer the sample with minimum opportunity for sample 
contamination, the SQUID straw was cut a little above and below the sample with a 
cleanroom-standard blade and the inner supporting straw used to push the sample directly 
from the straw into the vial. A test sample, T, taken from near the SN was also digested. 
A total of 1.5 ml of nitric acid was added to the vials in aliquots of 0.5 ml. Vials were placed in 
the oven at 55 °C for 5 hours, after which the tissue had visibly dissolved. Samples were then 
left in the oven at 55 °C overnight, for approximately 16 hours. After this time a very small 
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amount of fat was visibly floating on the top of the acid, however this was tiny compared to 
the original sample volume and it was judged that the iron in the tissue would be dissolved in 
the acid solution. 
A sample of the acid and tissue solution, pipetted from below the fat deposit, was dissolved to 
1:10 to achieve a safe acid concentration for ICP-MS. All water used for dilution was milliQ 
grade (18.2 MΩ).   
Before measuring the samples, the spectrometer was calibrated using a 1000 part per million 
(ppm) iron standard that was diluted in a 5% nitric acid solution to give a range from 5 to 2x105 
parts per trillion (ppt). Good curves were produced, with the best calibration curve achieved 
for the 57Fe isotope in the ‘no gas’ mode, therefore the values from this measurement were 
used.  
The ‘test’ sample was measured first and showed an iron concentration of 1.8 x 106 ppt. This is 
much more concentrated than the standards that were used for calibration. Ideally the sample 
would be in the x104 ppt range and therefore all samples were diluted by 1:10 and 1:100. The 
1:100 dilution test sample produced the best results, so the 1:100 dilutions of all the samples 
were measured. Two samples (MSA1 and MSA2) had to be further diluted by a factor of 10 to 
1:1000 in order to achieve an appropriate iron concentration. 
To ensure that there was no build-up of sample within the instrument, ‘blanks’ consisting of a 
1:100 dilution of the 72% nitric acid were run after every 4 samples. These consistently 





4.3 Magnetic resonance imaging 
MRI relaxometry was carried out at high fields (9.4 and 14.1 T). At high field the MRI signal is 
increased and this allows very high resolution mapping, whilst retaining a good signal to noise 
ratio. The effect of iron on the transverse relaxation rate R2, and the susceptibility related 
parameter R2*, increases with imaging field and therefore high field MRI relaxometry is more 
sensitive to tissue iron content [124].  
The MRI protocols used to measure T2 and T2*, and to produce the corresponding R2 and R2* 
maps, at the two different fields are described below. The full MRI protocols for the 
measurement of T1 are also included, however this not the focus of this study and therefore is 
not discussed in detail here and the data are not included in the results chapter. 
4.3.1 MRI data collection 
The MRI relaxometry in this project was carried out at two different field strengths, at two 
different research facilities. Mapping of the pons and amygdala was carried out using an 
established 600 MHz (14.1 T) probe at the Advanced Magnetic Resonance Imaging and 
Spectroscopy (AMRIS) facility in the McKnight Brain Institute at the University of Florida. A 
brand new 400 MHz (9.4 T) imaging probe at the Magnetic Resonance facility at the University 
of Warwick was used to map the caudate nucleus, putamen, globus pallidus and substantia 
nigra. Parameters specific to the 600 MHz probes are described in Section 4.3.1.2 and Section 
4.3.1.3 gives details of how the standard Bruker imaging sequences were optimised for 
mapping with the 400 MHz probe.  
4.3.1.1 Common features of measurement protocol at 600 and 400 MHz 
4.3.1.1.1 Sample temperature 
The temperature of the samples during imaging was kept at 3 °C in the 600 MHz probe and at 
2 °C in the 400 MHz probe. In both systems the temperature was maintained throughout the 
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measurement by a cooler blowing air around the sample. This was controlled by Topspin 
through feedback from a calibrated thermocouple in the sample space.  
Before using the new 400 MHz probe the temperature of the sample space was calibrated 
using an NMR tube filled with methanol. The NMR spectrum of methanol has distinct peaks for 
CH3 and OH. The distance between these peaks in ppm (∆) can be related to the temperature 
of the methanol in Kelvin, by the following equation [178]: 
                         (4.3) 
The desired temperature of the sample is just above freezing. Through trial and error a 
methanol temperature of 275 K was achieved by setting a target temperature of 270 K and an 
air flow of 800 litres per hour.  
 
 
Figure 4.2: FLASH image of a partially frozen 
tissue sample. As the core of the sample is still 
frozen, it shows little signal. 
 
 
Before carrying out MRI relaxometry it was important to wait for the samples to defrost, as in 
frozen tissue the water molecules are immobilised. Therefore, Fast Angle Low SHot (FLASH) 
images were used to monitor defrosting of the sample. In practice, a partially frozen sample is 
easily observed by the black core (absence of signal) at the centre of the block (Figure 4.2). 
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4.3.1.1.2 Tune and match and shimming 
Before imaging the probes were tuned and matched to the 1H channel. TopSpin was used to 
manually shim the gradients until a smooth free induction decay (FID) of maximum size, and a 
symmetrical, as narrow as possible water peak with a full-width-half-maximum (FWHM) of 
below 60 Hz was achieved. Shimming increases the field homogeneity within the sample space 
and is therefore necessary to produce good quality, reliable, reproducible data for high 
resolution imaging. 
4.3.1.1.3 Pulse sequences 
At both fields T2 was measured using a Carr-Purcell-Meiboom-Gill sequence (CPMG). This 
sequence is a multi-echo, spin echo sequence. After the initial 90° excitation pulse, a 180° 
pulse is repeated to produce a series of echoes at times TE, 2TE, 3TE etc. The decreasing 
magnitude of the echoe train follows the transverse decay. 
The shape of the transverse decay is described by Equation 2.4. With the addition of a 
constant (A) representing a finite background, this can be expressed as [132]: 
      
  
  
⁄   (4.3) 
Where y is equal to the signal in the transverse plane at a time, t, after the initial excitation 
pulse and C is the signal in the transverse plane at t = 0.   
The sequence to measure T2 was also a multi-slice sequence, i.e. many slices were measured 
within TR. Slice-selective RF pulses were used to create a stack of consecutive images for each 
slice, where each image is the RF signal measured at that time after the initial excitation pulse.  
The multi-slice multi-echo (MSME) sequence was chosen as it minimised the imaging time 
compared to single echo, or single slice imaging. The number of slices that can be measured is 




T2* was measured using a multiple gradient-echo (MGE) sequence. Selective slice excitation 
was followed by successive reversals of the readout gradient to produce a train of echoes. The 
echo train produces a decay with the same shape as described by Equation 4.3. 
4.3.1.1.4 Scan order and geometry 
A common approach was taken to arranging scan slices and scan order in both systems, as 
developed in prior work by the group [132, 179]. Low resolution scans were used first to 
measure the majority of the tissue sample volume. Data from these scans were then used to 
choose the volume of tissue to image at high resolution. The effect of any bubble artefacts, as 
well as the structure visible in the tissue, was taken into account before choosing the high 
resolution region.  
First, a FLASH pulse sequence was used to create tri-pilot images: a contrast image in each of 
the x, y and z planes (Figure 4.3 a). These were used as a reference for choosing the position of 
the mapping scans. A FLASH tri-pilot was carried out at the start of imaging, after the low 
resolution scans and again after the high resolution scans. This allowed any change in sample 
shape or position to be monitored. 
Low resolution data were collected by three sets of scans with interleaving geometry (Figure 
4.3 b). It is good practice to leave some space between slices when using multi-slice scan 
sequences in order to avoid interference between the slices. The Bruker option of ‘interlaced’ 
collection order of the slices within a scan was used, further reducing the likelihood of 
crosstalk. The multi-slice sequences can only measure a limited number of slices per scan and 
therefore three sets of scans were required to cover the entire tissue volume. A smaller 
volume of tissue was mapped at high resolution and two sets of interleaving scans were used 








Figure 4.3: Setting up slice geometry for MRI mapping. This is an example from the scan set up on the 
400 MHz probe. a) A FLASH scan shows the tissue in the x, y and z direction and this was used to set up 
the position of b) the low resolution scans which covered most of the tissue and c) the high resolution 
scans which covered only a small portion of the tissue. Note that the low resolution scans in c) had a gap 




4.3.1.1.5 Amplifiers and receiver gain 
During the set up for a scan Paravision has an option to run the pulse sequence and display the 
signal without recording data, allowing attenuation of the maximum amplifier power to the RF 
pulses to be optimised. Changing the power to the pulse affects its flip angle. If it is not 
optimised the pulses may not produce exactly 90° and 180° pulses and therefore a true T2 
decay or T1 recovery would not be produced. 
This is controlled through Paravision by setting the value of A0 (attenuation of power to the 
excitation pulse) and A1 (attenuation of power to the refocusing pulse). The values were 
optimised for each scan by adjusting the values until a maximum signal was detected (shown 
by the level of digitizer filling). The shape of the decay is also displayed in the Paravision set-up 
window and shows a smooth decay when the attenuation is optimised. Once optimised for 
each scan, on each system, these values were used as the default settings for each experiment. 
As the decay shape is displayed by Paravision during set-up, this was also checked by eye at 
the beginning of each experiment.   
The receiver gain was adjusted for each measurement so that for each scan type the digitiser 
filling reached approximately 70% (an arbitrary limit appropriate to the version of Paravision 
used) to ensure saturation did not occur. 
4.3.1.2 Imaging at the McKnight Brain Institute, University of Florida 
Quantitative MRI mapping was carried out on control, AD, PD and MSA samples from the pons 
and control and AD tissue from the amygdala. The protocol used is as described by Antharam 
et al. [132]. Each sample was imaged with a 10 mm TXI radiofrequency probe in the bore of a 
600 MHz (14.1 T) Bruker Advance spectrometer. Paravision version 3.0 was used to run the 
spectrometer and drive pulse sequences.  
The samples were prepared in NMR tubes as described in Section 3.3.2.1. The high and low 
resolution scans were set up as described in Section 4.3.1.1.4. Table 4.1 gives a summary of 
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the scan parameters used for mapping at 600 MHz. The low resolution scans had an in-plane 
resolution of 200 x 200 µm and a slice thickness of 250 µm. The in-plane resolution of the high 
resolution scans was 62 x 62 µm, with a slice thickness of 80 µm. Each high resolution scan had 














(high res) Parameter: 
Resolution (µm) 200x200 62x62 200x200 62x62 200x200 62x62 
Slice thickness (µm) 250 80 250 80 250 80 
Scan sequence MSME MSME MGE MGE MSMEVTR MSMEVTR 
Attenuators: A0, A1 16, 8.5 16, 8.5 21, -  21, -  18, 12 18, 12 
TR (ms) 4000 4000 3500 3500 * * 
TE [T first echo] (ms) 8.62 8.62 6.66 [3.70] 6.66 [3.70] 9.62 9.62 
No. echoes 20 15 18 18 1 1 
No. of averages 6 12 6 12 3 6 
Scan time 16m00s 1h42m24s 14m00s 1h29m36s 20m40s 2h9m58s 
 
Table 4.1: Scan parameters for MRI relaxometry at 600 MHz. MSME = multi-slice multi-echo; MGE = 
multi-gradient-echo; MSMEVTR = MSME variable repetition time. *T1 repetition times = 3500, 2250, 
1500, 1000, 750, 500, 350 and 250 ms. 
 
 
Although high resolution scans with interleaving geometry were set up for each sample, both 
scans were not collected in every case in order to reduce imaging time. For all samples only 
one high resolution T1 scan was run. Both sets of high resolution T2 and T2* scans were only run 
for one tissue from each disease group. The measurement time, including set up, was 
approximately 11 hours for the lesser number of scans and 14 hours for the full set of scans.  
The excitation and refocusing pulses of the MSME sequence were Sinc3 RF pulses and the T2 
decay was measured using 15 echoes at 8.62 ms intervals with the first echo at 8.62 ms. The 
repetition time (TR) was 4000 ms and the number of averages (NA) was 12. Twelve dummy 
102 
 
scans were also run at the beginning of the sequence to achieve a steady state before 
measurement was begun. 
The excitation pulse of the MGE sequence was a Gaussian pulse and was followed by a 
gradient-echo train created by reversals of the readout gradient. Eighteen echoes were used to 
measure the T2* decay with a spacing of 6.66 ms after an initial echo time of 3.7 ms.  The 
number of averages was 12, the number of repetitions was 12 and the number of dummy 
scans was 16. 
High resolution T1 measurement was carried out using an MSME, variable repetition time 
(MSMEVTR) scan. One echo time of 9.62 ms was used, with variable repetition times of 3500, 
2250, 1500, 1000, 750, 500, 350 and 250 ms. Twelve dummy scans were run before beginning 
data collection and the data for each echo was averaged from nine scans. 
4.3.1.3 Imaging at the University of Warwick 
A custom design Bruker micro-imaging MicWB40 probe (Figure 4.4), funded through the 
Birmingham Science City Translational Medicine project, was purchased in early 2010 and 
became the first MRI probe in the Milburn House NMR suit at the University of Warwick. The 
scans and data collection were controlled using Paravison version 4.0. 
The new probe was set up and tested as described below. The imaging parameters of the 
Bruker scan sequences were optimised to carry out high resolution MRI relaxometry on control 
and AD tissue from the caudate nucleus, putamen, globus pallidus and substantia nigra.  
4.3.1.3.1 Hardware 
The high resolution imaging probe gradients were designed to work with the existing 400 MHz 
spectrometer. A set of gradients (Figure 4.4 b) fit from the bottom into the vertical bore of the 
magnetic (Figure 4.4 a). They are maintained at approximately room temperature using cooled 
water, which is continuously pumped around the gradients and the temperature is monitored 
using an internal thermocouple. The imaging probe with RF coil (Figure 4.4 c and d) is then 
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inserted inside the gradient coils and the thermocouple inside the probe. The inner diameter 
of the probe is 3 cm and can hold a 2 cm diameter NMR tube, allowing space for air to 
circulate around the tube. The sample is loaded into the probe before both are positioned 
within the bore of the magnet. 
 
 
Figure 4.4: MRI hardware at the University of Warwick. a) The existing vertical bore 400 MHz magnet 
was fitted with b) gradient coils and c), d) an MRI probe. During the experiment the gradient coils are 
loaded into the bore of the magnet and the probe inserted inside the gradient. The temperature of the 




4.3.1.3.2 Testing the new probe 
During initial scanning inconsistent data were produced. Agarose gel samples (2% by weight) 
were used to trial scans as they should have reasonably uniform relaxation properties 
throughout the imaging volume. When only one slice was mapped the T2, T2* and T1 values 
were approximately as expected and showed reasonable uniformity across the slice. However, 
when multiple slices were imaged in a single sequence the relaxation values were inconsistent 
and ‘rings’ appeared in the image.  
A number of different parameters were altered in an attempt to achieve good quality high 
resolution mapping. This included: lengthening repetition time TR to ensure complete 
relaxation of spins; increasing the distance between slices in case crosstalk was causing 
artefacts and changing the order in which the slices were measured to further reduce the risk 
of interference.  
No improvement in the multi-slice imaging was observed and Bruker were asked to service the 
probe. Eventually a Bruker engineer discovered a problem in the way the hardware from the 
new probe had been connected to the old probe, which was quickly rectified. 
4.3.1.3.3 Adjusting Bruker scans 
Once the probe was working correctly, default Bruker scan sequences were adjusted to 
produce low and high resolution scans for mapping T1, T2 and T2* using agarose gel phantoms 
and finally testing the scans on a piece of chicken breast.  
Relaxometry sequences were chosen using advice from the Paravision help file and then 
adjusted for mapping the fresh-frozen, iron-rich tissues at high and low resolution. The aim of 
scan optimisation was to achieve i) high quality maps; ii) the ability to map rapid decays and iii) 
keeping imaging time to under 12 hours.  A time limit of 12 hours was set in order to minimise 
the tissue degradation over time and to maximise the use of limited instrument time. 
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In order to produce high quality maps, a good signal to noise ratio (SNR) was required in 
enough echoes in order to fit Equation 4.3. The SNR was found by dividing the difference 
between the tissue signal and background signal, by the standard deviation of the background 
signal. The scan protocols were designed to maintain a SNR of approximately ≥ 10 in the third 
echo. A number of competing factors had to be balanced in order to achieve high resolution 
mapping, with good SNR, with a total imaging time of less than 12 hours.  
A major challenge in the imaging was capturing very rapid T2 and T2* decays in regions of the 
samples with very high tissue iron concentration. The minimum TE values possible were used 
for both the MSME (for measuring T2) and MGE (for measuring T2*) sequences. The results of 
rapid decay fitting and the limit to what can be measured using these sequences is discussed in 
Section 4.3.3.3. 
As imaging resolution is increased, the voxel size is reduced, the number of spins contributing 
to the signal decreased, and therefore the SNR decreases. Increasing the number of averages 
for each scan can compensate for this, but this increases scan time. Additionally, the lower 
magnet strength of 400 MHz (compared to 600 MHz at the University of Florida), and the 
lower current gradients on the 400 MHz system, means less signal is obtained from the same 
sized voxel, resulting in a lower signal to noise ratio. Therefore the high resolution scans on the 
400 MHz system had larger voxels than the 600 MHz system in order to maintain signal quality.  
The in-plane resolution is defined by dividing the field of view (FOV) by a matrix of 128, 256, 
512, 1024 or 2048. Ultra-high resolution was selected by setting the matrix size to 2048. The 
FOV was set to 22 mm, to ensure the whole diameter of the NMR tube would be captured. The 
resulting in-plane resolution is 86 x 86 µm. A slice thickness of 150 µm was chosen after trial 
and error testing in order to achieve a good signal to noise ratio. 
A further practical consideration in pushing the resolution of imaging is that it increases the 
workload for the gradient coils. Steeper gradients are required to achieve high resolution, 
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which means a larger current is passed thought the gradients. This could cause them to 
overheat and become damaged. The problem is increased for scan sequences in which 
gradients are switched on and off very rapidly, without any periods of rest. Throughout scan 




Figure 4.5: Example data collected using the 400 MHz probe at the University of Warwick. a) A 25x25 
voxel area was selected for one slice of sample C3, globus pallidus. The average signal from this area is 
shown from the T1 b), T2 c) and T2* d) scans, where the points on the graph show the signal intensity for 
the series of echoes. The data shown was plotted and fitted in Paravision. 
 
 
The final scan parameters for the high and low resolution mapping are given in Table 4.2 and 
an example of the data produced by each scan is shown in Figure 4.5. Details of how each scan 
















(high res) Parameter: 
Resolution (µm) 195x195 86x86 195x195 86x86 195x195 86x86 
Slice thickness (µm) 250 150 250 150 250 150 
Scan sequence MSME MSME MGE MGE RAREVTR RAREVTR 
Attenuators: A0, A1 16, 3 16, 3 22.5,  -  22.5,  -  21, 8 22, 8 
TR (ms) 7000 7000 3500 4000 * ** 
TE [T first echo] (ms) 7.248 9.783 6.0 [3.08] 6.0 [3.90] 14 14 
No. echoes 16 16 16 16 1 1 
No. of averages 2 4 2 4 2 4 
Scan time 22m24s 1h29m36s 11m12s 51m12s 24m19s 1h41m32s 
 
Table 4.2: Scan parameters for MRI relaxometry at 400 MHz. MSME = multi-slice multi-echo; MGE = 
multi-gradient-echo; RAREVTR = rapid acquisition with relaxation enhancement, variable repetition 
time.* Low resolution T1 repetition times (ms) = 347, 481, 643, 841, 1095, 1449, 2043, 4500. ** High 
resolution T1 repetition times (ms) = 344, 496, 677, 896, 1179, 1573, 2234, 4500. 
 
 
Longitudinal recovery, T1 
For each sample T1 was mapped using a Rapid Acquisition with Relaxation Enhancement scan 
with Variable TR (RARE-VTR). This is the recommended scan for ultra-high resolution T1 
measurement given in the Paravision 4.0 Biospin manual. Hermite pulses are used for both 
excitation and refocusing and these were not altered from the automatic setting. 
The repetition times were calculated automatically by Paravision, which determines them 
based on the estimated approximate value of T1. By trial and error, using different T1 values, 
the approximate value of T1 was found to be 1100 ms. The only alteration made to the values 
of TR was extending the final repetition time to 4500 ms for both the high and low resolution 
scans. This was to ensure full T1 recovery between successive scans. 
During high resolution T1 mapping the gradients began to overheat. This was due to the way 
the RARE-VTR scan sequence measures all short TR values back-to-back, meaning the gradients 
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are working almost continuously during this period. The number of slices collected in the scan 
was reduced to from 7 to 5 which allowed enough rest time for the gradients to prevent 
overheating. 
Transverse decay, T2 
The MSME sequence was used to map T2 as suggested in the Paravision manual. This sequence 
uses CPMG pulse sequence with slice-selective RF pulses. The Bruker sequence uses a Hermite 
excitation pulse and Mao refocusing pulse. The time taken to apply the excitation and 
refocusing pulses determines the minimum TE. Different pulse combinations (Sinc3, Gauss) 
were tested to try and reduce minimum TE in order achieve better fits of rapid decays in the 
high iron tissue. However, changing the pulse shape compromised the measured T2 decay 
produced at high resolution and therefore the Bruker original scan sequences were used, with 
the minimum echo times.  
A long TR was used as it is important for the NMV to have completely returned to the 
longitudinal plane between successive excitation pulses. The minimum appropriate TR is 
considered to be at least four times T1, which is approximately 1100 ms in the tissue. This gives 
a minimum TR of 4400 ms. However, during scan testing a more consistent T2 was achieved 
using a longer TR of 7000 ms.   
Susceptibility related T2* 
A multiple gradient-echo (MGE) sequence was used to measure T2* in accordance with the 
Bruker manual recommendation. A Gauss excitation pulse is used and TE is short due to the 
fact that there is no refocusing pulse (refocusing is achieved by applying readout gradients). 
Shorter TR values (3500 ms at low resolution and 4000 ms at high resolution) could be used for 
the MGE measurements as the sequence is less susceptible to T1 not being fully recovered and 
as excitation angles of below 90 ° were used. 
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4.3.1.3.4 Final scanning protocol 
The samples were prepared for imaging as described in Section 3.3.2.2 before being taken on 
ice to the imaging facility. The scan parameters shown in Table 4.2 were used for imaging all of 
the tissues at 400 MHz. Table 4.3 shows a list of the scans in the order in which they were 
collected, which follows the same general principles that were described in section 4.3.1.1.4. A 
Paravision macro was used to run scans 3 to 18 automatically over approximately 11 hours.  
 
 
Table 4.3: The order of scans for MRI at 400 MHz. A FLASH (fast low angle shot) scan examines the 
overall shape and position of the tissue at the beginning, middle and end of the imaging process. Three 
sets of up to 10 interleaving scans were used to map T1, T2 and T2* at low resolution. Two sets of 5 (for 




4.3.2 Data Processing 
4.3.2.1 Paravision 
In addition to driving the hardware, Paravision can be used to fit the MRI data using the ‘Image 
Sequence Analysis’ tool. The contrast image of the first or second echo is used to select a 
region of interest (ROI) and then T2 (or T2*) is fitted to the decay produced from the average 
signal of the ROI in each echo. The ‘absolute bias’ is set to ‘varied’ in order to allow the 
software to take into account the finite background signal and ensure a better fit. Paravision 
uses a Levenberg-Marquardt nonlinear least squares fitting algorithm to fit the relaxation 
decays using Equation 4.3.  
Paravision does not provide very easy control of ROIs and was mainly used to visualise decays 
and examine data during imaging.   
4.3.2.2 ImageJ 
ImageJ [180] is a free, open-source, image processing software written in Java and available for 
download. It allows careful drawing and management of ROIs as well as image manipulation. 
In addition to the main software package a number of plugins are available, including plugins 
to process MRI data. Two plugins were used to process the MRI data. The ‘Bruker Opener’ 
plugin (available from the ImageJ website [181]) and the ‘MRI Processor’ plugin (available from 
the ImageJ wiki [182]). 
The Bruker Opener plugin allows ImageJ to open the ‘2dseq’ data file produced by Paravision 
to produce a stack of images made up from the consecutive echoes for each consecutive slice 
in the scan. These stacks were divided into separate stacks for each slice using the Substack 
Maker tool. 
The MRI Processor plugin was then used to produce a T2 or T2* map by fitting the signal decay 
in each pixel as produced by the sequence of echoes. The map type option ‘T2 Exponential’ 
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was used with the Levenberg-Marquardt fit algorithm. The echo times for the sequence were 
input and then the T2 (or T2*) map generated. 
Work carried out in 2011 by a summer project student (Kevin Ray, Department of Physics, 
University of Warwick) showed that fitting using the MRI Processor plugin produced the same 
numerical results as fitting using Paravision. The decay properties of individual pixels and the 
average over an ROI were also examined in OriginPro 8.5 (Origin). This showed that the best fit 
was obtained with a mono-exponential decay. 
Once the set of maps was produced for each sample, the ‘Math’ tool in ImageJ was used to 
find the reciprocal value for each pixel and therefore create an R2 or R2* map. The maps from 
consecutive slices could then be stacked to create a 3D volume of the sample. 
Initially only the high resolution MRI data were fitted, but for some samples, where further 
information was required, lower resolution data were also fitted.  
4.3.3 Artefacts and data quality 
4.3.3.1 Variation across the sample space 
Imaging at the AMRIS facility at the University of Florida was carried out early on in the project 
using established scan sequences. Upon examination of the T2 data it was found that the data 
were not consistent throughout the sample volume. A typical example of the variation 
observed is given in Figure 4.6, which shows T2 and T2* for an ROI of 2000 pixels overlaid onto 
the maps of amygdala AD3. The T2* data remains fairly constant for each slice, whereas the T2 
data increases to a maximum at slice 4 and then decreases.  
Although T2 data from other samples showed a similar trend, the exact shape and position of 
the peak was not consistent from sample to sample, even when corrected for relative slice 
position within the sample space. Therefore there was no reliable way of correcting the data 





Figure 4.6: Typical T2 and T2* data collected at AMRIS, University of Florida. T2 data show significant 
inconsistency with slice number, despite T2* data being consistent. 
 
 
It is likely that the unusable T2 data is due to a step in the scan set-up where the power to the 
gradient coils was limited for the MSME sequence. This was done to prevent overheating when 
driving the coils hard to image at such high resolution. As the power to the gradient coils was 
not as large for the MGE sequence, the same problem with the data is not observed for the T2* 
data. 
4.3.3.2 Artefacts 
Figure 4.7 shows some artefacts encountered during imaging. Part a) uses data from amygdala 
sample C1 to demonstrate an artefact that appeared in all T2* MRI maps made at the AMRIS 
facility. There is a vertical line of pixels which is visibly altered from the surrounding image. As 
the artefact is limited to a single line of pixels, and do not have a large difference in value from 
the surrounding map, it is unlikely to cause any significant difference to the average value of 





Figure 4.7: Typical artefacts in MRI maps. The vertical line artefact in a) appears in all T2* maps made at 
AMRIS. Squashed tissue at the edge of the NMR tube also provides an unusual signal. b) An artefact in a 
T2 map caused by an air bubble. c) The same slice of the corresponding T2* map, showing much larger 
artefacts caused by air bubbles. 
 
 
Also worth noting in this picture is the bright signal at one edge of the sample, where the 
tissue was particularly compressed against the NMR tube. Unusual signal at sample edges is 
always excluded from analysis.  
The main source of artefacts was from bubbles of air trapped around the sample. The air-
sample interface creates an artefact that can affect a large area of the map, as shown for 
caudate nucleus sample C2 in Figure 4.7 b) for a T2 map and part c) for a T2* map. As can be 
seen here, bubbles affect T2* maps much more significantly than T2 maps, with a relatively 
small bubble potentially causing large distortion of the image. When segmenting the maps of 
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R2 or R2*, ROIs were drawn to exclude these artefacts. In the case of c) no measurements 
would be made from this slice. 
4.3.3.3 Rapid decays 
When optimising the Bruker scans to measure T2 and T2* short TE values were used in order to 
try and capture the rapid decays expected in the tissue with a high iron content. However, 
some decays observed were still too rapid to be reliably measured. An estimation of the 
minimum echo decay that can be measured using the optimised scan sequences for the 400 
MHz probe at the University of Warwick was made. 
 
 
Figure 4.8:  ImageJ maps and Origin fitting of the same MRI data. a) A T2 map of putamen sample AD3 
with an ROI drawn over a region of signal drop-out. b) The pixel values from one row of the ROI are 
plotted for the 16 original echoes and fitted in OriginPro 8.5. c) and d) show the same principle for the  






Table 4.4: Comparing ImageJ calculations of T2 and T2* by ImageJ and Origin in a region of high signal 
drop out. a) Shows the value of T2 calculated by ImageJ and the results of fitting to the same points with 
OriginPro 8.5, which gives an error and r
2
 value for each fit. b) Shows the results for a set of T2* data. 
 
 
T2 (or T2*) is the time taken after the excitation pulse is switched off for the signal to decay by 
63% (37% remaining). Therefore a T2 of less than TE can be measured, as long as the signal is 
still sufficient above noise and TE cannot simply be taken as the minimum measureable 
relaxation. 
As detailed fitting information (error, r-squared) is not attached to each pixel in a fitted T2 map 
in ImageJ, a sample of pixels was selected and the decays for each pixel fitted in the software 
OriginPro 8.5 (Origin). Putamen sample AD3 was chosen as this contains a very high iron 
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inclusion that ImageJ struggles to fit. This is later shown to coincide with a region of very high 
iron due a blood vessel. An ROI was drawn so as to include some of this signal drop out as 
shown in Figure 4.8 a). Each ROI is 4 rows (labelled A-D) and 24 columns (numbered 1-24). The 
ROI can be saved as a text image providing the value of T2 for each pixel.  
The same ROI was overlaid onto the original 16 echoes and Origin was used to plot the decays 
of the all the pixels from row D of the ROI. These data were then fitted in Origin to the same 
exponential decay function used by ImageJ and Paravision: Equation 4.3. Figure 4.8 b) shows 
the fit to each pixel and the Table 4.4 a) shows the calculated value of T2 for each pixel 
calculated in Origin and the result from the ImageJ MRI processor plugin. The table shows that 
there is very good agreement between the T2 values calculated in ImageJ and by fitting in 
Origin. This holds for all T2 values from 5.9 ms (pixel D22) and above, but not so well for any of 
the pixels where T2 is less than 2 ms (D23, D21, D20, D18).  
The error in T2 is typically around 10% until the decay is faster than around 20 ms. At 
approximately this value the r-squared (r2) value of the fit begins to decrease. However, there 
are exceptions such as point D13 where a T2 of 14.405 is calculated by both Origin and ImageJ 
and the fit is good and r2=0.99. 
The ImageJ T2* map is shown in Figure 4.8 c) and the Origin fits in d). Table 4.4 b) provides T2* 
values as calculated in Origin and in ImageJ for pixels in row C. There is extremely good 
agreement between the results until T2* falls below ~ 2 ms. However, the fit quality drops and 
the error increases for values below ~ 5 ms.  
The minimum measureable decay is dependent to the size of the signal as well as the value of 
TE. Where there is higher initial signal, signal remains above background for long enough to fit 
a decay, even when it is very rapid. Therefore it is difficult to determine a precise value for the 
minimum measurable decay. However, after examining the sample data above T2 decays of 
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less than 20 ms and T2* decays of less than 5 ms will be treated with caution. This corresponds 
to R2 > 50 s
-1 and R2* > 200 s
-1. 
It is worth noting that in most instances the values of individual pixels are not examined, but 
instead the average over a particular region. If the majority of the pixels in the region have a 
decay that can be well fitted this reduces the impact of any individual pixels with very rapid 
decays which may be poorly fitted.  
4.4 Synchrotron X-ray fluorescence mapping 
Tissue sections cut from the MRI imaged tissue blocks and matched to the high resolution MRI 
maps (as described in Section 3.3.3) were taken for synchrotron X-ray fluorescence (SXRF) 
mapping at the Diamond Light Source where data were collected.  
 
 
Table 4.5: Summary of SXRF experimental details for all SXRF mapping experiments. The pons samples 
were mapped over a number of experiments. All other regions were mapped during experiment DLS5. 
These samples were from the caudate nucleus (CN); putamen (Pu); globus pallidus (GP); substantia nigra 




Data were collected during five visits to the Diamond Light Source (DLS). The experiments have 
been labelled in chronological order DLS1, DLS2 and so on. Table 4.5 lists all of the samples 
mapped, during which visit they were mapped and what the experimental set up was on that 
occasion. After mapping the data were processed to create iron, copper and zinc maps which 
show the relative metal concentration distribution across an individual map and between 
different samples. Note, experiments DLS1 and DLS2 were carried out by Dr Joanna 
Collingwood before the beginning of this PhD. 
4.4.1  Data collection at the Diamond Light Source 
The iron distribution in the tissue sections was mapped at the microfocus spectroscopy 
beamline, I18, at the DLS in a similar way to that described by Collingwood et al. 2005 [82]. 
4.4.1.1 Hardware 
The X-ray beam at I18 can be tuned to a specific energy and focused with silicon KB mirrors 
and slits to square spot sizes from approximately 100 x 100 to 3 x 3 µm. Focussing is carried 
out by Diamond beamline scientists at the beginning of each experiment and the hardware 
settings for a number of spot sizes is stored so that they can be recalled to focus the beam to 
the desired size during the experiment. 
The beam energy at I18 can be tuned to between 2 and 20 keV (core energy 5 to 17 keV) and 
was tuned at the beginning of each visit to 10 keV. The energy of the beam at the sample is 
very stable with a variation of only ± 0.05 eV per day.  
When the beam is tuned to 10 keV, the flux at the sample is 4 x 1012 photons per second 
(ph/s). However, before the beam impacts the sample there is the option of reducing the 
signal intensity by inserting attenuators into the path of the beam. It may be prudent to 
reduce beam intensity in order to protect a delicate sample or to reduce the intensity of 
scattered X-rays and to prevent detector saturation. The final X-ray beam that impacts the 
sample is named I0 and is monitored immediately upstream of the sample. 
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Figure 4.9 shows the experimental set-up of the sample and detector for SXRF mapping at 
beamline I18. The quartz slide containing the tissue sample is mounted onto a slide holder, 
which sits on the sample stage, and held in the path of I0 at an angle of 45°. The detector is a 9 
element Ge detector with an energy range of 4 – 20 keV and is positioned at 90° to I0. 
 
Figure 4.9: Experimental set-up for SXRF mapping at beamline I18. a) A photograph taken at I18 showing 
the configuration of the sample, detector, camera and the approximate position of I0. b) A slide, covered 
in a katpton film, mounted onto the sample holder. c)  A schematic of the experimental set-up. 
 
 
The microscope camera allows the sample position to be viewed from the experiment control 
station. The microscope focus is locked to the focal point of the beam. To bring the sample into 
the focal point of the microscope (and hence of the beam) it can be moved back and forth (z-
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direction) by moving the sample stage which is controlled by a piezoelectric motor. The sample 
stage can also be moved left and right (x-direction) and up and down (y-direction) in steps of 
one micron to create the SXRF map. When the sample is in focus the X-ray beam is at or near 
the centre of the image from the microscope. 
4.4.1.2 Software 
General Data Acquisition (GDA) software, co-developed by DLS and STFC (Science and 
Technologies Facilities Council) staff, is used to control the data acquisition at the beamline.  
Two different versions of the software were used over the duration of this project (see Table 
4.5 for details of which software was used for each map). All of the pons data were collected 
using the old GDA software, which produced a large number of data files, in multiple formats, 
for each map.  
At the last experimental visit to Diamond, when the majority of the samples were measured, 
the software had been updated to the RCP version of GDA, which exports all of the SXRF data 
for each map in one NeXus file. The data output from the different software requires slightly 
different processing – see 4.4.2 SXRF data processing.  
4.4.1.3 Mapping protocol 
4.4.1.3.1 Set up 
Once the slide was mounted on the sample stage the first step was to set up the coordinates 
for the map. The microscope camera was used to confirm that the sample was in the focal 
plane, after which z was kept constant throughout mapping. Then the x and y coordinates 
were chosen. The microscope camera allowed a reasonable amount of detail to be seen on the 
tissue section, in particular grey and white matter could be differentiated. Photographs of the 
slide and stained adjacent or neighbouring slides were used to help select the area. It is 
important to carefully select the map area as mapping at high resolution is time consuming 
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and experimental time at the facility was limited. A region of slide with no tissue was included 
in the map of each sample so that slide signal could later be subtracted. 
Whilst the map coordinates were being selected, the X-ray beam was prevented from reaching 
the samples by one of two shutters. This prevented unnecessary exposure of the tissue to the 
very high intensity X-rays, which can damage the sample over time. Keeping this shutter closed 
when not measuring is good practice at all times.  
The spot size used to make the large, main map for each sample was 60 x 60 µm. Therefore 
each point on the map was effectively measuring a volume of 60 x 60 x 30 µm of wet tissue. 
Maps with smaller area and higher resolution were also collected for the pons samples (see 
Table 4.5). 
Before mapping was initiated, the signal intensity to the detector from an area of tissue was 
assessed to see if the detector filling fell within the minimum and maximum ideal filling range 
defined in the software. If the signal was too high an attenuator was inserted into the beam to 
reduce the flux on the sample. For low detector filling the collection time could be increased, 
however this was not necessary for any of the experiments. To reduce variability between 
measurements the collection time and attenuation was kept the same where possible during 
each experimental visit (see Table 4.5 for details). 
4.4.1.3.2 Making a map 
There are two modes of mapping i) Step Mode and ii) Continuous Mode. In the first mode the 
sample is moved by one step (where step size is matched to beam spot size) and then the 
detector collects for a set time (one second per point for these samples), before the sample is 
moved to the next point in the map. In this mode approximately 0.5 seconds is lost between 
each point as the sample stage is moved. Therefore, with a collection time of 1 second per 
point, the actual mapping time is approximately equal to the number of points multiplied by 
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1.5 seconds. An overhead of 50% is significant when mapping 1 cm2 at 60 x 60 µm resolution 
(equating to 11.5 hours to map 28 000 pixels). 
In the second mode the detector collects continuously and the sample is moved continuously 
through the beam. The time to scan an entire row and the number of points in the row is set 
by the user. This information determines the collection time per point and the data are divided 
accordingly as the detector collects. In this mode the effective collection time per point is set 
by the user and there is no ‘lost’ time between points. Therefore up to 50% of mapping time is 
saved compared to stepwise mapping. However, there are some limitations to the time saving 
in this mode. Most significantly, the detector collection and mapping on I18 is set up so as to 
pause during electron beam top-up which happens every 10 minutes. This wait cannot occur 
during a row collection in continuous mode and therefore the software will not begin a row if 
it cannot complete it before the top up is due. Therefore, depending on row length, there 
could be regular long waits when no mapping is occurring. This wasted time can be minimised 
by calculating the optimum row lengths to fit between top-ups. This forces rows of certain 
lengths, reducing the flexibility of map dimensions.  
4.4.2 SXRF data processing 
The raw data files for each SXRF map contain the fluorescence spectrum for each pixel. In 
order to produce comparable maps of relative iron, copper and zinc concentration, the 
fluorescence peaks in these spectra need to be fitted and the area under the peaks calculated. 
Maps must also be normalised to correct for variation due to fluctuating beam intensity and 
minimise experimental error. The open source software packages PyMCA [183] and ImageJ 
[180] were used to process the data.  
4.4.2.1 Output data files 
Software updates at DLS beamline I18 mean that the data were exported in two formats. Data 
collected using the old GDA software (all of the pons maps) were exported in a number of 
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separate files: MCA (Multi-Channel Analyser), DAT and RGB files. The fluorescence spectra are 
exported in a large number of MCA files, one for each point on the map. DAT files contain the 
information needed to spatially arrange the MCA files into one SXRF map. 
In order to process the data in PyMCA the MCA files need to be converted into a set of EDF 
(ESRF (European Synchrotron Radiation Facility) Data File) files, one for each map row. A macro 
called ‘dls_writeedf2.exe’ written by DLS staff was used to convert MCA files into EDF files. 
The RGB files contain an initial estimate of the SXRF signal intensity for key metals expected in 
biological tissue. They are produced without fitting the fluorescence peaks but by assigning all 
fluoresced x-rays over a set range to a particular metal. This does not correct for any 
overlapping peaks or correct properly for background and therefore does not provide the 
accurate measurement of relative metal concentration that fitting the peaks does. However, 
the RGB files produce an instant estimation of metal distribution that is useful during mapping. 
They also contain the intensity of I0 for each point on the map.   
The majority of the data were collected using the RCP software. This exports the data in the 
form of NeXus files which can be read directly into PyMCA. A NeXus RGB file is also produced 
for each of these maps. 
4.4.2.2 Fitting SXRF spectra 
PyMCA was used to fit the fluorescence spectra that make up the SXRF maps. Firstly a master 
fitting configuration file was created by fitting the average fluorescence spectrum of the whole 
map and then this file was used to fit the individual spectra collected for each pixel on the 
map. Figure 4.10 shows the result of careful fitting to a typical fluorescence spectrum. 
The process of creating the configuration file is described in full in Appendix D. In summary: 
firstly, the energy of the detector channels was calibrated using the characteristic peaks in a 
fluorescence spectrum of brain tissue (as shown in Figure 2.8 in section 2.3.2) and secondly, 
the ‘Advanced Fit’ tool was used to fit the peaks and the background signal, including the edge 
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of the scatter peak. One master configuration file was saved and reused, however for each 
new map the fitting was checked and the fitting parameters adjusted if necessary. 
The output of batch fitting is a single DAT file for each map. When opened using the PyMCA 
‘RGB Correlator’ tool the file contains a map for each metal fitted. Each point on the map 
represents the area under the fluorescence peak for that particular metal: the map shows the 
relative metal concentration distribution for that sample. 
 
 
Figure 4.10: A typical fitted fluorescence spectrum in PyMCA. The spectrum is the average of a whole 
map. Each metal peak and the background, including the edge of the scatter peak, has been fitted. 
 
4.4.2.3 Normalising data and subtracting background signal 
Fitting the SXRF spectra provides very sensitive and specific maps of iron (and copper and zinc) 
distribution across individual tissue samples. In order for the maps to show relative 
concentration across the section and between different samples they must be carefully 
normalised to correct for a number of experimental variables. Table 4.6 lists the possible 
sources of experimental error and the normalising step which was taken in order to correct for 
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that factor. Note: these variables have been kept constant where possible, but some variation 
is unavoidable, particularly between visits to the DLS.  
 
Source of Experimental Error Correct by normalising to: 
Changing electron beam 
intensity 
I0 
Attenuator used I0 
Detector position  Fe signal of quartz slide  
Table 4.6: Normalisations made to SXRF maps. The sources of 
experimental error are corrected for by normalisation to I0 or the iron 
signal from the slide. 
 
Although the tuned energy of I0 is very stable the intensity can vary: between experiments, 
over the course of one visit and also during the time taken for a map to be made. The intensity 
of I0 is determined by the electron beam in the synchrotron and this has a step profile as the 
beam decays over time and is periodically topped up. Figure 4.11 shows the typical variation of 
I0 for each pixel of a map. Changes to the intensity of I0 (and therefore to the flux of X-rays on 
the sample) proportionately change the number of fluoresced X-rays. Normalising each pixel in 
a metal map to I0 for that pixel will correct for this variation. 
 
Figure 4.11: Variation of I0 over the course of SXRF map data acquisition. I0 varies over time 




Normalisation to I0 was done using the RGB Correlator tool in PyMCA. Both the fitted metal 
maps (in the DAT file produced by batch fitting) and the I0 map (from the RGB file) were 
opened in RGB Correlator and the Image Calculator Tool used to divide each metal map by the 
I0 map. The normalised maps were saved together into a new DAT file. The insertion of 
attenuators into the X-ray beam also affects the intensity of I0 and was therefore corrected for 
by this process. 
A potentially major source of experimental error was the detector position. The distance and 
angle of the detector relative to the sample affects the amount of fluoresced X-rays received. 
The position of the detector varied considerably between visits to the DLS as changes were 
made to the experimental set-up. During some visits the detector could remain untouched 
during the whole experiment, but in others it was moved in and out of position during sample 
changes. This was the case for DLS5 and although the position of the detector was set with 
marker to minimise error, small variation in position is possible. 
As all samples were mounted on the same type of quartz slide, and each map included an area 
of slide, the average signal from the slide can be used to normalise for changes in detector 
position. For each of the metal maps (iron, copper and zinc) the average slide signal for that 
metal was subtracted from the each pixel on the map. Then each pixel was normalised to the 
average iron signal of the slide. Details of the slide background signal and how the 
normalisation affected each sample are given in Chapter 6 Section 6.1.2 Normalising to slide 
background. 
4.4.2.4 Exporting maps for further analysis in ImageJ 
The normalised metal distribution maps were analysed using the open access, image 
processing software ImageJ. Before this was possible the maps had to be converted from the 
DAT format into an image format, TIFF, with one file produced for each metal map. This 
conversion was done using a macro written in Python by DLS beamline scientist Paul Quinn 
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called ‘rgb_to_manyimages2.py’. The resulting TIFFs are maps for which the value of each pixel 
is the fitted area under the fluorescence peak for that metal, normalised to incoming beam. 
As is the case for the MRI maps, ImageJ was used to create ROIs around different tissue 
structures and measure their mean normalised SXRF signal intensity. How maps were 
segmented will be further described in Chapter 6: Synchrotron X-Ray fluorescence mapping.  
4.5 Histology 
4.5.1 Staining sections on glass with Congo red and 
haematoxylin  
Tissue sections cut from the MRI blocks were sectioned at 30 µm (as described in Section 
3.3.3) and were stained with Congo red and haematoxylin using the solutions and staining 
protocols below, that were based on protocols from Histological and Histochemical Methods: 
Theory and Practice by Kiernan [99]. 
The haematoxylin solution used is an alum haematoxylin, or haemalum solution [99]. This is 
commonly referred to as haematoxylin and will be known as such throughout this thesis. 
Haematoxylin stains cell nuclei and therefore reveals the cell distribution in tissue sections. 
Congo red stains a number of substances including amyloid, however the amyloid staining can 
be confirmed by the apple green birefringence displayed under crossed polarised light.  
Two baths of xylene were used: the ‘dirty’ bath was used first and the ‘clean’ one second. This 
was to try and minimise any dust and dirt appearing on the slides after staining.  
Protocol for making Congo red stain: 
 100 ml ethanol 
 100ml water 





Protocol for making haematoxylin stain: 
 Boil 0.2 g haematoxylin in 100 ml ultrapure water 
 Add 100 ml ultrapure water 
 Add 10 g aluminium potassium sulphate 
 Add 0.04 g sodium iodate  
 Cool and filter 
 
Congo red and haematoxylin staining Protocol: 
i) Hydrate to 30%: 
a. 100% ethanol, 7 minutes 
b. 70% ethanol, 3 minutes 
ii) Congo Red, 5 minutes 
iii) Rinse in distilled water 
iv) KOH in ethanol to differentiate stain , about 2 minutes 30 seconds 
v) Tap water wash, 3 minutes 
vi) Haematoxylin: 4 minutes 
vii) Tap water wash in large beaker 
viii) Tap water and 6 drops NaOH 10 M: 1 minute  
ix) Tap water wash 
x) Dehydrate: 
a. 70% ethanol, 3 minutes 
b. 100% ethanol, 3 minutes 
xi) Clear in xylene 
a. ‘Dirty’, 3 minutes 
b. ‘Clean’, 3 minutes 
xii) DPX mountant and cover slip 
 
4.5.2 Staining post-SXRF 
In past SXRF studies in our group, problems have been encountered with staining SXRF 
mapped tissue. Sections tended to float off slides, breaking apart and crumpling when staining 
solutions were applied. As part of the work towards this thesis, a protocol was developed to 
provide reasonable quality staining of sections post-SXRF mapping.  
The difficulty in staining SXRF mapped sections is caused by tissue fragility due to exposure to 
extremely intense X-rays during mapping. Additionally, the very clean quartz slides the 
sections are mounted on do not have the adhesive coating that standard histology slides do.  
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It was noted that the sections began to float off the quartz slides as soon as the slides were 
placed in 70 % ethanol to begin section hydration and that detaching was aggravated by the 
motion of moving the slide in and out of staining baths. Therefore the protocol was designed 
to include gradual hydration and minimal turbulence. The protocol was tested using 
thoroughly dried tissue sections on quartz slides. Although these sections were not as fragile 
as the post-SXRF samples, they allowed protocol development without risking valuable 
mapped samples. 
The final protocol does not include staining with Congo red as at the stage of differentiating 
the staining intensity with KOH in ethanol the section lifted completely from the slide and 
crumpled. Therefore SXRF mapped samples were only stained with haematoxylin. Adjacent 
samples, which were also stained with Congo red, were used to look for signs of amyloid 
deposition. 
The preparation for staining began with removing the kapton film from the slide and carefully 
scraping off any epoxy glue on the front of the slide using a razor blade. This is an important 
step as any glue on the surface of the slide will create an uneven texture and prevent good 
contact between the cover slip and the slide at the end of staining. 
PAP pen is then used to draw a ring around each sample which is then left to dry for at least 10 
minutes. This creates a water-proof ring into which solutions can be carefully pipetted, using a 
200 µl pipette, making a droplet which covers the surface of the section. The reduced 
turbulence and volume of solution stopped the sections from detaching from the slide. The 
solutions were removed from the slide by carefully absorbing the droplet with a cotton bud.  
Once the PAP pen had dried, the tissue was stained following the protocol below.  
i) Fix in ice cold 100% ethanol for 10 minutes 
ii) Gradually bring to water, 2 minutes 30 seconds in each of the following: 
a. 95% ethanol 
b. 90% ethanol 
c. 80% ethanol 
d. 70% ethanol 
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e. 50% ethanol 
f. 30% ethanol 
iii) Ultra-pure water, 3 minutes 
iv) Haematoxylin, 1 minute 30 seconds 
v) Tap water wash, several changes 
vi) Tap water and NaOH, 1 minute 
vii) Dehydrate: 
a. 70% ethanol, 2 changes of 2 minutes 30 seconds each 
b. 100% ethanol, 3 changes of 1 minute 30 seconds 
viii) Clear in Xylene 
a. ‘Dirty’ xylene, 5 minutes 
b. ‘Clean’ xylene, 3 minutes 
ix) Cover slip with DPX mountant.  
 
To carry out step i) ‘fixing in ice cold ethanol’ the slide was placed in a petri dish on top of an 
ice pack and 100 % ethanol at -25 °C was pipetted onto the tissue. The petri dish was then 
covered and left for 10 minutes. Covering the dish is important in order to reduce both ethanol 
evaporation and water condensation onto the cold slide. Condensation across the surface of 
the slide reduced the efficacy of the PAP pen barrier and could lead to the droplets of liquid 
spilling out and running all over the slide, which reduced the control over staining. After 10 
minutes the petri dish was removed from the ice pack and the ethanol removed. Step ii) was 
carried out using chilled ethanol, but no ice pack.  
Note that sufficient dehydrating in step vii) required multiple changes of ethanol to make up 
for the small volume of ethanol that is in contact with the section in this droplet technique. 
It was not possible to carry out xylene clearing (step viii) using the droplet method for a 
number of reasons, including the fact that xylene dissolves PAP pen and also evaporates very 
quickly. Therefore the PAP pen was wiped off using a cotton bud dipped in xylene and then the 
slide was very carefully lowered into the two xylene baths, one after another. Occasionally the 






Figure 4.12: Staining of SXRF mapped tissue compared to non-mapped tissue. Slide scan images of 
haematoxylin stained sections from substantia nigra sample AD2. a) The stained section on glass shows 
good contrast between tissue types in addition to nuclear staining. b) The section on quartz, stained 
after SXRF mapping, still shows nuclear staining, but a predominantly uniform background stain. 
 
 
The result of staining post-SXRF sections using the above protocol, as compared to staining the 
fresh-frozen tissue on glass, is shown in Figure 4.12 for substantia nigra sample AD2. The 
staining for the tissue on glass (a) shows clearer differentiation between tissue types and is 
much sharper than the staining of the tissue post-SXRF mapping (b). The difference in staining 
quality is due both to the damaged tissue and to the protocol: the protocol does not allow for 
rapid changing between solutions or thorough soaking in each solution. 
As the staining is better for un-mapped tissues, and includes Congo red stain, in general an 
adjacent or near section is used for comparison to the SXRF maps to identify structures. 
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However, where this staining is particularly useful is for high resolution maps (as were made of 
the pons) where staining information at cellular level is required. Figure 4.13 shows the 
staining of pons sample AD2 after SXRF mapping. Part a) is a slide scan image of the entire 
sample and areas of high resolution mapping can clearly be observed. The higher resolution 
SXRF mapped areas are shown as microscope composite images in b), mapped at 10 µm, and 
c), mapped at 3 µm. The staining quality reduced as the resolution of the mapping increased. 
However, some individual cells can be identified in the area of the 3 µm map. This image is 
examined further in Chapter 6, Section 6.5.2 and is used to help compare the relative metal 
concentrations in the neurons of the pons.   
 
 
Figure 4.13: Staining of high resolution SXRF-mapped tissue. a) A slide scanned image of the section 
from pons sample PD1, which contains areas mapped at high resolution. Microscope images are shown 
of these areas: b) mapped at 10 µm and c) mapped at 3 µm. A band of neurons runs from top left to 
bottom right through b). Staining is very light in the mapped area in c), but some individual neurons can 





4.6 Statistical analysis techniques 
The data sets in this thesis are very small with n=3 for each disease group, therefore statistical 
analysis is non-trivial. A property of statistical testing is that it is hard to reach statistical 
significance with a low number of samples. However, in order to correctly describe the 
significance the test used must be suitable for the data. Where possible the tests used are 
those recommended for small sample sizes and all assumptions made about the data are 
tested as far as possible. 
Statistical analysis was carried out using SSPS Statistics Version 21 and Laerd Statistics tutorials 
(2013) [184] for reference. Unless otherwise stated statistical significance will be indicated as 
follows: * p<0.05; ** p<0.01; *** p<0.001.  
4.6.1 Analysis of variance 
One-way ANalysis Of VAriance (ANOVA) tests for statistically significant differences between 
group means of two or more groups of independent samples using an F-test. The data must be 
grouped by an independent, categorical variable (in this project this is always disease state) 
and the dependent variable data in each group must be continuous (for example, tissue iron 
concentration).  
The main principle of AVONA is to compare the within-group variance to the between-group 
variance, which is the total variance minus total within-group variance [185]. Here variance is 
the sum of squares. If the sum of the variance within the groups is approximately the same as 
the total variance, then any difference in means can be explained as being due to random 
sampling effects. If the between group variability is larger than the total within-group 
variability, then there may be a statistically significant difference between the means. One-way 
ANOVA uses F-test to calculate the p-value. 
The null hypothesis for one-way ANOVA is that there is no difference between the group 
means. Therefore when this is violated there is at least one group mean that is different. 
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However, one-way ANOVA does not compare between individual pairs of means and a post-
hoc test is required to find the p-value between each possible pairing. 
One-way ANOVA makes a number of assumptions about the data: i) there are no outliers; ii) 
the data follow an approximately normal distribution and iii) the data in each group have equal 
variance. It is important to assess whether the data fit these assumption. However, ANOVA is 
robust enough to provide valid results even if this assumption is a little violated.  
4.6.1.1 One-way ANOVA using SSPS 
First the data were tested for outliers and for normality. The ‘Explore’ option was selected 
from the ‘Descriptive Statistics’ menu and the options ‘Outliers’ and ‘Normality plots with 
tests’ selected. The results of the Shapiro-Wilk test for normality were used, which is the 
recommend test for small sample sizes. The null hypothesis, which is that the data follow a 
normal distribution, is violated if p<0.05. Provided the null hypothesis is not violated 
parametric statistical tests are suitable for analysing the data. 
SSPS can be used to test for the equal variances assumption using Levene's Test for 
Homogeneity of Variance at the same time as carrying out one-way ANOVA. Both one-way 
ANOVA assuming homogeneity of variance, and a second robust ANOVA (Welch's ANOVA) in 
case this assumption is violated, were performed simultaneously. The data were then 
interpreted based on the result of Levene's Test.  
The ‘One-way ANOVA’ option was selected from the ‘Compare Means’ menu. Then the options 
‘Descriptives’, ‘Homogeneity of variance’ and ‘Welch’ were selected. Post-hoc tests were also 
selected to examine the difference between individual group means when there are more than 
two groups. Tucky’s post-hoc test is valid if the data shows equal variance and the Games-




The result of Levene’s test are given in the output file. The null hypothesis is that homogeneity 
of variance is equal and this is considered violated if p<0.05. For a data set for which p>0.05 
the results of one-way ANOVA and Tucky’s test were recorded. Where p<0.05 the result of 
Welch’s ANOVA and the Games-Howell test are shown. When results are presented the result 
of the tests for normality and homogeneity of variance will not be stated in each case, but the 
type of AVONA and post-hoc test will be stated. 
4.6.2 Non parametric statistics 
ANOVA is only valid when the data follow a normal distribution. If the data were shown to 
violate the Shapiro-Wilk test for normality a non-parametric test, which does not make 
assumptions about the shape of the distribution, was used. 
The ‘Two or more independent samples option’ was selected from the ‘Nonparametric’ menu. 
The ‘Kruskal-Wallis’ test was chosen on the settings tab. This is a nonparametric equivalent to 
one-way ANOVA. The pairwise comparison option was selected so that the output will include 
comparison between pairs of groups. 
4.6.3 Linear regression analysis 
Linear regression analysis is used to create a linear model to describe the relationship between 
a dependent variable and one or more independent variables or predictors. When the model 
contains only one predictor the analysis is called simple linear regression and the model takes 
the form of the familiar equation for a straight line: 
        (4.5)  
Where y is the dependent variable; x is the predictor; m is the gradient of the line and c is the 
intercept where x is equal to zero. 
Where there is more than one predictor (multiple linear regression) the straight line 
relationship can be described by Equation 4.6, as given in SSPS: 
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                       (4.6) 
where yi is the value of i
th dependent variable; p is the total number of predictors; bj is the j
th 
coefficient and j=0 … p; xij is the value of the i
th case of the jth predictor and ei is the error in the 
observed value for the ith case. The intercept, b0, occurs when the value of all predictors is 
zero. 
The ‘Linear’ option was selected from the ‘Regression’ menu and the dependent and 
independent data entered. The statistics option ‘Collinearity diagnostics’ and ‘Covariance 
matrix’ were selected and the analysis run.  
The output for each model includes the value of the constant (b0) and the regression 
coefficient (b) for each predictor. The standardised coefficients (B), which can have values of 
between 0 and 1, allow a comparison of the strength of the relationship of each predictor to 
the dependent variable where a larger B indicates a stronger relationship. The sign of the 
regression coefficient gives the direction of the relationship. 
The correlation coefficient, r, describes the degree to which the total model is related to the 
dependent variable. For simple linear regression r is equal to the absolute value of the 
standardised correlation coefficient B. The goodness of fit can be described by r-squared (r2) 
which represents the percentage of the variation of the dependent data which is explained by 
the fit.  
SSPS calculates a p-value for the whole model and for each predictor. When the p-value for the 
model reaches significance (p<0.05) the prediction of the model is better than chance. The p-
value for each predictor tests the null hypothesis that the coefficient is zero (that the value of 
the predictor has no effect of the value of the dependent). When p<0.05 the null hypothesis is 
rejected and the predictor can be considered a significant addition to the model. 
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4.6.4 Discriminant analysis 
Discriminant analysis creates a predictive model to group observations based on the 
information provided by observations from known groups. Data should be from mutually 
exclusive groups and each case must belong to only one group. Discriminant analysis also 
makes the following assumptions about the data: i) predictors are not highly correlated with 
one another; ii) there is no correlation between the mean and variance of a predictor; iii) 
correlation between two predictors is constant across groups and iv) the data follow a normal 
distribution.  
In this project the groups are the disease state and the independent variables, also known as 
‘predictors’, could be iron concentration, IRM at 5 K, R2 or R2* in a particular brain region, i.e. 
iron in the pons is a different predictor from iron in the SN. Therefore discriminant analysis can 
be carried out to investigate how a discriminating model could be built using information from 
multiple brain regions, rather than looking for statistically significant differences between 
disease and control for one region at a time. 
As described in the previous section assumption iv) can be tested using the Shapiro-Wilk test 
for normality in the ‘Explore’ tool from the ‘Descriptive Statistics’ menu. Some of the other 
assumptions can be tested in SSPS at the same time as running discriminant analysis. The ‘Box 
M’ test (included in the discriminant analysis output file) examines the homogeneity of 
variance of the data. 
The statistical analysis software SSPS was used to carry out discriminant analysis, to test some 
of the assumptions made and to examine the quality of the model. The ‘Discriminant Analysis’ 
option was selected from the ‘Classify’ menu and the grouping variables (the disease state) 
and independent variable entered. Then the ‘Summary Table’ ‘Leave-one-out Classification 
options were selected. 
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4.6.4.1 Assessing contribution of variables to the model 
Another output of discriminant analysis generated by SSPS is a one-way ANOVA test. As 
described in Section 4.6.1 above, one-way ANOVA tests for any differences between means of 
each group for each variable. P-values are produced for each variable and low value suggests 
that the predictor contributes more to the model.  
The ‘standardized canonical discriminant function coefficients’ table shows the order of how 
important each variable is in discriminating between groups. A large absolute coefficient 
indicates more discriminating ability.  
4.6.4.2 Validating the model 
The model is used to classify each of the cases into one disease group. How well the model fits 
the data can be assessed by checking what proportion of samples were correctly grouped. 
Information for each individual sample is given by SSPS, meaning the cases which are 
incorrectly grouped can be identified. 
As only the data used to create the model are being assessed the successful classification rate 
for the model is inflated. In order to partially validate the model SSPS can cross validate each 
sample by leaving it out of the data used to calculate the model and then classifying it with the 
resulting model. This is what the ‘Leave-one-out Classification’ option was selected for. 
If a large sample set were available, a randomly selected sub-set of the data would have been 
excluded from the model. The model calculated using the rest of the data would then be used 
to classify this set of data and give the percentage of correctly classified samples. This is known 
as sub-set validation. However, with the small number of samples available for this study sub-
set validation was not possible. 
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Chapter 5:  
Bulk tissue iron analysis 
In this chapter the total and particulate iron content is investigated in samples from four brain 
regions: the pons, substantia nigra (SN), putamen (Pu) and caudate nucleus (CN). These 
measurements are referred to as ‘bulk tissue’ measurements as they do not have the spatial 
resolution that is achieved with MRI or SXRF mapping techniques, which are used to examine 
samples in later chapters. 
The literature review in Section 1.3 revealed a number of studies which report increased iron 
concentration in Alzheimer’s Disease (AD) in specific regions of the brain. However, there is 
disagreement in the literature with some studies showing no statistically significant change. 
The results of the literature review for the SN, Pu and CN regions are reproduced in Figure 5.1. 
No data for iron concentration in the pons were found during the literature search. 
Putamen 
A (↑p=0.07)  
FDIR 
K Fe Serum B ** FDIR C ** FDIR H * φ MRI P * φ MRI 
Caudate 
Nucleus 
K Fe Serum C * FDIR B * FDIR P * φ MRI A * FDIR   
Substantia 
Nigra 
K (↓ 25%)  
Fe Serum 
P φ MRI         
 
Figure 5.1: Literature review of publications comparing iron in control and AD tissue. Blue boxes 
indicate a study which showed no statistically significant change in iron in AD (where changes were 
large, or approached significance this information is given in brackets and the direction of change 
indicated by an arrow). Yellow boxes indicate a study which showed a statistically significant 
increase, where * p<0.05 and ** p<0.01. No studies showed a statistically significant decrease in 
iron with AD. The methods of iron measurement are: FDRI= field dependent R2 increase; Fe Serum = 
Ferrochem II serum analysis; φ MRI = phase shift MRI. The first letter in each box indicates the 
reference: A = Bartzokis (1994) [125]; B = Bartzokis (2000) [133]; C = Bartzokis (2004) [126]; H = Ding 
(2009) [137]; K = Loeffler (1995) [18]; P = Zhu (2009) [139]. 
 
 
For both the Pu and CN the literature review showed that an increase in iron concentration in 
AD has been indirectly measured using MRI [126, 133, 139], but that in direct measurements 
of iron concentration in post mortem tissue no increase was observed [18]. No statistically 
significant change in iron concentration with AD was observed by direct [18] or MRI 
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measurements [139] of the substantia nigra, however increased iron has been reported in this 
region with Parkinson’s Disease (PD) [145]. The literature search did not reveal any reports of 
iron concentration in control or AD pons tissue. 
In this study, iron concentration is measured by acid digestion of freeze-dried tissue samples, 
followed by GFAAS or ICP-MS. Table 5.1 details the age and sex of each case and Table 5.2 
summarises the measurements made on each sample. Three control and AD samples from the 
pons, substantia nigra, putamen and caudate nucleus are examined. Three PD and Multiple 
System Atrophy (MSA) samples from the pons, substantia nigra and putamen provide a 
comparison to other neurodegenerative diseases.  
 
Case Number Sex Age   Case Number Sex Age 
C1 F 47   PD1 M 73 
C2 M 78   PD2 M 56 
C3 M 76   PD3 F 79 
AD1 M 73   PD4 M 76 
AD2 F 75   MSA1 M 76 
AD3 F 98   MSA2 M 66 
        MSA3 F 46 
Table 5.1: Age and sex of each case measured by bulk tissue analysis. C = 
control; AD = Alzheimer’s Disease; PD = Parkinson’s Disease; MSA = 
Multiple System Atrophy. 
 
 
Quantifying the differences in the total iron concentration between control, AD and other 
neurodegenerative diseases is interesting in terms of increasing our understanding of 
homeostasis in neurodegenerative diseases. However, it is particulate iron which most affects 
MRI and is therefore of particular interest in this study. Furthermore, the form of the 
particulate iron determines the magnitude of the effect on MRI: magnetite, which has been 
shown to be increased in AD [110], has an approximately 200 times greater effect on R2 than 





Table 5.2: A summary of the bulk tissue iron and magnetometry measurements. Isothermal remanent 
magnetisation (IRM) measurements at 5, 50, 150 and 300 K. The iron concentration of the pons and 
substantia nigra samples was measured by Dr Emily House at the University of Keele, using graphite 
furnace atomic absorption spectrometry (GFAAS). The putamen and caudate nucleus samples (and SN 
sample MSA3) were measured at the University of Warwick using inductively coupled plasma mass 
spectrometry (ICP-MS). IRM curves at 5 and 50 K were measured for a subset of samples from the 
putamen and caudate nucleus with at least one curve measured for each disease group in each region. 




In order to investigate the concentration and form of particulate iron, Superconducting 
QUantum Interference Device (SQUID ) magnetometry measurements were made (Section 5.2) 
of the samples before they were digested for iron quantification. Particulate iron content is 
evaluated in terms of ferrihydrite-like iron in ferritin and magnetite. Examination of other iron 
oxide phases that have been observed in ferritin and haemosiderin, such as hematite, wustite 
and goethite [76-78], is beyond the scope of this thesis.  
In addition to making statistical comparisons between disease groups for each region, 
discriminant analysis is used to combine the data from multiple regions and create a model to 
predict the disease state of each sample (Section 5.4). 
The result of iron quantification and IRM at 5 K for the control, PD and MSA samples has been 
published in the paper Iron Deficiency in Parkinsonism: Region-Specific Iron Dysregulation in 
Parkinson's Disease and Multiple System Atrophy (Appendix H) [28]. This paper does not 
include data from the AD samples. 
5.1 Iron concentration 
Iron concentration in the pons and substantia nigra samples was measured by GFAAS, by Dr 
Emily House at Keele University. The exception being SN samples MSA3 which was measured 
with the putamen and caudate nucleus samples, by ICP-MS, at the University of Warwick. 
Figure 5.2 shows the iron concentration in micrograms of iron per gram of fresh-frozen tissue 
for each sample from each region. The mean and standard deviation for each group are given 
and statistically significant differences between groups indicated on the graph. Note that for 
the substantia nigra case MSA1 the fresh-frozen sample mass was not recorded and therefore 
this sample is not included in wet mass analysis. 
Table 5.3 shows the mean iron concentration for each disease group in each region and the 
change in iron relative to control. Iron concentration is given per gram of freeze-dried and 
fresh-frozen tissue. All data sets, apart from the AD pons wet mass data, followed a normal 
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distribution as examined by the Shapiro-Wilk test. Therefore statistical analysis in the pons was 
carried out by i) one-way ANOVA when excluding the AD data and ii) by the nonparametric 
Kruskal-Wallis test when including the AD data.  
 
Figure 5.2: Iron concentration per gram of fresh-frozen tissue. Measured by GFAAS in a) the pons and b) 
the substantia nigra; and by ICP-MS in c) the putamen and d) the caudate nucleus. (Note the exception: 
SN sample MSA3 was measured by ICP-MS.) A statistically significant increase in iron concentration is 
shown in MSA compared to control pons. Open symbol = individual sample with measurement error; 
closed symbol = mean for disease group with standard deviation; * = statistically significant difference 






Table 5.3: Mean iron concentration in each brain region. The average iron concentration of each disease 
group in each brain region is given in micrograms per gram of freeze-dried and fresh-frozen tissue. For 
each region the mean of each disease group is normalised to control and any statistically significant 
change compared to control indicated by: * = p<0.05 by one-way ANOVA. Iron quantification method is 
indicated for each brain region, where: GFAAS = graphite furnace atomic absorption spectrometry, ICP-
MS = inductively coupled mass spectrometry. Note: one substantia nigra MSA sample was measured 
with ICP-MS).  = one missing sample from the group. 
 
 
Iron concentration is doubled in the MSA and AD pons compared to control. This change is 
statistically significant for MSA in the fresh and dried mass comparison and for AD in the dried 
mass comparison only.  
In the substantia nigra there is no statistical significance between disease groups, however 
there is an increase in iron in the PD tissue compared to AD and control which agrees with 
what has been reported in the literature [23]. There is a marked decrease in the average iron 
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concentration in the MSA samples compared to the PD samples, however this does not reach 
statistical significance (p=0.11). 
For both freeze-dried and fresh-frozen putamen tissue the average iron concentration 
increases in all diseases compared to control, however this does not reach statistical 
significance. A particularly large difference in MSA compared to control was observed, but this 
was largely due to the extremely high iron concentration in sample MSA1, which has an iron 
concentration more than double that of any other sample. 
A statistically significant doubling of iron with AD is found in freeze-dried CN (p=0.04). 
However, when corrected for fresh tissue mass the difference decreases and loses significance. 
5.1.1 Comparison with the literature  
Table 5.4 shows the mean iron concentration in the control and AD samples of the putamen 
and caudate nucleus reported in two papers by House et al. [19, 26]. These were the only 




(µg/g fresh mass) 
Iron concentration 
AD 





House 2007 [26] 
House 2008 [19] 
85.8 ± 24.0 
102 






House 2007 [26] 
House 2008 [19] 
93.1 
100 





Table 5.4: Literature iron concentrations in control and AD putamen and caudate nucleus. 
Quantification was carried out by GFAAS (2007 paper) and ICP-AES (2008 paper). The ratio of iron 
concentration in AD tissue compared to control is given and varies considerably between the two 




The ratio of AD to control iron concentration is given for each paper. In the 2008 paper the 
ratios agree within error with the ratio reported in Table 5.3. However, a very different AD to 
control ratio is found in the 2007 paper.  
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The absolute iron concentrations measured in this study are higher than reported by House et 
al., in particular in the caudate nucleus. In their 2005 paper Haacke et al. included a review of 
iron concentration data for healthy brain tissue [107]. This showed that there is a large 
variation in the reported values within brain regions: 45 to 185 µg/g in the substantia nigra; 76 
to 164.8 µg/g in the putamen and 56 to 117.4 µg/g in the caudate nucleus. The measurements 
reported here for the putamen and substantia nigra fall within the range in the literature, 
however the caudate nucleus results do not.  
The standard deviation of the mean iron concentration for the control (and diseased) samples 
in each region is fairly large (Table 5.3), however this is also reflected in the literature. In 
Hallgren and Sourander’s landmark study of iron concentration in the brain [93], which is still 
widely used for reference today, the size of the standard deviation is also large. Their reported 
iron concentrations are: SN = 183.6 ± 65.2 µg/g; Pu = 133.2 ± 34.3 µg/g and CN = 92.8 ± 21.4 
µg/g. 
5.2 SQUID magnetometry measurements 
The majority of non-haem brain iron is stored as a nanoparticle in the core of the storage 
protein ferritin. Some studies have shown that ferritin concentration increases with iron 
concentration [22], whereas other papers report that iron increases are not accompanied by 
an increase in ferritin [133]. Normal ferritin iron has a ferrihydrite-like, antiferromagnetic 
structure, but changes in the structure of ferritin cores have been reported in AD [77]. 
Additionally, an increase in the ferrimagnetic material magnetite has been reported [141]. 
An MPMS-5S SQUID magnetometer was used to examine particulate iron in the tissue samples 
through isothermal remanent magnetisation (IRM) measurements. IRM is the remanent 
magnetisation of a sample at a fixed temperature after a magnetic field is applied and then 
abruptly switched off. As the measurement is made with no applied field it is free from 
diamagnetic effects which usually dominate the magnetic properties of biological samples 
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[108]. IRM signal is only present for materials which are magnetically blocked at the 
measurement temperature. Ferritin is typically blocked at temperatures below about 15 K 
[154] and any blocked magnetic material above this temperature is likely to be the 
ferrimagnetic iron oxide phases magnetite and/or maghemite which have been observed in 
post mortem human brain tissue [80].  
In the substantia nigra, antiferromagnetic grains with superparamagnetic properties are also 
present in neuromelanin, which stores 10-20% of the total iron in that region [85]. These 
grains have a range of blocking temperatures from 5 K to room temperature [88]. However, 
the majority of iron in the SN is still stored in ferritin. 
IRM measurements were made of each sample at temperatures 5, 50, 150 and 300 K, after an 
applied field of 10 000 Oe. IRM curves at 5 and 50 K were made for a sub-set of samples to 
check for characteristic properties of ferritin and magnetite. All SQUID measurements were 
corrected for sample length using the empirical formula described by Hautot et al. [108], which 
was given in detail in Section 4.1.3. The error given for each IRM measurement is the 
combined error from: the standard deviation of the averaged SQUID measurement; the 
measurement error in the weighing the sample and the measurement error in measuring 
sample length. 
Note that samples were freeze dried before SQUID magnetometry measurements were made, 
however in most instances the data are given per gram of fresh tissue. 
5.2.1 IRM at 5 K 
Figure 5.3 shows the IRM at 5 K, after an applied field of 10 kOe, in emu per gram of fresh-
frozen tissue. Each individual sample is shown in addition to the mean and standard deviation 
for each disease group in each region. Table 5.5 shows the mean IRM at 5 K of each 
neurodegenerative disease normalised to mean control for that region. All data sets passed 
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the Shapiro-Wilk test for normality and therefore ANOVA was used to test for differences 
between group means. 
 
Figure 5.3: Isothermal remanent magnetisation at 5 K, after an applied field of 10 kOe, per gram of 
fresh-frozen tissue in a) the pons, b) the substantia nigra, c) the putamen and d) the caudate nucleus. 
The pons is the only region for which a statistically significant difference is observed. IRM at 5 K is 
increased in PD compared to control. Case MSA1 is missing from the SN data set as this sample was not 
weighed before freeze drying. Open symbol = individual sample measurement with measurement error; 
closed symbol = mean for disease group with standard deviation; ^ = statistically significant difference 






Table 5.5: Average IRM at 5 K normalised to control. The average IRM at 5 K of each disease group in 
each brain region as normalised to the average control value in that region. Data per gram of freeze 
dried and fresh-frozen tissue is shown. ^ = statistically significant difference between means, where 
p<0.05 by Welch’s ANOVA;  = average of only two samples. 
 
 
Comparison of Figure 5.3 with Figure 5.2 shows that IRM at 5 K follows a similar trend to the 
iron concentration data for each sample across the four brain regions. IRM at 5 K is sensitive to 
particulate iron and therefore the preserved trend is consistent with a similar proportion of 
total iron being bound in ferritin for each of the samples. The relationship between iron and 
IRM at 5 K is examined further in Section 5.3. 
Similarly to the results of the iron concentration analysis, mean IRM at 5 K is approximately 
double in AD and MSA pons samples compared to control. However, in this case the difference 
does not reach statistical significance. For fresh-frozen tissue the only statistically significant 
difference between any disease groups is the small but statistically significant (p=0.048, by 
Welch’s ANOVA) increase in IRM in the PD pons compared to control.  
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The trend in the iron concentration data is preserved in the IRM at 5 K data for all disease 
groups in the substantia nigra: there is a slight increase in IRM in AD compared to control, with 
a doubling in PD and decrease in MSA. Although the mean IRM at 5 K of the PD is 2.8 times 
greater than for MSA (2.5 times larger for the freeze-dried tissue) the difference does not 
reach statistical significance.  
In the putamen the average IRM at 5 K is increased compared to control to a much larger 
degree for AD and MSA than would be predicted from the iron concentration measurements. 
This can be explained by the samples AD1 and MSA2 which have a much higher than expected 
IRM at 5 K. 
In the caudate nucleus the difference between control and AD is reduced to nearly nothing, in 
particular for the wet mass data. 
5.2.2 IRM at 50, 150 and 300 K 
Figure 5.4 shows the IRM at 50, 150 and 300 K, after an applied field of 10 kOe, for each 
sample in each brain region. Data are plotted on a log scale in order to show outliers.  
The blocking temperature for ferritin is around 15 K and therefore ferritin will not contribute 
to IRM at these higher temperatures. For most samples the majority of the IRM signal is lost at 
the 50, 150 and 300 K, which is consistent with the majority of IRM at 5 K being due to ferritin. 
However, the small, but non-zero, IRM at 50 K (and decreasing slightly at 150 and 300 K) 
shown for most samples is consistent with a small amount of magnetite. 
There are a small number of samples which show elevated IRM at 50, 150 and 300 K. Pons 
samples PD1 and MSA3 show elevated IRM at 50 and 150 K. In the data set from the putamen 
AD1 has very high IRM at 50, 150 and 300 K; approximately 1000 times greater than average. 
IRM is also elevated, to a lesser extent, in C3. In the caudate nucleus C1 has high IRM at 50, 





Figure 5.4: Isothermal remanent magnetisation (IRM) at 50, 150 and 300 K per gram of fresh tissue. All 
data are plotted on a log scale. a) All pons samples were measured at 50 and 150 K, with additional 
measurements at 300 K for AD1 and AD3.  Samples PD1 and MSA3 have increased IRM at 50 and 150 K. 
Note: Samples PD2 and C3 had a measured IRM of below zero at 150 K and are not shown on the graph. 
b) All substantia nigra samples show similar IRMs. Data from MSA3 was not available. c) Putamen 
samples AD1 and C3 have higher than average IRMs at all three temperatures with approximately 1000 
and 100 times greater signal, respectively. MSA3 is unusual in that the IRM at 150K and 300K is 
increased compared to at 50 K. d) Caudate nucleus sample C1 has increased IRM at all temperatures 
compared to the average for this region. Sample AD2 is atypical as the IRM is increased at 150 K and 300 




Figure 5.5 shows the ratio of IRM at 50K to IRM at 5K. This shows the magnitude of the signal 
at 5K compared to at 50 K. For the majority of samples the ratio is less than 0.05, showing that 
the size of the IRM signal at 50 K is less than 5% of the signal at 5 K. This is consistent with the 
majority of the particulate iron being in the form of ferrihydrite and the large majority of the 5 
K IRM being due to magnetically blocked ferrihydrite-like ferritin cores. 
 
Figure 5.5: Ratio of IRM at 50 K to IRM at 5 K. The majority of samples show a ratio below 0.05, showing 
that the IRM at 50 K is less than 5% of the IRM at 5 K. Pons samples PD1 and MSA3; putamen samples 
C3 and AD1 and caudate nucleus sample C1 have increased ratios. This suggests a greater proportion of 
iron in magnetite or a measurement error or contamination of the samples. Statistical analysis was 
carried out on the data, excluding the outliers. No statistically significant differences between disease 
groups within each region were observed. When data from each region were pooled (excluding outliers) 
the pons showed a statistically significantly (*p<0.05, **p<0.01) higher ratio than the other regions, 
suggesting that in the pons there is an elevated proportion of magnetite. 
 
 
A handful of samples have an increased 50 K to 5 K IRM ratio. These are the same samples 
which, in Figure 5.4, were identified as having elevated IRM at 50 K and are not grouped by 
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brain region or disease. Statistical analysis (excluding the outlying samples) revealed no 
significant difference in the 50 K to 5 K IRM ratio between disease groups in each region. 
However, when data from all diseases in each region was pooled a statistically significant 
increase in the ratio of IRM at 50 to 5 K was seen in the pons compared to the other three 
brain regions. This suggests that despite the lower total iron concentration, there is a higher 
proportion of particulate iron in the form of magnetite in the pons. 
As the superparamagnetic grains in neuromelanin in the SN have blocking temperatures 
ranging from 5 K to room temperature, an increase in the 50 K to 5 K IRM ratio may have been 
expected. However, this was not observed, perhaps because the fraction of iron in the 
neuromelanin is only 10 to 20% [85], and a smaller fraction again will remain blocked at 50K.  
5.2.3 IRM curves at 5 and 50 K 
IRM curves are produced by taking IRM measurements, at a fixed temperature, after a series 
of applied fields of increasing magnitude. In this section IRM curves at 5 and 50 K with applied 
fields ranging from 250 Oe to 10 kOe are presented for a sub-set of samples. The 5 K IRM curve 
of a biological sample would typically be expected to be dominated by ferrihydrite-like iron in 
ferritin, with a small component due to magnetite. A smooth curve that is not saturated at 10 
kOe is typical for the antiferromagnetic ferrihydrite-like core of ferritin [83, 186]. The 50 K IRM 
curve can confirm the presence of magnetite, which typically saturates at around 3000 Oe for 
particles with a diameter larger than about 13 nm [80, 83, 187]. 
IRM curves were not made for all samples, due to limited instrument time. They were made 
for substantia nigra samples MSA3 (Figure 5.6); putamen samples C1, AD1, AD2, PD4, MSA1, 
MSA2 and MSA3 (Figures 5.7 to 5.10); and for caudate nucleus samples C1, C2, C3 and AD2 
(Figures 5.11 and 5.12). Error bars indicate the combined measurement error. The IRM curves 
at 5 K for all samples are typical for ferritin. The only exception is the 5 K IRM curve for AD1 
putamen, which is shown in Figure 5.8 a). The curve has a ‘kink’ at around 3000 Oe, which is 
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around the saturation point of magnetite: recall that this sample showed a high 50 K IRM to 5 
K IRM ratio. This sample also shows a relatively large measurement error compared to the 
other samples. 
The 50 K IRM curves of most samples are consistent with the presence of a small amount of 
magnetite or maghemite. For some samples the raw IRM measurements at 50 K (before 
correction for sample mass and length) are pushing the detection limitations of the instrument 
and therefore there are large error bars on the curves for these samples. 
The 50 K IRM curve for CN sample C3 (Figure 5.11 f) does not appear to reach saturation, with 
the trend of the curve still rising at 10 000 Oe. There is very low signal for this sample (and 
therefore large error bars) which indicates little or no magnetite content. The iron 
concentration and IRM at 5 K measurements for this sample were as expected.  
The 50 K IRM curve for putamen sample AD1 (Figure 5.8 b) does not resemble a typical IRM 
curve. The IRM drops and then rises as the applied field is increased. This sample also showed 
a very high IRM at 5 K compared to its iron concentration and an atypical 5 K IRM curve. This 
sample was particularly small (only 0.0284 g, freeze-dried) and therefore the IRM signal from 
the sample was very small. This could have compromised the quality of the data, however 
examining the raw data shows good dipoles centred correctly at the 2 cm position.  
In the 50 K IRM curves of samples MSA3 putamen (Figure 5.10 f) and C1 caudate nucleus 
(Figure 5.11 b) the first point, measured after an applied field of 250 Oe, is significantly above 
zero compared to the other samples. This is may be due to the SQUID not reaching a perfect 
zero-field after quenching, which may not show the same effect on each sample due to the 
varying samples sizes. However, this small effect should not affect the overall results of the 













Figure 5.6 IRM curves at 5 K and 50 K for substantia nigra sample MSA3. a) The 5 K IRM curve does not 
saturate, which is consistent with the magnetic properties of ferritin. b) The 50 K IRM curve, which 
saturates at approximately 3000 Oe, is consistent with nanoparticles of magnetite larger than about 13 





Figure 5.7: IRM curves at 5 K and 50 K for putamen sample C1. a) The 5 K IRM curve does not saturate, 
which is consistent with the magnetic properties of ferritin. b) The 50 K IRM curve, which saturates at 








Figure 5.8: IRM curves at 5 K and 50 K for putamen samples AD1 and AD2. The 5 K curve for AD1 a) is not 
consistent with the typical curve for ferritin iron, unlike for AD2 c) which shows a smooth non-saturating 
curve. The AD1 50 K curve b) is also not as expected for magnetite, unlike the curve for AD2 d) which 
shows a curve saturating around 3000 Oe. 
 
 
Figure 5.9: IRM curves at 5 K and 50 K for putamen sample PD4. a) The 5 K IRM curve does not saturate, 
which is consistent with the magnetic properties of ferritin. b) The 50 K IRM curve, which saturates at 










Figure 5.10: IRM curves at 5 K and 50 K for putamen samples MSA1, MSA2 and MSA3. 5 K IRM curves a), 
c) and e) show a curve which does not saturate at 10 000 Oe and is typical for ferritin. The 50 K IRM 









Figure 5.11: IRM curves at 5 K and 50 K for caudate nucleus samples C1, C2 and C3. 5 K IRM curves a), c) 
and e) show a curve which does not saturate at 10 000 Oe and is typical for ferritin. The 50 K IRM curves 
in b) and d) saturate at around 3000 Oe which is typical for magnetite. f) The 50 K IRM curve for caudate 
nucleus sample C3 does not saturate at 3000 Oe as would be expected for magnetite. The large error 






Figure 5.12: IRM curves at 5 K and 50 K for caudate nucleus sample AD2. a) The 5 K IRM curve does not 
saturate, which is consistent with the magnetic properties of ferritin. b) The 50 K IRM curve, which 
saturates at approximately 3000 Oe, is consistent with nanoparticles of magnetite larger than about 13 
nm in diameter. 
 
5.2.4 Relative proportion of iron as ferritin and magnetite 
The 50 K IRM curves in the previous section confirm the presence of magnetite in the majority 
of the samples measured. Hautot et al. [83] showed that by fitting the 5 K and 50 K IRM curves 
an estimation of ferritin and magnetite concentration in each sample can be made. However, 
this could not be achieved with this data set as limited experimental time meant IRM curves 
were not measured for all samples and for those samples for which IRM curves were 
measured, not enough data points on each curve were collected to allow accurate fitting.  
Instead, an estimation of the relative proportion (between samples) of iron in ferritin is made 
by dividing the IRM at 5 K by the total iron concentration in the sample. The same is done for 
IRM at 50 K to estimate the relative proportion of iron in magnetite. For the 5 K comparison an 
assumption is made that the contribution of the magnetite particles to IRM at 5 K is negligible 
compared to the contribution from ferritin. For most samples this assumption is reasonable, as 
was demonstrated by the ratio of 50 K IRM to 5 K IRM in Figure 5.5.  
The outlying samples in Figure 5.5 are excluded from the estimation as they show elevated 
signal at 50 K and violate the assumption that the magnetite signal at 5 K is negligible. The 
elevated IRM at 50 K could be indicative of contamination, measurement error or a 
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concentration of magnetite that is much larger than normal. The data collected from these 
samples and the conclusions that can be made about the sample are summarised in Table 5.6. 
Blocking temperature is dependent on particle size and at 50 K magnetite particles with a 
diameter larger than about 13 nm are blocked [83]. The tissue may contain nanoparticles of 
magnetite which become magnetically ordered at lower temperatures. Therefore the 
estimation of relative proportion of iron in magnetite does not include nanoparticles smaller 
than around 13 nm in diameter.  
 
Figure 5.13: Estimation of the relative proportion of iron in ferritin and magnetite. a) An estimation of 
the relative proportion of iron in ferritin was made by dividing IRM at 5 K (emu/g) by total iron 
concentration (µg/g). The mean is shown for each disease group in each region. b) An estimation of the 
relative proportion of iron in magnetite was made by dividing IRM at 50 K (emu/g) by total iron 
concentration (µg/g). The mean is shown for each disease group in each region. The ratios are scaled by 
10
7
 for ease of comparison. No statistically significant difference was found between disease groups 
within each region or between the mean of each region. 
 
 
Figure 5.13 a) shows the mean relative proportion of iron in ferritin for each disease group in 
each brain region and part b) shows the mean relative proportion of iron in magnetite for each 
disease group in each brain region. For ease of comparison the ratios (IRM in emu per g/ iron 
concentration in µg per g) are scaled by 107. The data passed the Shapiro Wilk test for 
normality and therefore one-way ANOVA was used to test for differences between means, but 
no statistically significant differences between means were observed. There was also no 
statistically significant difference between brain regions, when disease groups were pooled. 
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Table 5.6 shows that there is no reason to suspect contamination in the samples which have 
elevated IRM at 50 K. Sample AD1 from the putamen was very small and therefore may have 
been difficult for the SQUID to centre on. However, sample C1 from the caudate nucleus 
showed typical IRM curves at 5 and 50 K and therefore there is no reason to suspect the high 
IRM at 50 K is not real.  
 
 
Table 5.6: Summary of samples which showed an elevated IRM at 50 K. These five samples showed 
elevated IRM at 50 K, when compared to IRM at 5 K. The IRM measurements at 5 and 50 K for each 
sample are above the detection limit for the SQUID magnetometer. Sample Pu AD1 was very small in 
size, and although the signal was large it showed large error bars which may indicate a measurement 
error. On the other hand the IRM curves at 5 and 50 K for sample CN C1 were typical of ferritin and 




In conclusion there is evidence for increased magnetite in a number of individual tissue 
samples, but not for any particular disease group.  
5.3 The linear relationship between iron concentration 
and IRM at 5 K 
The analysis thus far has suggested that a similar proportion of total non-haem iron is stored in 
ferritin for each disease group and across each brain region. This was shown by the ratios of 
IRM at 5 K to total iron concentration in Figure 5.13 and the preserved trend in the iron 
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concentration and IRM at 5 K in Figures 5.2 and 5.3. In this section the relationship between 
total tissue iron concentration and IRM at 5 K is further examined using simple linear 
regression analysis. Firstly simple linear regression analysis is used to fit a straight line to all 
data from all regions, then to the data from each disease group and finally for all samples 
within each region. 
5.3.1 All samples and individual disease groups 
 
Figure 5.14: IRM at 5 K versus iron concentration for all samples. Data from the pons are in dark grey, 
the substantia nigra are in red, the putamen are in blue and the caudate nucleus are in green. A straight 
line is fitted to the data, excluding the outlying data point from the putamen samples MSA2 and AD1, 
and shows a strong (r=0.97), statistically significant (p<0.001) linear relationship. 
 
 
Figure 5.14 shows a plot of the IRM at 5 K against iron concentration of all samples measured. 
The straight line represents the result of linear regression analysis, excluding two outlying 
samples from the putamen: MSA2 and AD1. There is a strong, positive linear correlation 
(r=0.97), which is statistically significant (p<0.001), between iron concentration and IRM. The r-
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squared value shows that over 90% of the variation in the data is explained by the linear fit. As 
the variation in the pooled data is so well explained by the model, it suggests that there is a 




Table 5.7: Results of simple linear regression analysis of iron concentration versus IRM at 5 K, with data 
grouped by disease state. A strong, statistically significant linear relationship is shown between iron 
concentration and IRM at 5 K for each disease state and for all of the data combined. The r-squared 
values show that the majority of the variation in data is explained by the linear relationship in each case. 
The AD and MSA data are analysed without the outliers AD1 and MSA2. When these points are included 
(result in square brackets) the r-squared value is reduced, in particular for the AD data. 
 
 
The intercept of the fit is very close to zero, which is consistent with the majority of iron in the 
tissue being stored as ferrihydrite-like iron in ferritin. An intercept much above zero could 
indicate a significant IRM contribution at 5 K from non-ferritin iron, such as magnetite, 
whereas an intercept below zero may indicate a significant amount of non-particulate iron. 
The two outlying points, both from the putamen, are indicated on the graph: AD1 and MSA2. 
The point that lies furthest from the fitted line is AD1. This sample has already been observed 
to show abnormal IRM measurement (Table 5.6), which may be due to the sample’s small size. 
In Section 5.2.1 it was noted that both AD1 and MSA2 had higher than expected IRM at 5K 
than would be expected for their iron content, but otherwise MSA2 has not shown any out of 
the ordinary characteristics.  
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In addition to pooling the data from all samples measured, Table 5.7 shows the results of 
simple linear regression analysis for each disease group individually. When the outlier AD1 is 
excluded, the linear relationship is highly statistically significant (p<0.001) for each disease 
group. The r-squared values show that over 90% of the variation in the data for the AD, PD and 
MSA samples and over 80% for control samples is explained by the fit.  
The gradient of the fit of the control and AD data agree within error, however a steeper 
gradient is given for the PD data and steeper again for the MSA data. This suggests that 
relationship between total iron and ferritin iron may be slightly different in PD and MSA 
compared to control and AD. However, as 94% of the variation in the pooled data was 
explained by the linear fit, the difference is not very large. 
5.3.2 Individual regions 
Iron versus IRM was also plotted for each region and the results are shown in Figure 5.15. In 
each figure the fit to the data from all regions is shown in red and the fit to the data from that 
particular brain region is shown in black. Table 5.8 summarises the results of the linear 
regression analysis for each region and for the combined data from all regions. The r-squared 
values show that at least 80% of the variation in the data in each region is explained by the 
linear model. The gradients and intercept of each region do not agree within error, suggesting 
that the relationship between iron and IRM also varies slightly in the different brain regions.  
In Figure 5.15 the different disease groups are labelled and this reveals clustering of data 
points by disease group, particularly in the pons and CN. In the pons the data seem to be 
clustered into two groups: one containing the AD and MSA data and the other containing the 
control and PD data. Within each of these two groups, the data are arguably clustered further 
into each disease group. In the CN graph there is a clear separation of the AD and control data. 
This clustering of samples in the IRM vs. iron data is investigated further using discriminant 








Figure 5.15: IRM at 5 K versus iron concentration in each brain region. The linear fit to data from all 
regions (from figure 5.14) is shown in red and the black line in each graph shows the fit to data from a) 
the pons, b) the substantia nigra, c) the putamen and d) caudate nucleus. In the putamen two outlying 
samples were excluded from the fit and are circled. The data in each region show a strong linear 
relationship between iron and IRM at 5 K with r ≥ 0.9. In some regions the data seem to be clustered by 






Table 5.8: Properties of the linear fits to IRM at 5 K versus iron concentration. A statistically significant 
linear relationship between IRM at 5 K and iron is observed in all regions. When the outliers are 
excluded the minimum r value is 0.9, which shows a strong linear correlation. 
 
 
5.4 Discriminant analysis 
In Sections 5.1 and 5.2 one-way ANOVA was used to look for differences between the means 
of each disease group for one variable (iron concentration or IRM at 5 K) in one brain region at 
a time. In Section 5.3 the relationship between these two variables was examined using linear 
regression analysis.  
In this section discriminant analysis, a multivariate statistical analysis technique is used to 
combine the data from multiple brain regions or multiple variables (i.e. iron concentration and 
IRM). Discriminant analysis creates a model using the data from samples (e.g. pons C1, pons 
C2, pons C3 etc.) from known groups (i.e. control, AD, PD, MSA), and then groups the cases 
(e.g. C1, C2, C3 etc.) based on the model. The proportion of cases correctly grouped by the 
model shows how successful the model is at distinguishing between disease groups. Cross-
validation of the model excludes each case from the model calculation and then uses the 
resulting model to classify the excluded case. Analysis was carried out using the statistical 
software SSPS and protocols described in Section 4.6.4. 
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5.4.1 Iron concentration or IRM at 5 K in multiple brain regions 
Iron concentration or IRM at 5 K, per gram of fresh frozen tissue was not very successful in 
distinguishing between disease groups in most of the regions examined. The pons was the only 
region which showed statistically significant differences between groups. Discriminant analysis 
was carried out on all different combinations of brain regions to examine how using data from 
multiple regions as predictors can improve the potential of these measurements to distinguish 
between disease states. Discriminant analysis excludes a sample from analysis when there is 
not a complete data set for it, i.e. data for each variable. Therefore, in some models not every 
sample is included and the total number of samples involved in the model is given in the 
results tables.  
For three brain regions (pons, SN and Pu) tissue samples from four diseases (control, AD, PD 
and MSA) were measured and the results of discriminant analysis of these data are shown in 
Table 5.9 a). Additional control and AD samples were measured from the CN and the result of 
discriminant analysis for these two disease states, across all four regions, is shown in Table 5.9 
b). 
Table 5.9 a) shows that no combination of data from the three brain regions can group the 
cases from all four diseases with 100% accuracy, using either the iron concentration or IRM 
data. The best iron concentration model, which correctly grouped 80% of the cases, was 
achieved using data from all three brain regions. The best IRM model also achieved 80% 
correct classification and used data from the pons and the SN. However, cross-validation 
showed a significant reduction in the success of the model. Cross-validation involves removing 
one sample at a time from the model and with such small data set, this is a significant 
proportion of the information and it is therefore unsurprising that it has such a large effect on 






Table 5.9: Proportion of cases correctly classified by discriminant analysis of iron concentration 
(microgram of iron per gram fresh-frozen tissue) or IRM at 5 K (emu per gram of fresh-frozen tissue). 
Every possible combination of brain regions was analysed. Table a) shows the result of analysis of 
control, AD, PD and MSA samples from the pons, SN and Pu and Table b) shows the results of analysis of 
control and AD samples for the pons, SN, Pu and CN. The table gives the proportion of correctly 
classified cases for the model and for cross-validation. The best results for each parameter are 




Table 5.9 b) shows the results of discriminant analysis of control and AD cases from the 
different combinations of measurements of the pons, SN, Pu and CN samples. Classification is 
achieved with 100% accuracy in more than one model. For the iron concentration data this 
always drops to 83.3% with cross-validation, however for the IRM at 5K data 100% correct 
classification is maintained in three combinations. 
In Table 5.9 b) regional combinations which include the pons samples show at worst 83.3% 
successful grouping with iron data and 100% success with IRM data. All of the top IRM models 
included data from the pons, however with the iron data one of the most successful models 
used data from the SN, Pu and CN.  
In both tables the iron concentration data in particular support the hypothesis that considering 
data from multiple regions of the brain may allow differentiation between disease and control, 
which was not possible when comparing measurements in just one region. Although with this 
data set differentiating between multiple neurodegenerative diseases is more difficult than 
between just control and AD, 80% success could still be achieved by combining data from more 
than one region. Consequently, this also supports the hypothesis that the iron changes across 
different regions of the brain are different for different neurodegenerative diseases. It is 
important to note that some combinations of regions reduced the accuracy of the model. For 
example, for the IRM data in Table 9 a) the combination of all three regions produced a model 
that was less good at grouping the cases than the one using pons and SN data only.  
Something common to both tables is that the best IRM model is better than the best iron 
concentration model, when cross-validation is taken into account. This is a positive finding in 
terms of clinical usefulness as IRM at 5 K is a measure of particulate iron, which is the iron 
content of the tissue which most affects MRI.    
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5.4.2 Iron concentration and IRM at 5 K 
In some of the IRM at 5 K versus iron graphs for individual brain regions in Section 5.3 it was 
noted that the data points seemed to cluster by disease group: for example for the pons data 
in Figure 5.15 a). Discriminant analysis of IRM at 5 K and iron concentration (per gram of fresh-
frozen tissue) was carried out to examine this clustering and the results are described in Table 
5.10. The table shows how the data from known groups was assigned to new groups, the 
proportion of correctly placed samples for each disease group and the total correct proportion 
for each region.  
 
 
Table 5.10: Results of discriminant analysis of iron concentration and IRM at 5 K. The table shows how 
cases were grouped, compared to their known group. The total proportion of correctly grouped cases 
for each region is given as well as the proportion correctly grouped for each disease. The numbers in 
brackets refer to the cross-validation results. The highest proportion of correctly grouped cases was 
achieved using samples from the pons. For the caudate nucleus only control and AD data were 




In the caudate nucleus, for which only control and AD samples were available, cases were 
grouped with 100% accuracy. However, this is unsurprising as 100% accuracy was also 
achieved using just the IRM at 5 K data (Table 5.9 b). The classification of cases using data from 
the putamen was worse using the combined IRM and iron data, than using the IRM data alone 
(Table 5.9 a). On the other hand, the classification using pons or SN data was improved by 
combining the iron and IRM data, giving a success rate of 75% and 72.7% compared to 66.7% 
and 54.5% respectively. However, in both cases poor results were shown with cross-validation.  
5.5 Water content of the tissue samples 
The water content of tissue also has a significant influence on the MRI relaxation properties of 
the tissue. It has been hypothesised that increased water content in degenerating tissue 
causes a decrease in R2 and R2* which may counteract the increase in R2 that is caused by 
increased iron concentration [125, 128]. 
 
Figure 5.16: Dry to wet mass ratio of tissue samples. A statistically significant decrease in DWR 
is found in MSA compared to PD pons and in the AD compared to control caudate nucleus. A 
decrease in DWR indicates an increase in water content of the tissue. ^ = p<0.05 by Welch’s 




Figure 5.16 shows the average dry to wet mass ratio (DWR) for each disease group in each 
region. DWR is equivalent to one minus the water mass fraction of the tissue and therefore a 
decrease in DWR indicates an increase in water content of the tissue. Data from the control 
pons and AD putamen violated the Shapiro-Wilk test for a normal distribution (p<0.05), but all 
other groups passed this test. Therefore both parametric (ANOVA) and nonparametric 
(Kruskal-Wallis) statistical analysis was carried out in SSPS, with both tests giving agreement. 
A statistically significant decrease in DWR was found in the pons for MSA compared to PD 
tissue and in the caudate nucleus for AD compared to control tissue. This shows an increase in 
tissue water content which may cause decreased R2 and R2* in these regions.   
5.6 Discussion 
5.6.1 Total and particulate iron concentration can differentiate 
between control and AD cases 
The tissue iron concentration measurements in the pons, substantia nigra, putamen and 
caudate nucleus showed no statistically significant differences between AD and control tissue 
samples. Despite this, discriminant analysis was used to create a model which successfully 
grouped all of the cases into AD or control, when the iron concentration data from more than 
one brain region was used. The ability of information from multiple brain regions to 
differentiate between AD and other neurodegenerative diseases (PD and MSA) was also 
demonstrated with 80% success rate.  
The SQUID magnetometry measurements of IRM at 5 K provided an estimate of the relative 
concentration of particulate (mainly ferrihydrite-like iron in ferritin) iron in each sample. Again, 
no statistically significant differences were observed between control and AD, but correct 
classification could be achieved with discriminant analysis. This result is particularly relevant 
for disease diagnosis as it is particulate iron which most influences MRI. 
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5.6.2 Iron concentration measurements are mostly in 
agreement with the literature 
The mean iron concentrations measured in control substantia nigra and putamen samples fell 
within the range reported in the literature for healthy tissue in a review compiled by Haacke et 
al. [107]. The measured iron concentration in the caudate nucleus was higher than reported in 
the literature and no studies could be found of iron concentration in the pons. In this study, 
only a fairly small sample of tissue was taken from each region for iron quantification as other 
tissue was preserved for MRI. If the iron concentration throughout the region is non-
homogeneous this could explain the increased iron observed in the control CN compared to 
the literature. For this reason, the position of the samples within the region was matched for 
each case as closely as possible in order to obtain comparable data. However, perfect 
matching was not achieved in every case and the consequences of this are discussed further in 
Section 9.3. 
A small number of samples was measured and there was a relatively large variation across the 
different cases within each region and disease group, however this compared favourably to 
the size of standard deviations reported in the literature [93]. 
Although the only statistically significant difference in iron concentration was observed 
between control and MSA pons, the trend of other changes agrees with findings in the 
literature. Increased iron in the AD putamen and caudate nucleus is similar in size to a result 
reported by House et al. [19]. There was also evidence for increased iron concentrations in the 
PD substantia nigra, which again did not reach statistical significance, but is in agreement with 
the literature [23, 146]. 
5.6.3 There is no evidence for increased iron with age 
Control and disease samples were not perfectly aged matched (Table 5.1), however there is no 
evidence of age being a dominant factor in the iron concentration measured for any disease 
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group. The order of samples from highest to lowest iron concentration changes in each brain 
region studied for the control samples and for each disease group (Figure 5.2). 
In Table 3.5, Chapter 3 the empirical equations for iron concentration with age, produced by 
Hallgren and Sourander [93], were used to predict the consequence of the difference in mean 
age of the control and AD sample set. A predicted increase in iron concentration of 3.2% in the 
putamen and 1.9% in the caudate nucleus was made. These changes are much smaller than 
the standard deviations in mean iron concentration in each region. 
5.6.4 There is no evidence for increased magnetite 
concentration in AD 
In general the individual IRM measurements and IRM curves at 5 and 50K were consistent with 
the majority of particulate iron being in the form of ferritin with ferrihydrite-like core and a 
small amount of iron in being in the form of magnetite. 
Without ferritin extraction or further magnetometry measurements, it is not possible to fully 
characterise the magnetic structure of the particulate iron. However, a ratio of IRM at 50 K to 
IRM at 5 K provided an estimation of the relative proportional of particulate iron in the form of 
magnetite. This showed an increase in magnetite concentration in the pons compared to in 
other regions. However, there was no evidence for an increase in proportion or total 
concentration in any particular disease group. Additionally, there was evidence of an increasde 
proportion of iron being in the form of magnetite in some individual samples (Table 5.6).  
5.6.5 What is the potential clinical significance of these results 
in terms of detecting AD with MRI? 
The ability of discriminant analysis to differentiate between control and AD supports the 
hypothesis that iron homeostasis is altered in the AD brain. Additionally, samples from 
Parkinson’s Disease and Multiple System Atrophy cases have also been examined and provide 
evidence of iron changes in the brain that are disease specific. For example, a statistically 
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significant increase in iron was observed in the MSA pons where there was a trend for a 
decrease in iron in the substantia nigra.  
If the changes in iron (more specifically in particulate iron) seen here can be detected with 
enough sensitivity by MRI, it should be possible to distinguish between AD and control by 
discriminant analysis of R2 or R2* measurements. 
The results of discriminant analysis of IRM at 5 K (Table 5.9) show that the pons is a strong 
candidate both for aiding in the differentiation between AD and control and between AD and 
other neurodegenerative diseases. However, the total iron concentration in the pons is much 
lower than in the other brain regions studied and therefore the absolute differences in iron 
may be too small to be detected with MRI.   
5.7 Summary 
I. No statistically significant difference in total or ferritin iron (as estimated by 
measurement of IRM at 5 K) was observed between AD and control tissue in any of the 
four brain regions studied. 
II. However, discriminant analysis was used to successfully differentiate between AD and 
control samples using iron concentration, or IRM at 5 K data, from multiple brain 
regions.  
III. There was no evidence of increased magnetite in the AD samples compared to control, 
but there was evidence for at least some magnetite in most samples. 
IV. From these results it is hypothesised that R2 and/or R2* measurements of multiple 
brain regions may allow differentiation between control and AD samples, even if no 




Chapter 6:  
Synchrotron X-ray fluorescence mapping 
In Chapter 5 the iron concentration of 0.1 to 0.5 g blocks of tissue, which were cut from the 
caudate nucleus, putamen, substantia nigra and pons, was measured using GFAAS (Graphite 
Furnace Atomic Absorption Spectrometry) or ICP-MS (Inductively Coupled Plasma Mass 
Spectrometry). This achieved accurate quantification of total tissue iron concentration for the 
carefully dissected samples and allowed a comparison to be made between Alzheimer’s 
Disease (AD) and control tissue. However, this technique does not provide comparable spatial 
resolution to the high resolution MRI mapping at 600 MHz (in plane resolution = 62 µm) or 400 
MHz (in plane resolution = 86 µm) that will be presented in Chapter 7.  
Synchrotron X-ray fluorescence (SXRF) mapping is a technique which allows highly sensitive 
and specific mapping of iron and other elements in biological samples, with a spatial resolution 
of down to approximately 1 µm2. Alternative elemental mapping techniques such as electron 
microprobe and particle induced X-ray emission (PIXE) can provide similar or enhanced spatial 
resolution, but have lower detection limits and can cause beam damage to the sample [117]. 
Laser Ablation Inductively Coupled Plasma Mass Spectroscopy (LA-ICP-MS) can produce metal 
maps of tissue sections with a similar sensitivity and resolution to SXRF [119]. However, as it is 
a destructive technique there is no opportunity to create multiple maps at different 
resolutions for the same sample.  
30 µm thick tissue sections that had been cut from the MRI mapped blocks were mapped at 
beamline I18 at the Diamond Light Source (DLS) to produce 60 µm resolution maps of relative 
iron, copper and zinc concentration. The samples were prepared using a protocol developed 
by our group that minimised the chance of contamination with metal particulates [132]: 
sections are cut using a non-metal blade from the un-embedded tissue and mounted on high 
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quality quartz slides. Samples were not fixed before sectioning as fixatives have been shown to 
leach metals from tissue [91]. 
The SXRF maps collected at the beamline I18 at the Diamond Light Source show the relative 
concentration distribution of metals, and not the absolute concentration. With careful control 
of variables and normalisation of each map, comparisons of relative concentration can also be 
made between different samples. The absolute iron concentration of adjacent blocks of tissue 
for some of the samples was measured and presented in Chapter 5. This information is used to 
approximately calibrate the SXRF iron maps as described in Section 6.4. This then allows 
estimation of iron concentration in regions for which SXRF maps were made, but bulk tissue 
measurements were not.  
The SXRF metal maps show the inhomogeneity of metal distribution within and between brain 
regions. Each map is segmented into distinct anatomical structures and the mean and variance 
of each structure compared for the control and AD example. In Chapter 8 the SXRF maps will 
be spatially matched to the corresponding MRI maps to investigate the relationship between 
R2 and R2* and iron concentration in control and AD tissue.  
6.1 SXRF metal maps 
The details of each SXRF mapping experiment are given in Table 4.5 in Section 4.4 and the 
details of each case are given in Table 3.4 in Section 3.2.2. SXRF mapping of the caudate 
nucleus (CN), putamen (Pu), globus pallidus (GP), substantia nigra (SN) and amygdala (Amyg) 
was carried out over one 5 day experiment at the Diamond Light Source: experiment DLS5. The 
pons tissue samples were mapped over 4 experiments numbered DLS1 to DLS4. Collecting data 
over multiple visits increases the potential sources of experimental error and therefore the 
pons data are examined separately in Section 6.5. 
Due to the time required to collect each map and the limited time available at the 
experimental facility, only one control and one AD sample were imaged for each brain region. 
179 
 
The samples to be mapped were chosen based on the results of MRI mapping (Chapter 7). 
Sections for mapping were collected on quartz slides and prepared as described in Section 
3.3.3.1. No samples from control C1 were mapped as this sample was not well age-matched to 
the other controls or to the AD samples. 
Section 4.4.2 describes fitting the SXRF spectra, using the software PyMCA, to produce metal 
maps and the normalisation of each pixel to the incident X-ray beam, I0. The conversion of the 
data files into individual metal maps compatible with the image processing software ImageJ 
was also described. However, normalisation to I0 does not correct for variation in the distance 
between the sample and the X-ray detector, which changes the intensity of the X-rays at the 
sample. Therefore each map is normalised to the chemically constant ‘background’ provided 
by the quartz slide. The slide contribution to each map is also subtracted from the map in 
order to leave only signal from the tissue section in the final SXRF iron, copper and zinc maps. 
6.1.1 Subtracting slide background 
Figure 6.1 shows a typical fluorescence spectrum for an area of quartz slide, where the 
fluorescence intensity is averaged over the number of pixels sampled. The iron and copper 
peaks are clearly present, but the zinc peak is only just visible on the edge of the scatter peak, 
showing that there is a very low concentration of zinc present in the slide. There is also a small 
concentration of nickel present in the slide.  
Comparison of the zinc signal of the quartz slide to the typical signal on a tissue section shows 
that the background signal is around 1% of the total signal and therefore is considered 
negligible and not subtracted from the tissue map. In contrast, the copper signal of the slide is 
relatively high and is typically 50% of the on-tissue fluorescence signal. The iron signal in the 
quartz is well above background and so can be fitted in PyMCA and is subtracted from the 
map, although it is only around 5 % of the typical on-tissue signal. When each SXRF map was 
collected an area of quartz slide was included. ImageJ was used to find the mean and standard 
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deviation of the area of slide in the metal maps (which had been fitted in PyMCA and 
normalised to I0). The average copper and iron signal, shown in Figure 6.2, was then subtracted 
from the whole map.  
 
Figure 6.1: Typical fluorescence spectrum of an area of quartz slide, with the signal intensity averaged 
over the number of pixels sampled. The iron Kα and Kβ peaks can be seen above background, as can the 
nickel and copper Kα peaks. The Zn Kα is only just visible on the edge of the scatter peak from the 
incident beam I0. 
 
 
Figure 6.2: Quartz slide SXRF signal intensity. The mean and standard deviation of the a) copper and b) 





6.1.2 Normalising to slide background 
In experiment DLS5 the detector was moved in and out of position between samples and 
although the position of the detector was marked with a gauge, slight variation between 
samples’ position is possible. Figure 6.2 shows the mean and standard deviation of the iron 
and copper SXRF signal intensity of the area of the quartz slide included in each map. The 
trend of signal intensity is very similar for copper and iron, which is as expected as the same 
brand of high quality quartz slides was used in each case. As iron is the main focus of this study 
all three metal maps were normalised to the average background iron fluorescence intensity. 
Table 6.1 gives the percentage difference in the iron SXRF signal from the slide background of 
the AD sample compared to the control sample for each of the brain regions measured during 
DLS5, calculated using the formula:  
(
              
      
)       (6.1) 
This calculation shows the proportional change that normalising to the slide background has 
on the whole map. 
Brain 
Region  
Difference in slide Fe 
signal for AD compared 
to control 
 
Table 6.1: Percentage difference of the 
measured iron fluorescence intensity of 
the quartz slides for AD samples 
compared to the control. Data were 
normalised to slide background to 


















6.1.3 Final adjustments and error estimation 
6.1.3.1 Estimation of measurement error 
Estimating the measurement error is important in order to compare relative metal 
concentrations within and between maps. As no standards with known metal concentration 
were available, estimating the measurement error is not trivial. A number of factors may 
contribute to the error in the maps including fitting the spectra in PyMCA and normalising to 
background. 
The quartz slides provided a constant background and were used for normalising the data (as 
described above) and also to estimate the measurement error. As can be seen in Figure 6.2 
there is a large standard deviation in the mean iron SXRF signal of each slide. However, the 
copper signal provides a second point of reference, where the ratio between the iron and 
copper in the slide should be the same across all maps. The ratio of iron to copper of the 
quartz slide in each map was calculated and the mean and standard deviation found. The 
standard deviation is ± 5% and this provides an estimation of the error in the normalisation of 
each map. As this error estimation is made from fitted SXRF maps it includes the effect of the 
error in fitting the SXRF spectra. Furthermore, as the quartz slide has the minimum SXRF signal 
intensity of any area of the map it is likely to have the greatest fitting error. Therefore ± 5% is 
used as a standard measurement error in the relative metal concentration measured by SXRF. 
The other major potential source of error in comparing metal concentration between maps is 
variation in section thickness. Sections were cut at 30 µm using a recently serviced and 
calibrated cryomicrotome and therefore should be consistent. 
6.1.3.2 Setting the threshold 
Once the average slide background had been subtracted, individual pixels values for the slide 
were approximately zero. The ‘adjust threshold’ function in ImageJ was then used to set the 
slide pixels to ‘NaN’ meaning that they have no value and are therefore not included in any 
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measurements made on the maps. This is particularly useful for sections with tears or cracks, 
as it means there is no need to manually draw around the gaps in the tissue.  
The upper threshold limit was set to remove very high signal due to any specks of 
contamination, for example from dust landing on the slide, or to remove areas where the 
tissue had folded or curled during sectioning. The threshold limits were set very carefully so as 
not to exclude the real variation in metal concentration in the tissue. Therefore in some cases 
areas of folded tissue were manually deleted from the map. 
6.1.3.3 Colouring conventions  
The individual iron, copper and zinc maps shown in Section 6.3 were assigned to a 
temperature colour scale, as this provides good contrast for the relative metal concentration 
distribution within each map. The normalisation to I0 and slide background means that, in 
conjunction with the calibration bar, these maps can be used to visually compare relative 
metal concentrations between samples.  
The different metal maps can also be overlaid in ImageJ, with each map assigned to a different 
colour channel. The convention in our group is to assign iron to red, copper to green and zinc 
to blue. These maps show the variation in distribution in the different metals across the 
section and also often highlight the boundaries between anatomical features more clearly than 
individual metal maps do.  
After the final metal maps were produced (as described above) segmentation of the maps into 
regions of interest (ROI) and measurement of the average SXRF signal in each ROI were used to 
quantitatively compare between disease and control. Note that due to differences in 
fluorescence efficiency between different metals, comparisons of concentration between 
different metals are not simply reflected by signal intensity.   
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6.2 Segmenting SXRF maps 
The brain regions studied in this thesis are introduced in Section 3.2.1 and Appendix A. In 
Section 3.2.3 and Appendix B the way in which each sample was cut from a larger tissue block 
is shown. This information, together with the contrast in the combined metal SXRF maps, 
haematoxylin stained tissue sections and a selection of reference materials [167, 171, 188], 
was used to identify the different neuroanatomical structures present in each map. As some 
contrast between tissue type was lost in the stained post-SXRF sections, adjacent sections 
were also used to aid in segmentation. 
Each structure was manually drawn around using the region of interest (ROI) tool in ImageJ. 
The analysis is not limited to the six brain regions which were the main target of this study, but 
includes the surrounding structures present in the SXRF maps. This is important as the 
surrounding tissues may show changes in metal concentration and distribution with AD. 
Therefore examining these structures will help to answer the question: are changes in iron 
concentration localised to specific structures? Figures 6.3 to 6.12 show the segmentation of 
the combined iron, copper and zinc maps for each sample. The colour range in each map is set 
to give the best contrast between structures and is not the same for different samples. 
Caudate Nucleus 
Both the control (Figure 6.3) and AD (Figure 6.4) caudate nucleus samples contain the same 
structures: a portion of the head of the caudate nucleus (CN), tissue from the anterior limb of 
the internal capsule (AIC) and white matter medial to the CN (WM-CN).   
Putamen 
In addition to putamen tissue (Pu) both samples (control Figure 6.5 and AD Figure 6.6) contain 
white matter lateral to the putamen (Pu-WM). The control sample C3 also has tissue from the 
anterior limb of the internal capsule (AIC). The AD sample seems to be from a slightly more 
inferior level than the control and does not contain the top of the putamen.  
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In terms of iron concentration the putamen is observed as two distinct regions. The majority of 
the putamen had a high concentration of iron (Pu_high), whereas along the lateral edge there 
was a band of relatively low iron concentration (Pu_low).  
The AD sample contains a very high inclusion of iron which surrounds a blood vessel and this 
was excluded from the segmentation of the regions Pu and Pu_high. 
Globus Pallidus 
In both the control (Figure 6.7) and AD (Figure 6.8) sample of the globus pallidus a region of 
the external globus pallidus (GPe) and high iron putamen (Pu_high-GP) are segmented. The 
thin lamina of white matter (WM-GP) separating the external globus pallidus and putamen is 
also segmented in both maps. 
Additionally, in the control map tissue from the internal capsule (IC) is present and in the AD 
map the internal globus pallidus (GPi) and low iron region of the putamen (Pu_low-GP) are 
segmented. 
Substantia Nigra 
From the section stained with haematoxylin and the metal maps it is not straight forward to 
divide the substantia nigra into the pars reticulata and (SNr) and pars compacta (SNc). 
Therefore the image was segmented into the substantia nigra (SN) and cerebral crus (CC). The 
segmentation is shown for sample C2 in Figure 6.9 and AD2 in Figure 6.10.  
In both maps a ‘gap’ in the high iron band is observed towards the LHS of the image. This is 
excluded from the SN segmentation and assigned its own ROI. Finally the SXRF section was 







Figure 6.3: Segmentation of the SXRF map of caudate nucleus sample C2. a) Anatomical reference of the 
caudate nucleus at level –15 mm, with the approximate position of the SXRF map outlined in red. b) An 
adjacent section to the SXRF mapped section, stained with haematoxylin and with the approximate area 
of the map outlined in red. c) The SXRF map of iron, copper and zinc, showing the segmentation of the 





Figure 6.4: Segmentation of the SXRF map of caudate nucleus sample AD1. a) Anatomical reference of 
the caudate nucleus at level –15 mm, with the approximate position of the SXRF map outlined in red. b) 
An adjacent section to the SXRF mapped section, stained with haematoxylin and with the approximate 
area of the map outlined in red. c) The SXRF map of iron, copper and zinc, showing the segmentation of 







Figure 6.5: Segmentation of the SXRF map of putamen sample C3. a) Anatomical reference of the 
putamen at level –15 mm, with the approximate position of the SXRF map outlined in red. b) A 
haematoxylin stained section, adjacent to the SXRF mapped section. c) The SXRF map has been 
subdivided into three main regions: the putamen (Pu), the anterior limb of the internal capsule (AIC) and 
white matter adjacent to the putamen (WM-Pu). The putamen was further subdivided into two distinct 
areas: high iron (Pu_high) and low iron (Pu_low). This division between high and low iron is not visible in 





Figure 6.6: Segmentation of the SXRF map of putamen sample AD3. a) Anatomical reference of the 
putamen at level –8 mm, with the approximate position of the SXRF map outlined in red. b) A 
haematoxylin stained section of the putamen, adjacent to the SXRF mapped section. c) The SXRF map 
has been subdivided into three main regions: the putamen (Pu), the anterior limb of the internal capsule 
(AIC) and the white matter adjacent to the putamen (WM-Pu). The putamen was further subdivided into 
two distinct areas: high iron (Pu_high) and low iron (Pu_low). This division between high and low iron is 
not visible in the stained section. This sample contained a blood vessel which was surrounded by a very 







Figure 6.7: Segmentation of the SXRF map of globus pallidus sample C3. a) Anatomical reference of the 
globus pallidus at level 4 mm, with the approximate position of the SXRF map outlined in red. b) An 
adjacent section stained with haematoxylin. c) The combined metal SXRF map is segmented into the 
external globus pallidus (GPe), internal capsule (IC) and high iron region of the putamen (Pu_high-GP).  




Figure 6.8 Segmentation of the SXRF map of globus pallidus sample AD2. a) Anatomical reference of the 
globus pallidus at level 12 mm, with the approximate position of the SXRF map outlined in red. b) The 
mapped section stained with haematoxylin. c) The combined metal SXRF map is segmented into the 
putamen (Pu), external globus pallidus (GPe) and internal globus pallidus (GPi). d) The putamen was 
further segmented into: the high and low iron regions (Pu_high and Pu_low) and the lamina of white 





Figure 6.9: Segmentation of the SXRF map of substantia nigra sample C2. a) Anatomical reference of the 
substantia nigra with the approximate area of the mapped section outlined in red.  b) The haematoxylin 
stained mapped section, with the dopaminergic neuron (DPN) dense region outlined in yellow. c) SXRF 
map with the cerebral crus (CC) and substantia nigra (SN) and ‘gap’ segmented. d) The SXRF map 




Figure 6.10: Segmentation of the SXRF map of the substantia nigra sample AD2. a) Anatomical reference 
of the substantia nigra with the approximate area of the mapped section outlined in red.  b) The 
haematoxylin stained mapped section, with the dopaminergic neuron (DPN) dense region outlined in 
yellow. c) SXRF map with the cerebral crus (CC) and substantia nigra (SN) and ‘gap’ segmented. d) The 




The amygdala control sample C3 and Alzheimer’s Disease sample AD2 are shown in Figures 
6.11 and 6.12 respectively. It was not possible to segment the amygdala maps into any of the 
amygdala sub-nuclei due to the small sample which included no surrounding structures to aid 
identification. However, the feedback from neuropathologist Dr Lili-Naz Hazrati is that the 
tissue is from inside the amygdala and from a similar position in both samples. 
 
Figure 6.11: SXRF map of amygdala sample C3. a) A section cut from adjacent to the mapped section and 




Figure 6.12: SXRF map of amygdala sample AD2. a) A section cut from adjacent to the mapped section 




6.3 SXRF maps: qualitative and quantitative analysis 
With the anatomical features in the SXRF maps identified, it is possible to examine the iron, 
copper and zinc distribution within each region and between the AD and control samples. 
6.3.1 Qualitative observations 
Figures 6.13 to 6.17 show the maps of relative concentration distribution of iron, copper and 
zinc in the control and AD example from the caudate nucleus, putamen, globus pallidus, 
substantia nigra and amygdala respectively. Due to the careful normalisation and subtraction 
of slide background, the concentrations can be directly compared between each map (of the 
same metal). A calibration bar is shown for each map, with units of ‘normalised SXRF signal 
intensity’.  
The maps are displayed using a temperature colour scheme for maximum contrast. The 
segmented, multi-metal maps are also included to show the main neuroanatomical features, 
with the intensity of each metal distribution within these maps set to produce the best 
contrast. In order to aid comparison of metal concentration distribution between pairs of AD 
and control maps the same intensity range was used where possible. However, in many cases 
this was not sensible as detail was lost in one or both of the maps if the same range was used 
and priority was given to showing the detail of metal distribution within the individual maps. 
Caudate Nucleus 
Figure 6.13 shows the metal distribution in the caudate nucleus samples C2 and AD1. In the CN 
the concentration of all three metals is higher in the AD sample compared to the control. 
There is also evidence for altered iron distribution within the CN and between the CN and 
surrounding structures. In the control CN the iron concentration decreases from the AIC 
towards the WM, whereas it remains high in this direction in the AD sample. In the control 
sample the concentration of iron in the AIC is higher than in the CN, whereas in the AD map 




Figure 6.14 shows the SXRF maps of iron, copper and zinc in putamen samples C3 and AD3. A 
region of very high iron concentration in the AD putamen coincides with the location of a 
blood vessel. The distribution of copper and zinc is similar in the AD and control samples, but 
the overall concentration of zinc is increased.  
A region of decreased iron concentration, Pu_low, was defined in the combined metal maps as 
a band of reduced iron concentration, which runs along the lateral edge of the putamen. The 
individual maps reveal that copper and zinc concentration are unchanged in this area 
compared to the rest of the putamen, whereas the iron concentration is reduced. The same 
feature is observed in the AD map of the globus pallidus in Figure 6.15, which includes tissue 
from the putamen. 
Globus Pallidus 
The iron, copper and zinc SXRF maps of the globus pallidus for samples C3 and AD2 are shown 
in Figure 6.15. In the control sample iron is elevated in the external globus pallidus, compared 
to the putamen, whereas the opposite is true in the AD map. The SXRF maps of the CN and Pu 
(Figures 6.13 and 6.14) show a close relationship between the distribution of copper and zinc. 
This is the case for most structures in the Figure 6.15, apart from the GPi where an elevation in 
copper is not matched by an elevation in zinc. 
The putamen is a large structure and the tissue in these sections is approximately 10 to 20 mm 
away from the tissue in Figure 6.14. The iron concentration in Pu_high is higher in Figure 6.15 
than in Figure 6.14. This shows that iron concentration changes throughout this nucleus, over 
distances that would be resolvable with clinical MRI. 
Substantia Nigra  
The normalised SXRF metal maps of C2 and AD2 substantia nigra are shown in Figure 6.16. 
Each metal shows a distinct distribution within the SN, which is seen in both the control and 
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AD sample. Iron is highest at the medial end of the substantia nigra. Conversely, copper is 
highest toward the lateral side of the SN and is particularly high in the region of the ‘gap’ in the 
high iron signal. This is particularly clear in the maps of sample C2. Zinc concentration remains 
more consistent across the SN with a slight increase at the medial end. The concentration of 
iron and zinc is higher in the SN of the AD sample compared to the control. 
The ‘gap’ in iron seems to correspond approximately to nigrosome 1, which is an area defined 
by Damier et al. based on its poor staining for calbindin [189]. 
Amygdala 
Figure 6.17 shows the SXRF metal maps for the amygdala from cases C3 and AD2. No 
structures could be positively identified within the map. The pattern of iron distribution is 
different in the AD sample compared to control, which could be due to the inclusion of 
different sub-nuclei of the amygdala in each map. However, this could not be confirmed by 













Figure 6.13: Iron, copper and zinc distribution in the caudate nucleus. The anatomical features present 
are the: caudate nucleus (CN), anterior limb of the internal capsule (AIC) and the white matter medial to 
the caudate nucleus (WM-CN). Individual metal maps show the relative concentration distribution of 
iron, copper and zinc, plotted on a temperature scale, where the calibration bars show the normalised 
SXRF signal intensity. In the CN tissue the concentration of each metal is higher in the AD sample 
compared to control. The distribution of Cu and Zn is similar in AD and control. The iron concentration in 
the control CN reduces gradually from the AIC towards the WM-CN, whereas it remains high throughout 
the CN in the AD map. The concentration of iron in the AIC is higher than in the CN in the control map, 








Figure 6.14: Iron, copper and zinc distribution in the putamen. The anatomical features present are the 
high and low iron regions of the putamen (Pu_high and Pu_low), the white matter lateral to the 
putamen (WM-Pu) and the anterior limb of the internal capsule (AIC, C3 map only). Individual metal 
maps are plotted using a temperature scale, where the calibration bars show the normalised SXRF signal 
intensity. Very high iron concentration is observed around a blood vessel in the AD sample. Copper 
concentration is elevated in the AD map. The distribution of copper and zinc is similar in the control and 






Figure 6.15: Iron, copper and zinc distribution in the globus pallidus. Individual metal maps are plotted 
using a temperature scale. The anatomical features present in the control map are: the high iron region 
of the putamen (Pu_high-GP), the internal globus pallidus (GPe), the lamina of white matter separating 
the putamen and GPe (WM-GP) and the internal capsule (IC). The AD map also includes: the internal 
globus pallidus (GPi) and the low iron region of the putamen (Pu_low-GP). The range of concentration of 
each metal is similar for control and AD and therefore the pairs of maps are plotted over the same 
range, where the calibration bars show the normalised SXRF signal intensity. Iron concentration is higher 












Figure 6.16: Iron, copper and zinc distribution in the substantia nigra. The anatomical features present 
are: the substantia nigra (SN), cerebral crus (CC) and a distinctive gap in the high iron signal of the SN 
(gap). Individual metal maps are plotted on a temperature scale, where the calibration bars show the 
normalised SXRF signal intensity. The concentrations of iron and zinc are higher in the SN of the AD 
sample compared to the control sample. The distribution of each metal shows a distinct pattern within 






Figure 6.17: Iron, copper and zinc distribution in the amygdala. Individual metal maps show the relative 
concentration plotted on a temperature scale, where the calibration bars show the normalised SXRF 
signal intensity. The distribution of each metal is different in the control and AD example. This may be 
due to different sub-nuclei of the amygdala being included in each sample, but this could not be verified 




6.3.2 Quantitative analysis 
Figure 6.18 shows the mean normalised SXRF signal intensity for the segmented regions of 
each map. The error bar shows the estimated measurement error of 5%. Iron concentration is 
increased above error in more than half (9 out of 14) of the regions, including the caudate 
nucleus, putamen and substantia nigra. On the other hand, iron is increased in the control data 
in two regions: WM-GP and WM-Pu.  
Copper and zinc concentration are also increased in the AD data in a majority of the 
segmented regions, however an increase is not always observed for all three metals in the 
same region. For example, although the AD3 Pu map shows an increase in copper 
concentration compared to C3 across all segmented regions, there is little or no change in the 
concentration of zinc and iron in the same regions. 
Across the different brain regions iron shows greater inhomogeneity than copper or zinc. 
Copper also varies significantly, whereas zinc concentration is more consistent. For example, 
the concentration of zinc in the amygdala is similar to the other regions, whereas the 
concentrations of copper and iron are lower compared to most other regions. 
The putamen is mapped twice. Firstly at a level where it is lateral to the caudate nucleus and 
secondly where it is lateral to the globus pallidus. As was observed by visual comparison of the 
maps in Figures 6.14 and 6.15, the iron concentration in Pu in the samples lateral to the GP is 
much higher than where it is lateral to the CN (for both AD and control samples). The AD 













Figure 6.18: Mean relative iron, copper and zinc concentration in the segmented regions of SXRF maps 
from experiment DLS5. The mean normalised SXRF signal intensity for each metal for each tissue 
structure, which appeared in both the control and AD samples, is given. n=1 for each region. The error 
bars show the estimated 5% measurement error. The segmented regions are grouped according to 
which map they were segmented from. From the caudate nucleus maps: the caudate nucleus (CN), 
anterior limb of the internal capsule (AIC) and the white mater medial to the CN (WM-CN). From the 
putamen maps: the whole putamen (excluding the blood vessel in AD3) (Pu), the white matter lateral to 
the putamen (WM-Pu), the low iron part of the putamen (Pu_low) and the high iron part of the 
putamen (Pu_high). From the globus pallidus maps: the external globus pallidus (GPe) and the high iron 
part of the putamen (Pu_high). From the substantia nigra: the whole substantia nigra (SN), the gap in 
the iron signal of the SN (gap) and the cerebral crus (CC). The mean signal was taken from the whole of 
each amygdala map (Amyg). a) Relative mean iron concentration in the segmented brain regions. The 
iron concentration varies across the different regions more than copper or zinc does. Nine out of 
fourteen regions show an increase in iron, greater than the 5% measurement error, in the AD sample 
compared to control. In particular iron is increased in the CN, WM-CN, Pu_high-GP and SN. Iron is only 
increased in control compared to AD in the WM-Pu and WM-GP. b) Relative mean copper concentration 
in the segmented brain regions. Copper is increased in AD in the segmented regions of the caudate 
nucleus and putamen and to a lesser extent in the globus pallidus. Copper concentration is only 
increased in control tissue in the amygdala and the ’gap’ region of the SN. c) Overall, zinc has the least 
variation in concentration between brain regions. Zinc is increased with AD in the segmented regions of 





6.3.3 Standard deviation of pixel intensity in each region 
Figure 6.18 shows the mean metal concentration of the pixels within each segmented region 
of the SXRF maps, but does not include any information about the variation in pixel intensities 
within each ROI. Therefore the standard deviation (σ) within each segmented area is shown in 
Figure 6.19. Standard deviation is equal to the square root of the variance and large variance 





Figure 6.19: Standard deviations of pixel values in 
the segmented regions of the SXRF maps. a) 
Standard deviation in the iron SXRF maps. The 
variance is very high in the GP maps, in particular 
for the control sample. b) Standard deviation in 
the copper SXRF maps. There is high standard 
deviation in the control globus pallidus regions and 
in the regions from of putamen and substantia 
nigra maps for the AD sample. c) Standard 
deviation in the zinc SXRF maps. Standard 
deviation varies less than in the iron or copper 
maps. It is high for GP regions in the control map 
and for AD in the CN, WM-CN and SN map. 
There is no overall trend to suggest that larger variance is seen in AD tissue compared to 
control. In half of the 14 regions the AD samples have the higher variance, whereas in the 
other half it is higher for the control samples. The largest variance in iron is seen in the 
segmented regions of the GP map. In these regions the control samples show the greater 
variation. However, this pair of samples is the least well anatomically matched of all the brain 
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regions (see Figures 6.7 and 6.8) and this may account for the large difference in variance 
within the segmented regions. Similarly to variation between means, the variance of zinc 
concentration at a 60 µm resolution is more consistent across the regions of the brain than the 
variance of iron or copper.  
6.4 Using bulk tissue iron concentration to calibrate 
SXRF signal intensity 
No suitable standards for calibrating the metal concentrations in the SXRF maps were available 
at beamline I18. Hence, in past publications and in this chapter the data have been described 
as a relative concentration. However, the iron concentration of adjacent tissue from a number 
of the samples has also been measured and this can be used to approximately calibrate the 
SXRF signal intensity. The calibration allows estimation of tissue iron content of regions not 
measured by ICP-MS or GFAAS.  
6.4.1 Comparing SXRF and bulk tissue iron measurements 
Measurements of iron concentration made by bulk tissue iron quantification and SXRF 
mapping are over a significantly different scale. For the bulk tissue measurements iron 
concentration in approximately 0.5 g of fresh-frozen tissue is quantified, whereas for SXRF 
mapping the relative iron concentration is examined over around 1 cm2 of a 30 µm slice of 
tissue, which equates to approximately 0.003 g (assuming that tissue density is approximately 
the same as water). Additionally, the tissue in the two different measurements is from 
adjacent blocks within the region at a distance of around 10 mm. The comparison will 
therefore be affected by any changes in iron concentration throughout the region. 
In order to estimate how well these two measurements compare, the ratio of the AD to 
control iron concentration (ACR) was found for: i) the relative mean iron concentration 
measured by SXRF mapping and ii) for the bulk tissue iron quantification. The ARC ratios are 
given in Table 6.2. The substantia nigra was bisected for bulk tissue analysis in the same plane 
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as the SXRF map. Therefore, the whole map is most closely representative of the tissue that 
was dissolved for iron quantification in Chapter 4. For the other regions, the mean SXRF signal 
from within the segmented regions is used. The SXRF comparison for the putamen excludes 
the very high iron region in the AD sample, which surrounds a blood vessel, as there is no 
reason to assume that a similar blood vessel would be found in the adjacent tissue taken for 
ICP-MS.  




Caudate Nucleus  3.04 2.80 
Putamen 1.28 1.24 
Substantia Nigra (whole map) 1.50 1.41 
Table 6.2: Ratio of AD to control iron concentration (ARC), measured by bulk 
tissue analysis (ICP-MS: inductively coupled mass spectrometry or GFAAS: 
graphite furnace atomic absorption spectrometry) and SXRF mapping. The 
agreement between techniques is good for all regions. 
 
 
Overall the ratios are in good agreement. In the putamen the results differ by only 0.04 and for 
the SN the difference is 0.09. The largest difference is in the CN data which disagrees by 0.24, 
however by both techniques this is the region which showed the largest increase in iron in AD 
compared to control.  
6.4.2 Calibrating the SXRF data 
The good agreement between the SXRF and ICP-MS/GFAAS measurements in Table 6.2 led to 
the hypothesis that the bulk tissue measurements could be used to calibrate the normalised 
SXRF iron data. This calibration assumes that the volume of tissue measured by ICP-MS or 
GFAAS and the area tissue mapped by SXRF have an equal concentration of iron. It has already 
been established that careful normalising of the SXRF maps from experiment DLS5 means that 
the SXRF signal intensity is comparable between maps and therefore the data from the 
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different samples can be pooled. The segmented ROI is used, rather than the average across 
the whole map, as the bulk tissue samples were carefully cut from the surrounding structures.  
The iron concentration represented by 1 unit of normalised SXRF signal intensity was 
calculated for the control and AD sample from the SN, CN and Pu and then the mean result 
found and the standard deviation calculated. The result, shown in Table 6.3, gives an average 
iron concentration of 7.3 ± 12% µg/g of iron for every unit of normalised SXRF intensity.  
 
 
Table 6.3: Estimation of iron concentration per unit of normalised iron SXRF intensity. The bulk tissue 
iron concentration is divided by the mean normalised SXRF signal intensity for each control and AD 
sample. The average iron concentration per unit of normalised SXRF signal intensity is calculated from all 
AD and control samples. The standard deviation (σ) is calculated to give an approximate error in the 
estimation of 12%. 
 
 
6.4.3 Estimating iron concentration using calibrated SXRF 
The amygdala and globus pallidus were mapped during experiment DLS5, but did not have an 
adjacent sample taken for bulk analysis. The calibrated SXRF signal intensity was used to make 
an estimation of the iron concentration in the control and AD iron maps. The estimated iron 
concentration in the control and AD amygdala and globus pallidus are shown in Table 6.4, 
alongside the values for those regions reported in the literature. The amygdala data compare 
extremely well with the iron concentration measurements made by Samudralwar et al. [16], 
where a concentration of 50.8 ± 3.7 µg/g was measured for control amygdala and 70.8 ± 4 
µg/g for AD. The estimated concentration in the globus pallidus is much higher than the values 
for control (132.7 µg/g) and AD (160 ± 49.4 µg/g) published by House et al. [26], where the 
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concentration was measured by GFAAS. However, it is not more than the maximum 




Table 6.4: Estimated iron concentrations in the control and AD amygdala and globus pallidus and the 
values reported in the literature. The estimated values are most comparable with the higher values 
given in the literature. The estimated amygdala data agree particularly well with the values reported by 
Samudralwar et al. [16] (underlined). The globus pallidus estimation is higher than most published data, 
but less than that published by Griffiths and Crossman [106] (underlined). 
 
 
6.5 The pons 
The 60 µm resolution pons maps were made over three experimental visits to the DLS (Table 
4.5) and the normalisation of these samples proved particularly difficult. The slide signal for 
the low resolution pons maps is shown in Figure 6.20 a), with the experiment number for each 
map indicated on the graph. The data varies more considerably than for the other samples, 
with the largest variation being between the samples AD2 and PD1. This is unexpected as 
these samples were measured during the same experiment. This is most likely due to varying 
detector position as during this experiment the detector was moved in and out when the 
sample was changed and the gauge to mark detector position had not yet been introduced. 
Figure 6.20 b) shows the iron SXRF signal for the quartz slide for control, AD, PD and MSA pons 
maps at 3 µm resolution taken during experiment DLS4. There is very little variation between 
the different samples as the detector was not moved during this experiment. Table 6.5 shows 
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the percentage change of the iron signal of the quartz slide for each sample compared to 
control. The slide background is subtracted from the 60 µm and 3 µm resolution maps and 
then used to normalise the data. 
 
Figure 6.20: Iron SXRF signal intensity for the quartz slide background for the pons samples. a) 60 µm 
maps in experiments DLS1, DLS2 and DLS3 and b) 3 µm resolution maps in experiment DLS4. 
Fluorescence intensity has been normalised to I0. Error bars indicate the standard deviation of signal in 
the area of quartz slide selected for the background. Pons samples were mapped from control, AD, PD 





Table 6.5: Percentage difference of the 
measured iron fluorescence intensity of 
the quartz slides for disease samples 
compared to control. The difference 
between slide background for each 
disease is compared to the control 
sample for low and high resolution maps 
of the pons. 
Table 6.6 shows the ratio of the mean normalised iron SXRF signal between the different 
samples and the equivalent ratio for bulk tissue iron quantification of the same samples. None 
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of the ratios agree as well as those shown for the samples measured in DLS5. The best 
agreement is for the ratio of the AD to Parkinson’s Disease (PD) samples. These samples were 
measured during the same experiment so there is no reason to distrust the normalisation of 
these maps and as the bulk tissue iron measurements were made of adjacent samples, it is not 
unreasonable to expect some disagreement.  
 
The Multiple System Atrophy (MSA) and control samples were measured over two different 
experimental visits to the DLS and as the set up at the beamline is often updated there may be 
a measurement error which is not being corrected for by the normalisation to slide 
background and I0. As the ratios do not agree well, no quantitative comparisons using the 
control and MSA pons maps will be made. 
6.5.1 Sixty micron resolution SXRF maps 
6.5.1.1 Qualitative observations 
The normalised SXRF metal maps for the control and MSA samples are shown in Figure 6.21 
and for the AD and PD samples in Figure 6.22.  
 
  
  GFAAS SXRF  
Table 6.6: Iron concentration ratio between 
disease groups in the pons. For tissue iron 
concentration by GFAAS (graphite furnace 
atomic absorption spectrometry) and SXRF 
mapping. The best agreement is between 
the AD:PD ratios. 
AD : control 2.4 6.08  
PD : control 0.84 2.55  
MSA : control 1.99 2.83  





Figure 6.21: Metal distribution in the control and MSA pons. Individual metal maps show the relative 
concentration of iron, copper and zinc plotted on a temperature scale, however no calibration is given 






Figure 6.22: Metal distribution in the AD and PD pons. Individual metal maps show the relative 
concentration of iron, copper and zinc plotted on a temperature scale, where the calibration bar shows 
the normalised SXRF intensity. A similar distribution in the control and AD samples is observed for each 
metal, although the concentration of iron is higher in the AD sample. 
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As the normalisation of the control and MSA maps has been shown to be unsatisfactory, 
calibration bars are not included for these maps. Stripes of grey and white matter can be seen 
in each of the metal maps for the control, AD and PD samples, where higher metal 
concentration indicates grey matter. The MSA maps also show a fibrous structure, but at this 
resolution these are not clearly defined into grey and white matter. This indicates that this 
sample may have been cut from a slightly different region of the pons. 
The AD and PD maps contain grey and white matter bands of similar widths and are 
anatomically well matched. The concentrations of zinc and copper show a very similar pattern 
and concentration across both sections, but the iron concentration is increased across the 
whole section in the AD sample.  
6.5.1.2 Quantitative comparison between AD and PD maps 
ImageJ was used to segment the grey and white matter tissue in the AD and PD maps of the 
pons as shown in Figures 6.23 and 6.24.  
The mean and standard deviation of iron, copper and zinc relative SXRF signal intensity for the 
whole pons and for the segmented grey and white matter is shown in Figure 6.25. Iron is 
approximately doubled in both the grey and white matter of the AD pons compared to PD. 
There is a small increase in copper and zinc in the PD grey matter compared to AD. However, 
this is not observed in the white matter, or across the whole map. The fact that the copper and 
zinc comparisons give a different result than for iron adds confidence to the normalisation of 
these maps. If all metals were increased in the AD sample compared to control it might suggest 




Figure 6.23 Segmentation of the SXRF map of pons 
sample AD2. a) The mapped section stained with 
haematoxylin, with the mapped area outlined in 
red. An area where a high resolution map was 
collected is also visible in the stained section. b) 
The grey matter segmentation in the SXRF map 








Figure 6.24: Segmentation of the SXRF map of 
pons sample PD1. a) The mapped section stained 
with haematoxylin, with the mapped area outlined 
in red. Two areas where high resolution maps 
were collected are also visible in the stained 
section. b) The grey matter segmentation in the 






Figure 6.25: Relative metal concentrations in the segmented regions of the AD and PD pons maps. The 
mean and standard deviation of a) iron, b) copper and c) zinc SXRF signal intensity for the segmented 
grey and white matter tissue and for the whole map. Iron is increased in the AD map compared to PD. 
There is a small increase in copper and zinc in the GM of the PD samples. 
 
6.5.2 High resolution SXRF mapping of the pons 
6.5.2.1 Making 3 µm SXRF maps of the pons  
To investigate the changes in pons iron concentration in greater detail, higher resolution SXRF 
maps were made of small areas of tissue. The location of each of these high resolution maps 
was chosen so as to include grey and white matter. First, the microscope and camera pointed 
at the slide were used to select a striped area of tissue and a small 30 µm resolution map was 
made. The contrast in iron concentration between the grey and white matter allowed the 
position of the high resolution (3x3 µm) map to be selected. Figure 6.26 shows this process for 
the AD sample. Due to the small spot size only a very small area could be mapped within the 
available time and therefore this careful region selection is extremely important. Inserts were 
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only made for the control, AD and PD samples as the MSA sample did not show the same 
stripes of grey and white matter.  
 
Figure 6.26: Choosing the position of a high 
resolution SXRF map for the AD pons sample. a) 
The image from the microscope camera at the 
beamline was used to choose the coordinates of 
b), a small 30 µm resolution map. The 30 µm 
resolution map is used to select the position of c), 




The 3µm maps were normalised to I0 and to slide background, and the slide background was 
subtracted. The combined and individual iron, copper and zinc maps for the control, AD and 
PD samples are shown in Figure 6.27. The grey matter tissue has a higher iron, copper and zinc 
concentration (as was shown in the 60 µm resolution maps in Figures 6.23 and 6.24) than the 
white matter tissue. The 3 µm resolution maps show that within the grey matter all metals 
follow a similar distribution, with small, roughly oval shaped areas of increased concentration. 
In the white matter the copper signal is fairly low and even, whereas the zinc and, to a great 













































































































































































































6.5.2.2 Identifying neurons in the 3 µm maps 
 
Figure 6.28: Identification of neurons in the 3 micron resolution SXRF maps. The SXRF maps and 
microscope images of the sections, which were stained with haematoxylin after mapping, were 
compared to identify neurons. Eight neurons are circled in black in the stained sections and in yellow in 
the SXRF maps. a) and b) show the neurons selected for the control sample, c) and d) show the neurons 




The mapped pons sections were stained with haematoxylin using the post-SXRF staining 
protocol (Section 4.5.2). The areas of tissue mapped at 3 µm were particularly fragile due to 
the exposure to intense X-rays. This has the advantage of the precise area of the map being 
easily determined, but the disadvantage that the staining is not taken up as well and is not 
very clear. Despite the faint staining some neuronal bodies could be identified due to their 
staining, size (around 20-30 µm) and position (in the grey matter) within the section. These 
neurons are also visible in the SXRF maps as bright spots in the metal maps. They are 
particularly clear in the zinc maps.  
A sample of eight neurons was identified in the stained mapped area for the control, AD and 
PD samples as shown in Figure 6.28. The neurons in the stained section were drawn around in 
ImageJ, which was then used to make a mask to select the same neurons in the SXRF map. The 
neurons can be seen as areas of increased metal concentration, appearing as near white in the 
combined metal maps. In order to compare the neurons to the surrounding tissue, the 3 µm 
maps were also segmented into grey (including neurons) and white matter. 
6.5.2.3 Relative iron, copper and zinc concentration in the neurons of the 
control, AD and PD pons 
Figure 6.29 shows the mean iron, copper and zinc concentration in the 8 neurons sampled for 
each case with the error bar representing the standard deviation. The mean relative metal 
concentration in the grey and white matter is also shown. As observed in the maps, the 
concentration of all metals is increased in the neurons compared to the surrounding tissue. 
A statistical comparison of the mean metal concentrations of the neurons showed: a 
statistically significant increase in iron in AD compared to control and PD, a statistically 
significant decrease in copper for AD and PD compared to control and a statistically significant 
increase in zinc in the PD neurons compared to control. The data were normally distributed for 
each group as reported by the Shapiro-Wilk test (p<0.05). The copper and zinc data passed the 
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Levene’s test of homogeneity of variance and therefore were assessed by one-way ANOVA and 
Tukey post-hoc analysis, whereas the iron data violated the test for homogeneity of variance 
and therefore Welch’s ANOVA followed by Games-Howell post-hoc analysis were used. The 
results of the statistical analysis are indicated on the graph in Figure 6.29. 
 
 
Figure 6.29: Relative metal concentrations in the neurons, grey matter and white matter of the pons.  
The mean and standard deviation of the eight neurons is shown in addition to the mean SXRF signal 
intensity in the white matter and grey matter. a) A statistically significant increase in iron in the AD 
neurons, compared to control and PD, is shown. b) A statistically significant decrease in copper was 
found in the AD and PD neurons.  c) A statistically significant increase in zinc concentration is shown in 




However, Figure 6.29 also shows that there is a similar increase in each of the metals in the 
grey and white matter of the tissue. This indicates that the changes in metal concentrations 
observed in the regions of the map which have been identified as neurons may not be due to a 
change within the cell. The 30 µm thickness of the section means that the region containing 
the neuronal body will likely contain neuropil and/or glial cells (which are both also found in 
the grey matter). Table 6.7 shows the metal concentration for each region normalised to 
control. Iron concentration is more than doubled in both the grey and white matter of the AD 
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pons, however the largest increase is in the neurons and GM (which includes the neurons). 
Conversely, the table shows that for copper the greatest decrease is in the white matter. For 
the increase in zinc in PD the change is entirely in the GM (and neurons) with no change 
observed in the WM.  
 
    Normalised to control  
Table 6.7: Metal concentration in the 
neurons, grey matter and white matter of 
the pons for AD and PD tissue normalised 
to control. 
    Neurons GM WM  
Iron  
Control 1.00 1.00   1.00  
AD 2.59 2.97 2.43  
PD 1.23 1.30 1.08  
Copper  
Control 1.00 1.00 1.00  
AD 0.72 0.87 0.53  
PD 0.72 0.82 0.51  
Zinc  
Control 1.00 1.00 1.00  
AD 1.10 1.11 0.84  
PD 1.24 1.32 0.99  
 
Ideally the concentration of metals in the neuronal bodies would be measured separately from 
the surrounding tissue in the grey matter, however with the staining quality of the post-SXRF 
mapped sections this could not be achieved. Therefore, despite the fact that individual 
neuronal bodies can be observed in the SXRF maps, it cannot be stated with confidence to 
what extent the metal concentration in the neurons of the pons is changed with disease.   
6.6 Iron and amyloid deposition 
Tissue sections adjacent to those mapped with synchrotron radiation were captured on glass 
and stained with Congo red and haematoxylin. These were examined under a microscope with 
and without cross-polarisers to look for evidence of amyloid deposition. Only the AD amygdala 
samples showed evidence of amyloid deposition. This is as expected as this is the only region 
being studied here that is widely reported to show AD pathology. The limited experimental 
time meant that high resolution mapping of the amygdala to look for changes in metal 
concentration in the region of amyloid plaques was not carried out. However, this could be an 
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interesting region to use in future to examine the relationship between iron, copper and zinc 
distribution and amyloid plaques. 
6.7 Discussion 
6.7.1 Comparison of bulk tissue and SXRF data 
There was good agreement between bulk tissue and SXRF measurements, as investigated by 
comparing the ratio of iron content between AD and control samples (Table 6.2). This suggests 
that changes in iron concentration are relatively consistent throughout the two samples, 
where the bulk tissue sample was cut from tissue adjacent to the SXRF map, in a coronal tissue 
block (Figures 3.7 to 3.9). However, although the ratios agree well, this does not guarantee 
that the absolute concentration is constant throughout the regions. In fact there is evidence to 
show that this is not the case and this is discussed below. 
6.7.2 Inhomogeneity of metal distribution  
A significant observation made from examination of the SXRF maps is the inhomogeneity of 
metal distribution. Inhomogeneity is seen in the variation between mean concentrations in the 
segmented maps (Figure 6.18) and within anatomical structures (Figures 6.13 to 6.17). The 
distribution of iron is particularly inhomogeneous, which can be seen by the large standard 
deviations in mean iron concentration of segmented tissue structures (Figure 6.19).  
The putamen was mapped at two different levels: where it is lateral to the caudate nucleus 
and where it is lateral to the globus pallidus. The control example at each level is from case C3 
and therefore these maps can demonstrate how iron concentration within the putamen varies 
at these two positions, which are at a distance of approximately 2 cm. Figure 6.18 shows that 
the mean iron concentration in the map of the putamen lateral to the globus pallidus is 1.8 
times greater than in the map lateral to the caudate nucleus. This demonstrates a substantial 
inhomogeneity in iron concentration within a brain structure, at a distance that would be 
resolvable at the resolution of clinical MRI.  
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It is common for the post mortem specimens to be sliced in 1-2 cm thick blocks (as was the 
case in this project) and therefore for large nuclei to be divided amongst several blocks. In the 
literature the size of samples taken for digestion varies from a small sample from within a 
region [27] to the whole region [19]. The data from the putamen highlight the importance of 
anatomically matching the position of samples taken. One consequence of this finding is that 
when comparing MRI relaxometry data to iron concentration values reported in other studies 
(as is often done [134]) the precise anatomical position of the tissue samples should always be 
considered. Unfortunately this is not always made clear in publications.  
In the literature there is a wide variation in reported iron concentrations for the same brain 
region. This can be seen in a review by Haacke et al. [107] and in Table 3.2, which reproduces 
some of these data. It is possible that there is some inconsistency in the dissection of samples 
between studies and that consequently the spatial variation in iron concentration within a 
structure causes some of the spread in the data.  
6.7.3 The potential of cellular resolution SXRF mapping 
The development of a staining protocol for post-SXRF mapped tissue sections allowed the 
examination of metal concentrations within individual neurons in 3 µm resolution SXRF maps. 
However, the tissue is left very fragile and difficult to stain and therefore the identification of 
cells is difficult. It may be possible to reduce the damage to the tissue by using a slightly 
reduced X-ray intensity, which can easily be achieved at the beamline by insertion of 
attenuators. This would require some trial and error to find the optimum beam intensity to 
allow above background signal detection, but minimise tissue damage. 
Although individual neurons could be resolved in the SXRF maps, changes in metal 
concentration within the neurons could not be fully separated from changes in the 
surrounding tissue. The development of a new beamline at the Diamond Light Source which is 
capable of creating beam sizes at nanometre resolution may help to enable this in the future. 
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At higher resolution it would be possible to more carefully define neurons and to compare 
their metal concentration to the rest of the grey matter.  
6.7.4 Novelty of these measurements 
SXRF mapping of metal distribution in biological samples is a fairly new technique. Other 
groups carrying out SXRF mapping have used thick (1 mm or more) sections of fixed tissue [89, 
90, 136]. The thick tissue increased signal intensity and reduced mapping time, however 
variation in X-ray penetration and escape depth for X-rays of different energies means that 
different depths are being sampled for each metal. 
The mapping of thin, unfixed sections mounted on spectroscopically clean slides is a technique 
developed by our group [113, 190] in parallel with a small number of other groups world-wide. 
It allows penetration of the X-rays through the whole section and avoids the need for fixatives, 
which can leach metal from tissue. The number of samples mapped using this technique is 
small and this is the first study of these regions of the basal ganglia. 
The use of thin sections provides high depth resolution (30 µm in this case), in addition to high 
in-plane resolution. Therefore, very highly detailed maps of relative distributions of iron, 
copper and zinc were produced. This revealed features such as the low iron band at the lateral 
edge of the putamen and the distinct distributions of iron, copper and zinc in the substantia 
nigra. These patterns of metal distribution are not easily discerned from the thick sample 
mapping as can be seen in a study of the basal ganglia by Popescu et al. [89].  
6.8 Summary 
I. Sixty micron resolution maps of the relative iron, copper and zinc distribution in a 
control and AD sample from the caudate nucleus, putamen, globus pallidus, substantia 
nigra and amygdala were made. These maps revealed the distinct distribution of each 
metal across the brain regions.  
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II. The iron concentration measured in neighbouring tissue samples was used to calibrate 
the SXRF iron signal intensity, allowing estimation of iron concentration of tissue 
structures within the SXRF maps. 
III. The inhomogeneity of iron was shown within brain nuclei, highlighting the importance 
of careful spatial matching when comparing between samples. 
IV. High resolution SXRF mapping, followed by the new post-mapping haematoxylin 
staining protocol, demonstrated the potential for investigation of metal concentration 
within individual neurons. 
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Chapter 7:  
MRI relaxometry  
MRI relaxometry has been proposed as a method of detecting changes in brain iron 
concentration in Alzheimer’s Disease and other neurodegenerative diseases [26]. Increased 
iron concentration (in particular particulate iron in the form of ferritin-encapsulated 
ferrihydrite and magnetite) causes increased R2 and R2*. At high field the effect of iron is 
increased [120] and due to the increased MRI signal higher imaging resolution can be 
achieved. 
Region Cases Imaging field 
Caudate nucleus C1, C2, C3 
AD1, AD2, AD3 
400 MHz 
Putamen C1, C2, C3 
AD1, AD2, AD3 
400 MHz 
Globus pallidus C1, C2, C3 
AD1, AD2, AD3 
400 MHz 




Amygdala C1, C2, C3 
AD1, AD2, AD3 
600 MHz 
Pons C1, C2, C3 
AD1, AD2, AD3 
PD1, PD2, PD4 
MSA1, MSA2 
600 MHz 
Table 7.1: List of samples measured with MRI relaxometry. Samples 
were imaged at 400 MHz (9.4 T) or 600 MHz (14.1 T). The details for 
each case are given in Table 3.4. 
 
 
MRI mapping was carried out on control and AD samples from all of the regions chosen for 
investigation based on the literature review (Section 3.2). The protocol described in Section 4.3 
was used to map R2 and R2* in the caudate nucleus (CN), putamen (Pu), globus pallidus (GP) 
and substantia nigra (SN) at 400 MHz, and the amygdala and pons at 600 MHz. Table 7.1 lists 
the samples mapped for each region at each field. Pons and substantia nigra tissue was also 
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measured for Parkinson’s Disease (PD) and Multiple System Atrophy (MSA) cases, as indicated 
in the table. 
In Chapter 5 the total and particulate iron concentration of samples from the pons, substantia 
nigra, putamen and caudate nucleus was examined. The results showed that although 
statistically significant differences between control and AD samples were not observed, 
discriminant analysis using data from multiple regions enabled 100% correct differentiation 
between AD and control samples. The same analysis was applied to the R2 and R2* data: the 
group means were compared first, followed by discriminant analysis. 
Tissue iron content is just one factor affecting the MRI relaxation in each pixel within the 
segmented region of an SXRF map. Other factors include water and fat content. Increased 
water concentration has the opposite effect to increased iron concentration and decreases R2 
and R2*. In a study by Schenck and colleagues an increase in pixels with both short and long 
transverse relaxation rates was observed within structures in the AD brain [191]. It was 
hypothesised that this is due to effects of both increased iron (causing pixels with rapid decay) 
and increased water (causing pixels with slow decay) within the AD tissue structures. The 
standard deviation within the regions is compared to examine this effect. 
7.1 Segmentation of the R2 and R2* maps 
In most cases, the mapped volume of tissue contained surrounding structures in addition to 
the target region. In order to include these structures in the analysis the maps were 
segmented into several regions of interest (ROIs). Segmentation was carried out manually 
using the open-source software ImageJ. Sections cut from the imaging block at 30 µm 
thickness, and stained with haematoxylin, were used to aid identification of anatomical 
structures. As far as possible the sections were cut in the same plane as the MRI imaging to 
provide the best reference. However, a certain amount of tissue compression/deformation can 
be expected due to the density of the Fluorinert in which the tissue was suspended during MRI 
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and some tissue features are more prominent in the MRI than in the stained sections and vice 
versa. 
A selection of reference materials for these brain regions were used to aid segmentation [167, 
170, 171]. These contained anatomical drawings or images of stained or fixed tissue but not 
MRI images, as there is little MRI imaging at such a high resolution of these regions of the 
human brain. Finally, advice was sought from pathologist Dr Lili-Naz Hazrati who also provided 
guidance on anatomy throughout the sample dissection process. 
7.1.1 400 MHz maps 
The caudate nucleus, putamen, globus pallidus and substantia nigra were mapped using the 
400 MHz probe at the University of Warwick. Two stacks of seven interleaving maps with a 
resolution of 86 x 86 µm and a slice thickness of 150 µm (total imaged volume 1.05 mm) were 
produced. The main anatomical regions of interest were segmented in each high resolution 
slice in which they appeared. Other anatomical features common to all, or most, of the 
samples for that region were also segmented. These were only segmented in a subset of slices 
as segmentation is a labour intensive process. Where possible the data were taken from slices 
1, 4, 7, 10 and 13, so as to include data from both interleaving stacks. For each ROI the mean 
R2 and R2* for each slice was measured using ImageJ and then the mean of these values 
calculated to give a final mean for the volume mapped. The mean and standard deviation of 
the standard deviation from each slice were also calculated.  
Figures 7.1 to 7.7 show an example of the segmentation of one slice from an R2 and R2* map 
for one sample from each region. In addition to the segmented maps a stained section from 
the sample and the approximate anatomical position, as compared to the coronal sections 
from the Atlas of the Human Brain [167], is shown. Appendix E shows the segmentation of all 





Figure 7.1 Segmentation of the MRI maps of caudate nucleus sample C1. a) The R2 map, before 
segmentation; b) a stained tissue section cut from the imaged block; c) the approximate anatomical 
position of the tissue; d) the segmented R2 and e) R2* maps, showing the caudate nucleus (CN), anterior 
limb of the internal capsule (AIC) and the white matter medial to the caudate nucleus (WM-CN). 
Artefacts caused by bubbles were present in the R2* map. These were excluded from the segmented 
regions.  
 
Figure 7.2: Segmentation of the MRI maps of putamen sample C3. a) The R2 map, before segmentation; 
b) a stained tissue section cut from MRI block; c) the approximate anatomical position of the tissue; d) 
the segmented R2 and e) R2* maps, showing the putamen divided into the bright and dark region 
(Pu_high and Pu_low) and the white matter lateral to the putamen (WM-Pu). A small number of pixels 




In addition to the caudate nucleus (CN), the maps are segmented in to the white matter 
medial to the caudate nucleus (WM-CN) and the anterior limb of the internal capsule (AIC) as 
shown in Figure 7.1 for sample C1. In this example the AIC is small and is only segmented 
where it can be clearly defined. 
Putamen 
The images were segmented into the entire putamen (Pu) and the white matter lateral to the 
putamen (WM-Pu). The putamen was further divided into areas named here as ‘Pu_high’ and 
‘Pu_low’ as shown in Figure 7.2 for sample C3. ‘Pu_high’ makes up the majority of the 
putamen and has a relatively high R2. ‘Pu_low’ forms a band of lower R2 tissue along the lateral 
edge of the putamen and corresponds to the region of decreased iron that was observed in the 
SXRF maps in Chapter 6. In many cases the boundary of the ‘Pu_high’ region could be mistaken 
as the edge of the structure, but confirmation of the true edge was made by comparison to 
stained sections. The boundary of ‘Pu_high’ may appear to be the boundary of the putamen at 
typical clinical resolution, where less detail is captured. As the proportion of Pu_high 
compared to Pu_low included in each map varies depending on exactly how the sample was 
cut, Pu_high is used for a more consistent comparison between samples. 
Globus Pallidus 
The globus pallidus samples were segmented into the internal and external globus pallidus 
(GPi and GPe) and the high R2 region of the putamen lateral to the globus pallidus (Pu_high-
GP). The putamen in these maps is approximately 10 to 20 mm posterior to the putamen 
lateral to the caudate nucleus (shown in Figure 7.2). Figure 7.3 shows the segmentation of the 
GP for sample AD2, for which all ROIs were present. Cutting well matched samples for this 
region of the brain proved particularly challenging and the GPi was not present in many cases. 
Figure 7.4 shows the sample from case C2 which was excluded from analysis due to the 
uncertainty about its anatomy.  
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In some GP samples a proportion of pixels in the R2* maps could not be fitted due to extremely 
rapid signal decay. These pixels were removed from the maps using the ImageJ threshold tool 
or by manual deletion.  
 
Figure 7.3: Segmentation of the MRI maps of globus pallidus sample AD2. a) The R2 map, before 
segmentation; b) a stained tissue section cut from the imaged block; c)  the approximate anatomical 
position of the tissue; d) the segmented R2 and e) R2* maps, showing the external globus pallidus (GPe), 
internal globus pallidus (GPi) and putamen (Pu_high-GP).  The gap between each segmented region is 
the location of a thin lamina of white matter separating the nuclei. The R2* map contains a number of 




Figure 7.4: MRI of globus pallidus sample C2. The anatomy of this sample is hard to define. It may 
contain the internal globus pallidus (GPi) and thalamus (Th) as indicated on the stained section a). b) 
One slice of the R2 map of the sample and c) the best approximation of the anatomical position. This 





The cerebral crus (CC) and the substantia nigra (SN) were segmented from the tissue as shown 
for sample C2 in Figure 7.5. The SN was defined as the bright band of tissue in the R2 and R2* 
maps, as is standard practice in clinical MRI [122].  Due to the thin pieces of tissue available for 
MRI, extra care had to be taken to avoid any imaging artefacts caused by bubbles next to the 
tissue. As bulk tissue measurements were prioritised for the substantia nigra there were only 




Figure 7.5: Segmentation of the MRI maps of substantia nigra sample C2.  a) A photograph of the tissue 
before MRI; b) a stained tissue section cut from the imaged block; c) the approximate anatomical 
position of the tissue; d) the segmented R2 and e) R2* maps, showing the substantia nigra (SN) and 
cerebral crus (CC). The R2* map contains some artefacts due to bubbles. However, these are around the 
edge of the sample are not included in the segmented regions. 
 
 
7.1.2 600 MHz maps 
The amygdala and pons tissues were imaged at 600 MHz at the University of Florida, producing 
maps with an in-plane resolution of 62 x 62 µm and a slice thickness of 80 µm. After imaging it 
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was discovered that the R2 maps were unreliable due to variation in relaxation rate across the 
tissue volume, due to a parameter in the scan set-up (Section 4.3.3.1). Therefore only the R2* 
maps are analysed.  
Amygdala 
The amygdala contains a number of different nuclei and as far as was possible tissue was cut 
from a similar area for each case. No distinct structures can be identified in the MRI maps and 
advice from neuropathologist Dr Lili-Naz Hazrati is that all tissue was cut from within the 
amygdala. No segmentation was carried out other than to exclude any artefacts and the mean 
was found from each high resolution slice. A representative slice from each amygdala sample is 
shown in Figure 7.6. 
 
 
Figure 7.6: A representative slice from each of the R2* MRI maps of the control and AD amygdala. The 
contrast gradient for each map was chosen to best display the features in each sample and is not the 




In addition to finding the average signal of the whole tissue volume, the stripy tissue of the 
pons was segmented into grey and white matter. The stained sections from the pons were 
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particularly useful in identifying the grey and white matter, where the MRI map contrast was 
ambiguous. Figure 7.7 shows the segmentation of the pons into grey and white matter for 
sample PD4. 
In addition to the three control and AD cases, three PD and 2 MSA pons cases were imaged. 
For one of each of the control, AD and PD cases two samples were imaged. For the control and 
AD samples one of the duplicates provided a better example of the grey and white matter 
stripes than the other and the data from this case was used. For the PD case, both samples 
showed the typical grey and white matter stripes of the pons and therefore the data from both 
samples was averaged before finding the total average for the group. One R2* slice from each 
pons sample is shown in Appendix F. 
 
 
Figure 7.7: Segmentation of the R2* map of pons sample PD4. a) The R2* map before segmentation; b) a 
haematoxylin stained section from approximately the same level;  c) the white matter segmentation of 





7.2 Comparison of means 
Once the mean R2 and R2* for each segmented region in each sample was measured, the 
means for the AD and control samples were calculated. This was followed by discriminant 
analysis, which has already been used to create a model to differentiate between disease and 
control using the bulk tissue measurement in Chapter 5. 
7.2.1 Control and AD samples 
Figure 7.8 shows the mean R2 and R2* for the tissue structures segmented in the MRI maps of 
the AD and control samples. Figure 7.9 shows the data from the pons and substantia nigra 
maps, for which additional disease groups were imaged. The number of samples for each 
region is indicated on the graph. For regions where n=3 for each disease group, the statistical 
software SSPS was used to look for statistical differences between groups. Data were normally 
distributed as reported by the Shapiro-Wilk test (p<0.05) and were therefore examined using 
parametric statistics. No statistically significant differences were observed between group 
means. Where n=2 no statistical comparisons were made, due to the small group size. 
R2 is higher with AD in 6 out of the 10 brain regions mapped at 400 MHz (control is higher in 3 
of 10, in the CC there is no change) and for the mean R2* data this is reduced to 5 of 10 





Figure 7.8: Mean R2 and R2* values in the segmented regions of MRI maps of the control and AD 
samples. The number of cases is indicated on the bar for each data set. a) Data from the R2 maps of 
samples imaged at 400 MHz. b) Data from the R2* maps, where all samples were imaged at 400 MHz, 
apart from the amygdala which was imaged at 600 MHz. One-way ANOVA revealed no statistically 
significant differences between control and AD for any region. CN=caudate nucleus; AIC=anterior limb of 
the internal capsule; WM-CN=white matter medial to the CN; Pu=putamen; WM-Pu=white matter 
lateral to the Pu; GPe= external globus pallidus; GPi=internal globus pallidus; Pu-GP=Pu lateral to the 




7.2.2 AD, PD and MSA samples 
Figure 7.9 a) shows the mean R2 and R2* in the substantia nigra and cerebral crus of the 
control, AD and PD samples. The mean values for the CC are very similar between the disease 
groups, whereas R2 and R2* in the SN are increased in AD and PD samples compared to control. 
As only two samples were measured for each disease, statistical comparisons were not made.  
Figure 7.9 b) shows the mean R2* values for the grey and white matter of the control, AD, PD 
and MSA pons. The average for the whole volume of the pons is also included. No statistically 
significant differences were observed between group means, although there is a trend of 
increased R2* in disease samples compared to control. 
 
Figure 7.9: Data from MRI maps of control, AD, PD and MSA tissue. a) Mean R2 and R2* in the substantia 
nigra (SN) and cerebral crus (CC) imaged at 400 MHz. Both R2 and R2* are increased in AD and PD tissue 
compared to control, but as n=2 no statistical comparisons were made. b) R2* of the grey matter, white 
matter and the whole pons imaged at 600 MHz. In each case the control shows a lower R2* than the 




7.2.3 Discriminant analysis of data from multiple regions 
Although one-way ANOVA identifies no statistically significant differences between group 
means, analysis of total iron concentration in Chapter 5 showed that creating a model using 
discriminant analysis can increase the ability to distinguish between disease and control 
samples. This hypothesis was tested using the R2 and R2* data from the 400 MHz imaging and 
the R2* data from the 600 MHz imaging. Only the regions for which n=3 for AD and control are 
included, as discriminant analysis requires a full data set for each case.  
7.2.3.1 400 MHz measurements 
100% correct classification of samples was achieved using R2 data from the CN, Pu, AIC and 
WM-Pu regions (Table 7.2 a). Only 50% of the samples were classified correctly (no better than 
guessing) with cross-classification. Cross-classification involves removing a sample from the 
data set, creating a model with the remaining data and then using this model to classify the 
excluded sample. This is carried out (automatically, in the software SSPS) for each sample. It is 
not unexpected that poor cross-classification would be achieved with such a small number of 
samples as there is a limited amount of data to create the model. 
Tables 7.2 b) and c) can be examined to see which variables are most important in the model. 
A larger absolute function coefficient in 7.2 b) indicates greater contribution to the model, 
whereas a small Wilks’ Lambda and significance value in Table 7.2 c) indicate greater 
contribution. The data in both tables show that the CN data contributed the most to the model 
and that the white matter lateral to the putamen (WM-Pu) contributed the least. However, 
there is a disagreement as to whether the Pu or AIC contributes more to the model. Therefore 
discriminant analysis was carried out with different regional combinations which include the 
CN, but not the WM-Pu. 
The results of this analysis are shown in Table 7.3. 100% correct classification was achieved 
with the data from just two regions: the CN and AIC. When cross-validation is considered this 
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actually produced a better result than combining data from all regions. Looking back at Figure 
7.8 shows that the mean R2 in the CN was increased in the AD samples compared to control, 
whereas the mean R2 in the AIC was decreased in AD.  
 
 
Tables 7.2: Results of discriminant analysis of R2 data collected at 400 MHz. a) The model has grouped all 
samples into the correct disease group, but only 50% with cross-validation. b) The standardised 
canonical discriminant function coefficients suggest that the order of importance of the regions to the 
model is CN, AIC, Pu and then WM-Pu. c) The equality of group means suggests that the order of 





Table 7.3: The results of discriminant analysis using combinations of R2 data from different brain regions. 




Similar analysis was carried out with the R2* data from the regions measured at 400 MHz 
(Tables 7.4 and 7.5). Although the WM-Pu was least important to the R2 model it contributes 
the most to the R2* model. When cross-validation is considered the best model is produced 
using data from the CN and WM-Pu. As with the R2 model, the direction of change between 
mean R2* of control and AD is different for these two regions: mean R2* is increased in the 
Alzheimer’s disease CN, but decreased in the WM-Pu compared to control. 
 
 
Tables 7.4: Results of discriminant analysis of R2* data collected at 400 MHz. a) The model has grouped 
all samples into the correct disease group. b) The standardised canonical discriminant function 
coefficients suggest that the order of importance of regions to the model is WM-Pu, CN and then the Pu. 




Table 7.5: The result of discriminant analysis using combinations of R2* data. The minimum number of 
regions needed to achieve 100% correct classification is two: using data from the CN and Pu or data 




7.2.3.2 600 MHz data 
The result of discriminant analysis of the data from the pons and amygdala samples is shown in 
Tables 7.6 and 7.7. 100% correct classification was achieved for a combination of data from the 
amygdala, pons white matter and pons grey matter, however this dropped to 50% with cross-
validation. The information in Tables 7.7 b) and c) suggests that the pons white matter 
contributed the most to the model, but it is not clear which region contributed least. When 
cross-validation is considered, the best combination of regions for differentiating between AD 
and control was the amygdala and the grey matter of the pons (Table 7.7). 
Discriminant analysis was carried out on control, AD and PD pons samples, where the R2* 
measurements of the pons GM and WM were used as predictors. This only achieved 44% 
correct classification (not shown). The similarity in the mean R2* of the AD and PD samples in 
this region (shown in Figure 7.9) does not provide the information required to differentiate 
between the disease groups.  
 
 
Tables 7.6: Results of discriminant analysis of R2* data collected at 600 MHz. a) The model has grouped 
all samples into the correct disease group. b) The standardised canonical discriminant function 
coefficients suggest that order of importance of regions to the model is Pons WM, Pons GM and then 
the amygdala. c) The equality of group means suggests that the order of importance is the pons WM, 






Table 7.7: The results of discriminant analysis using combinations of R2* data collected at 600 MHz. 
100% classification was not achieved. However, the pons GM and amygdala achieved 83.3% correct 
classification and 66.7% with cross-validation. 
 
 
7.2.4 Further comparisons 
The results of discriminant analysis of R2 data in Table 7.4 showed that 100% classification 
could be achieved using data from the CN and AIC regions. Revisiting the data shown in Figure 
7.8 reveals that the mean R2 in the CN is higher in AD tissue, whereas the mean R2 in the AIC is 
lower in AD tissue. This suggests that there is an increase in contrast between these 
neighbouring tissue structures. The mean CN:AIC ratio for control and AD tissue is shown in 
Figure 7.10. A strong statistically significant increase (p<0.01 by one-way ANOVA) in the ratio 





Figure 7.10: Mean ratio of R2 in the caudate 
nucleus (CN) to R2 in the anterior limb of the 
internal capsule (AIC). A statistically 
significant increase in the ratio was 
observed for the AD data (**p<0.01). 
 
7.3 Comparison of standard deviations 
Increased tissue water content decreases R2 and R2*, whereas they are increased by elevated 
iron concentration. Schenck and colleagues have shown that within some regions of the AD 
brain there is both an increase in the number of rapid and slow R2 pixels [191]. This was 
examined here by comparing the standard deviation (the square root of variance) of the 
control and AD samples.  
When mean R2 and R2* values were calculated from multiple slices, the variance within each 
segmented region was preserved by calculating the mean of the standard deviations from each 
slice. Figure 7.11 shows the mean R2 and R2* standard deviation for the control and AD 
samples, with the error bars indicating the standard deviation (of the standard deviations for 
each sample). Figure 7.12 shows the same for the whole pons and the segmented grey and 
white matter tissue for the control, AD, PD and MSA samples. Statistical comparisons for the 






Figure 7.11: Mean standard deviation of R2 and R2*. Error bars represent the standard deviation of the 






Figure 7.12: Mean standard deviation of R2* in the pons. Error bars represent the standard 
deviation of the standard deviations. No statistically significant differences between disease 




7.4.1 R2 and R2* data can be used to differentiate between AD 
and control cases 
The discriminant analysis of the R2 and R2* data has shown that by combining data from 
multiple regions 100% correct classification of control and AD cases can be achieved, even 
when there is no statistically significant difference between group means. This is in agreement 
with the analysis of the bulk tissue iron measurements and supports the hypothesis that MRI 
relaxometry could be used to differentiate between control and AD cases. 
7.4.2 Contrast between the caudate nucleus and anterior limb 
of the internal capsule is increased in AD 
A statistically significant increase was observed in the ratio of R2 in the caudate nucleus to R2 in 
the anterior limb of the internal capsule, for AD compared to control samples. The fact that 
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the statistically significant difference is observed in a ratio, and not in absolute R2 values, is an 
advantage as it could be less sensitive to variations that exist between different imaging 
systems and scan sequences.  
7.4.3 No difference in pixel variance was observed 
No statistically significant difference was found between the standard deviation of pixel values 
of the control and AD tissues. This does not agree with previously published results which have 
reported a greater variance of R2 in AD tissue in some regions [132, 191]. However, these 
findings were mostly limited to brain regions associated with significant AD pathology (such as 
the hippocampus), which may also be contributing to the variance in R2 and R2*. 
The small bore sizes of the high resolution imaging systems used in this study meant that 
whole brain structures could not be imaged and small samples were taken from within these 
relatively large structures. Although the samples were cut carefully to provide as close 
matching as possible, there was some variation of the anatomical position of each sample. 
Therefore variance measured for each sample may not accurately reflect the variance of the 
whole structure 
7.5 Summary 
I. No statistically significant differences were found between R2 or R2* measurements of 
control and AD tissue.  
II. As predicted in Chapter 5, discriminant analysis achieved differentiation between 
control and AD samples using data from multiple regions.  
III. The ratio of R2 in the caudate nucleus compared to the anterior limb of the internal 
capsule was statistically significantly increased in AD samples compared to control.  
IV. Considering the MRI relaxation values in multiple brain regions may be more clinically 
useful than looking for a difference between individual regions. 
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Chapter 8:  
The relationship between iron and MRI 
The iron content of control and AD brain tissue was examined in bulk tissue samples by SQUID 
magnetometry and iron quantification in Chapter 5. The distribution of iron within regions was 
examined using high resolution SXRF mapping in Chapter 6 and in Chapter 7 high resolution 
MRI relaxometry was used to create R2 and R2* maps of the same set of cases. In this chapter 
the MRI and iron data will be compared in order to examine the relationship between iron 
concentration and R2 and R2*. 
Tissue iron has been shown to increase the relaxation rates R2 and R2*, with the effect of iron 
increasing with field strength. This has been well studied at fields of up to 4.7 T [25, 26], with 
some additional studies at 7 T [27], however it is understudied at even higher fields. Here the 
relationship between tissue iron content and R2 and R2* at 9.4 T (400 MHz) and 14.1 T (600 
MHz) is investigated. 
8.1 Comparing SXRF and MRI relaxometry maps 
SXRF maps were made of tissue from a sub-set of MRI imaged samples. Table 8.1 gives the 
SXRF experiment number and MRI field for each sample. The data for each SXRF map have 
been presented in Chapter 6 and the MRI data from all samples were investigated in Chapter 
7.  
The SXRF mapped sections were cut from the region of the MRI tissue block which was 
mapped at high resolution and in approximately the same plane as imaging. This protocol was 
described in more detail in Section 3.3.3.1 and was designed to allow good spatial matching 
between the SXRF section and one of the high resolution MRI slices. In this chapter the 
spatially matched data are used to investigate the relationship between iron concentration 












C2 DLS5 400 MHz 
AD1 DLS5 400 MHz 
Putamen C3 DLS5 400 MHz 
AD3 DLS5 400 MHz 
Globus pallidus C3 DLS5 400 MHz 
AD2 DLS5 400 MHz 
Substantia 
nigra 
C2 DLS5 400 MHz 
AD2 DLS5 400 MHz 
Amygdala C3 DLS5 600 MHz 
AD2 DLS5 600 MHz 
Pons C2 DLS2 600 MHz 
AD2 DLS3 600 MHz 
PD1 DLS3 600 MHz 
MSA1 DLS1 600 MHz 
 
Table 8.1: SXRF experiment number and the MRI spectrometer 
frequency for 
1
H imaging used to image each sample. The majority of 
samples were mapped during experiment DLS5 and imaged at 400 
MHz. The amygdala samples also had SXRF data collected during 
experiment DLS5, but were mapped at 600 MHz. The pons samples 
were also mapped at 600 MHz and the SXRF data were collected over 
a number of different experiments. The details of each case are given 
in Table 3.4. 
 
 
Tissue sections, including those for SXRF mapping, were cut at 30 µm, whereas MRI slice 
thickness for the samples mapped at 400 MHz was 150 µm and at 600 MHz was 80 µm. 
Therefore the sections represent only around 20% and 38% of the volume being imaged. 
Additionally, perfect matching across the whole tissue section and MRI slice is not possible, in 
particular due the difficulty in matching sectioning and imaging plane. However, overall very 
close matching was achieved (as will be shown below) and therefore the iron (and copper and 
zinc) concentration of the SXRF matched section can be considered a very good representation 
of the iron concentration of the matched MRI slice.  
In Chapter 6, Section 6.4 the normalised SXRF signal intensity for iron was calibrated using the 
iron quantification measurements made in Chapter 5. This calibration is carried into this 
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chapter and the iron concentration in the SXRF maps is reported as micrograms of iron per 
gram of tissue. The calibration had an approximate error of ± 12%, which must be taken into 
account when considering absolute iron concentrations. However, this does not affect the 
relative concentration of iron measured by normalised SXRF signal intensity, which has an 
estimated measurement error of ± 5%. 
8.1.1 400 MHz data 
8.1.1.1 Matching SXRF and MRI maps 
Figure 8.1 shows the selection of the MRI slice which is most closely matched to the SXRF map 
for the caudate nucleus, case C2. Appendix G contains an equivalent figure for each sample 
and the final result of matching for each sample is shown in Figures 8.2 to 8.11. 
Matching was carried out manually in ImageJ by comparing anatomical features in the SXRF 
map, MRI maps, the stained and unstained SXRF section and adjacent stained tissue sections. 
Firstly, the best matched slice for the high resolution MRI stack was chosen and then it was 
rotated into the same orientation as the SXRF map. The map was then trimmed to match the 
area of the SXRF map. Rotation and trimming were carried out using ImageJ. In addition to 
visual matching, the dimensions of the SXRF map (pixel size = 60 x 60 µm) were used to 
determine what the size the trimmed MRI map (pixel size = 86 x 86 µm) should be.  
In Figure 8.1 matching is shown for the T2 map, but was also carried out in parallel for the T2* 




Figure 8.1: Matching the SXRF and MRI maps of the caudate nucleus for case C2. The anatomical 
structures visible in the SXRF map, adjacent stained section and unstained SXRF sample are compared to 
the high resolution T2 maps in order to find the best matched slice. This is then rotated into the 
orientation of the SXRF map, before being trimmed to leave just the area matching the SXRF map.  
Finally, the reciprocal of the T2 map is taken to produce an R2 map. There is good matching of the 
detailed structure of the AIC at the left hand side of the map, but at the right hand side of the map there 




In general good matching was achieved. Where matching is not perfect this may be due to not 
sectioning in precisely the same plane as imaging, slight deformation of the tissue under 
pressure in the Fluorinert during MRI or mapped sections taken from slightly outside the high 
resolution MRI region. In addition cracks, tears or folding of the tissue section occasionally 
occurred during sectioning, due to the fragile un-fixed, un-embedded tissue.  
For the control GP sample the accurate matching between the SXRF map and the high 
resolution MRI maps could not be achieved. This was due to the SXRF section being cut from 
outside the high resolution region and a better match was achieved with low resolution data. 
The matching process is shown in Appendix G and the final result in Figure 8.6. For 
comparison, a low resolution match to GP sample AD2 is also found and this is shown in Figure 
8.7. 
8.1.1.2 Segmenting the matched MRI and SXRF maps 
The segmentation of maps to create regions of interest (ROIs) surrounding different 
anatomical structures has been shown for SXRF maps in Chapter 6 and similarly for MRI maps 
in Chapter 7. The segmentation of the same structures was refined in the matched maps to 
ensure the ROIs are also spatially matched. 
The ROIs that were drawn around structures in the SXRF maps in Chapter 6 were scaled to 
account for the different pixel size in the MRI maps. Where necessary, small adjustments were 
made to the shape of the ROIs to compensate for slight miss-matching of structures. Small and 
detailed structures more often required correction. Figures 8.2 to 8.9 show the segmentation 
of the matched maps for the control and AD example from each brain region. 
In each figure the SXRF combined metal map shows iron in red, copper in green and zinc in 
blue. The segmented regions are labelled on the SXRF map, with the same regions drawn onto 
the MRI maps. For the CN, Pu and GP samples the approximate anatomical position of the map 





Figure 8.2: Segmentation of matched SXRF and MRI maps of caudate nucleus sample C2. a) Approximate 
position of the maps. b) The SXRF map and matched c) R2 and d) R2* maps are segmented into the 
caudate nucleus (CN), the anterior limb of the internal capsule (AIC) and the white matter medial to the 
caudate nucleus (WM-CN). Good matching of the detailed structure of the AIC was achieved. More WM-






Figure 8.3: Segmentation of matched SXRF and MRI maps of caudate nucleus sample AD1. a) 
Approximate position of the maps. b) The SXRF map and matched c) R2 and d) R2* maps are segmented 
into the caudate nucleus (CN), the anterior limb of the internal capsule (AIC) and the white matter 
medial to the caudate nucleus (WM-CN). Good matching was achieved, only requiring a few 




Figure 8.4: Segmentation of matched SXRF and 
MRI maps of putamen sample C3. a) Approximate 
position of the maps. b) The SXRF map and 
matched c) R2 and d) R2* maps are segmented into 
the bright and dark areas of the putamen (Pu_high 
and Pu_low), the anterior limb of the internal 
capsule (AIC) and the white matter lateral to the 
putamen (WM-Pu). This sample was very fragile 
during sectioning and there are cracks in the 
Pu_high region. Tissue was folded at the top left of 






Figure 8.5: Segmentation of matched SXRF and MRI maps of putamen sample AD3. a) Approximate 
position of the maps. b) The SXRF map and matched c) R2 and d) R2* maps are segmented into the bright 
and dark areas of the putamen (Pu_high and Pu_low) and the white matter lateral to the putamen 
(WM-Pu). The very high iron region of the Pu is excluded from the analysis as this is due to a blood 






Figure 8.6: Segmentation of matched SXRF and MRI maps of globus pallidus sample C3. a) Approximate 
position of the maps. b) The SXRF map and matched c) high resolution R2 map, d) high resolution R2* 
map, d) low resolution R2 map and e) low resolution R2* map. The maps are segmented into the external 
globus pallidus (GPe), the bright part of the putamen (Pu_high), the internal capsule (IC) and the lamina 
of white matter separating the Pu and GPe (WM-GP). The tissue for the SXRF map was cut from outside 
the high resolution MRI region and better anatomical matching was achieved using a slice from the low 









Figure 8.7: Segmentation of matched SXRF and MRI maps of globus pallidus sample AD2. a) Approximate 
position of the maps. b) The SXRF map and matched c) high resolution R2 map, d) high resolution R2* 
map, d) low resolution R2 map and e) low resolution R2* map. The matched maps are segmented into 
the external globus pallidus (GPe), the internal globus pallidus (GPi), the bright part of the putamen 
(Pu_high), the dark part of the putamen (Pu_low) and the lamina of white matter separating the Pu and 








Figure 8.8: Segmentation of matched SXRF and MRI maps of substantia nigra sample C2. a) Approximate 
position of the maps. b) The SXRF map and matched c) R2 and d) R2* maps are segmented into the 





Figure 8.9: Segmentation of matched SXRF and MRI maps of substantia nigra sample AD2. a) 
Approximate position of the maps. b) The SXRF map and matched c) R2 and d) R2* maps are segmented 
into the substantia nigra (SN) and cerebral crus (CC). Good matching was achieved. 
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When the SXRF and MRI maps were processed in ImageJ the threshold tool was used to 
remove the background and main artefacts from the maps. Therefore the pixel value of the 
black background in the MRI and SXRF maps represents a value of ‘NaN’ meaning that these 
pixels will be discounted from any analysis (such as mean calculation) in ImageJ. This means 
that any cracks in the tissue included in the segmented regions do not need to be manually 
drawn around. 
Caudate Nucleus 
Figures 8.2 and 8.3 show the matching between the SXRF and MRI maps in the caudate 
nucleus samples C2 and AD1 respectively. The maps are segmented into the caudate nucleus 
(CN); the anterior limb of the internal capsule (AIC) and the white matter medial to the 
caudate nucleus (WM-CN). 
Putamen 
Segmentation and matching of SXRF and MRI maps are shown in Figure 8.4 for sample C3 and 
in Figure 8.5 for sample AD3. In these maps the putamen is segmented into ‘Pu_high’ and 
‘Pu_low’ (as in Chapters 6 and 7), where Pu_high is the majority of the putamen which has a 
high iron concentration and R2 or R2* signal and Pu_low is the band of low iron concentration 
and R2 or R2* signal along the lateral edge of the structure. The white matter lateral to the Pu 
(Pu-WM) and the AIC are also segmented when present. 
Globus Pallidus 
The matched and segmented SXRF and  high and low MRI maps for the globus pallidus samples 
are shown in Figure 8.6 for sample C3 and Figure 8.7 for sample AD2. The main segmented 
structures of the map are the high iron part of the putamen (Pu_high) and the external globus 
pallidus (GPe). Other regions which are segmented, when present, are the internal globus 
pallidus (GPi); the internal capsule (IC); the lamina of white matter separating the putamen 
and globus pallidus (WM-GP) and the low iron of the putamen (Pu_low). 
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Substantia Nigra  
The segmentation of the matched SXRF and MRI maps of the substantia nigra samples is 
shown in Figure 8.8 for sample C2 and in Figure 8.9 for sample AD2. The tissue from the 
cerebral crus (CC) is segmented in addition to the approximate location of the substantia nigra 
(SN).  
8.1.1.3 Mean iron concentration, R2 and R2* in the segmented regions 
The mean iron concentration, R2 and R2* of segmented regions for each control and AD sample 
are shown in Figure 8.10. The main regions are the structures which were specifically chosen 
for investigation in this project. Also included are those which appeared in the maps of both 
the AD and control samples. The ‘error bars’ on the graph indicate the standard deviation of 
the pixel values within the segmented area. 
 
Figure: 8.10: Iron concentration, R2 and R2* in the matched SXRF and MRI maps. The mean and standard 
deviation of the pixels in each segmented area is given.  a) The mean iron concentration in the 
segmented regions of the SXRF maps. b)  Mean R2 and c) mean R2* in the segmented regions of the MRI 
maps after spatial matching with the SXRF map. The overall trend in iron concentration in the 
segmented regions is preserved in the R2 and R2* data. 
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Inspection of the bar charts indicates a similar trend in the iron concentration, R2 and R2* data. 
This agrees with the hypothesis that iron concentration has a significant effect on the value of 
R2 and R2*. This relationship is investigated using simple linear regression analysis in Section 
8.1.1.5. 
Another observation is the larger variation in the R2* data compared to the R2 data. This 
supports the hypothesis that effect of iron on R2* is larger than on R2. This is explored further 
in Section 8.1.1.6 by investigating the relationship between iron and R2’. 
The direction of change between AD and control seen in the iron data is generally conserved in 
the MRI data. For example, there is an increase in iron in the AD CN and a corresponding 
increase in R2 and R2*.  
 
Figure 8.11: Relative standard deviation in control and AD SXRF and MRI maps. The standard deviation 
(σ) of the pixel values within each segmented region in the matched SXRF, R2 and R2* maps is given as a 
percentage of the mean for a) the control maps and b) the AD maps. The general trend is for the largest 
relative standard deviation to be shown by the iron maps, followed by the R2* and the R2 maps. Overall 
the control maps show a larger relative standard deviation than the AD maps. The relative standard 
deviation of the Pu_high-GP region in the AD R2* map is extremely high (154%, the full height is not 
shown). However this is due to poor data quality in this region: very rapid decays could not be well 
fitted. The relative standard deviation in the WM-Pu AD iron map is high, however the absolution 
standard deviation is low as this is a region with low iron concentration (Figure 8.10). 
 
 
The relative standard deviation of the pixel values within each segmented region of the control 
and AD SXRF, R2 and R2* maps is shown in Figure 8.11. In most cases the iron maps show the 
largest relative standard deviation, followed by the R2* and R2 map. This is in agreement with 
the hypothesis that R2* maps are more sensitive to local field inhomogeneities caused by 
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tissue iron. Overall the control maps show a larger relative standard deviation that the AD 
maps. This is somewhat unexpected as some studies have shown greater variance with more 
outliers in the R2 maps of AD tissue [132, 191]. 
There are couple of notable anomalies in the AD data in Figure 8.11. The relative standard 
deviation of the Pu_high-GP region in the AD R2* maps is extremely high. However, as was 
previously described, the R2* decays in this region were very fast and not well fitted by ImageJ. 
Although the relative standard deviation in the WM-Pu AD iron map is high, the absolute 
standard deviation is low as this is a low iron region (shown in Figure 8.10). 
The approximate lower limit for T2 and T2* decays which could still be fitted reliably was 
examined in Section 4.3.3.3. The result of this was to be cautious of R2 and R2* values above 50 
and 200 s-1 respectively. The mean values for the WM-GP region of the control and AD samples 
either approaches, or just exceeds this limit.  
8.1.1.4 Effects of mismatching and of imaging resolution 
Figure 8.12 shows the mean and standard deviation of R2 and R2* for the segmented regions of 
the high and low resolution maps of the globus pallidus (matched maps shown in Figures 8.6 
and 8.7). Table 8.2 shows the percentage change in the low resolution compared to the high 
resolution data.  
The control SXRF sample was better matched to the low resolution MRI maps. The biggest 
change in the control data is an increase of 11 % observed in the GPe R2* data. However, a 
larger difference between the high and low resolution data is seen for the AD case, where both 
the high and low resolution MRI maps were from approximately the same position and both 
were matched to the SXRF map. Therefore this change cannot be attributed to the different 
position.  
The largest change between high and low resolution MRI data is an increase of 33% in the high 
iron region of the putamen (High_Pu-GP) for the AD sample. The high resolution map of this 
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region contained some pixels with particularly high R2* values, as shown by the large standard 
deviation. Many of the pixels have an R2* much greater than the estimated limit of reliable 
fitting (200 s-1) and some could not be fitted at all by ImageJ. When the low resolution data are 
considered the mean R2* has increased, but the standard deviation has reduced.  
This highlights both an advantage and disadvantage of imaging at a lower resolution. At the 
lower resolution each voxel is sampling a larger area (both in-plane and slice thickness) and the 
effects of the high iron concentration are averaged with the surrounding tissue to produce a 
decay which can be more easily measured. However, some detail of the iron distribution is lost 
as can easily be observed by inspection of the high and low resolution maps in Figure 8.7. 
 
Figure 8.12: R2 and R2* of high and low 
resolution maps of the globus pallidus. a) 
The mean R2 value of each segmented 
region. The most notable difference is a 
reduction in R2 in the AD GPe at low 
resolution. b) The mean R2* values in each 
segmented region. The biggest change is an 
increase in R2* in the Pu_high-GP region in 






Table 8.2: Percentage difference in R2 and 
R2* in low compared to high resolution maps 
of the globus pallidus. The largest 
discrepancy between high and low 






8.1.1.5 The linear relationship between iron concentration, R2 and R2*  
 
Figure 8.13: Iron concentration versus R2 and R2* at 9.4 T. Graphs a) and b) shows the linear relationship 
between iron and MRI (R2 and R2* respectively) for the pooled control and AD data. The light grey error 
bars represent the standard deviation within the segmented region. The x-axis at the top of each graph 
shows the normalised iron SXRF signal intensity and the lower x-axis shows the calibrated iron 
concentration (with an estimated error of ±12%). A straight line was fitted to the data using simple 
linear regression analysis. The prediction bands show the region in which 95% of any new 
measurements would be predicted to fall. Graphs c) and d) show the relationship between iron and R2 
and R2* respectively for control samples and graphs c) and d) show the relationship between iron and R2 
and R2* respectively, for AD samples. All linear fits to the data show a strong relationship (r=0.87 or 
greater) and high statistical significance. The liner fit is made to the combined grey matter and white 






Table 8.3: Results of linear regression analysis of iron versus R2 or R2*. a) The linear relationship 
between iron and R2. b) The linear relationship between iron and R2*. The relationship is examined for 
the control and AD data separately and with both sets of data pooled. Data from grey and white matter 
regions is also examined separately. In all cases there a statically significant, strong linear relationship. 
The r-squared values show that at least 67% of the variation in the data is explained by the linear 
relationship. All R2 models show a slope and intercept which agree within error. The same is true for all 
of the fits to the R2* data. *p<0.05; **p<0.01; ***p<0.001 
 
 
Figure 8.13 shows the mean iron concentration versus R2 and R2* for the segmented regions of 
the control and AD matched SXRF and MRI maps. Table 8.3 shows the results of simple linear 
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regression analysis of the relationship between iron concentration and R2 or R2* with different 
sets of data.  
In Figure 8.12 data are only included from the ‘paired’ segmented regions: those which were 
measured in both the control and AD samples, whereas Table 8.3 also shows the fit to all 
segmented regions (including those only measured for either control or AD). In Figure 8.12 a) 
and b) the top x-axis shows the normalised iron SXRF signal intensity and the lower axis shows 
the calibrated iron concentration. Recall that the absolute iron concentration has an estimated 
error of ±12% arising from the calibration. The prediction bands show the range within which 
95% of any new measurements would be expected to fall. Figure 8.13 c) and d) show the 
relationship of iron concentration in control samples to R2 and R2* respectively and the 
relationship for AD samples is shown in e) and f). 
The results of simple linear regression in Figure 8.13 and Table 8.3 show a strong, statistically 
significant relationship for all data, regardless of whether it is broken down by disease group. 
Furthermore, the slope and intercept of the fitted lines agree within error for each model for 
both R2 and R2*.  The r-squared values show that at least 67% (minimum for AD, GM regions in 
R2 model) of the variation in the data is explained by the linear fit.  
The mean R2 and R2* values for one control and AD data point approach or slightly exceed the 
maximum reliable values of 50 and 200 s-1 respectively (as defined in Section 4.3.3.3). 
However, these data points do not appear as outliers in Figure 8.13 and therefore do not need 
to be excluded from the analysis. 
The grey and white matter structures were also fitted separately (Table 8.3). These also show 
strong linear relationships with gradients and intercepts that agree within error for both the R2 
and R2* data. In clinical MRI imaging the different relaxation rates of grey and white matter 
tissues provide contrast in the image and this is attributed to their differing fat and water 
content in addition to iron. However, the agreement of the linear relationship between iron 
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and R2 and R2* for both grey and white matter, suggests that at this field (400 MHz) iron is the 
most significant factor in determining change in R2 and R2*. 
Although all fits agree within error, the r-squared values of the AD data are slightly lower in 
each case (apart from for the fit to R2 for only WM regions). This suggests that there may be 
another factor, such as water content, which is affecting R2 and R2* slightly more for AD 
samples than for control samples. 
8.1.1.6 Iron and R2’ 
The susceptibility related relaxation rate R2* represents the combination of the transverse 
relaxation rate R2 and the field inhomogeneity induced R2’. It is reported in the literature that 
R2* is more sensitive to changes in tissue iron concentration than R2 [123] and this has been 
shown here in Figure 8.13 and Table 8.3. The hypothesis is that the increased sensitivity of R2* 
to iron is due to increased tissue iron content causing increased local field inhomogeneities 
within the tissue.  
Approximate mean R2’ was calculated for each segmented region, using the formula (from 
Equation 2.6): 
      
     
and is plotted against iron concentration in Figure 8.14. The result of linear regression analysis 
for the combined and separated control and AD data is given in Table 8.4. A strong, statistically 
significant relationship is shown for all three models with slopes and intercepts which agree 




Disease n Slope (s-1/(µg/g)) Intercept (s-1) r r2 P 
pooled 22 0.27 ± 0.03 16 ± 7 0.88 0.77 *** 
Control 11 0.28 ± 0.04 18 ± 9 0.92 0.84 *** 
AD 11 0.27 ± 0.05 12 ± 14 0.86 0.74 ** 
 
Table 8.4: Results of linear regression analysis of iron concentration and R2’. The 
slope and the intercept of the fit agree within error for both the pooled and 
separated control and AD data. The majority of the variation in the data in each 






Figure 8.14: Iron concentration versus R2’. The x-axis at the top of the graph shows the normalised iron 
SXRF signal intensity and the lower axis shows the calibrated iron concentration (with an estimated 
error of ±12%). A straight line was fitted to the data by simple linear regression analysis and shows a 
strong (r=0.88), statistically significant (p<0.001) linear relationship. The prediction bands show the 




8.1.1.7 Copper and zinc versus R2 and R2* 
The SXRF metal maps presented in Chapter 6 showed that zinc and copper have a distribution 
distinct to that of iron and often also from one another. Figure 8.15 shows the copper and zinc 
plotted against R2 and R2* for all of the segmented regions in the control and AD maps. A 
simple linear regression analysis was carried out on the pooled control and AD data and 
separately on the data from each disease group (Table 8.5). 
 
Figure 8.15: Copper and zinc concentration versus R2 and R2*. The copper and zinc concentrations in the 
segmented SXRF maps are plotted against the carefully matched regions in the R2 and R2* maps for the 
combined control and AD samples. Linear regression analysis showed no statistically significant linear 
relationship between copper and a) R2 or b) R2*. However, when the outliers (circled) are excluded a 
statistically significant relationship is observed. There is a statistically significant relationship (p<0.05) 
between zinc and c) R2 and d) R2*, however the correlation coefficients are low and show that the 
relationship is not very strong.   
 
 
There was a statistically significant linear relationship (p<0.05) between zinc and R2 and R2* for 
the pooled control and AD data and also between zinc and R2* for the control data only. 
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However, the r-squared values are small (0.2 and 0.24) and show that the zinc concentration 
data do not explain the majority of the variation in the data. 
Copper did not show a statistically significant linear relationship with R2 or R2* when all of the 
data points were included. However, two regions with an elevated copper concentration 
appeared to be outliers from the rest of the data set. When these were excluded from the 




Table 8.5: Results of linear regression analysis of zinc and copper with R2 and R2* for segmented regions 
of control and AD tissue. Zinc concentration showed a statistically significant linear relationship with 
both R2 and R2* for the pooled data. When the outliers (shown in figure 8.14) are excluded from the 
copper model a statistically significant relationship is observed and the result is given in squared 
brackets. *p<0.05; **p<0.01. 
 
 
The linear relationship between zinc and copper (excluding outliers) and MRI may be due to 
the metal distribution correlating with another property (such as iron concentration) of the 
tissue, which is influencing the relaxation rates. To investigate this, a multiple linear regression 
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analysis is carried out on the zinc, copper and iron data to test whether each metal contributes 
to the model.  
 
 
Table 8.6: Results of multiple linear regression analysis of iron, copper and zinc with R2 and R2* for 
control and AD tissue. The statistical significance of the coefficient for each metal in the model is given, 
in addition to the overall statistical significance of the model. *p<0.05; **p<0.01; ***p<0.001.  
 
 
Table 8.6 shows that a multiple linear regression analysis of the iron, copper and zinc data 
achieves the best fit for the pooled control and AD data for both R2 and R2*. However, the 
additional fit information provided by the statistical analysis software SSPS suggests that 
copper does not contribute significantly to the models: it has a high p-value of 0.29 in the R2 
mode and 0.17 in the R2* model. The multiple linear regression models using iron and zinc 
data show a higher correlation coefficient, r, for the separated control and AD samples, when 
compared to simple linear regression analysis of iron only (Table 8.3). Interestingly, the 
correlation coefficient of the Fe and Zn model is reduced for the pooled data, suggesting that 
there is a difference between the relationship for the control and AD samples. This was not 
observed with the iron or zinc data individually. 
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Zinc ions in solution have been shown to shorten T2 [192] (and therefore increase R2). 
However, it is also possible that zinc distribution is coinciding with another parameter that 
influences MRI, such as tissue water or fat content.  
8.1.2 600 MHz data 
MRI relaxometry of the pons and amygdala samples was carried out using the 600 MHz probe 
at the University of Florida. For reasons detailed in Section 4.3.3.1 only the R2* data are 
considered reliable and analysed here. SXRF maps of the amygdala samples were collected 
during experiment DLS5 and therefore the estimated calibration of the iron concentration for 
the normalised SXRF signal applies.  
The pons samples, which included control, AD, PD and MSA cases, were mapped over a 
number of different experiments. As described in Section 6.5, normalising the data between 
experiments produced unsatisfactory results. Therefore only the data from the AD and PD 
pons (both measured during experiment DLS3) are matched to MRI maps.  
8.1.2.1 Amygdala 
The bore size of the 600 MHz probe restricted the sample size to less than 8 mm in diameter 
and for the amygdala this contributed to difficulty in matching the SXRF and MRI maps. Each 
sample was taken from completely within the amygdala so there were no surrounding 
structures for reference and additionally there were limited distinguishing features within each 
map. The process of finding the best matched R2* map to the SXRF map for the control and AD 
amygdala is shown in Appendix F and the final result of matching in Figure 8.16. 
Matching for sample C3 is not perfect as some tissue from the top of the SXRF section was lost 
during sectioning and the outside edge of the sample was pressed into the shape of the NMR 
tube during MRI, which can be seen in the R2* map. The matching was more straightforward 
for sample AD2, although the lack of distinctive structures within the MRI map meant the 
shape of the section was the only reference point.  
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As the amygdala sample contained no distinct regions for segmentation, the correlation 
between iron concentration and R2* is examined across the whole map. ImageJ was used to 
create a series of square ROIs that effectively produce a grid overlay onto the matched SXRF 
and MRI maps (Figure 8.16).  
The square ROIs are 5x5 pixels for both maps. However, the resolution of the MRI and SXRF 
maps are slightly different (64 x 64 µm and 60 x 60 µm respectively) and ImageJ can only divide 
the image into whole numbers of pixels. Therefore a 5x5 pixel ROI in the SXRF map is slightly 
smaller than in the MRI map. The remaining pixels are divided up as evenly as possible across 
the SXRF map and can be seen as rows and columns of ‘skipped’ pixels in Figure 8.16 a) and c). 
 
 
Figure 8.16: Matched SXRF and R2* maps of the amygdala with a grid of square ROIs overlaid on each 
map. The matching for sample C3 is difficult as in the SXRF map, a), tissue from the top of the section 
was lost during sectioning and b) the R2* map shows that the tissue was slightly deformed to the NMR 






Figure 8.17: Iron concentration vs. R2* in maps of the control and AD amygdala. There is a weak, but 
statistically significant linear relationship between iron concentration and R2* for both a) sample C3 and 
b) sample AD2. 
 
 
The ROI ‘multi-measure’ tool was used to sequentially measure the mean value of all of the 
square ROIs, so that ROI1 from the SXRF map corresponds spatially to ROI1 from the R2* map.  
As the background pixels had been set to ‘NaN’ these were discounted when they fell within 
an ROI. When any ROI had a mean value of ‘NaN’ it, and its counterpart in the matched map, 
were deleted from the data set. 
Figure 8.17 shows iron concentration versus R2* for all of the ROIs, for sample C3 and AD2. 
Linear regression analysis shows that there is a highly statistically significant linear relationship 
between iron and R2* for both samples. However, the r-squared values are very low: 0.27 for 
C3 and 0.09 for AD2. This shows that the linear regression model does not account for the 
majority of variation in the data.  
The correlation coefficient for the relationship between iron and R2* in the amygdala is much 
smaller than for the linear regression of maps from multiple brain regions (Table 8.3 and Figure 
8.13). This may be due to the lower iron concentration, and smaller range of concentrations 
present in the amygdala map, compared to the magnitude and range of the segmented 
regions from multiple samples. If in Figure 8.13 only the data from regions with an iron 
concentration of below 50 µg/g are considered (comparable to the iron concentration in the 
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amygdala) a linear relationship is not clear; although the data points do not disagree with the 
overall trend, there is a large scatter about the fit. 
8.1.2.2 Pons 
The selection of the best matched MRI slice to the SXRF maps of the AD and PD pons is shown 
in Appendix G and the result of the matching in Figure 8.18. Good matching of the very fine 
stripes of grey and white matter was not achieved uniformly across the samples. Due to their 
small size, any difference between sectioning and imaging plane results in a miss-matching of 
structures and this appears to be what has happened in this case. 
 
 
Figure 8.18: The result of matching the SXRF and R2* maps of the AD and PD pons. Only partial matching 
is achieved between maps in both cases. In the a) SXRF and b) R2* maps of sample AD2 a matched 
region of matched white matter is shown. In the c) SXRF and d) R2* maps of sample PD1 an area of 
approximately matched grey matter is highlighted. 
 
 
Although good matching was not achieved across the sample, it was sufficient to show that 
whereas iron concentration is highest in the grey matter of the pons, R2* is higher in the white 
272 
 
matter. This can be seen by inspection of the matched maps in Figure 8.18 and also in Figure 
8.19 which shows the mean iron concentration and R2* in the grey and white matter of the 
samples, after the maps were segmented using ImageJ. 
Comparison between the disease cases shows that iron is increased in the AD sample 
compared to PD and that this corresponds to a slightly increased R2* in both the grey and 
white matter. However, despite the overall increase in iron in the grey matter the white 
matter has increased R2*. This is not in agreement with the linear relationship between iron 
concentration and R2* that was demonstrated in Section 8.1.1.5 for both grey and white 
matter tissue measured at 400 MHz.  
 
Figure 8.19: Relative iron concentration and R2* in the grey and white matter of the AD and PD pons. 
The mean and standard deviation of the pixel values in the segmented regions of grey and white matter 
are given for a) the normalised iron SXRF maps and b) the R2* maps. For both samples, iron 
concentration is higher in the grey matter, whereas R2* is higher in the white matter. 
 
 
Although the SXRF signal intensity of the pons maps was not calibrated, the bulk tissue iron 
concentration of adjacent tissue samples was measured and the results were given in Chapter 
5. For case AD2 an iron concentration of 37.8 ± 1.1 µg/g was measured and for sample PD1 
iron concentration was 13.2 ± 0.4 µg/g. As with the amygdala, the iron concentration is low. At 
this low concentration it may be that the difference in water content (concentration and 
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availability) between white and grey matter dominates the value of R2*. However, when 
comparing the same type of tissue the increased iron concentration in the AD sample 
(compared to PD) corresponds to an increase in R2*. 
8.2 MRI versus bulk tissue iron concentration and SQUID 
measurements 
In Chapter 5 SQUID magnetometry was used to examine the particulate iron content of the 
control and AD samples of tissue from the caudate nucleus (CN), putamen (Pu), substantia 
nigra (SN) and pons. The isothermal remanent magnetisation (IRM) of each sample was 
measured at 5 K, which gives an approximation of the relative ferritin concentration in the 
tissue. The iron concentration of each sample was then measured by GFAAS or ICP-MS.  
In Chapter 7 R2 and R2* were calculated for adjacent blocks of tissue taken from within the 
same brain regions of the same cases. The CN, Pu and SN were imaged at 400 MHz, whereas 
the pons samples were imaged at 600 MHz.  
8.2.1 Data summary 
Figure 8.20 shows the average bulk tissue measurements: a) dry to wet mass ratio (DWR, a 
measure of tissue water content); b) iron concentration; c) IRM at 5 K (an approximate 
measurement of particulate iron) for the control and AD samples of each region measured in 
Chapter 5. The mean d) R2 and e) R2* from the corresponding cases is also given. 
Only the R2* data are included for the pons as the R2 data collected at 600 MHz were not 
reliable (see Section 4.3.3.1). It is also important to note that R2* is field dependent and 




In Figure 8.20 there is no immediately obvious relationship between the bulk tissue and MRI 




Figure 8.20: Summary of bulk tissue and MRI relaxometry measurements of tissue from the caudate 
nucleus, putamen, substantia nigra and pons. a) The dry to wet mass ratio showed a statistically 
significant increase in water content of the AD caudate nucleus. No statistically significant relationships 
were observed between control and AD in b) the mean iron concentration, c) the mean IRM at 5 K (an 
approximate measure of ferritin iron), d) the mean R2 or e) the mean R2*. Note that MRI relaxometry of 




8.2.2 Linear regression analysis 
8.2.2.1 MRI at 400 MHz 
Multiple linear regression analyses were carried out to investigate the relationship between 
bulk tissue iron and water content and the R2 and R2* measured in the adjacent blocks of 
tissue. Data from the different regions (CN, Pu and SN) were pooled, as a strong linear 
relationship between iron and MRI was shown across multiple regions for the matched MRI 
and SXRF maps (Figure 8.13). 
Simple linear regression was carried using iron concentration, IRM at 5 K (which gives an 
approximate, relative concentration of ferritin) and DWR (dry to wet mass ratio) as the 
independent variables. Multiple linear regression analysis was then carried out using iron and 
DWR, and then IRM at 5 K and DWR, as pairs of independent variables. Data from control and 
AD samples were pooled and examined separately. The results are given in Table 8.7. 
For most combinations of variables the model did not reach statistical significance and this was 
the case for all iron measurements. When statistical significance was shown, the direction of 
the relationship was negative: an increase in IRM at 5K resulted in a decrease in R2 or R2*. This 
does not agree either with the positive linear relationship observed between ferritin and R2 
that has been shown in the literature [120] or that shown between total iron and R2 and R2* 
using matched SXRF and MRI maps in Section 8.1. Additionally, the linear regression analysis 
between the matched maps showed a much stronger linear relationship with high regression 






Table 8.7: Results of linear regression analysis of bulk tissue and MRI data. Linear regression analysis was 
used to examine the relationship between the dependent variables R2 or R2* and the independent 
variables iron concentration, IRM at 5 K and DWR for tissue from the control and AD caudate nucleus, 
putamen and substantia nigra. Statistically significant linear relationships were only observed between 
IRM at 5 K and R2 or R2*.  *p<0.05; **p<0.01; - p>0.05. 
 
 
Figure 8.21 shows IRM at 5 K versus R2 and R2*, where it can be seen that one sample has a 
higher IRM at 5 K value than the others. This data point belongs to putamen sample AD1. 
Referring back to Figure 5.14 shows that this sample had a higher than expected IRM at 5 K, 
considering its iron content. If this data point is excluded from the analysis (shown by the 
dashed line in figure 8.12), there is no longer a statistically significant linear relationship 
between IRM at 5 K and R2 or R2*. Additionally, the statistical significance of the multiple linear 





Figure 8.21: IRM at 5 K versus R2 and R2*. IRM measurements of bulk tissue samples are plotted against 
the mean a) R2 and b) R2* of the samples taken from adjacent tissue blocks. The measurement error for 
the IRM at 5 K and MRI is similar in size or smaller than the data markers. Linear regression analysis of all 
data points (solid line) showed a statistically significant negative relationship between IRM at 5 K and R2 
and R2*. When putamen sample AD1 (circled) was excluded, the linear fit lost statistical significance. 
 
 
The exclusion of putamen sample AD1, does not produce the expected positive linear 
relationship between bulk iron concentration or IRM with R2 and R2*. This disagreement is 
most likely due to the fact that the bulk tissue and MRI measurements were not made from 
the same blocks of tissue, but from adjacent blocks. Although these were cut from within the 
same structures, it is likely that the tissue did not display uniform properties. 
8.2.2.2 MRI at 600 MHz 
Similarly to the analysis of the 400 MHz data, linear regression analysis was carried using bulk 
tissue iron concentration, IRM at 5 K, DWR and R2* measurements of the pons. No statistically 
significant model was found using any combination of variables by simple or multiple linear 
regression analysis. This is not unexpected considering the fact that no linear relationship was 




8.3.1 A very strong linear relationship was demonstrated 
between iron concentration and R2, R2* and R2’ at 9.4 T 
The matching of SXRF and MRI maps of the caudate nucleus, putamen, globus pallidus and 
substantia nigra and their surrounding structures showed a very strong, statistically significant 
linear relationship between iron concentration and R2, R2* and R2’. In each case, the gradient 
and intercept of the relationship agreed within error for control and AD tissue. 
8.3.1.1 The linear relationship between iron and R2 is shown in both grey 
and white matter 
A number of studies have shown that the linear relationship between iron concentration and 
R2 does not hold for white matter tissue. This includes studies by House et al. at 1.4 T [19] and 
4.7 T [26]. Additionally Gelman et al. showed that the R2 and iron data from the frontal white 
matter were not in line with data from grey matter regions [134]. 
Table 8.3 shows that in this study the data from both the grey and white matter regions show 
a statistically significant linear relationship between iron and R2 (and R2*), with gradients and 
intercepts which agree within error. However, this result is not directly comparable to the 
studies mentioned above as it does not include the same regions of the brain. In this thesis 
grey matter regions were the main focus and the white matter regions included are 
neighbouring structures which happened to be included in the MRI samples. Additionally, the 
white matter regions in this study have a wider range of iron concentrations than those 
included in the House et al. papers. This means that a linear relationship can more easily be 




The pons provided evidence that this relationship may not hold at lower iron concentrations. 
In this region, where total iron concentration is less than 50 µg/g, the white matter showed 
higher R2* than grey matter, despite the fact that the grey matter had a higher iron 
concentration. However, increased iron lead to an increase in R2* when the same tissue type 
(e.g. grey matter compared to grey matter) was compared. This suggests that although iron 
concentration is still contributing to R2*, other factors such as the water concentration, are 
dominating the value of R2*. 
8.3.2 Predicting the concentration of iron from an MRI 
measurement 
A strong statistically significant linear relationship between iron concentration and R2 and R2* 
was demonstrated in Figure 8.13 and Table 8.3. The linear equations which describe the 
relationship are: 
                 (8.1) 
  
                (8.2) 
Where [Fe] is the concentration of iron in micrograms per gram of fresh-frozen tissue and R2 
and R2* are measured in s
-1. 
Equations 8.1 and 8.2 can be rearranged to estimate the concentration for iron from R2 or R2* 
measured at 2 °C, at 400 MHz: 
                  (8.3) 
            
       (8.4) 
However, the 95% prediction bands in Figure 8.13 indicate a large uncertainty. 
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8.3.3 Iron concentrations below 50 µg/g did not dominate the 
value of R2* at 14.1 T 
A very strong linear relationship was demonstrated between iron concentration and R2 and R2* 
at 9.4 T. However, this was not successfully demonstrated at 14.1 T, using either data from the 
amygdala or the pons. A statistically significant relationship linear relationship was observed in 
the amygdala, however the gradient was low and the r-squared values small.  
The number of samples measured at 14.1 T and also mapped by SXRF was small and this was 
exacerbated by the fact that the pons and amygdala data had to be handled separately due to 
their SXRF maps being collected during different experiments. This meant that less data were 
available to examine the relationship between iron and MRI at 14.1 T than for MRI at 9.4 T.  
However, the most likely reason that a strong relationship was not shown is that the iron 
concentration in the pons and the amygdala is low compared to the other regions studied. 
Both regions have iron concentrations below 50 µg/g (iron concentration of the pons was 
measured in Chapter 5 and the iron concentration of the amygdala was estimated from SXRF 
measurements and is widely reported in the literature [107]). Even though a strong linear 
relationship between iron concentration and R2* at 9.4 T is shown in Figure 8.13 b), if the data 
points from regions with an iron concentration below 100 µg/g are considered the relationship 
is not clear. Linear regression analysis of these 8 data points was carried out and revealed no 
statistically significant relationship. Therefore it is not unexpected that, even at a higher field, 
the linear relationship between iron concentration and R2* is not observed in the pons or 
strongly in the amygdala. This is in agreement with the findings of House et al. who, in a 4.7 T 






I. The SXRF metal maps were successfully matched to the MRI R2 and R2* maps. 
II. The matched maps revealed a strong, statistically significant, positive linear 
relationship between iron concentration and R2, R2* and R2’ at 9.4 T, which was the 
same for control and AD samples and for grey and white matter tissue.  
III. A corresponding strong linear relationship was not observed between iron 
concentration and R2* at 14.1 T, however the most likely reason for this is that the iron 
concentration of the samples measured at this field was low, below 50 µg/g. 
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Chapter 9: Discussion and conclusions 
9.1 The linear relationship between iron and MRI  
A very strong linear relationship between iron concentration and transverse relaxation, R2, and 
the susceptibility related parameter, R2*, was demonstrated in Chapter 8. Linear regression 
analysis of data from matched ROIs in the matched iron SXRF and MRI relaxometry maps 
showed a statistically significant relationship (p<0.001), where the relationship accounted for 
around 75% of the variation in the data. Both grey and white matter regions were included in 
this fit. Contrast between these regions in clinical MRI is usually attributed to differences in the 
fat and water content of the tissue, however the linear regression analysis shows that iron 
concentration dominates at this field.  
This is thought to be the first demonstration of the linear relationship between iron 
concentration and R2 and R2* in human brain tissue at 9.4 T and the first demonstration, with 
quantified iron values, above 7 T.  
9.1.1 Comparison with the literature 
The effect of iron on R2 increases linearly with field strength, a property which has been 
utilised by Bartzokis et al. in their field dependent R2 increase (FDRI) method of assessing brain 
iron concentration [125, 126, 133]. However, it has been suggested that the effect will saturate 
at high field due to the saturation of the magnetisation of ferritin iron [25]. Vymazal et al. 
measured the effect of iron concentration on R2 at multiple field strengths (0.05 to 1.5 T) using 
fresh (never-frozen) brain tissue from a Rhesus monkey [135] at an imaging temperature of 37 
°C. They produced an empirical equation to give the gradient of change in R2 (in s
-1) with iron 
concentration (milligrams of iron per gram of fresh tissue) at an imaging field B: 
                        g (9.1) 
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where B is the imaging field in tesla. 
House et al. concluded that the relationship they observed between iron and R2 at 4.7 T agreed 
with Vymazal’s prediction, once certain experimental differences had been taken into account 
[26]. Yao et al. have also shown that R2* displays a linear dependence on field strength up to 7 
T [27], however they did not measure R2. 
9.1.1.1 R2 
To test whether any saturation effects are shown at 9.4 T, Equation 9.1 was solved for the 
imaging field of 9.4 T (400 MHz), which gives a slope of 0.0724 s-1/µg/g. This compares 
extremely well with the gradient of the linear fit to the matched R2 and SXRF iron maps in 
Figure 8.12 of 0.072 ± 0.008 s-1/µg/g.  Therefore there is no evidence of saturation of the field 
dependent R2 increase at 9.4 T. 
The degree of agreement is extraordinarily close considering a number of experimental 
conditions which varied between the Vymazal paper and the experiments conducted here. It is 
important to consider the impact of the differences in experimental protocol, although they 
appear to have combined here to give good agreement. Firstly, Vymazal shows that R2 is 
increased by 13-22 % in tissue which has been frozen and defrosted, as these samples have 
been (but Vymazal’s samples were not). This would result in a corresponding change to the 
gradient. Conversely, R2 decreases with decreasing temperature [193] and therefore the low 
imaging temperature of our samples (2 °C) would result in a decreased gradient compared to 
that observed by Vymazal et al. 
Another experimental difference is that in the Vymazal paper the interecho time, TE, is 4 ms 
compared to 9.78 ms in this study. This is important as in the same paper Vymazal also 
described how increased interecho spacing increased the effect of iron content on R2 [135]. 
From Figure 7 in the paper by Vymazal et al. an estimated 5-10% increase in the effect of iron 
on R2 could be expected with TE of 10 ms compared to 4 ms in MRI at 37 °C with a field of 1.5 
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T. The size of this effect may be field and temperature dependent. Exploring the relationship 
between TE and R2, with the MRI protocols used here, may be an interesting area of future 
work. 
In summary an increase in the gradient of the relationship between R2 and iron concentration 
is expected, due to the tissue having been frozen. In contrast the low temperature and longer 
TE used in this study would be expected to decrease the gradient. A final source of error in the 
gradient of the fit in Figure 8.12 is calibration of the absolute iron concentration in the SXRF 
map. This has an estimated error of ± 12%. 
9.1.1.2 R2’ 
Tables 8.3 and 8.4 give the gradient of the linear relationship between iron concentration and 
R2 and R2’ respectively. Comparing the data shows that the gradient for R2’ is 3.75 times larger 
than the gradient for R2. In a study at 3 T by Gelman et al. [134], the magnitude of the 
gradients were shown to be approximately equal. Therefore, not only is there field dependent 
contribution to the gradient of R2 with iron (as described by Vymazal et al. and shown above in 
Equation 9.1 [135]), but there is an additional field dependent contribution to the relationship 
of R2’ with iron concentration.  
Assuming that this relationship is also linear, the 9.4 T data in this study can be combined with 
the 3 T data reported by Gelman et al. to produce an equation for the slope of R2’ with iron 
concentration at a particular imaging field B: 
                              (9.2) 
Yao et al. [27] have shown that there is a linear relationship between the magnitude of the 




9.1.2 Measuring iron by MRI 
The matched SXRF and MRI maps in Chapter 8 showed that at 9.4 T iron concentration 
dominates the value of R2 and R2*. Equations were produced to estimate the iron 
concentration of tissue from MRI relaxometry at 400 MHz. The prediction bands show that 
although the relationship is strong, the predicted R2 or R2* for a given iron concentration (or 
vice versa) covers a large range. This means that a large increase in iron would be required to 
ensure a significant change in R2 or R2*. In addition to this, bulk iron measurements in this 
study, and in the literature, show a large standard deviation. It is hard to say whether this is 
due to measurement error (which is suggested by the variation in means between different 
studies and further discussed in Section 9.3) or natural variation (which is supported by large 
standard deviations within studies). The combination of these two observations means that a 
very dramatic change in iron in one particular region would be required to differentiate with 
certainty between control and AD. 
In this study the linear relationship between iron concentration and R2 and R2* was 
demonstrated with only n=2 for each region (one control and one AD example). Other tissue 
properties that vary between regions, such as fat and water content, will be contributing the 
value of R2 and R2* and therefore may be contributing to the spread about the fit in Figure 
8.13. It is difficult to observe this effect with such a small number of samples. In a study by 
Langkammer et al. [123] there is some evidence of tissue samples from the same regions 
clustering together. Therefore comparing like-with-like tissue (i.e. from the same region) may 
reduce the size of the prediction bands, and therefore increase the sensitivity of MRI to 
changes in iron concentration. 
9.2 Combining information from multiple brain regions 
enables the differentiation of control and AD tissue 
Discriminant analysis has been used here to show that combining data from multiple regions 
increases the ability to distinguish between disease and control, even when no statistically 
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significant differences between AD and control for individual regions have been observed. This 
was demonstrated with total and particulate iron concentration in Chapter 5, and translated to 
R2 and R2* measurements in Chapter 7. 
The literature review showed mixed results when comparing iron concentration (directly, or 
indirectly through MRI) between AD and control tissue, with some positive and negative 
findings reported for all regions. However, as has been shown in this data set, it is possible that 
discriminant analysis could be used to produce a model that is clinically useful in distinguishing 
between disease and control, without there being statistically significant differences between 










Pons, Pu, CN 
SN, Pu, CN 
100% 83.3% 





R2 at 400 MHz 
CN, AIC 
CN, Pu, AIC 
100% 83.3% 
R2* at 400 MHz CN, WM-Pu 100% 66.7% 
R2* at 600 MHz Pons GM, Amyg 83.3% 66.7% 
 
Table 9.1: Summary of the best results from discriminant analysis of different 
measurements. The combination of brain regions which provided the most successful 
differentiation between control and AD is given for each measurement. In some 
cases more than one combination produced the same result. The percentage of the 
samples which were correctly grouped is given and the percentage correctly grouped 
with cross-validation. Pu = putamen; CN = caudate nucleus; SN = substantia nigra; AIC 
= anterior limb of the internal capsule; WM-Pu = white matter lateral to the 
putamen; GM = grey matter; Amyg = amygdala. 
 
 
Table 9.1 shows the combinations of regions which provided the best differentiation between 
AD and control for each set of measurements. However, as not all regions were measured by 
all different methods, this cannot be considered a definitive guide to the best potential regions 
for further study. Other factors also need to be considered. For example, the pons provided 
good discrimination between diseases with iron concentration and IRM at 5 K data. However, 
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as this region has a low absolute iron concentration it may not be a good candidate for 
differentiation by MRI and in fact this was demonstrated in Chapter 8, Section 8.1.2.2. 
9.2.1 Would 3 T MRI measurements give the same result? 
The effect of iron on R2 is field dependent, as is discussed in Section 9.1 above. Therefore, the 
sensitivity of R2 to iron concentration is reduced at lower imaging fields. Routine clinical 
imaging systems currently do not have fields above 3 T (and are typically lower). Therefore it is 
important to consider whether the successful differentiation of AD and control samples, which 
was observed at 9.4 T, could in principle be achieved at 3 T. This was tested using R2 data from 
the CN and AIC, which gave 100 % correct classification of samples using discriminant analysis 
(Table 9.1). 
First, the linear relationship between iron and R2 at 3 T was estimated. Equation 9.1 was used 
to predict the gradient of the relationship, giving a value of 0.0327 s-1/µg/g. The empirical 
results from Langkammer et al. gave an intercept of 8.5 s-1 [123] and this value was used in the 
estimation. The final equation is  
                  (9.3) 
Equation 8.3, which predicts iron concentration from R2 measured at 9.4 T, was then used to 
estimate iron concentration in each control and AD sample from the CN and AIC. These values 
were substituted into Equation 9.3 to estimate R2 for each sample at 3 T.  
 CN (mean ± σ) AIC (mean ± σ) 
Mean R2, measured at 9.4 T (s
-1) Control 24.9 ± 1.8 37.7 ± 4.0 
AD 31.1 ± 5.4 31.6 ± 5.7 
Mean iron concentration per unit 
mass of tissue, predicted from 
Equation 8.3 (µg/g) 
Control 
68.7 ± 25 245.5 ± 56.2 
AD 
 
157.2 ± 75.4 160.7  ± 78.7 
Mean R2 predicted at 3 T (s
-1) Control 10.7 ± 0.8 16.4 ± 1.8 
AD 13.6 ± 2.4 13.8 ± 2.6 
Table 9.2: The mean predicted R2 of the caudate nucleus (CN) and anterior limb of the internal capsule 
(AIC) at 3 T. Also given are the mean R2 measured at 9.4 T and the mean predicted iron concentration of 
the AD and control samples. σ = standard deviation. 
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Table 9.2 shows the mean R2 for the control and AD tissue from the CN and AIC, as measured 
at 9.4 T. It also gives the mean predicted iron concentration for each region, and the mean 
predicted R2 at 3 T. Discriminant analysis of the predicted R2 values for the three control and 
AD cases achieved 100% correct classification, and 83.3% with cross-validation. This is the 
same result as shown for the 9.4 T data in Table 9.1. In conclusion, these data predict that 
discriminant analysis of R2 data from multiple regions, collected at 3 T, may allow 
differentiation between AD and control tissue. 
However, it is important to note that a limitation of this study is that all imaging was of post 
mortem tissue which has slightly different properties compared to living tissue. Therefore, an 
important future study would be to test this result with clinical imaging.   
9.2.2 Other comments 
Although iron is associated with AD pathology, increased iron concentration is not limited to 
regions of the brain in which AD pathology exists. This is shown in the literature review and 
further supported by the evidence in this thesis. These regions may provide a potential target 
for clinical MRI as the tissue is likely to have experienced less degeneration and the R2 and R2* 
decrease caused by increased water content may not be a problem. 
A statistically significant difference between AD and control was observed in the ratio of R2 in 
the caudate nucleus and the anterior limb of the internal capsule (Figure 7.10). As 
measurement of R2* is machine dependent [149] and measurement of R2 is sequence 
dependent [135], implementing consistent MRI relaxometry in a clinical setting may be difficult 
when a wide variety of scanners are used. Therefore an internal ratio between different brain 
regions may provide an interesting opportunity as it will, to some extent, correct for 
measurement errors. Looking at ratios between different regions of the brain may be an 
interesting future study. 
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9.3 The inhomogeneous distribution of iron within 
nuclei of the basal ganglia 
SXRF mapping is a technique which provides high spatial resolution, and in Chapter 6 was used 
to demonstrate the inhomogeneity of iron distribution within brain structures. In particular 
this was demonstrated for the putamen from case C3, which was mapped twice.  The two 
samples were approximately 2 cm apart and one sample had a mean iron concentration 80% 
higher than the other.  
In Chapter 6, a comparison was made between the ratio of the AD to control iron 
concentration (ARC) for: i) the relative mean iron concentration measured by SXRF mapping 
and ii) for the measured bulk tissue iron concentration. The samples compared were from the 
caudate nucleus, putamen and substantia nigra and the tissue for each technique was cut 
adjacently, as shown in Figures 3.7 and 3.9. In general, the agreement for the ARC values was 
much better than described above, with a difference between the two techniques of 4% for 
the putamen, 9% for the substantia nigra and 24% for the caudate nucleus (Table 6.2). This 
suggests that either the concentration of the iron over these particular regions of tissue was 
relatively consistent, or that the relative change in iron concentration was proportionally the 
same throughout the sample, even if the absolute iron concentration varied.  
As has been previously noted, the values of iron reported in the literature vary considerably 
between papers. This was shown in Tables 3.2 and 3.3 which summarised some of the data in 
the literature. Additionally, individual studies, such as the landmark study by Hallgren and 
Sourander [93], have large standard deviations which are comparable with the standard 
deviations of the samples measured here (Section 5.1.1). In this study, it is likely that small 
variation in the positions of the different samples cut from within the larger blocks has 
contributed to the variance in the data. This may well also be a factor in the values reported in 
the literature. For example, House et al. commented on the difficulty of precisely dissecting 
nuclei from the surrounding tissue [26]. 
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In their paper Imaging markers for Alzheimer disease: Which vs how, Frisoni et al. compared a 
large number of imaging markers of AD, including volumetric MRI [53]. They concluded that 
the way in which an imaging marker is measured is at least as important to its success as the 
marker itself. The protocol for segmentation of MRI images was one of the parameters they 
considered. Due to the inhomogeneity of iron distribution within individual structures, 
demonstrated by SXRF mapping in Chapter 6, it is highly likely that carefully standardising the 
protocol for segmenting MRI relaxometry maps would be very important before any clinical 
application of this technique.  
9.4 The form of iron in Alzheimer’s disease tissue  
In the literature review in Section 1.3 it was reported that some studies have shown an 
increase in magnetite in AD tissue from the superior temporal gyrus [110, 141]. This was not 
demonstrated in the regions studied in this thesis.  
In Chapter 5 it was concluded that there was no evidence of a change in the form of iron in the 
AD tissue samples compared to control. Some individual samples showed evidence of 
increased magnetite concentration (Table 5.6), however there was no trend specific to AD (or 
Parkinson’s disease or Multiple System Atrophy). This conclusion is supported by Figure 5.13, 
which shows the ratio of iron to IRM at 5 K (approximate, relative concentration of iron in 
ferritin) and IRM at 50 K (approximate, relative concentration of iron in magnetite), where no 
statistically significant differences were observed between disease groups. Additionally, Figure 
5.14 shows a strong, statistically significant linear relationship between iron concentration and 
IRM at 5 K for samples from all disease groups.  
The data in Figure 8.13 also support the conclusion that there is no significant difference 
between the particulate iron content of the control and AD samples. The SXRF maps represent 
the distribution of total iron, whereas MRI is most sensitive to particulate iron, with magnetite 
having a larger effect than ferrihydrite-like iron [158]. Therefore if there was a significant 
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difference in the proportion or form of particulate iron in the AD samples, the gradient of the 
linear relationship would be affected. This is not the case and the gradient of the fits to the 
control and AD data agree within error. However, it is possible that variations in the proportion 
of total iron as particulate iron in individual samples may be contributing to the scatter about 
the linear fit in Figure 8.13.  
In this thesis particulate iron was evaluated in terms of ferrihydrite and magnetite, but not 
other iron oxide phases (such as those associated with neuromelanin and haemosiderin), as 
this was beyond the scope of this study. Additionally, the effect of clusters of ferritin on the 
magnetic properties of the tissue was not explored. In particular, it should be noted that 
significant intracellular accumulations of ferritin have been observed in MSA pons tissue, as 
reported in the study which ran parallel to this thesis [28]. This may have affected IRM values, 
but a full investigation of the effect was beyond the scope of the investigation. 
9.5 Development and demonstration of techniques 
In this project a unique set of complementary techniques was used to investigate changes in 
iron in the AD brain and the relationship between iron and high field MRI. The specific 
combination of techniques had certain advantages and disadvantages as described below. 
9.5.1 Matching MRI and SXRF maps 
A literature search has revealed that no other studies have used matched SXRF and MRI maps 
to show the relationship between iron concentration and R2 and R2*. Hopp et al. used SXRF 
maps of 1 mm slices of fixed tissue to calibrate susceptibility-weighted MRI images [90]. In a 
previous publication by our group SXRF and 14.1 T MRI maps of the hippocampus were 
matched, however as the iron maps had not been calibrated the relationship was not 
quantified in this preliminary study [132]. 
The use of the matched maps allowed the comparison between iron concentration and MRI to 
be made with high spatial accuracy. There are some limitations to this which reduce the 
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accuracy of matching, including: misaligned sectioning and imaging planes, differences 
between MRI and SXRF slice thicknesses and ambiguity about the boundaries of certain 
structures. However, this is still a more accurate technique than MRI followed by tissue 
dissection. Accurate dissection of specific brain nuclei is very challenging and particularly 
difficult when working with fresh-frozen tissue. The difficulty in dissecting structures without 
including adjacent tissue is commented on in the paper by House et al. [26] in which they 
suggest that this may be a cause of outlying data points. 
9.5.2 Bulk iron analysis in adjacent blocks of tissue 
In this study, adjacent blocks of tissue were cut from within tissue structure so as to allow a 
parallel investigation of bulk tissue iron and matching of MRI and SXRF maps in the same cases. 
Therefore the comparison of MRI and bulk tissue data is not a comparison between two 
measurements of exactly the same tissue sample. The result of this was that the expected 
positive linear relationship between iron concentration and R2 and R2* was not observed. 
However, this did serve to highlight the importance of spatial matching when comparing sub-
regions of nuclei.  
9.5.3 High field MRI 
Although high field MRI relaxometry has the advantage of providing detailed structural 
information and increasing the sensitivity of R2 and R2* to iron concentration, it also has some 
limitations and some additional challenges. In particular, the small bore sizes of the high field 
spectrometers limited the maximum sample size, making anatomical matching and 
identification of samples very challenging. 
The MRI of the amygdala at 14.1 T is a good example of this. The size of the sample was limited 
to fit inside the 8 mm diameter NMR tube and therefore no surrounding tissue structures were 
included in the sample, making confirmation of the anatomy extremely difficult. This is 
compounded by working with fresh rather than fixed tissue, which would have given clearer 
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contrast in the tissue blocks when they were initially cut. It is also difficult to guarantee 
anatomically matched samples when such a small block of tissue is cut. This was demonstrated 
in the globus pallidus data set, where some samples did not include all the targeted regions 
(Section 7.1.1). 
One positive aspect of this study, is that imaging at this resolution provided an exceptional 
level of detail and may therefore be particularly useful in investigating smaller, highly complex 
structures: for example, for investigation of the substantia nigra (shown in this project) and the 
hippocampus, as already been demonstrated by our group [132]. 
9.5.4 Staining section post-SXRF mapping 
The development of a staining protocol which allowed the staining of post-SXRF mapped tissue 
with haematoxylin, allowed the identification of individual neurons in the stained section and 
the SXRF map. This allowed comparison of the relative iron, copper and zinc concentration in 
AD and PD pons (Section 6.5.2).  
9.6 Further work 
9.6.1 The discriminant analysis model 
The ability of discriminant analysis to differentiate between control and AD samples has been 
demonstrated repeatedly with this sample set. The next stage in using discriminant analysis 
would be to further validate the model by testing how well it classifies a set of samples that 
were not used in creating the model. This was not possible with the small number of samples 
available in this thesis.  
Therefore, a suggestion for future work would be to test discriminant analysis on a larger data 
set. Using data from a whole brain (post mortem or in vivo) would have the advantage of 
allowing a large number of different regional combinations to be considered. However, the 
imaging field, and therefore sensitivity to differences in iron concentration would be reduced.  
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From the work in this thesis, and the data reported in the literature, regions of the basal 
ganglia remain an interesting target area for this purpose. Although no statistically significant 
differences between AD and control are reported here, the trend of increased iron in the 
putamen and caudate nucleus was observed.  
9.6.2 T1 data 
As outlined in the methodology chapter, high resolution T1 data were also collected for all of 
the samples measured by MRI. These data are available for analysis and would be expected to 
also show shortening with increased iron concentration, but to a lesser degree than was 
observed for T2 [153]. It would also be interesting to compare T1 to the relative zinc and copper 
concentrations measured by SXRF. Zinc ions in solution have been shown to shorten T1 [192] 
and the paramagnetic properties of copper can also cause T1 shortening [194]. 
9.7 Conclusions 
Comparison of iron concentration, IRM at 5 K (an approximate indicator of ferritin-bound iron), 
R2 and R2* showed no statistically significant differences between control and AD tissue in the 
brain regions selected for this study. Despite this, discriminant analysis was used to 
demonstrate that the measurement of these properties can be used to differentiate between 
control and AD cases when data from multiple brain regions are combined. This shows that 
there is potential for iron changes in the brain in AD to provide a clinically useful marker of AD. 
A limitation of this study is that only post mortem samples were measured. Therefore it is now 
important to confirm that changes observed post mortem may also be observed in living 
persons. 
A strong linear relationship between iron concentration and R2, R2* and R2’ was observed at 
9.4 T, regardless of disease state or tissue type. The linear relationship between iron and R2 
agreed very well with the relationship predicted at 9.4 T using an empirical equation produced 
by Vymazal et al. [135], with no sign of saturation of the field dependent R2 increase. However, 
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in brain regions with iron concentrations below 50 µg/g a strong linear relationship was not 
observed. This is in agreement with a prediction by House et al. [26] who gave a threshold 
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Appendix A: Brain anatomy reference material 
The following images of coronal sections of the brain were used to determine the approximate 
anatomical position of the caudate nucleus, putamen, globus pallidus and amygdala samples. Below is 
a summary of the set of continuous sections and the following pages show the anatomy of the target 
regions for this study in more detail. The images are reproduced from thehumanbrain.info. 
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The caudate nucleus and putamen 
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4.0 mm 
lateral amygdaloid nucleus 
The amygdala is made up of a large number of nuclei, not all of which are labelled here.  
basolateral  amygdaloid nucleus 
central and medial amygdaloid nuclei 
8.0 mm 
lateral amygdaloid nucleus 
hippocampal head 
The amygdala 
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These samples were cut as described in Section 3.2.3.1 of the main text, with the cutting of 
sample C1 shown in Figure 3.7.  
Appendix B:  
Sample dissection for MRI and bulk tissue analysis 
The following pages show how each sample was dissected from the tissue block received 
from the Canadian Brain Tissue Bank. Block A was cut for MRI and included the surrounding 
tissue structures. Block B was cut for bulk tissue analysis (SQUID magnetometry, followed by 
ICP-MS or GFAAS) and was cut carefully so as to include only tissue from the target region. 
Both A and B were not cut from every sample. 
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Additional putamen samples will also prepared from the 3 Parkinson’s Disease and 3 Multiple 
System Atrophy cases. However, tissue was only cut for SQUID magnetometry and iron 
quantification (block B). 





























Anatomical identification of 
the putamen in this sample 
was difficult, however the 
tissue was cut based on 
advice from neuropathologist 
Dr Lili-Naz Hazrati. 
B 
B 
Anatomical identification of 
the putamen in this sample 
was difficult, however the 
tissue was cut based on 
advice from neuropathologist 
Dr Lili-Naz Hazrati. 
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Appendix B-2: Globus Pallidus Samples 
These samples were cut as described in Section 3.2.3.2 of the main text, with the cutting of 
sample C1 shown in Figure 3.8. The aim was to include tissue from the external and internal 
globus pallidus (GPi and GPe) and the putamen (Pu.) Only tissue for MRI (block A) was cut 
from the GP. 
MRI and sectioning and staining of this sample (Figure 7.4), showed that it did not contain the 
target regions and its anatomy was difficult to identify. Advice from neuropathologist Dr Lili-
Naz Hazrati was that may contain the internal globus pallidus and possibly the thalamus (Th), 
as indicated above. 
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Case AD1 8 mm 
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Case AD3:  4 mm 
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Case C1 
top half for SQUID 
bottom half for MRI MRI sample 
Substantia nigra 
cut from tissue 
block and   
bisected 
Appendix B-3: Substantia Nigra Samples 
These samples were cut as described in Section 3.2.3.3 of the main text, with the cutting of 
sample C2 shown in Figure 3.9. Where possible, tissue was cut for both MRI (block A) and 
bulk analysis (block B), however when there was only a small volume of tissue present the 
bulk tissue analysis was prioritised.  
B 
A 





Due to the small 
sample size, both 
samples were 
taken for bulk 
tissue analysis 







As this sample was very thin, 
it was not bisected and the 
whole nigra was taken for 
bulk tissue analysis 
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bottom half is 
from below the 
SN, so is not 
used for MRI 
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Case C1 
Appendix B-4: Amygdala Samples 
These samples were cut as described in Section 3.2.3.4 of the main text, with the cutting of 
sample C3 shown in Figure 3.10. The anatomy of the amygdala was particularly difficult to 
identify and therefore neuropathologist Dr Lili-Naz Hazrati identified the area of tissue 
containing the amygdala with a blue oval. Tissue for MRI was cut from within this area (block 
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Appendix B-5: Pons Samples 
These samples were cut as described in Section 3.2.3.5 of the main text, with the cutting of 
sample C1 shown in Figure 3.11. Tissue samples for bulk tissue analysis (bock B) were cut 
from an adjacent block of tissue, by Dr Joanna Collingwood, before the commencement of 
this PhD. This is not shown here, however tissue was cut using the same guide. Cutting of the 

























No tissue was available for MRI from the pons sample from case MSA1. 
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Appendix C-1: IRM Curves 
The SQUID magnetometry sequence used to produce IRM curves at 5 and 50 K is given 
below. This is the sequence referred to in Section 4.1.2.1 of the main text. 
The sample set up as follows: 
i. The sample was inserted into the SQUID. 
ii. The temperature was set to 300 K and the demagnetising sequence run. 
iii. The temperature was returned to 5 K. 
iv. A field of 250 Oe was applied. 
v. A full direct current (DC) centring scan was run and the sample automatically 
centred. 
Then the sequence was run: 
1. Set field to 250 Oe (this should have already been done for centring). 
2. Measure magnetic moment. 
3. Reset magnet. 
4. Measure the remanent magnetisation of the sample 8 times, where each 
measurement recorded by the SQUID is the average of 5 measurements. 
5. Repeat steps 1 to 4, with the field set to 500, 750, 1000, 1500, 2000, 3000, 4000, 
5000, 7500 and 10000 Oe. 
6. Set the temperature to 300 K and wait for stability, 
7. Run demagnetisation sequence, 
8. Set temperature to 50 K, 
9. Measure magnetic moment twice (this should be close to zero). 
10. Apply 250 Oe. 
11. DC centre automatically. 
12. Repeat steps 1-5. 
Appendix C: SQUID Sequences 
  xxxi 
Appendix C-2: IRM at 300, 150, 50 and 5 K 
The SQUID magnetometry sequence used to measure IRM at 300, 150, 50 and 5 K, from and 
applied field of 10 000 Oe, is given below. This is the sequence referred to in Section 4.1.2.2 
of the main text. 
Sample set up: 
i. The sample was inserted into the SQUID, at 150 K. 
ii. Once the temperature had stabilised a field of 1000 Oe was applied. 
iii. A full DC scan was run and the sample centred based on this. 
iv. After centring the field was switched off. 
 
The following sequence was then run: 
1. Temperature set to 300K. 
2. Run demagnetising sequence. 
3. Apply a field of 10000 Oe and wait for stable field. 
4. Automatically DC centre. 
5. Measure magnetic moment of the sample. 
6. Reset magnet. 
7. Measure the remanent magnetisation of the sample 8 times, where each measure-
ment recorded by the SQUID is the average of 5 measurements. 
8. Temperature set to 150 K and wait for stability. 
9. Repeat steps 3-7. 
10. Temperature set to 50 K and wait for stability. 
11. Repeat steps 3-7. 
12. Temperature set to 5 K and wait for stability. 
13. Repeat steps 3-7. 
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Appendix D: Fitting SXRF spectra in PyMCA 
This appendix provides a detailed protocol for fitting the SXRF spectra, which is described briefly in 
Section 4.4.2.2 of the main text. A selection of screen shots from this process is shown in Figure D. The 
EDF or NeXus data are opened using the ‘ROI imaging tool’, Figure D a). The average of all of the 
fluorescence spectra contained in the map is automatically shown in the PyMCA Main Window, Figure 
D b). The average spectrum for each map was used to create its configuration file, as this provided 
good signal to noise ratio and contained a contribution from all metals the present in the map. 
The first step in the fitting process is to calibrate the energy of the detector channels to the energy of 
the fluoresced X-rays. In the main window select ‘Calibrate’ and then ‘Compute’. A separate window 
opens showing the SXRF spectrum. Clicking the ‘Peak’ button highlights all of the peaks in the spectrum 
which can  then be individually selected by clicking on them, Figure D c). In the fluorescence spectrum 
typical of a biological tissue a number of peaks can be easily identified by their relative heights and 
positions: typically the Fe, Cu, and Zn peaks are clearly visible above background. In Figure D c) the Fe 
peak has been selected by clicking on the line associated with its peak. Each easily identified peak is 
manually selected and then assigned to the correct elemental fluorescence peak. PyMCA uses this 
information to calibrate the energy of the entire spectrum. The energy calibration can be saved and 
loaded for subsequent maps, although it is good practice to recalibrate when looking at data from 
different visits to the DLS. 
The next step is to begin fitting the spectrum by clicking ‘Fit’ in the main window and selecting 
‘Advanced’ which opens the fitting window, Figure D e). Select configure to open the ‘MCA Fit 
Parameters’ window. This contains a number of tabs which are used to provide PyMCA with the 
information required to fit the spectrum.  
Highlight the metals expected in the sample in the ‘PEAK’ tab, Figure D e). In addition to the metals 
expected to be present in the tissue (iron, copper and zinc), other transition metals which fluoresce in 
the same energy range (manganese, cobalt, chromium and nickel) should be selected. These metals 
may show up naturally or in contamination on the sample (for example from stainless steel) and 
therefore fitting these peaks is important to identify any false iron data due to contamination.  
The ‘FIT’ tab, Figure D f), is used to set the range of the fit to just the energy range of the metals of 
interest. Check the box ‘Limit fitting region to:’ and choose the channel (and therefore energy) range. 
After choosing the fitting parameters click ‘OK’ again, to display the fit to the spectrum in the 
‘McaAdvancedFit’ window, Figure D d). In this window fit function, background function and the peak 
shapes can be adjusted to achieve the best fit to the data. This window also shows the breakdown of 
how each peak is fitted to a particular metal or combination of metals.  
The fit includes the background, which is elevated towards the Zn peak end of the spectrum due to the 
scatter peak , from I0 at 10 keV. It is important that this background is fitted well, as it is in the example 
here, because it will be subtracted from the spectrum before the area under each peak is calculated. 










selected peak specified 







sign of I0 fluctuation 
Figure D: Fitting a fluorescence spectrum in PyMCA. a) The ROI Imaging Tool window showing an SXRF 
map. b) The main PyMCA window showing the average SXRF spectrum for the map in a). The tool 
shown in c) is used to calibrate the energy of the detector channels.  






Figure D: Fitting fluorescence spectra in PyMCA continued. The Advance Fit tool is shown in d) 
displaying the fitted SXRF spectrum. The fit is achieved by choosing parameters such as the expected 
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Appendix E : Segmentation of MRI maps made at 9.4 T 
The following pages show the segmentation of a typical slice of an R2 and R2* map for all 
samples mapped at 9.4 T (and not already shown in Section 7.1.1 of the main text). Contrast 
in the maps was chosen to best reveal the structure and is not the same for each sample. 
CN = caudate nucleus; AIC =  anterior limb of the internal capsule;  
WM-CN = the white matter medial to the caudate nucleus 
-15 mm 
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Caudate nucleus AD2 
CN = caudate nucleus; AIC =  anterior limb of the internal capsule;  











CN = caudate nucleus; AIC =  anterior limb of the internal capsule;  
WM-CN = the white matter medial to the caudate nucleus 








Pu_high = the bright area of the putamen; Pu_low = the dark band along the lateral edge of 
the putamen; Pu=WM = white matter lateral to the putamen 
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Sample was 
deformed between 








Pu_high = the bright area of the putamen; Pu_low = the dark band along the lateral edge of 


























Pu_high = the bright area of the putamen; Pu_low = the dark band along the lateral edge of 
the putamen; Pu=WM = white matter lateral to the putamen 
R2 R2* 
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GPe = external globus pallidus; GPi = internal globus pallidus;  
Pu-GP = putamen  lateral to the globus pallidus 
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4 mm 
Globus pallidus AD1 





The GPe was not segmented in the R2* as rapid decays prevented fitting of to a large number of pixels  
R2 R2* 
GPe = external globus pallidus; GPi = internal globus pallidus;  
Pu-GP = putamen  lateral to the globus pallidus 
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Substantia nigra C1 
Substantia nigra AD1 







SN = substantia nigra; CC = cerebral crus 






Substantia nigra AD2 






SN = substantia nigra; CC = cerebral crus 
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Substantia nigra PD4 








SN = substantia nigra; CC = cerebral crus 







Alzheimer’s disease pons samples. The first AD2 sample was used in the analysis. 
Control pons samples. The first C2 sample was used in the analysis. 
Appendix F : MRI maps of the pons at 14.1 T 
The R2* MRI maps of the pons, as discussed in Section 7.1.2 of the main text. 
(s-1) 
(s-1) 





PD pons samples. The average R2* from both PD1 samples was used. 
MSA pons samples. 
(s-1) 
(s-1) 
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Appendix G: Matching SXRF and MRI maps 
The following pages shows how the MRI slice that best matches the SXRF map was chosen 
and trimmed. This process is described in Section 8.1.1.1 of the main text.  
Caudate Nucleus AD1 
T2 high resolution 
maps 
Slice 10  is the 
best match. 
Section stained with haematoxylin, 
adjacent to mapped section 
Slice 10 T2 map is rotated into the 
same orientation as the SXRF map. 
T2 map is trimmed to 
the same dimensions as 
the SXRF map. 
Finally the reciprocal of the 
matched, rotated & trimmed 
map is calculated to produce 
the R2 map. 
Final R2 map 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  
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Putamen sample C3 
T2 high resolution 
maps 
Slice 6  is the best 
match. 
Slice 6 T2 map is rotated into the 
same orientation as the SXRF map. 
T2 map is trimmed to 
the same dimensions as 
the SXRF map. 
Final R2 map 
Adjacent stained section on 
glass 
Unstained, mapped section 
on quartz. 
Finally the reciprocal of the 
matched, rotated & trimmed 
map is calculated to produce 
the R2 map. 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  
  xlix 
Putamen sample AD3 
Adjacent stained section on 
glass 
Unstained, mapped section 
on quartz. 
T2 high resolution 
maps 
Slice 8  is the best 
match. 
Slice 6 T2 map is rotated into the 
same orientation as the SXRF map. 
T2 map is trimmed to 
the same dimensions as 
the SXRF map. 
Final R2 map 
Finally the reciprocal of the 
matched, rotated & trimmed 
map is calculated to produce 
the R2 map. 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  
  l 
Globus pallidus sample C3 
Slice 14 gives the best match in high resolution data, however a better match was achieved 
with the low resolution data (see below).  




Best matched high resolution (above) 
and low resolution (below) are 
rotated into the SXRF map orientation 
High resolution map 
(above) and low 
resolution map (below)  
are trimmed to the 
same dimensions as the 
SXRF map. 
The reciprocal of the maps 
are taken to produce R2 maps 
Final high resolution R2 map 
Final low resolution R2 map 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  




SXRF map.  
red = iron; 
green = copper; 
blue = zinc.  
T2 high resolution 
maps 
Slice 11  is the 
best match. 
Slice 11 T2 map is rotated 
into the same orientation 
as the SXRF map. 
T2 map is trimmed to the same 
dimensions as the SXRF map. 
Finally the reciprocal 
of the matched, 
rotated and trimmed 
map is calculated to 
produce the R2 map. 
Final R2 map 
A matched low 
resolution MRI map 
is also produced to 
compare to the low 
resolution control 
GP map. 
Globus pallidus sample AD2 
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Stained section, after 
mapping 
Unstained, mapped section 
on quartz. 
Substantia nigra sample C2 
Slice 12 T2 map is rotated 
into the same orientation 
as the XRF map. 
T2 map is trimmed to the 
same dimensions as the 
SXRF map. 
Final R2 map 
T2 high 
resolution maps 
Slice 12  is the 
best match. 
Finally the reciprocal of the 
matched, rotated & trimmed 
map is calculated to produce 
the R2 map. 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  
  liii 
Substantia nigra sample C2 
Stained section, after mapping 
T2 high 
resolution maps 
Slice 8  is the 
best match. 
Slice 8 T2 map is rotated 
into the same orientation 
as the SXRF map. 
T2 map is trimmed to the 
same dimensions as the 
SXRF map. 
Final R2 map 
Finally the reciprocal of the 
matched, rotated & trimmed 
map is calculated to produce 
the R2 map. 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  
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Amygdala sample C3 
Neighbouring section stained on glass 
Combined metal SXRF map. 
red = iron; green = copper; blue = zinc.  
Folded tissue 
deleted from map 
T2* high resolution maps. Slice 15 is the best match. 
Slice 15 T2* map is rotated 
into the same orientation as 
the SXRF map. 
T2* map is trimmed to the same 
dimensions as the SXRF map. 
Finally the reciprocal of the 
matched, rotated and trimmed 
map is calculated to produce the 
R2* map. 
Final R2* map 
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Amygdala sample AD2 
Neighbouring section stained on glass 
T2* high resolution maps. Slice 2 is the best match. 
Slice 2 T2* map is rotated 
into the same orientation as 
the SXRF map. 
T2* map is trimmed to the 
same dimensions as the SXRF 
map. 
Finally the reciprocal of the 
matched, rotated and trimmed 
map is  calculated to produce 
the R2* map. 
Final R2* map 
Combined metal SXRF map. 
red = iron; green = copper; blue = zinc.  
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T2* high resolution maps. Perfect matching is not achieved for any slice. Slice 11 is the best match. 
Slice 11 T2* map is rotated 
into the same orientation as 
the SXRF map. 
T2* map is trimmed to the 
same dimensions as the SXRF 
map. 
Finally the reciprocal of the 
matched, rotated and trimmed 
map is  calculated to produce 
the R2* map. 
Final R2* map 
Amygdala sample AD2 
SXRF section, stained 
post-mapping 
Combined metal SXRF map. 
red = iron; green = copper; blue = zinc.  
  lvii 
Amygdala sample AD2 
SXRF section, stained 
post-mapping 
Combined metal SXRF map. 
red = iron; green = copper; 
blue = zinc.  
T2* high resolution maps. Perfect matching is not achieved for any slice. Slice 1 is the best match. 
Slice 1 T2* map is rotated 
into the same orientation as 
the SXRF map. 
T2* map is trimmed to the same 
dimensions as the SXRF map. 
Finally the reciprocal of the 
matched, rotated and trimmed 
map is calculated to produce the 
R2* map. 
Final R2* map 
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Abstract. Alpha synuclein pathology is widespread and found in diverse cell types in multiple system atrophy (MSA) as
compared to Parkinson’s disease (PD). The reason for this differential distribution is unknown. Regional differences in the
distribution of iron are associated with neurodegenerative diseases, and here we characterize the relationship between iron
homeostasis proteins and regional concentration, distribution and form of iron in MSA and PD.
In PD substantia nigra, tissue iron and expression of the iron export protein ferroportin increased, while the iron storage
protein ferritin expression was unchanged. In the basis pontis of MSA cases, increased total iron concentration coupled with
a disproportionate increase in ferritin in dysmorphic microglia and a reduction in ferroportin expression. This is supported by
isothermal remanent magnetisation evidence consistent with elevated concentrations of ferritin-bound iron in MSA basis pontis.
Conventional opinion holds that excess iron is involved in neurodegeneration. Our data support that this may be the case
in PD. While region-specific changes in iron are evident in both PD and MSA, the mechanisms of iron dysregulation appear
quite distinct, with a failure to export iron from the MSA basis pontis coupling with significant intracellular accumulation of
ferritin iron. This pattern also occurs, to a lesser extent, in the MSA putamen. Despite the excess tissue iron, the manner of
iron dysregulation in MSA is reminiscent of changes in anemia of chronic disease, and our preliminary data, coupled with the
widespread pathology and involvement of multiple cell types, may evidence a deficit in bioavailabile iron.
Keywords: Parkinson’s disease, multiple system atrophy, iron, ferritin, inflammation, ferroportin
INTRODUCTION
Multiple system atrophy (MSA) and Parkinson’s
disease (PD) are both neurodegenerative disorders
∗Correspondence to: Naomi Visanji, Morton and Gloria Shul-
man Movement Disorders Centre, Toronto Western Hospital, 399
Bathurst Street, Toronto, ON, M5T 2S8, Canada. Tel.: +1 416
603 6482; Fax: +1 416 603 5004; E-mail: naomi.visanji@
uhnresearch.ca.
characterised by aggregation of intracellular alpha
synuclein. However, a key difference between these
two synucleinopathies is the distribution of the
underlying pathology. In PD alpha synuclein-positive
aggregates, termed Lewy bodies, are restricted to neu-
rons and found in a limited number of structures
including the substantia nigra (reviewed in [1]). How-
ever, in MSA, multiple regions and multiple cell types
are affected, with insoluble deposits of alpha synuclein
ISSN 1877-7171/13/$27.50 © 2013 – IOS Press and the authors. All rights reserved
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found in both neurons and glia accompanied by
widespread neurodegeneration apparent in many brain
regions (reviewed in [1]).
Disrupted iron homeostasis has long been associated
with neurodegenerative diseases, yet the role of iron in
neurodegeneration remains elusive. Within the brain,
iron is vital to many different cell types for many pro-
cesses, including oxidative phosphorylation, myelin
synthesis, nitric oxide metabolism, neurotransmitter
synthesis and oxygen transport. However, excess iron
has been shown to lead to the production of reac-
tive oxygen species which in turn can lead to cellular
damage and degeneration (reviewed in [2]). The oxida-
tion state of iron in the tissue is therefore particularly
important, and tightly regulated processes involving
many proteins ensure that bioavailable highly reactive
Fe(II) is minimised, with the majority being bound as
Fe(III) in the course of normal brain iron homeosta-
sis. Iron demonstrably affects, and is affected by, the
aberrant peptide aggregation observed in neurodegen-
erative disease, including alpha synuclein, and recent
evidence indicates that alpha synuclein is a cellular
ferrireductase [3], and as recently demonstrated in an
alpha synuclein knockout mouse model, may play a
significant role in regulation of iron homeostasis [4].
Changes in iron at the cellular and sub-cellular scale
are reflected in detectable disease-related shifts in the
regional distribution of iron in the brain [5]. It has been
shown that high iron levels correlate with regions of
neurodegeneration, with evidence of increased iron in
the PD and MSA substantia nigra and in the MSA stria-
tum, particularly in putamen [6, 7]. Within the brain,
the majority of iron is sequestered within ferritin, a
450 kDa protein found in every cell type, each protein
capable of storing up to 4500 iron ions [8, 9]. Ferritin
levels are typically closely coupled to iron levels, such
that increased iron leads to increased ferritin produc-
tion. However, in PD substantia nigra there is evidence
of a loss of this coupling such that iron is increased, but
levels of ferritin are reportedly decreased [6, 7]. This
may lead to an increase in free, reactive iron, although
this remains to be elucidated.
Recent advances in the understanding of iron home-
ostasis and in the application of modern techniques
able to probe the status of iron within the brain allow
for a more detailed investigation of this complex rela-
tionship. We studied the relationship between iron
homeostasis proteins and the levels, distribution and
form of iron in control, MSA and PD brain with a view
to investigating a potential role of iron in the differ-




All human brain tissue was obtained from the Cana-
dian Brain Tissue Bank. Each brain was bisected at
the time of death with one side dissected rapidly and
different regions of the brain frozen at −80◦C and
the other half immersed in 10% buffered formalin
for subsequent blocking and embedding in paraffin.
The median post mortem delay was 10 hours, with a
range of 2–20 hours. Distributions of group size, sex,
and mean age ± SEM were: control (n = 3; 2 male, 1
female; ages 47, 63 and 78 years); PD (n = 3; 2 male, 1
female; ages 56, 73 and 79 years); MSA (n = 3; 2 male,
1 female; ages 46, 66 and 76 years). For MSA the mean
disease duration was 6 ± 1.1 years and all three cases
presented clinically with MSA-P. The mean duration
disease for PD cases was 21 ± 3.8 years and pre-
sented as akinetic-rigid. The diagnosis of all cases was
confirmed neuropathologically. The brain areas used
for western blotting, graphite furnace and Isothermal
Remanent Magnetisation (IRM) analysis were from
the frozen side whereas brain tissue used for immuno-
histochemistry was from the formalin fixed side of the
brain. Different areas of interest included the substan-
tia nigra (pars compacta), the basis pontis (pons) (both
white and grey matter) and the lentiform nucleus (puta-
men, external/internal segments of the globus pallidus
complex).
Western blotting
Frozen brain tissue was homogenised in 10x volume
homogenisation buffer (100 mM NaCl, 50 mM Tris,
1 mM EDTA, 1% CHAPS, broad spectrum protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
After 20 minutes of incubation at 4◦C, homogenates
were centrifuged at 20,000 × g for 5 minutes. Protein
concentration was determined by BCA assay (Thermo
Scientific, Waltham, MA). Western blotting was car-
ried out according to standard protocols. Briefly,
samples were heated for 10 minutes at 70◦C in 25%
NuPage® LDS sample buffer (Invitrogen, Carlsbad,
CA). Proteins were then separated on 4–12% Bis-Tris
NuPage® Novex® Mini gels (Invitrogen, Carlsbad,
CA) and transferred onto nitrocellulose membranes
(Life Sciences, Frederick, CO). Blots were probed with
antibodies to ferritin (SigmaAldrich), ferroportin (kind
donation from Dr D Haile), transferrin receptor (Gene-
Tex) and Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, SigmaAldrich). Bound HRP-conjugated
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anti-mouse or anti-rabbit IgG (Sigma-Aldrich, St.
Louis, MO) were revealed by chemiluminescence
using ECL Plus (GE Healthcare, UK) and detected
with a Storm 860 fluorescent imager. Protein levels
were quantified by densitometric analysis using Image-
Quant software (GE Healthcare, UK). All proteins
were expressed as percent of GAPDH to control for
variability in volume loaded. For each protein mea-
sured by western blot, 1 sample per patient was run on
each gel for a total of 3 control samples, 3 PD sam-
ples and 3 MSA samples. Analysis was performed on
a single blot and expressed as the mean ± s.e.m of the
3 samples in a given group.
Immunohistochemistry
Formalin-fixed brain tissue was embedded in paraf-
fin blocks, sectioned at 5m and mounted on glass
slides. Immunohistochemistry was performed accord-
ing to standard protocols using antibodies for ferritin
(SigmaAldrich), ferroportin (kind donation from Dr D
Haile) and ionized calcium binding adaptor molecule
1 (iba1) (Abcam) and all tissue was counterstained
with Mayer’s Haematoxylin. Immunostained sections
were scanned at 40x using a Scanscope digital slide
scanner (Aperio Technologies, Inc., Vista, CA). Image
files were viewed with ImageScope (Aperio Technolo-
gies, Inc., Vista, CA). Positive pixel analysis of iba1
stained tissue was carried out using a custom designed
algorithm in ImageScope. The mean number of iba1
positive pixels in 3 equal sized regions of each sample
was calculated.
Superconducting quantum interference device
(SQuID) magnetometry
The fraction of brain iron that is contained in the iron
storage protein ferritin (the ferritin core) is present as
nanoscale iron oxide clusters, which typically have a
ferrihydrite-like mineral structure. The magnetic prop-
erties of these ferritin cores are well-documented, and
so magnetic analysis of tissue can be used to quantify
the signal arising from the ferritin cores. If total iron
concentration is measured subsequent to the magnetic
analysis, the proportion of iron bound in ferritin may
be estimated. In practice, a variety of iron biomineral
phases are observed in ferritin cores, and the extent
to which ferritin is clustered within tissue may vary;
both factors can potentially affect the magnetic prop-
erties of the tissue. It should also be noted that other
forms of bio-iron may contribute to IRM signal at
5 Kelvin (K), including neuromelanin-bound iron [10]
and iron oxide deposits including magnetite which may
be associated with pathologic features such as amyloid
plaques [11, 12].
The parameter used to identify the signal from
ferritin cores in the tissue was Isothermal Rema-
nent Magnetisation (IRM). In this measurement,
samples are exposed to a magnetic field. Biologi-
cal material is primarily diamagnetic, which results
in a negative linear magnetic response. This gives
the ‘background’ signal, onto which the small but
detectable positive response from the ferritin cores
is superimposed. At body temperature, the positive
response from the ferritin cores vanishes as soon as
the applied magnetic field is removed. However, at
very low temperatures (below approximately 20 K),
the ferritin cores retain, for a temporary period, a mag-
netisation that can be detected and quantified using
the sensitivity of a SQuID magnetometer. The sig-
nal from normal ferritin cores is almost absent at
higher temperatures, making it possible to estimate
their concentration in a known mass of tissue. This
approach, to analyse biomineralized iron in human tis-
sue, is now well established and described elsewhere
[13].
Fresh-frozen samples were dissected to obtain the
region of interest, and then prepared for SQuID mea-
surement by freeze drying and compressing each
sample into a dense pellet. Acid-washed ceramic
blades and non-metallic piston rods were used for
cutting and compression respectively, to avoid envi-
ronmental contamination of the samples with iron-rich
particulates.
A Quantum Design MPMS-5S SQuID was used to
measure the isothermal remanent magnetisation (IRM)
at 150 K, 50 K and 5 K. A demagnetising sequence was
run prior to each IRM measurement to ensure that the
initial condition for each sample was the same. IRM
was obtained by applying a magnetic field of 1.0 Tesla,
measuring the magnetic moment (the response from
the tissue), and then removing the magnetic field. The
IRM signal decays after the magnetic field is removed,
so the remanent magnetisation is sampled eight times
over approximately 10 minutes, and the final four
readings (where the decay curve has stabilised) are
averaged to obtain a measurement of the IRM; the error
is the standard deviation for these four values. Only
material capable of retaining a magnetic moment after
application and removal of the 1.0 Tesla field can con-
tribute to the IRM signal; this excludes the significant
majority of biological material. The ferrihydrite-like
iron oxide cores normally found in ferritin are assumed
to be the primary contributor to the IRM signal at 5 K,
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as tested by measurement of IRM saturation curves,
and evidenced by loss of IRM signal at higher temper-
atures. All values were corrected for dry sample mass.
Correction for finite sample length was applied using
the method outlined by Hautot et al. [13].
Graphite furnace atomic absorption spectroscopy
Samples were digested using a Mars Xpress
microwave (CEM Microwave Technology Ltd, UK)
and analysed with an AAnalyst 600 atomic absorption
spectrometer with a transversely heated graphite atom-
izer and longitudinal Zeeman-effect background cor-
rector (Perkin Elmer, UK). The microwave digestion
temperature program, GFAAS instrument parameters
and calibration procedure were as described previously
[14].
Freeze-dried tissue samples from the SQuID mag-
netometry analysis were dried to a constant weight
(36–231 mg dry wt) in Teflon© vessels and microwave
digested in 1 mL nitric acid (HNO3 analytical reagent
grade 15.8 M, Fischer Scientific, UK) and 1 mL hydro-
gen peroxide (H2O2, ARISTAR grade 30% w/v).
After cooling, 3 mL ultrapure water (conductivity
≤6.8 × 10−6 S m−1) was added to each vessel, digest
volumes were determined gravimetrically and ranged
from 4.44 to 4.82 mL. Digests were yellow and clear
with no precipitate or fatty residue visible. Iron concen-
tration was determined in 800 and 200 fold dilutions
of the digests (12.5L and 50L of digest diluted
to 10 mL in 1% HNO3, respectively). Vessels were
cleaned by digesting with 1 mL HNO3, rinsing with
ultrapure water and storing in 5% HCl.
Samples were analysed in two batches. In each
batch quality assurance (QA) samples included three
method blanks, one reagent spike and two standard
reference materials (NIST SRM 1566B oyster tissue
and IAEA-407 fish homogenate). Two additional ves-
sels containing spiked standard reference materials
were included in the first batch. These QA were dried,
digested and diluted, including the further 800 fold
dilution, as for the tissue digests.
The mean of iron concentrations measured in 800
fold dilutions of the ca 5 mL method blank digests in
batch one was 0.15g L−1 (S.D. 0.34g L−1, n = 3)
and 0.17g L−1 (S.D. 0.05g L−1,n = 3) in batch two.
Background contamination was corrected for by sub-
traction of the mean plus three standard deviations of
the method blanks analysed in the same batch. This
corresponded to 31.2g g−1 dry wt (S.D. 10.2g g−1,
n = 9 samples) in batch one and 23.3g g−1 dry wt
(S.D. 7.1g g−1, n = 13 samples) in batch two.
The reagent spike recoveries were 97.2% and
103.5%. The measured IAEA407 iron concentrations
were 166.4g g−1 dry wt (S.D. 0.9g g−1 dry wt),
and 147.2g g−1 dry wt (S.D. 1.0g g−1 dry wt),
compared to a certified value of 146g g−1 (95 % CI
3g g−1). The measured SRM1566B iron concentra-
tions were 205.0g g−1 dry wt (S.D. 2.3g g−1) and
173.6g g−1 dry wt (S.D. 0.9g g−1) compared to the
certified value of 205.8 ± 6.8g g−1. Spike recover-
ies from SRM1566B and IAEA407 were 103.7% and
92.5% respectively.
The calibration curves had a correlation coeffi-
cient ≥0.998, and instrumental detection limits of
0.14g L−1 and 0.21g L−1.The mean of character-
istic masses derived from absorbance at each iron
calibration standard for all calibrations was 13.3 pg per
0.0044 s (SD 0.9 pg per 0.0044 s n = 16), within ±20%
of the 12.0 pg per 0.0044 s cited by the manufacturer.
Initial and continuing calibration verification standards
were analysed and were within 10% and 15% respec-
tively of expected concentrations. A standard addition
calibration was performed on one brain tissue digest. A
t-test showed that the slope was not significantly differ-
ent from that of the linear non-zero fit of the calibration
performed in 1% HNO3 at the = 0.05 level.
Statistical analysis
Data were analysed using one-way ANOVA, hav-
ing passed the Shapiro-Wilk test for normality, and
this was followed by Dunnett’s post-hoc analysis or
Linear regression where appropriate (GraphPad Prism
4.0, San Diego, CA). In all cases, P < 0.05 was taken as
the level of significance. Linear Discriminant Analy-
sis (Minitab) was used to assign the individual regional
samples from each case into groups, based on data from
multiple variables, and the proportion of samples cor-
rectly assigned to their true groups was reported for
each parameter set considered.
RESULTS
Ferritin expression is selectively increased in MSA
and unchanged in PD
In MSA basis pontis, there was an ∼2.5 fold
increase in ferritin protein as compared to control lev-
els (P < 0.01 cf control), with no change apparent in
PD tissue (Fig. 1a and d). A similar pattern was seen in
the putamen where ferritin levels in MSA tissue were
significantly increased by ∼4.5 fold of control levels
(P < 0.05 cf control, Fig. 1c and d). In addition there
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Fig. 1. Ferritin expression in control, PD and MSA brain. Ferritin signal relative to GAPDH was quantified by western blot in A) pons, B)
substantia nigra and C) putamen. Individual values are shown, with the mean indicated by a black line. ∗represents significant difference
from control levels, 1-way anova with Dunnett’s post hoc, (∗P < 0.05, ∗∗P < 0.01). Representative blots for each region are shown D). Ferritin
immunostaining in control E, F) PD G) and MSA H–J) pons. Ferritin immunostaining in control K) PD L) and MSA M) nigra. Scale bar
represents 40m in E, G, H & K–M, and 10m in F, J & I.
was an ∼1.4 fold increase in ferritin in PD putamen
(P < 0.05). In contrast, in the substantia nigra, ferritin
levels remained unchanged in either PD or MSA as
compared to control (both P > 0.05, Fig. 1b and d).
Immunohistochemical analyses of basis pontis sec-
tions from human control, PD and MSA tissue further
supported differences in the intensity of ferritin expres-
sion. In control pons, ferritin was localised to microglia
with no apparent neuronal staining (Fig. 1E), and the
microglia displayed the typical features of a resting
state with a round dense nucleus without a visible cyto-
plasm surrounding it and long thin processes (Fig. 1F).
Similarly in PD basis pontis, ferritin was also predomi-
nantly expressed in microglia with an apparent resting
morphology (Fig. 1G). In MSA pons the gross level
of ferritin immunostaining appeared increased com-
pared to both control and PD pons, confirming the
observed increase by western blot (Fig 1H). Further-
more, in MSA basis pontis intense ferritin staining was
seen in microglia which had thicker branches and an
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enlarged cytoplasm, a morphology associated with an
activated state (Fig. 1I). There was no ferritin stain-
ing apparent in neurons in the pons of MSA cases
(Fig. 1J). Immunohistochemical analysis of ferritin in
the substantia nigra revealed the presence of microglia
with an activated morphology clustered around the
pigmented dopaminergic cells in both MSA and PD
(Fig. 1K–M).
Iron concentration, and ferritin-bound iron, is
altered in MSA and PD
In the basis pontis, total iron quantification with
Graphite Furnace Atomic Absorption Spectroscopy
(GFAAS) revealed an ∼1 fold increase in iron in
MSA as compared to control (P < 0.01), with levels
in PD pons equivalent to control (Fig. 2a). The cor-
responding isothermal remanent magnetisation (IRM)
measurements at temperatures of 5 K, 50 K, and 150 K
revealed an ∼1.6 fold increase in IRM at 5 K in MSA
pons as compared to control pons (P < 0.01), with PD
IRM again being unchanged (Fig. 2c). The observed
increased IRM signal in MSA pons at 5 K is consistent
with MSA pons containing a higher concentration of
nanoscale iron oxide particles in the tissue than either
the control or PD pons, where indications are that these
are ferritin cores.
In the substantia nigra, the pattern of iron and IRM
in MSA and PD was reversed. Thus on average there
was approximately a 2-fold increase in iron in PD as
compared to control (although this did not reach sig-
nificance in this small group, testing at p < 0.05), with
levels in MSA pons equivalent to control (Fig. 2b).
The corresponding IRM signal from the same sam-
ples paralleled the trend indicated in the total iron data,
revealing on average a 2-fold increase in IRM in PD
nigra as compared to control nigra (approaching sig-
nificance at p = 0.06), with MSA IRM from the nigra
again equivalent to control (Fig. 2d). The evidence
for increased IRM signal in PD nigra is consistent
with a higher concentration of iron being present in
nanoparticulate form in the tissue than in either con-
trol or MSA substantia nigra. There are various forms
of iron that may contribute to IRM signal at 5 K, includ-
ing ferritin iron oxide cores, and neuromelanin-bound
iron, so it is not possible to differentiate the ferritin
iron and neuromelanin iron fractions in the substan-
tia nigra from these data alone [10]. However, lack of
elevation in ferritin protein expression in the PD sub-
stantia nigra (Fig. 1B), and the increase in total iron
and IRM in this same region, points towards an eleva-
tion of neuromelanin-bound iron (and a proportional,
if not absolute, decrease in ferritin-bound iron) in the
substantia nigra.
Increased iron is stored within ferritin in MSA
pons
Linear regression analysis reveals a positive corre-
lation between iron concentration and IRM at 5 K in
tissue from both the pons (r2 = 0.95, P < 0.0001) and
substantia nigra (r2 = 0.97, P < 0.0001) (Fig. 2e and f
respectively). This indicates that the proportion of iron
stored in the form of iron oxide clusters (as found in
ferritin) increases in a linear fashion with total iron
in the MSA pons (as opposed to an increase in the
fraction of iron that is unbound or associated with
low-molecular-weight species). There are no clear data
in the literature showing accumulation of iron in the
basis pontis, as most neuropathological data empha-
sise changes in the striatum in cases of MSA. Our own
results show increased iron deposition in the pons in
comparable density to observed changes in the stria-
tum. A similar linear relationship between the IRM
signal at 5 K and iron concentration in the substantia
nigra is also observed.
Free iron may be decreased in MSA pons
Total tissue iron may be considered as that which
is bound in ferritin, and that which is free or bound
as individual ions to low molecular weight complexes
such as transferrin (Tf). Notable exceptions include
neuromelanin in the substantia nigra, which incorpo-
rates iron in ferritin-like oxyhydroxide clusters [15],
and haemosiderin, reportedly a degradation product
of ferritin, and which is more commonly observed in
organs responsible for iron storage such as the liver.
Tissue is primarily diamagnetic, and any magnetic sig-
nal from tissue at ultra-low temperatures, which is lost
at higher temperatures, and follows ferritin-core-like
magnetization saturation behaviour, would normally
be attributable to the iron oxide cores in ferritin [13]. If
we assume equivalent size distributions and biomineral
properties of the ferritin cores in these pons tissue sam-
ples, then from inspection of the results shown in Fig. 2,
it is evident that the proportion of non-ferritin-bound
iron decreases in the MSA cases compared to con-
trols, and to a greater extent than in PD. This indicates
that in addition to an approximately 2-fold increase
in iron concentration, the proportion of ferritin-bound
iron also increases in the MSA pons. As shown previ-
ously, ferritin protein is elevated approximately 3-fold
in this region of the brain (Fig. 1A).
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Fig. 2. Levels of iron and isothermal remanent megnetisation (IRM) in the pons and substantia nigra in control, PD and MSA brain. Total iron
levels (g/g−1) are shown in A) pons and B) substantia nigra. IRM (emu/g−1) at 5 Kelvin in corresponding tissue is shown. Individual values
are shown, with the mean indicated by a black line. ∗represents significant difference from control levels, 1-way anova with Dunnett’s post hoc,
(∗∗P < 0.01). IRM (emu/g−1) at 5 Kelvin are plotted against total iron levels (g/g−1) in E) pons and F) substantia nigra. R2 is shown. Line of
best fit indicated by solid line, error by broken line.
Ferroportin and transferrin receptor expression is
differentially altered in MSA and PD
In MSA pons, there was an ∼0.75 fold decrease
in ferroportin protein as compared to control levels
(P < 0.01 cf control), with no change apparent in PD
tissue (Fig. 3A). A similar pattern was seen in the
putamen where ferroportin levels in MSA tissue were
decreased by ∼0.75 fold of control levels (P < 0.05
cf control, Fig. 3C) with no significant change in
PD putamen. In contrast, in the PD substantia nigra,
there was an ∼1.4 fold increase in ferroportin pro-
530 N.P. Visanji et al. / Iron Dysregulation in Parkinsonism
Fig. 3. Ferroportin (Fpn) and transferrin receptor (TfR) expression in control, PD and MSA brain. Ferroportin signal relative to GAPDH was
quantified by western blot in A) pons, B) substantia nigra and C) putamen. Individual values are shown, with the mean indicated by a black line.
∗represents significant difference from control levels, 1-way anova with Dunnett’s post hoc, (∗P < 0.05, ∗∗P < 0.01). Ferroportin immunostaining
in control D, E) PD F, G) and MSA FH, I pons and control J), PD K) and MSA L) substantia nigra neurons. Scale bar represents 200m in D,
F, H and 20m in E, G, I–L. Transferrin receptor expression relative to GAPDH was quantified by western blot in pons, substantia nigra and
putamen, mean and range are shown M) ∗represents significant difference from control levels, 1-way anova with Dunnett’s post hoc, (∗P < 0.05).
Representative blots for each brain region are shown N).
tein as compared to control levels (P < 0.05 cf control),
with no change apparent in MSA substantia nigra
(Fig. 3B).
Immunohistochemical analyses of pons sections
from human control, PD and MSA tissue revealed
a selective neuronal expression of ferroportin and a




Fig. 4. Correlation between ferritin and ferroportin levels as measure by western blot in the pons, substantia nigra and putamen in control,
PD and MSA brain. Ferritin and ferroportin signal relative to GAPDH was quantified by western blot in control, PD and MSA brain. Ferritin
expression was plotted against ferroportin expression in A) pons, B) substantia nigra and c) putamen. R2 is shown. Line of best fit indicated by
solid line, error by broken line.
co-localization with the Golgi apparatus. In con-
trol pons, ferroportin staining was apparent in most
neurons displaying a filiform perinuclear distribution
(Fig. 3D and 3E). In PD pons the pattern of ferro-
portin staining was similar to control with an intact
filiform appearance (Fig. 3F, G). In MSA pons, the
ferroportin signal appeared weaker and more diffuse
(Fig. 3H, I). Analyses of sections from human con-
trol, PD and MSA substantia nigra similarly revealed
a selective neuronal expression of ferroportin. Indeed
the signal for ferroportin was prevalent in all pig-
mented neurons. However, in the PD substantia nigra
expression of ferroportin appeared diffuse and frag-
mented in comparison to control and MSA tissues
(Figs. 3J–L).
Transferrin receptor expression was unaffected in
all groups in the substantia nigra and pons (Fig. 3M).
However, in the PD putamen, transferrin receptor
expression was significantly lower than in the control
putamen (P < 0.05). This contrasts with MSA, where
transferrin receptor expression was unchanged as com-
pared to control putamen.
Linear regression analysis reveals a strong nega-
tive correlation between ferritin levels and ferroportin
levels in the pons (R2 = 0.85,P < 0.001) (Fig. 4a). How-
ever, this strong negative correlation is not present in
either the substantia nigra or putamen (Figs. 4b and c).
Microglia display activated morphology in MSA
pons
Immunohistochemical analysis of the microglial
membrane specific protein iba1 demonstrated that in
MSA pons, microglia exhibit the morphology of an
activated state: a large cell body with cytoplasmic
hypertrophy and enlarged less defined nucleus and
shorter thickened processes (Fig. 5c). This morphol-
ogy was also apparent, albeit it to a lesser extent, in
PD pons (Fig. 5b) but not in control pons (Fig. 5a).
Positive pixel analysis of iba1 stained tissue revealed
an ∼10 fold increase in iba1 positive pixels as com-
pared to control levels (P < 0.01), and an ∼3.6 fold
increase in PD pons (P < 0.01 cf control) (Fig. 5d).
Regional iron status differentiates MSA, PD, and
healthy controls
A summary of the quantitative differences in mea-
sures of iron status is provided in Table 1. Although the
cases are carefully matched in terms of age and gen-
der, the sample size (n = 3 in each disease group) means
that some relationships already well-established in the
literature (such as elevated iron in the PD SN com-
pared to healthy controls) do not reach significance
in the present study at the 5% level using one-way
ANOVA. Linear discriminant analysis (LDA) was used
as a method appropriate to small groups to test whether
individual samples are correctly assigned to their true
disease groups on the basis of measured values of iron
status in each brain region. As shown in Table 2a,
the majority of samples were correctly assigned as
controls, MSA, and PD when considered in terms of
measured iron status values (ferritin, ferroportin, total
iron, and IRM at 5 K) for each region in turn. For basis
pontis and putamen, 8 out of the 9 individual samples
were correctly assigned in each region, and 7 out of
9 in the substantia nigra. Assignment of the PD sam-
ples to the PD disease group on the basis of iron status
was 100% correct (9/9) in all three brain regions. The
results in Table 2a indicate a high degree of discrimina-
tion between disease groups, supporting the hypothesis
that modes of iron dysregulation are disease-specific.
An even higher degree of success was achieved when
considering each measure of iron status in turn, and
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Fig. 5. Microglial morphology in control, PD and MSA pons. iba1 immunostaining in control A, B) PD C, D) and MSA E, F) pons. The number
of iba1 positive pixels per m2 was calculated G). Individual values are shown, with the mean indicated by a black line. ∗represents significant
difference from control levels, 1-way anova with Dunnett’s post hoc, (∗∗P < 0.01). Scale bar represents 30m in A, C & D and 75m in B, D
& E.
Table 1
Summary of differences between MSA, PD, and control (C) groups (n = 3), for measures of iron status. Using one-way analysis of variance
(ANOVA), statistically significant increases ( ) and decreases ( ) are indicated, with and used where values approach (but do not reach)
significance at P < 0.05
Basis pontis Substantia nigra Putamen
Total iron concentration MSA c.f. C, PD PD vs. MSA Unchanged
p < 0.005 P = 0.09
Particulate iron (IRM @ 5K) MSA c.f. C, PD PD vs. MSA MSA vs. C
p < 0.001 P = 0.06 p < 0.05
Total vs. particulate iron Strong positive Strong positive –
[concentration vs. IRM @ 5K] (all cases) correlation, (r2 = 0.95) correlation, (r2 = 0.96)
p < 0.0001 p < 0.0001
Iron storage ferritin protein MSA c.f. C, PD Unchanged MSA & PD vs. C
p < 0.005 p < 0.005
Iron export ferroportin protein MSA c.f. C, PD PD vs. C MSA vs. C,
p < 0.005 p < 0.05 p < 0.005
Storage vs. export [ferritin vs. Strong negative No correlation Weak negative
ferroportin] (all cases) correlation, p < 0.001 (r2 = 0.01) correlation
(r2 = 0.85) (r2 = 0.33)
Iron uptake transferrin protein Unchanged Unchanged PD vs. C
p < 0.05
assigning the individual samples on the basis of brain
region (basis pontis, substantia nigra, putamen). These
results are shown in Table 2b, where 100% of the sam-
ples were correctly assigned for ferritin, ferroportin,
and IRM at 5 K, and all but one (a control assigned
as PD) were correctly assigned for total iron. This
supports the hypothesis that there are region-specific
differences in iron as a function of disease, in addi-
tion to the disease-specific modes of iron dysregulation
evidenced in Table 2a.
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Table 2a
Linear Discriminant Analysis (LDA) of the individual cases, allo-
cating each into disease groups (MSA, PD, control) on the basis of
a) iron analyses performed for each region, and b) regional profile
for a given analytical measure of iron. Correctly assigned samples
are shown in bold font, incorrectly assigned are in brackets. a) LDA
of the quantitative measures of iron status in each region, using fer-
ritin, ferroportin, total iron, and particulate iron (IRM at 5 K) as
the variables, gives a high degree of discrimination between disease
groups, supporting the hypothesis that modes of iron dysregulation
are disease-specific
Allocated group True group control MSA PD
Basis pontis Control 2 0 0
89% success MSA 0 3 0
PD (1) 0 3
Substantia nigra Control 2 (1) 0
78% success MSA (1) 2 0
PD 0 0 3
Putamen Control 2 0 0
89% success MSA 0 3 0
PD (1) 0 3
Table 2b
LDA of the samples by iron status, using the regions (basis pon-
tis, substantia nigra, putamen) as variables, gives 100% success in
assigning each sample to the correct disease group for three of the
four independent measures of iron status. This supports the hypoth-
esis that there are region-specific differences in iron as a function of
disease. (Only 8 samples were included in this analysis; one matched
PD SN sample was from another case.)
Allocated True group MSA PD
group control
Ferritin Control 3 0 0
100% success MSA 0 3 0
PD 0 0 2
Ferroportin Control 3 0 0
100% success MSA 0 3 0
PD 0 0 2
Total iron Control 2 0 0
88% success MSA 0 3 0
PD (1) 0 2
Particulate iron (IRM @ 5K) Control 3 0 0
100% success MSA 0 3 0
PD 0 0 2
DISCUSSION
Conventional opinion holds that excess redox-active
iron is implicated in neurodegeneration via produc-
tion of reactive oxygen species which cause lipid
peroxidation, protein damage and finally precipitate
aggregation (reviewed in [16]). Although there is some
controversy in the literature regarding alterations in
the level of iron the substantia nigra in PD (reviewed
in [17]), our demonstration of an approximately two-
fold increase in iron in PD substantia nigra compared
to age-matched controls is consistent with similar
increases demonstrated by several other groups using a
range of techniques including X-ray fluorescence [18],
spectrophotometry [19] and atomic absorption [20].
Furthermore, in a previous study of unfixed human tis-
sue, using quantitative electron microprobe analysis,
we demonstrated an approximately two-fold increase
of cellular iron within individual nigral dopamine neu-
rons in PD as compared to age-matched controls [21].
This approximate doubling of iron in the PD nigra,
observed at cellular and whole tissue level, has thus
been demonstrated to stand the test of time, and the
demonstration of a strikingly similar level of increased
iron by a range of techniques certainly adds validity
to the GFAAS analysis employed in the present study.
Here, we also demonstrate that the increased tissue iron
and IRM signal is not accompanied by a statistically
significant increase in the iron storage protein ferritin in
the PD nigra, or a significant change in TfR expression.
In isolation, the total tissue iron and ferritin expression
data for the PD nigra support the findings of Dexter et
al., who suggest that an decoupling of the relationship
between iron and ferritin protein levels may lead to
increased levels of redox active iron in the substantia
nigra of PD [6]. We can extend this observation, as the
IRM data, which parallel the increase in total tissue
iron, indicate that the additional iron is coordinated
in iron oxide clusters. Given the confirmed absence
of ferritin elevation, this material that retains remanent
magnetization at 5 K is most likely to be neuromelanin-
bound iron [10]. The elevated IRM signal in MSA pons
tissue may reasonably be attributed to an elevated con-
centration of ferritin iron oxide cores, indicating that
the excess iron in this tissue is ferritin-bound. This is
the most straightforward interpretation of these data;
it is acknowledged that the SQuID measurements per-
formed in this study cannot unambiguously prove that
the IRM signal in the pons is directly and proportion-
ately due to ferritin concentration, as the presence of
other iron biomineral phases within the ferritin, cluster-
ing of ferritin, or the presence of other iron nanoparticle
inclusions in the tissue could bias the IRM value.
Detailed analysis of the biomineral cores in ferritin
extracted from these cases will be undertaken in future
work.
Interestingly, we find the level of tissue iron, IRM
and ferritin protein to be unchanged in the MSA nigra.
While others have noted an increase in both tissue
iron and ferritin in this region [6], our data are consis-
tent with prior studies which found no evidence for a
decoupling of ferritin expression from tissue iron con-
centration in MSA nigra; this feature appears specific
to PD. The extent to which this feature is specific to the
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substantia nigra in PD remains to be confirmed. Other
studies have shown an increase in iron in the putamen
[22] and a decreased expression of transferrin receptors
in the putamen in PD compared to age-matched con-
trols [23]. We also note a decreased level of transferrin
receptors in the putamen in PD, suggestive of increased
levels of free iron in this region. Furthermore, we see a
trend towards increased ferritin expression in the puta-
men in PD. It is interesting that the decoupling between
iron and ferritin reported in the PD nigra is not appar-
ent in MSA despite the loss of nigral dopamine cells
and similarities in nigral pathology between MSA and
PD.
We contrast these observations in the substantia
nigra with the relationship between iron and ferritin
in the basis pontis, a region heavily affected by neu-
rodegeneration in MSA but spared in PD and devoid of
neuromelanin. As expected we found levels of tissue
iron, IRM and ferritin to be statistically unchanged in
PD pons as compared to control, but we found a two-
fold increase in total tissue iron concentration in the
MSA pons mirroring the scale of the change observed
by us and others in the PD nigra. Interestingly, in con-
trast to the PD nigra where ferritin expression was
unchanged, we observed an approximately three-fold
increase in the level of ferritin protein in the MSA
pons. Thus, there is a distinct difference in the rela-
tionship between ferritin and total iron concentration in
these two neurodegenerative diseases. We suggest that
in MSA, although there is significantly elevated iron in
the pons, this excess iron is sequestered by dispropor-
tionately elevated levels of the storage protein ferritin
in reactive microglia, potentially leading to a net reduc-
tion in the levels of free iron. It remains unknown
whether an initial increase in the number of activated
microglia precedes an increase in ferritin, leading to
an increased sequestration of iron, or an increased con-
centration of iron precipitates an increased production
of ferritin and microglial activation. However, regard-
less of which is the initiating factor, the net result is
a disproportionately high amount of ferritin protein
(as determined by western blotting), as compared to
the amount of iron, suggesting a deficit in bioavailable
iron. As iron is vital to the function and survival of mul-
tiple cell types, we propose that a deficit in bioavailable
iron may account for the involvement of multiple cell
types in the pathology of MSA as compared to the more
selective targeting of neurons in PD. As the presence
of reactive microglia is well established in PD nigra,
[24–27] the fact that we do not see a disproportion-
ate increase in microglial ferritin in the PD nigra, as
compared to in the MSA pons, is again indicative of a
disease specific uncoupling of the relationship between
ferritin and total iron concentration in MSA.
To further explore this hypothesis we investigated
the neuronal iron export protein ferroportin. Iron
homeostasis in the brain is performed by a variety
proteins and a variety of cell types. Indeed, there are
many mechanisms by which iron can be transferred
between different cell types within the brain (reviewed
in [28]). Given that synthesis of iron regulatory pro-
teins is dependent on availability of iron for binding
and that iron is readily transferred between cell types,
it is important to examine relative levels of iron export
and iron storage proteins at a system (whole tissue)
level. Ferroportin expression typically parallels iron
levels such that in times of iron excess more fer-
roportin is expressed (reviewed in [16]). As would
be expected, we demonstrate a significant increase
in ferroportin in the PD nigra as compared to con-
trol, with no change evident in MSA nigra, mirroring
the changes we see in tissue iron concentration. The
MSA pons is the exception, where despite a clear
increase in tissue iron concentration, we observed a
significant decrease in ferroportin expression. This
decrease is accompanied by loss of the normal pat-
tern of ferroportin distribution on the Golgi apparatus
and implies possibly degradation of the iron exporter
ferroportin and Golgi rearrangement [29]. This obser-
vation supports our hypothesis that the MSA pons
may have a deficit in free cytosolic iron despite over-
all iron levels being increased, and that the cells’
response to a perceived reduction in iron is a reduced
expression of ferroportin. Consistent with previous
reports, immunohistochemical analysis demonstrated
the localisation of ferroportin to neurons in both the
pons and substantia nigra, with some mild staining
present in oligodendrocytes in the putamen [30]. There
appeared to be two patterns of ferroportin subcellular
signal. The most prevalent signal appeared to be bound
to an intracellular cytoplasmic membrane and the other
a more punctate signal suggestive of an endosomal
localisation. Indeed it has been shown that ferro-
portin can be internalised and stored within endosomes
prior to degradation [31]. Both patterns of expression
were apparent in all positive neurons. Conventional
opinion holds that ferroportin should be located on
the extracellular membrane [28, 30]. Our findings,
and those reported elsewhere, contradict this with an
apparent lack of ferroportin signal on cell surface mem-
branes [32]. Thus, although trafficking of ferroportin
to the cell surface is likely regulated, this phenomenon
certainly requires further investigation within the
brain.
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Another avenue that warrants further study is the
potential role of ceruloplasmin (Cp) in MSA. Cp plays
a critical role in cellular iron efflux; it is respon-
sible for oxidation of the ferrous iron exported by
ferroportin, and impaired function of Cp impacts ferro-
portin stability, leading to reduced ferroxidase activity
and mislocalization in the endoplasmic reticulum [33].
Mutant Cp has been shown in cell culture to drive loss
of Golgi morphology, and degradation of ferroportin
[29]. Hypoceruloplasminemia and mutant Cp have also
been reported in cases of MSA [34, 35]; further inves-
tigation is required to determine the extent to which
impaired Cp function might affect ferroportin in MSA.
The gene sequences for both ferritin and ferroportin
contain an upstream 5′ iron response element (IRE)
allowing translation to be controlled by the relative
affinity of iron response protein 1 and 2 (IRP 1 and
2 respectively) themselves regulated by iron levels
(reviewed in [16]). As the expression of both ferritin
and ferroportin are controlled by this same mechanism,
our observation that ferritin is increased, and ferro-
portin decreased, in MSA pons suggests that in MSA
the levels of these two key homeostatic proteins are
influenced by more than just iron levels. Others have
shown that during liver regeneration, an increased acti-
vation of IRP also led to divergent effects on ferritin
and transferrin receptor expression, in spite of both
proteins having the same 5′ IRE [36]. We found the
levels of IRP1 to be unchanged in MSA pons (data
not shown). An alternative explanation for the appar-
ently paradoxical alterations in ferritin and ferroportin
in MSA pons involves the hormone hepcidin. Systemic
iron homeostasis is maintained by the hepcidin which
is secreted by hepatocytes in response to increased
iron and signals for the internalisation and subsequent
degradation of ferroportin (reviewed in [16]). Hepcidin
has been identified throughout the brain in areas known
to contain ferroportin and has also been shown to be
induced by the pro-inflammatory cytokine interleukin-
6 (IL-6) [37, 38]. Interestingly, the presently observed
alterations in levels of iron, ferritin and ferroportin are
reminiscent of those underlying the anemia of chronic
disease (ACD), a paradoxical condition mediated by
pro-inflammatory cytokines whereby total body iron
stores are elevated, but there is reduced bioavailable
iron leading to an anemic condition [39]. We demon-
strate that microglia in the MSA pons have a reactive
profile with an enlarged irregular cell body and shorter
thicker processes with little branching. Thus, we pro-
pose that a local inflammatory response, mediated by
IL-6 secreted by activated microglia, may, via hep-
cidin, underlie the apparently paradoxical changes in
ferroportin expression in MSA in the present study.
Further, this situation may be more widespread than the
pons, as there is much evidence of microglial activation
throughout the MSA brain [40].
The link between iron levels and alpha synuclein
is not well understood and any explanation would
be speculative. However, recent evidence has demon-
strated in vitro that alpha synuclein serves as a cellular
ferrireductase, responsible for reducing iron (III) to
bioavailable iron (II) [3]. As PD and MSA both involve
aggregation of alpha synuclein, it is possible that the
ferrireductase function of alpha synuclein is perturbed
in these synucleiopathies. On the other hand, PD is
associated with an increased expression of alpha synu-
clein which may lead to increased levels of bioavailable
iron II. Indeed it is possible that both these mechanisms
may contribute to different timepoints in the lengthy
disease process. Accumulation of alpha synuclein,
either as lewy bodies in PD or filamentous nuclear and
cytoplasmic inclusions in neurons and glia in MSA,
likely reflects an end-point stage reflective of stressed
dying cells. The differences between the types of alpha
synuclein aggregates in PD and MSA is poorly under-
stood, but our findings suggest that Lewy bodies may
form where there is excess iron and MSA aggregates
where there are decreased levels of iron. The distribu-
tion of alpha synuclein pathology may be a reflection
of differences in the regional susceptibility of some
neurons and glia to changes in iron levels. Exploration
of the specific role of alpha synuclein in iron dysregu-
lation in all synucleinopathies clearly warrants further
investigation.
In conclusion, while it is recognised that the low
number of samples is a limitation of this study,
our present findings raise the distinct possibility that
despite an increase in total tissue iron concentration,
there may a deficit in bioavailable iron in MSA. Future
studies will determine the potential role of local inflam-
matory signalling in maintaining this paradoxical low
bioavailable iron state. Furthermore, this deficit may
account for the degeneration of multiple cell types in
MSA pathology.
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